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Summary of the thesis 
Title: Investigating the Role of Inflammatory Biomarkers and Incretins in the Aetiology of Type 
2 Diabetes and Coronary Heart Disease using Human Genetics. 
Name: Nicholas Grant Bowker 
Background: The relevance of inflammatory and incretin-related signalling pathways in the 
aetiology of cardiometabolic diseases is of considerable pharmacological interest but remains 
uncertain. Evidence from animal models and epidemiological studies point to a role for chronic 
inflammation for the pathophysiology of type 2 diabetes (T2D), with interleukin-6 (IL-6) 
proposed as a key player. Incretins such as glucagon-like peptide-1 (GLP-1) and gastric 
inhibitory polypeptide (GIP) are hormones that stimulate a decrease in blood glucose. Their 
receptors are existing T2D drug targets, yet the efficacy and safety of GIP mono- and dual 
agonists e.g. tirzepatide are still unknown. Genetic approaches can help to address limitations 
of earlier studies and systematically assess the roles of IL-6 and GIP mediated signalling for 
cardiometabolic diseases. 
Aims: To investigate the potential causal roles of IL-6 and GIP receptor signalling for the risk 
of cardiometabolic diseases, specifically T2D and coronary heart disease (CHD), through 
analysis of large-scale genetic data from patient and population-based studies. 
Methods: 1) Systematic literature searches were conducted for each topic and the existing 
evidence summarised in the introduction. 2) A partial loss-of-function missense variant 
(Asp358Ala) in the IL-6 receptor gene (IL6R) was used to estimate the effect of IL-6R inhibition 
on T2D risk in 260,614 cases and 1,350,640 controls. 3) An observational meta-analysis of 
new unpublished and published studies (5,421 T2D cases, 31,562 non-cases) was conducted 
to compare observational and genetically predicted effects of IL6 levels on T2D. 4) The 
specificity of the IL6R variant was tested by including genetic and observational associations 
from a range of other inflammatory markers. 5) Large-scale genomic data from 23 
cardiometabolic diseases as well as anthropometric, lipid, glycaemic and ~6,000 ‘omic 
(metabolomic and proteomic) traits were brought together to systematically assess 
associations of a known missense variant in GIPR, E354, and infer specificity and potential 
beneficial or harmful effects of GIPR mono agonism. Bayesian multi-trait colocalisation was 
used to distinguish trait clusters driven by shared causal variants to identify independent 
causal variants driving specific trait associations. 
Findings: IL-6 levels (both measured and genetically predicted) were associated with T2D 
risk, with a small but significant effect (odds ratio (OR) 95% confidence interval (CI) for the 
Asp358Ala partial loss of function variant 0.98 (0.97, 0.99); p=2x10-7). Genetic mediation 
analyses estimated that IL-6 levels mediated up to 5% of the association between BMI and 
T2D. Colocalisation results at the GIPR locus identify E354 as the driver of a shared signal for 
GIP (higher), T2D and related traits (lower risk), and adiposity (higher) with high posterior 
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probability (>0.97), and demonstrate that this is distinct from cardiovascular and lipid 
associations nearby in APOE (rs7412; PP >0.99). 
Interpretation: Large-scale genetic and prospective observational data provide evidence that 
IL-6 mediated inflammation is implicated in T2D aetiology but suggest that the impact of this 
pathway on disease risk in the general population is likely to be small. At the GIPR locus, 
distinct genetic signals were shown to drive associations of glycaemic and adiposity traits 
versus CHD and lipid traits. This study provides evidence that inclusion of GIPR agonists in 
dual agonists could potentiate the protective effect of GLP1 agonists on diabetes without 
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The central aim of this PhD thesis is to identify the aetiological pathways underpinning the 
roles of inflammatory biomarkers and incretins, two areas of considerable pharmacological 
interest, in cardiometabolic diseases. This will be based on the integration of large-scale 
genomic data in deeply phenotyped cohorts with multiple ‘omics datasets to further our 
understanding of the molecular underpinnings of type 2 diabetes (T2D) and coronary heart 
disease (CHD). The primary focus for sections investigating inflammatory biomarkers is on 
levels of four pro-inflammatory cytokines: interferon-γ (IFNγ), interleukin-6 (IL-6), interleukin-
8 (IL-8) and tumour necrosis factor α (TNFα) but is later expanded to all inflammatory proteins. 
 
I will address the following sub-aims and objectives: 
 
➢ Sub-aim 1: To review the current observational, genetic and clinical literature on the 
aetiological role of inflammation in T2D and CHD. 
o Objective 1.1: Review and critically evaluate the literature to identify knowledge 
gaps which can be addressed. 
o Objective 1.2: Perform a systematic literature search to gain an understanding 
of the current knowledge of the genetic determinants of IFNγ, IL-6, IL-8 and 
TNFα levels. 
➢ Sub-aim 2: To investigate the observational associations of IFNγ, IL-6, IL-8 and TNFα 
levels with cardiometabolic diseases and related risk factors. 
o Objective 2.1: Estimate the association between cytokine levels and risk factors 
for T2D and CHD. 
o Objective 2.2: Estimate the association between cytokine levels and incident 
T2D and CHD. 
➢ Sub-aim 3: To conduct genome-wide association studies (GWAS) and meta-analysis 
to estimate the association between genetic variants and levels of IFNγ, IL-6, IL-8 and 
TNFα. 
o Objective 3.1: Perform conditional analyses and Bayesian fine mapping to 
identify independent secondary signals in each locus and the putative causal 
variants underlying each association signal. 
o Objective 3.2: Estimate the observational and SNP-based correlation between 
IFNγ, IL-6, IL-8 and TNFα as well as their SNP-based heritability  
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o Objective 3.3: Estimate the colocalisation between variants associated with 
cytokine levels and T2D and CHD. 
➢ Sub-aim 4: To investigate the role of IL-6 and IL-6 receptor (IL-6R) mediated 
inflammation in the pathophysiology of T2D. 
o Objective 4.1: Conduct a systematic review of prospective studies investigating 
the association between IL-6 levels and incident T2D and meta-analyse 
estimates from these studies with estimates from this thesis. 
o Objective 4.2: Estimate the association of a loss-of-function missense variant 
(Asp358Ala) in IL6R, previously shown to mimic the effects of IL-6R inhibition, 
in a large trans-ethnic meta-analysis of T2D case-control studies. 
o Objective 4.3: Estimate the proportion of the association between body mass 
index (BMI) and risk of cardiometabolic diseases that is mediated by IL-6 levels 
on both an observational and genetic level.  
o Objective 4.4: Project the putative therapeutic efficacy of IL-6R antagonism on 
T2D risk by comparing the effects of Asp358Ala to evidence from clinical trials 
of established IL-6R antagonists. 
➢ Sub-aim 5: To investigate the inflammatory proteins and the biological pathways 
involved in risk of cardiometabolic diseases by integrating large-scale proteomic and 
genetic data. 
o  Objective 5.1: Identify inflammatory proteins and perform a reciprocal lookup 
of the sentinels for inflammatory proteins and cardiometabolic diseases. 
o Objective 5.2: Identify loci that are shared between inflammatory proteins and 
cardiometabolic diseases. 
o Objective 5.3: Perform a gene set enrichment analysis to estimate whether 
inflammatory proteins which colocalised with cardiometabolic diseases were 
enriched in particular pathways.  
o Objective 5.4: Estimate the association between polygenic scores for 
established cardiometabolic risk factors and inflammatory protein levels to 
determine whether inflammation is partly driven by established risk factors. 
➢ Sub-aim 6: To review the current clinical and genetic literature on the aetiological role 
of incretins in T2D and CHD. 
o Objective 6.1: Review and critically evaluate the literature to identify knowledge 
gaps which can be addressed. 
o Objective 6.2: Perform a systematic literature search to review the current 
understanding of the genetic determinants underpinning incretin levels.  
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➢ Sub-aim 7: To estimate whether glucose-dependent insulinotropic polypeptide (GIP) 
receptor (GIPR) mediated signalling is associated with raised CHD risk. 
o Objective 7.1: Characterise the clinical consequences of the GIPR missense 
variant rs1800437 (E354). 
o Objective 7.2: Estimate distinct clusters of colocalised cardiometabolic traits 
driven by shared causal variants in the GIPR region. 
o Objective 7.3: Perform conditional analyses to identify variants contributing to 




Outline of the thesis 
Chapter 1 provides an overview of the current literature. I begin with a brief outline of both 
T2D and CHD, including their definition, global impact and aetiology. Next, I provide an 
overview and critical evaluation of recent genetic and integrative ‘omics approaches to the 
identification of causal risk factors for cardiometabolic diseases as well as their uses in drug 
target discovery and validation. Following this, I provide an overview of chronic inflammation 
in cardiometabolic diseases and critically review existing observational and clinical evidence 
linking inflammation to cardiometabolic diseases. I finish with an overview of studies 
investigating the genetic architecture of four proinflammatory cytokine levels: IFNγ, IL-6, IL-8 
and TNFα. 
Chapter 2 investigates the observational association of levels of the four cytokines with 
incident cardiometabolic diseases and related risk factors. Firstly, the association between 
cytokine levels and anthropometric, glycaemic and lipid traits is estimated using multivariable 
linear regression in up to 10,335 participants from the Fenland study. Next, the association 
between cytokine levels and incident T2D and CHD is estimated using Cox regression in up 
to 7,514 participants from the EPIC-Norfolk cohort. 
Chapter 3 describes a GWAS and meta-analysis of the four cytokine levels in approximately 
17,000 participants from the Fenland and EPIC-Norfolk studies. I start by outlining the 
phenotype preparation and move to describe how the GWAS and meta-analysis were 
conducted, and the quality control measures used at each step. Next, I describe the 
independent signal selection to identify secondary signals at each locus and the Bayesian fine 
mapping to refine each association signal to a likely causal variant. Following this, I outline the 
SNP-based heritability and correlation estimation across the four cytokines using LD score 
regression. Finally, I describe a colocalisation analysis to estimate whether association signals 
are shared between any of the four cytokines and either T2D or CHD.  
Chapter 4 details an in-depth investigation into the role of IL-6 mediated signalling risk of T2D. 
I begin with a description of a systematic review of 15 prospective studies investigating the 
association between IL-6 levels and T2D risk and the meta-analysis of estimates from these 
studies with estimates from this thesis in up to 5,421 cases and 31,562 non-cases. Next, I 
describe a trans-ethnic meta-analysis estimating the association of a loss-of-function 
missense variant in IL6R, Asp358Ala, with T2D in 260,614 cases and 1,350,640 controls. 
Following this, I describe an analysis estimating the proportion of the association between BMI 
and risk of cardiometabolic diseases that is mediated by IL-6 levels on both an observational 
and genetic level. Finally, I outline an analysis where I project the putative therapeutic efficacy 
of IL-6R antagonism on T2D risk by comparing the effects of Asp358Ala to evidence from 
clinical trials of established IL-6R antagonists. 
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Chapter 5 focusses on identifying the inflammatory proteins and biological pathways involved 
in the aetiology of cardiometabolic diseases by integrating large-scale genomic data with 
aptamer-based proteomic data. I begin by describing how inflammatory proteins were 
identified using GO terms and how a reciprocal lookup of sentinel variants was performed 
between inflammatory proteins and cardiometabolic diseases. I then describe how Bayesian 
multi-trait colocalisation was applied to identify candidate variants where inflammatory 
proteins colocalised with cardiometabolic diseases. I then describe a gene-set enrichment 
analysis that estimated whether the colocalised inflammatory proteins were enriched in 
particular pathways. Finally, I describe an analysis to determine whether inflammation is partly 
driven by cardiometabolic risk factors wherein I estimate the association between polygenic 
scores for established cardiometabolic risk factors and inflammatory protein levels.  
Chapter 6 provides a critical review of the current literature surrounding the role of incretins 
in cardiometabolic diseases. I begin by describing the physiological role of incretins in 
cardiometabolic diseases and how this is perturbed by obesity and T2D. I then review recent 
epidemiological evidence linking incretin levels to raised cardiovascular disease risk. 
Following this, I review clinical studies and data from randomised-controlled trials targeting 
incretins as potential therapies for use in obesity and T2D. I end with an overview of studies 
investigating the genetic architecture underpinning incretin levels. 
Chapter 7 describes genetic analyses to estimate whether higher GIPR-mediated fasting GIP 
levels are associated with raised CHD risk. I begin by describing two-sample Mendelian 
randomisation (2SMR) analyses integrating large-scale genomic data for cardiometabolic 
diseases, anthropometric, glycaemic, lipid and ~6,000 metabolomic and proteomic biomarkers 
to characterise the clinical consequences of the GIPR missense variant E354. Next, I describe 
how a Bayesian multi-trait colocalisation framework was used to estimate distinct clusters of 
cardiometabolic traits driven by shared causal variants in the GIPR region. Finally, I outline 
conditional analyses to identify independent variants driving associations between the GIPR 
locus and cardiometabolic traits of interest.  
Chapter 8 is a concluding discussion which summarises the findings of this thesis, highlights 
the general limitations of research, discusses the clinical implications and outlines possible 





The establishment of large population-based biobanks such as UK Biobank together with 
reduced costs for genotyping and sequencing has facilitated an unprecedented increase in 
the scale and availability of genomic data. In addition, biobanks collect detailed clinical 
information such as electronic health records, lifestyle and anthropometric measures on all 
participants making them an invaluable resource for the “hypothesis free” investigation of the 
mechanisms underpinning complex disease risk. As a result, human genetic data is now being 
applied at scale for the purposes of drug development. Genetics provides a framework which 
is robust to non-genetic forms of confounding and reverse causality that may be applied 
efficiently to in drug development efforts to facilitate the discovery, characterisation, 
prioritisation and prediction of candidate drug target efficacy. Recent technological advances 
in ‘omics methods have facilitated the simultaneous measurement of thousands of molecular 
traits such as gene expression, protein and metabolite levels in large epidemiological cohorts. 
This has facilitated the integration of genomic data with ‘omics data at scale in deeply 
phenotyped cohorts. The availability of this large-scale ‘omics data in deeply phenotyped 
epidemiological cohorts at scale offers a timely opportunity to investigate the molecular 
underpinnings and pathways involved in cardiometabolic diseases such as T2D and CHD. 
While much of the aetiology of cardiometabolic diseases is largely understood, there are areas 
such as the roles of inflammatory biomarkers and incretins, which are unclear and of 
considerable pharmacological interest. 
 
Chronic inflammation in cardiometabolic diseases is hypothesised to be one of the links 
between obesity and risk of cardiometabolic diseases, partly mediating this relationship. The 
causal relationships underpinning the role of inflammation in cardiometabolic diseases are still 
unclear, however, a role for inflammation in insulin resistance has been posited. It is unknown 
whether inflammation is an independent causal risk factor for cardiometabolic diseases or 
whether it is resultant of established risk factors such as obesity. In addition, the inflammatory 
proteins and pathways involved in cardiometabolic diseases are unknown.  
 
Until recently, our knowledge of glucose homeostasis was largely limited to insulin and 
glucagon, however, the discovery of the insulin potentiating action of incretin hormones has 
sparked considerable interest in the pharmacological modulation of these hormones in T2D. 
However, recent epidemiological evidence has implicated higher GIPR-mediated fasting GIP 
levels in raising cardiovascular risk, jeopardising the development of therapies targeting this 
pathway. Investigation of the relationship between GIPR agonism and cardiovascular risk 
using genetics will provide an efficient, systematic, cost-effective method of assessing the 
cardiovascular safety of these therapeutics.  
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Chapter 1: Overview of the literature 
1.1: Background 
Definition of type 2 diabetes and coronary heart disease 
Type 2 diabetes (T2D) is a chronic condition characterised by hyperglycaemia resulting from 
an inability to mount an adequate insulin response, defined as insulin resistance1,2. To cope 
with the hyperglycaemia, the body attempts to compensate by increasing insulin secretion 
relative to the degree of insulin resistance1. Diagnostic criteria set out by the WHO2 state that 
diabetes may be diagnosed if one of the criteria for hyperglycaemia are met (Table 1.1).  
 
Table 1.1: WHO diagnostic criteria for diabetes a 
Risk factor Threshold 
Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL)  
Two-hour plasma glucose ≥ 11.1 mmol/L (200 mg/dL)  
HbA1c ≥ 6.5% 
Abbreviations: HbA1c; glycated haemoglobin 
a. Adapted from the WHO Global Report on Diabetes 20162 
 
Coronary heart disease (CHD) is characterised by a narrowing or blockage of the coronary 
arteries over time via a process known as atherosclerosis3. In atherosclerosis, lipids and 
cholesterol within a fibrous matrix are ectopically deposited within the arterial wall, eventually 
forming atherosclerotic plaques4. Over time, this leads to an irregular arterial surface, causing 
the arteries to narrow, limiting the flow of blood and increasing the risk of myocardial infarction 
or stroke3,4. Diagnosis consists of blood tests to measure cholesterol levels, a major risk factor 
for CHD4,5, which are followed by functional assessments such as electrocardiogram (ECG) 
or imaging techniques such as computed tomography (CT)6. 
 
Cardiometabolic disease is a collective term referring to the co-occurrence of several 
metabolic perturbations, chief among which are: insulin resistance or glucose intolerance, 
obesity (central adiposity), dyslipidaemia and hypertension7,8. Cardiometabolic disease 
represents a cluster of correlated risk factors that identify individuals at high risk for both T2D 




Worldwide impact of cardiometabolic diseases 
Global increases in the prevalence of obesity preceded subsequent increases in the 
prevalence of both T2D and CHD, supporting the notion that obesity leads to a series of 
metabolic perturbations that have the capacity to mediate or accelerate processes underlying 
both diseases9,10. In 2019, the global prevalence of diabetes was estimated to be 9.3%, 
translating to 463 million people living with diabetes1. Of the three most common forms of 
diabetes, T2D is the most prevalent, accounting for approximately 90% of all cases1. By 2045, 
this is projected to increase to 700 million people1 (Figure 1.1). This increase is not limited to 
countries of lower socioeconomic status, however, the predicted rate of growth is higher in low 
to middle income countries2. This places a huge burden on healthcare infrastructure 
amounting to an estimated $760 billion per year in 2019, a 4.5% increase on the estimate for 
2017, and is likely to increase to $845 billion in 20451,11,12. 
Figure 1.1: The age adjusted prevalence of diabetes in adults worldwide in 2019. Figure 
taken from the IDF Diabetes Atlas, 9th edition (2019)1. 
 
In line with the notion of obesity being a major driver for T2D and CHD, the prevalence of 
cardiovascular disease (CVD) has increased. CVD is the leading cause of all-cause mortality 
and places a huge burden on economies worldwide13. Globally, more than 75% of deaths 
resulting from CVD occur in low to middle income countries13. In 2017, 92 million people in the 
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USA were estimated to have at least 1 form of cardiovascular disease14. This is projected to 
increase to 44% of the adult population of the USA by the year 203014. Empirical evidence of 
the correlation between T2D and CVD shows that T2D patients have between 1.5 to 3 times 
higher risk of developing a form of CVD compared to the general population15. T2D is also 
associated with earlier onset16 and greater severity17 of CVD events.  
 
These global trends are driven by the current socioeconomic climate where greater 
consumption of energy-dense, convenience foods leads to chronic positive energy balance, a 
risk factor for obesity1. This effect is exacerbated by aging populations and a lack of physical 
activity, which leads to a more sedentary lifestyle, all of which are risk factors for obesity. 
Taking this into consideration, a better understanding of the mechanisms linking obesity to 
T2D and CHD is critical for the design of prevention and treatment interventions aimed at 
reducing the burden of these conditions on global health.  
 
Hyperglycaemia and the initiation of insulin resistance in T2D pathogenesis 
Glucose homeostasis in healthy individuals is governed by the key peptide hormone insulin 
and is maintained by a balance between insulin secretion and sensitivity18. In the healthy 
fasted state, blood glucose concentrations are maintained by balancing endogenous glucose 
production via glycogenolysis and gluconeogenesis in the liver and its subsequent use by 
tissues such as the brain (Figure 1.2, lower half)19. Endogenous glucose production provides 
a buffer against hypoglycaemia supplying glucose-dependent tissues such as the brain with 
glucose10. Tissues such as skeletal muscle that are able to metabolise other carbon sources, 
are provided with non-glucose substrates such as non-esterified fatty acids from adipose 
tissue lipolysis to preserve fuel for the brain10,19. Following a carbohydrate-rich meal, blood 
glucose levels are raised, providing the stimulus for pancreatic insulin secretion. Insulin-
mediated glucose uptake into tissues such as skeletal muscle and adipose tissue follows, 





Figure 1.2: The glucose homeostatic model in healthy individuals. The lower half depicts 
glucose homeostasis in the fasting state. The top half shows the fed state. Taken from: 
Principles of Molecular Medicine, 16th Ed.20   
 
In healthy individuals, pancreatic β cells are adaptable to variations in insulin action and are 
able to compensate accordingly10,18,19. When this compensatory capacity is exceeded, the 
expected effects of insulin on tissue glucose uptake from blood are insufficient18,21. Obesity 
and physical inactivity are established risk factors for insulin resistance and often precede its 
development10,19,21. Insulin resistance is characterised by several metabolic effects: insulin-
mediated glucose uptake into skeletal muscle and adipose tissue is reduced, incomplete 
suppression of hepatic glucose production and incomplete suppression of adipose tissue 
lipolysis10,18,21. The ensuing hyperglycaemic state impairs β cell function through glucose 
toxicity, leading to impaired insulin secretion18,19. Additionally, due to the limited availability of 
intracellular glucose, fatty acids from increased adipose tissue lipolysis are metabolised, 
leading to higher blood plasma lipid levels10. Together with an inability of the β cells to 
compensate and maintain euglycemia, these metabolic disturbances further the onset of 
insulin resistance and together contribute to T2D pathogenesis. The compensatory capacity 
of β cells to counteract the effects of insulin resistance varies between individuals and is 
thought to have a substantial genetic component22.  
 
Risk factors influencing T2D incidence can be broadly categorised into modifiable and 
unmodifiable factors. Differences in T2D risk have been shown to vary with ethnicity23–25, 
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previous family history of T2D26, age27, sex27 and genetic predisposition all of which are 
unmodifiable. Despite this, a larger proportion of T2D risk factors are behavioural lifestyle or 
environmental factors which can be modulated via interventions to alter T2D risk. These 
include: being overweight or obese28,29, high central adiposity30, socioeconomic inequalities 
regarding treatment access31, unbalanced diet32,33, lack of physical activity28,32, sedentary 
lifestyle34,35 and smoking32.  
 
The role of cholesterol in the initiation of atherosclerosis in CHD pathogenesis 
Atherosclerosis is the process underlying many cardiovascular diseases, including CHD, 
stroke and peripheral artery disease, and refers to the formation of fibrous, lipid-rich lesions 
embedded in the arterial wall4. LDL cholesterol particles, which are lipid-rich packets coated 
in phospholipids with apolipoprotein B running through their centre, are designed to transport 
cholesterol in blood4. LDL levels in excess of the required physiological range of between 0.5–
0.8 mmol/L36 have been causally linked with atherosclerosis in both observational37 and 
genetic studies38. This chronic excess of LDL leads to the accumulation of LDL in the arterial 
intima, the innermost layer of the arterial wall4. The exact mechanism whereby arterial LDL 
accumulation leads to localised inflammation still remains to be elucidated4. However, this 
process leads to the recruitment of monocytes, immature circulating phagocytic cells of the 
innate immune system that later mature into macrophages, to the arterial wall by chemokines 
secreted by activated endothelial cells4,39. Monocytes then bind to adhesion molecules on the 
endothelial cell surface, facilitating their entry to the intima (Figure 1.3)4,40.  
 
Figure 1.3: The initial stages of atherosclerosis. The layers of the arterial wall are shown, 
along with the immune cell recruitment as a result of LDL deposition. Figure taken from4. 
 
Arterial macrophages sequester LDL via scavenger receptors with the aim of maintaining lipid 
homeostasis to the point of overload, thus forming foam cells41 a hallmark of atherosclerotic 
lesions40. Along with monocytes, T cells of the adaptive immune system and smooth muscle 
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cells are also recruited to the lesion via chemoattraction and play roles in the growth and 
maintenance of the lesion to eventually form a plaque4.  
 
The growth and maintenance of the plaque is characterised by a number of processes, chief 
among which are a thickening of the intima layer, the formation of a fibrous cap and the 
establishment of a necrotic core in the centre of the plaque (Figure 1.4)4,40. Smooth muscle 
cells secrete extracellular matrix molecules such as collagen and elastin which accelerate the 
accumulation of lipids, thickening of the intima and the formation of the fibrous cap4,42. Foam 
cells become trapped in the intima as their capacity to migrate is compromised leading to their 
eventual death, forming part of the necrotic core along with cholesterol crystals and other 
cellular material4,40. Over time, impaired clearance of dead smooth muscle cells and 
macrophages contributes to the formation and maintenance of the necrotic core. Finally, T cell 
secreted cytokines such as interferon-γ (IFNγ) can impair collagen formation by smooth 
muscle cells, affecting repair of the fibrous cap4. Along with this, macrophage secretion of 
matrix metalloproteinases (MMPs) that degrade collagen, weakens the cap further thus 
increasing the likelihood plaque rupture, often leading to acute myocardial infarction40,43. 
 
Figure 1.4: Progression of atherosclerotic lesions to plaques. Intima thickening, cellular 
apoptosis and the formation of the fibrous cap and necrotic core are shown. Figure taken 
from4. 
 
Much like T2D, risk factors for CHD can be sub-divided into modifiable and non-modifiable 
risk factors. The non-modifiable risk factors are similar to those of T2D, with the inclusion of 
T2D as an additional risk factor15,44–48. The modifiable lifestyle factors include: being 
overweight or obese49, high central adiposity30, smoking50, lack of physical activity51 but with 
the addition of: alcohol use52, hypertension53, prevalent T2D15 and hyperlipidaemia54.  
 
13 
1.2: Genetics as a framework for causal inference and risk factor 
prioritisation 
Human genomic data are now being employed at scale for the purposes of drug discovery 
and validation efforts55–58. This is partly because only 10% of candidate therapies are 
estimated to proceed through development from Phase 1 trials to release59. Approximately 
79% of drug candidates fail due to a lack of efficacy or safety concerns59. Evidence from 
human observational studies is useful for identifying putative drug targets, however, is liable 
to confounding and reverse causality55. Comparatively, genetic variants are robust to reverse 
causality60 and non-genetic forms of confounding60 while also segregating at random61, 
analogous to a randomised-controlled trial (RCT)62. Genetics therefore has the potential to 
efficiently prioritise candidate targets but also lower drug attrition rates57,58. This is exemplified 
by successes such as HMGCR, a target of statins, which was prioritised on the basis of its 
association with cholesterol synthesis and therefore its inhibition confers cardio-protective 
benefits63. Retrospective studies have shown that the proportion of drug mechanisms 
supported by genetic evidence increases throughout the development process making targets 
twice as likely to be approved57,64. These estimates assume that the causal mechanism is 
clear64 and are dependent on the strength of the genetic evidence, as targets associated with 
Mendelian disorders are five times more likely to reach approval65.  
 
The establishment of large population-based biobanks such as UK Biobank66 facilitates the 
unbiased prioritisation and characterisation of putative drug targets at scale. Large biobanks 
have tripled the effective sample size for T2D GWAS studies, dramatically improving the 
statistical power of these analyses22,67. Recent technological advances in ‘omics methods 
have facilitated the simultaneous measurement of thousands of molecular traits in large 
epidemiological cohorts. Combining this with lifestyle and anthropometric measures allows for 
greater characterisation of the molecular mechanisms underpinning complex disease68.  The 
vast majority of therapeutics perturb protein function58. Therefore, integrating genomic 
information with gene expression and proteomic data enables the characterisation of the 
molecular consequences and mediators of this perturbation67.  
 
Due to the properties of genetic variants60–62, they may be used in a Mendelian randomisation 
(MR) framework to empirically estimate the effects of molecular traits on disease risk69–72. MR 
methods are well established, efficient methods of prioritising evidence from observational 
studies, that treat genetic variants as instrumental variables (IVs)69,71–73. The assumptions 
surrounding the use of IVs in MR have been reviewed elsewhere62, briefly, 1) the IV must be 
reliably associated with the exposure, 2) the IV must not be associated with confounder of the 
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association between the exposure and outcome, 3) there is no independent pathway from 
variants to outcome that is not mediated via the exposure71. Methodological advancements 
have facilitated multivariable analyses accounting for the effects of genetic variants on 
correlated traits74,75 as well as methods accounting for the effects of pleiotropy76 or outliers77–
80 in a model. An example of this is the causal association of LDL cholesterol with CHD risk, 
an established risk factor for CHD81. In univariable analyses, both LDL cholesterol and 
apolipoprotein B (ApoB) were associated with CHD risk81. However, in multivariable MR, only 
ApoB was significantly associated with CHD risk, suggesting that ApoB and not LDL is 
causally associated with CHD risk81. This work would not have been possible without the scale 
and availability of publically available genotypic data which facilitates the estimation of variant–
exposure and variant–outcome associations from independent studies of unrelated individuals 
in a framework termed two-sample MR (2SMR)71,79. This approach has several advantages, 
firstly, ‘winners’ curse’, which underestimates causal effects in one-sample MR, is unlikely in 
two-sample MR82, secondly, weak IVs bias estimates towards the null83.  
 
Genetic variants may further support the drug development process by predicting any off-
target or adverse effects, estimating the target specificity56,58. Returning to the example of 
HMGCR84, while statins have been shown to lower LDL cholesterol levels, there appears to 
be an dose-dependent increase in T2D risk85,86. Using variants in the HMGCR gene, the 
associations with glycaemic, anthropometric and lipid traits were estimated, with the authors 
concluding that T2D risk was partly mediated via HMGCR inhibition84. Later studies 
demonstrated that lowering triglyceride levels via lipoprotein-lipase (LPL) may be used in 
conjunction with statins to further reduce CHD risk while negating any statin-mediated 
increases in T2D risk5.  
 
Pharmacomimetic genetic variants mimic the effects of established therapies and may 
therefore be used to uncover new treatment indications for existing drugs67. This strategy 
reduces the risk of failure as the safety profile of existing drugs is established, it accelerates 
the development process and finally reduces the overall cost of development87. The initial 
evidence that this may be possible is often gleaned through systematic phenome-wide scans 
estimating the association of the variant with diverse well-defined phenotypes87. Critically, the 
pathway of interest needs to be causal for both disease indications and the drug mechanism 
must be shared87. An example of particular relevance to this thesis, involves antagonism of 
the interleukin-6 receptor (IL6R) using a monoclonal antibody, tocilizumab, an established 
treatment for rheumatoid arthritis88. Observational evidence has suggested that IL-6 levels 
play a role in CHD risk89,90. Using variants in the IL6R gene in an MR framework, the potential 
efficacy of IL6R antagonism on CHD risk was investigated88. IL6R signalling was estimated to 
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be causal for CHD, suggesting that antagonism of IL6R signalling in CHD may confer 
protective effects88. 
 
There are several challenges and considerations of this work. Firstly, the translation of GWAS 
findings into meaningful biological insights with a clear mechanism of action, is a challenge 
related to the interpretation of any GWAS result. This is largely because the majority of GWAS 
findings lie in non-coding regions with comparatively small effect sizes91. Secondly, linkage 
disequilibrium (LD) between variants in the genome often makes discrimination of a causal 
variant underlying a GWAS association signal in a genomic region challenging92. Thirdly, 
pleiotropic effects whereby a variant may affect two or more unrelated traits via diverse 
pathways (horizontal pleiotropy) are challenging to use in an MR framework as they invalidate 
the assumption that there is no independent pathway from variants to outcome that is not 
mediated via the exposure71. Therefore, elucidating the mechanism of action of a pleiotropic 
variant on a particular trait is challenging, as the variant may influence the trait via many 
different mechanisms. Finally, often quantification of the target of interest is not possible, 
therefore, a proxy which is directly impacted by the target of interest may need to be quantified 
instead. In the case of HMGCR and LDL cholesterol, the quantification of HMGCR activity is 
challenging compared to LDL. Therefore, quantification of the reduction in LDL levels may be 
used as a proxy for HMGCR activity84,93.  
 
In summary, genetics is an efficient and robust framework to the types of confounding that 
affects observational studies60–62. Genetics has the potential to accelerate and improve the 
success rate of the drug development process as well as prioritise drug potential drug targets 
by empirically estimating their efficacy, safety and potential for use in other indications56,58,67,69–
72. This capacity for large-scale genetic studies will only increase with the establishment of 
biobanks that integrate genetic data with high throughout ‘omics methods for deep molecular 
characterisation.  
 
As eluded to in previous sections, much of the aetiology of cardiometabolic diseases is largely 
understood. However, there is still uncertainty in areas which are of considerable scientific, 
clinical and pharmaceutical interest. Two such examples, which are the topics of this thesis, 
are the role of inflammatory proteins and incretins in the aetiology of cardiometabolic diseases. 
This thesis will integrate large-scale genomic data with multiple ‘omics datasets to further our 
understanding of the molecular underpinnings of inflammatory proteins and incretins to 
estimate how levels of these traits relate to risk of T2D and CHD.  
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1.3: Inflammation as a link between obesity and cardiometabolic 
diseases 
Inflammation: the body’s natural defence to insult 
Inflammation is an evolutionarily conserved, coordinated response by the immune system to 
disturbances in cellular or systemic physiology such as tissue injury or infection94. The immune 
system is composed of both the innate and adaptive immune responses. Innate immunity 
serves as a first-line, immediate and non-specific defence to immune insult95. In contrast to 
this, adaptive immunity is a delayed and specific response that centres on priming highly 
specialised T and B lymphocytes using antigens from the insult itself95. Innate immune cells 
such as phagocytic macrophages or neutrophils sense pathogen- or endogenous cell 
damage-associated molecular patterns (PAMPs or DAMPs) using pattern recognition 
receptors on their surfaces96. This stimulus leads to the secretion of soluble effector molecules 
called cytokines and chemokines which facilitate signalling between diverse cell types to 
coordinate and regulate the immune response on both a local and systemic level96–98.  
 
Cytokines can be divided into two broad groups, pro- or anti-inflammatory, depending on 
whether they contribute to the propagation or resolution of inflammation96. Under normal 
conditions, stimulation of the immune system leads to the production of proinflammatory 
cytokines and chemokines which recruit leukocytes and other immune cells to the insulted 
tissue (Figure 1.6)98. Once the pathogen or cellular debris has been removed, the 
inflammatory stimulus diminishes, and a period of resolution begins. The secretion of anti-
inflammatory cytokines provides the signal for infiltrating immune cells to return to the 
circulation and allow for tissue repair94,98. Thereafter, a post-resolution phase is thought to 
occur where adaptive immunity is established in the insulted tissue through the infiltration of 
T and B lymphocytes. These are subsequently primed against future reoccurrence of the 
threat98. This delicate balance between pro- and anti-inflammatory processes allows for a 




Figure 1.6: The healthy acute inflammatory response. This is characterised by a rapid 
initialisation phase to eliminate insults, followed by a resolution phase to enable tissue 
recovery. Finally, the persistent post-resolution phase is initiated which primes the adaptive 
immune system to future insults. Figure taken from98. 
 
In cardiometabolic diseases, resolution of the inflammatory response can be hindered, 
resulting in a state of chronic low-grade inflammation94,98. This is characterised by persistent 
activation of proinflammatory mediators such as cytokines, leading to significant tissue 
damage due to constant cytokine upregulation94. The triggers for this are unknown, however, 
tissue damage arising from obesity-related metabolic dysfunction is thought to disrupt immune 
homeostasis and play a role in its establishment99. Several correlated risk factors for chronic 
inflammation have been identified such as: diet-induced microbiome dysbiosis100–103 and 
lifestyle factors such as chronic stress104, insomnia105,106 and physical inactivity107,108, many of 
which are shared risk factors for obesity94. The following section will expand upon some of the 
inflammatory mechanisms thought to link obesity to cardiometabolic diseases. 
 
Inflammatory mechanisms linking obesity to T2D and CHD 
Historically, the sole function of adipose tissue was thought to be long-term energy storage, 
however, recently  this notion has been challenged and it is now appreciated that it plays a 
crucial role in the regulation of metabolic homeostasis109. Several key immune and metabolic 
signalling pathways converge upon adipose tissue, facilitating cross-talk between the two 
systems to maintain homeostasis of both systems110–113. Two key features of adipose tissue 
allow it to perform this integrated role, firstly, adipose tissue sequesters blood lipids for storage 
as triglycerides114. Secondly, adipose tissue is capable of secreting adipokines, molecules 
which regulate systemic metabolism by relaying information about energy stores to 
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neuroendocrine systems and maintain the adipose cellular environment115,116. Adipose tissue 
is therefore a key regulator of metabolic homeostasis that is adaptable in response to dynamic 
metabolic stimuli. 
 
A hallmark of obesity is adipose dysfunction, one of the consequences of which, is the onset 
of chronic inflammation111,113. Obesity induces systemic low-grade inflammation in many 
metabolically active organs such as the pancreas117, liver118 and skeletal muscle119. However, 
dysfunctional white adipose tissue is the most studied of these given its roles in energy storage 
and metabolic homeostasis120. Adipocytes respond to positive energy balance by expanding 
rapidly in both size and number to accommodate further lipid storage121. As a result, a mildly 
hypoxic environment develops, inducing stress signals that facilitate extracellular matrix 
remodelling and angiogenesis to restore adequate oxygen supply122. Adipose tissue 
expansion is constrained by pre-defined limits of expansion121 which, when exceeded, 
stresses the adipose compartment leading to dysfunction and the propagation and 
maintenance of chronic inflammation110–113,121,123–126. Evidence from several different forms of 
partial lipodystrophy6,7 and functional studies of peripheral adipose storage compartments8-
10 suggests that a primary inability to expand gluteofemoral or hip fat can also underpin sub- 
sequent risk of cardiometabolic diseases.  
 
In obesity, adipose tissue expands beyond the capability to sustain adequate angiogenesis, 
leading to a state of chronic hypoxia127,128 and therefore an unresolved stress signal, triggering 
inflammation113,123,126,129. Coupled to this, efficient adipose expansion requires the remodelling 
of the surrounding extracellular matrix to ensure proper angiogenesis and functionality of the 
tissue113,126. The rate at which adipocytes expand in obesity leads to dysfunctional extracellular 
matrix  remodelling and fibrotic deposition of collagen, placing physical stress upon 
adipocytes113,126,130,131. Impeding further expansion of adipose tissue results in raised 
circulating lipid levels132,133, a risk factor for atherosclerosis38,134. This, in turn, may result in 
lipid deposition within organs, namely ectopic deposition121. The combined effects of the 
above-mentioned adipose dysfunctions often result in adipocyte death and necrosis135,136, 
further propagating the inflammatory response and recruiting phagocytic macrophages to the 
inflamed adipose tissue137,138.  
 
Over 25 years ago, the seminal finding that tumour necrosis factor alpha (TNFα) is over-
expressed in obese murine adipose tissue established the first link between obesity and insulin 
resistance, through inflammation139. This finding was later replicated in humans140,141. This led 
to a proliferation in studies identifying other pro-inflammatory adipokines that are expressed 
in adipose tissue such as monocyte chemoattractant protein 1 (MCP-1)142, interleukins 6143,144 
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and 8145 (IL-6 and IL-8) and interferon-γ (IFNγ)146,147, the expression of which becomes 
dysregulated in obesity109. Furthermore, higher TNFα and IL-6 levels have been associated 
with adipose lipolysis through the inhibition of lipoprotein lipase111,148, leading to dysfunctional 
triglyceride storage and higher circulating fatty acids which may have implications for CHD 
risk. Two later studies revolutionised inflammation research in obesity, firstly, adipose-resident 
macrophages were discovered137 which regulate adipose function and provide immune 
surveillance149. Secondly, macrophage infiltration into obese adipose tissue was 
demonstrated138, dramatically increasing the proportion of macrophages to an estimated 41% 
of cells in obese adipose tissue compartments137. Furthermore, the predominate source of the 
observed TNFα overexpression in obese adipose tissue was attributed to these adipose-
resident macrophages rather than adipocytes137.  
 
Based on this new evidence, focus shifted to further characterising the role of macrophages 
in dysfunctional obese adipose tissue with reference to how they propagate and maintain 
chronic inflammation. Macrophage infiltration was found to be driven, in part, by MCP-1 
mediated chemotaxis150, the levels of which are raised during obesity151. In addition to 
increasing in number, adipose macrophages alter their inflammatory state in obesity from an 
anti-inflammatory to a proinflammatory phenotype, resulting in higher pro-inflammatory 
cytokine secretion152. The trigger for this phenotypic switch is unclear, however, fatty acids as 
a result of metabolic dysregulation have been posited as a possible trigger153, along with 
adipose dysfunctions mentioned previously. Related to this, macrophages have been 
observed to cluster around dying adipocytes in necrotic clusters called crown-like structures 
which are characterised by high levels of proinflammatory cytokine secretion135. Given this 
evidence, obesity is a likely driver for chronic inflammation, however, further research into the 
obesity-mediated inflammatory pathways in cardiometabolic diseases is needed. 
 
Observational evidence establishing cytokines as therapeutic targets of interest  
Cytokines have been posited as a possible link between obesity and cardiometabolic diseases 
due to their function as key signalling and effector molecules109. Observational evidence has 
established an association between obesity and higher proinflammatory cytokine levels, which 
are predictive of incident T2D154 and CHD155 independent of BMI and relevant risk factors. 
This is evidenced by strict weight loss interventions in obese individuals at risk for T2D which 
demonstrate a reduction in cytokine levels such as C-reactive protein (CRP) and others156–158, 
during weight loss159. CRP is an acute-phase protein produced in the liver and routinely 
measured in clinical trials160, upon which many inflammatory pathways converge, making it a 




In this study, the levels of four cytokines: IFNγ, IL-6, IL-8 and TNFα are of interest because of 
their putative roles in the aetiology of cardiometabolic diseases. IFNγ is secreted by T 
lymphocytes and adipocytes and is thought to function as a potent activator of macrophages, 
promoting the switch to a proinflammatory phenotype and subsequent secretion of IL-1 and 
IL-6162,163. IL-8 has been shown to recruit macrophages and neutrophils to atherosclerotic 
plaques through a process known as chemotaxis164–166. IL-6 and TNFα are two of the most 
studied cytokines in cardiometabolic diseases94,109,148,154,167,168. While both have been 
associated with insulin resistance in murine models139,140,169–171, the translation of these 
findings to human systems remains uncertain. The finding that IL-6 levels are acutely raised 
by skeletal muscle secretion during exercise hampers interpretation of the role of IL-6 in insulin 
resistance, as skeletal muscle is the main source of insulin-mediated glucose disposal172. 
Furthermore, differences in cardiometabolic risk may exist with regards to acute vs. chronic 
exposure to raised cytokine levels, thus further complicating the interpretation of their role in 
disease pathophysiology. 
 
Since the initial description of an association between TNFα and insulin resistance139, the 
number of epidemiological studies investigating cytokines and risk of cardiometabolic 
diseases has increased. A recent cross sectional study of 1,558 multi-ethnic participants 
reported that TNFα levels were higher in participants with impaired glucose tolerance and 
T2D, and were correlated with insulin resistance metrics173. However, a smaller European 
study of 519 German adolescents failed to replicate this association, adding uncertainty to the 
literature174. In addition to TNFα, IL-8 and IL-6 levels and their association with fasting insulin 
and homeostatic model of insulin resistance (HOMA-IR) were investigated. Like TNFα, 
contradictory results have been shown for the association between IL-8 levels and fasting 
insulin or HOMA-IR174,175. In contrast, IL-6 levels were significantly associated with both after 
adjustment for age, sex and lipids174. However, both associations were attenuated after 
adjustment for BMI, suggesting that these effects may be mediated by obesity174. Despite BMI 
being a simple and widely available proxy for obesity, there have been questions surrounding 
its validity as a proxy for body fat distribution30,176–179, thought to be one of the underlying 
causes for cardiometabolic diseases. Similar questions surrounding the validity of HOMA-IR 
as a proxy for insulin resistance have been raised180. This has implications for research using 
these measures as proxies for obesity and insulin resistance, respectively, as they may 
incompletely capture the phenotype of interest or fail to capture the truly causal aspect. This 
may lead to inaccurate inferences from results while also impacting the statistical adjustment 




In the largest prospective study of up to 7,683 European participants, IL-6 levels were 
associated with both HOMA-IR and fasting but not 2-hour insulin levels181. A doubling in IL-6 
levels from baseline corresponded to a 2.2% increase in fasting insulin levels from baseline, 
identical to that of HOMA-IR181. The same was true for HOMA-β, a metric of pancreatic β-cell 
function, indicating raised β-cell function as a compensatory mechanism. These associations 
remained significant despite extensive adjustment for age, sex, BMI, lifestyle factors and lipid 
traits181. In contrast, while IFNγ levels have been proposed to play a role in insulin resistance 
on a cellular level182, no epidemiological studies have examined this effect in a suitably 
powered cohort. 
 
When testing the association between IL-8 levels and incident T2D, again no evidence for 
association was found, when BMI and extensive lifestyle and cardiometabolic risk factors were 
accounted for183,184. The largest systematic review and meta-analysis to date of TNFα levels 
and their association with incident T2D is comprised of five prospective studies amounting to 
509 incident T2D cases and 4,716 controls185. The association between TNFα and incident 
T2D was shown to be non-significant, with substantial heterogeneity between studies. 
However, in a sensitivity analysis that removed low-quality studies, TNFα levels were shown 
to be significantly associated with incident T2D185. This highlights the uncertainty surrounding 
the association between TNFα levels and incident T2D and presents an opportunity for 
suitably powered studies to provide clarification. 
 
The number of studies investigating the association between IL-6 levels and incident T2D are 
comparatively more abundant. Two systematic reviews have been performed on the 
subject185,186, the first consisting of 10 prospective studies in up to 4,480 cases and 19,709 
non-cases. This first study showed a 33% higher risk of incident T2D per 1 log pg/mL higher 
IL-6 levels186. This was replicated in the second meta-analysis of 16 prospective studies 
comprising 4,751 cases and 24,929 non-cases, which showed a 32% higher risk of incident 
T2D per 1 log mg/L higher IL-6 levels185. In sensitivity analyses, neither systematic review 
displayed evidence of publication bias or significantly different estimates within subgroups of 
included studies. Again, there was a lack of epidemiological studies investigating the 
association of IFNγ with incident T2D.  
 
Two previous studies have investigated the association of IL-8 levels with incident CHD187,188. 
The first, a case-cohort study consisting of 381 European cases and 1,977 non-cases, showed 
38% higher risk of incident CHD for individuals in the highest tertile of the IL-8 distribution187. 
This association held despite extensive adjustment for relevant cardiometabolic risk factors, 
however, was attenuated when adjusted for IL-6 and CRP levels187. The second, a prospective 
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Swedish cohort of 4,011 participants, replicated this finding using similar adjustment and also 
showed no significant association with either myocardial infarction or ischemic stroke188. 
Similar to T2D, two systematic reviews have examined associations between IL-6 levels (an 
established CHD risk factor) and incident CHD90,189. The first of these comprised 17 studies 
amounting to 5,730 cases and 19,038 non-cases, and showed a 26% higher CHD risk per 1 
SD higher IL-6 levels90. The second and larger meta-analysis of 25 studies with a total of 7,982 
CHD cases found a 25% higher CHD risk per 1 SD higher IL-6 levels189. This second meta-
analysis also examined associations of TNFα with incident CHD in 7 studies, comprising 1,656 
CHD cases and 4,346 non-cases189. They found a 17% higher CHD risk per 1 SD higher TNFα 
levels189. Finally, in a case-control study consisting of 931 CHD cases and 974 controls, IFNγ 
levels were found to be significantly associated with CHD risk, corresponding to a 46% higher 
risk in individuals in the top tertile of the IFNγ distribution190. However, upon adjustment for IL-
6 levels this association was attenuated and no longer significant190. This finding is consistent 
with established IL-6 biology and CHD risk39. 
 
In conclusion, comparatively fewer studies have investigated IL-8 and IFNγ levels in CHD and 
T2D patients. Typically, these studies have also been conducted in smaller sample sizes 
compared to those studying IL-6 or TNFα. The consequence of using a few small studies as 
an evidence base translates to unclear association evidence between IL-8 and IFNγ and 
cardiometabolic diseases. Comparatively, association estimates for IL-6 and TNFα with CHD 
and T2D are more established. While this highlights the potential for larger, suitably powered 
studies to clarify the associations of IL-8 and IFNγ with cardiometabolic diseases, the causal 
evidence for each cytokine of interest in cardiometabolic diseases is also yet to be established.  
 
Clinical trials targeting cytokines in cardiometabolic diseases 
Several established therapeutic and lifestyle interventions used in clinical practice have 
demonstrated anti-inflammatory properties alongside their primary mechanism of action9. 
Interventions such as weight management diets191 and bariatric surgery192 have proven anti-
inflammatory effects. Similarly, glucose-lowering therapies such as metformin193–197 and 
incretin modulators198–201 are associated with small reductions in circulating levels of 
inflammatory markers. This appears to be a beneficial secondary feature shared by many 
interventions that seek to lower blood glucose levels. Anti-inflammatory therapies commonly 
used in rheumatic disease like salicylate202,203 or low-dose methotrexate204,205 have broad anti-
inflammatory effects and are effective at lowering glucose levels in cardiometabolic diseases. 
However, this is not always the case, as glucocorticoids have been shown to raise glucose 




As previously discussed, TNFα was the first cytokine thought to participate in insulin 
resistance139. Despite this, relatively few clinical trials using TNFα antagonists have been 
conducted. This is surprising given that several TNFα antagonists have been developed and 
are routinely used to treat conditions such as rheumatoid arthritis206 and psoriasis207.  
Observational studies using these antagonists have shown improved glycaemia and a 
concurrent protective effect against incident T2D206,207. However, their results need to be 
treated with caution as they were not randomised controlled trials. Trials of TNFα antagonists 
in patients with cardiometabolic diseases have enrolled small patient numbers and have often 
involved short treatment exposures208–210. Their results indicate that whilst lower TNFα-
mediated inflammation was observed, no significant improvements in glycaemia or insulin 
sensitivity were found208–210. This apparent lack of effect may be due to statistical power issues 
or short trial durations. The largest trial to-date enrolled 40 obese participants without diabetes, 
randomised to either placebo or 50mg doses of Etanercept™, a TNF receptor antagonist, for 
6 months211. Contrary to observational results, Etanercept™ treatment led to 10.8% lower 
fasting glucose levels and 22.1% higher adiponectin levels, when compared to placebo211. 
However, no significant differences in fasting insulin levels were observed211. These results 
lend support to continued investigation using larger sample sizes with sufficient trial duration 
to assess the efficacy of TNFα antagonism in patients with cardiometabolic diseases.  
 
To-date, no clinical trials of IFNγ antagonists in cardiometabolic diseases have been 
conducted. Comparatively, clinical trials for IL-6212 and IL-8213 antagonists have been initiated 
but only the IL-6 trial has been completed. Sarilumab™, an IL-6Rα antagonist previously 
trialled for use in rheumatoid arthritis214, was tested in combination with disease-modifying 
anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients with and without T2D212. A 
total of 179 T2D patients were compared to 1,803 non-T2D patients from 2 randomised, 
placebo-controlled studies214,215. A greater reduction in fasting glucose was observed in the 
Sarilumab™-treated T2D group after 24 weeks compared to the non-T2D group. Similarly, 
HbA1c levels were lower in both the Sarilumab™ treated groups but not in the placebo. This 
effect was largest in the T2D group at week 24 where HbA1c was 0.43% lower compared to 
baseline levels212. These results are encouraging and support future trials of Sarilumab™ in 
T2D patients without rheumatic disease and not in combination with other therapies. 
 
While relatively few trials have focussed on the cytokines of interest, considerably more effort 
has been invested in IL-1ß antagonism trials. IL-1 acts as a master cytokine, capable of 
inducing the expression of diverse cytokines216. There are 2 forms of IL-1, namely IL-1α and 
IL-1ß, the latter requires processing by the NLRP3 inflammasome for maturation to its active 
form217. IL-1ß signals through the type 1 IL-1 receptor (IL-1R1) to activate NF-κB, a central 
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transcription factor controlling IL-6, IL-8 and TNFα expression, among others217. Given IL-1ß’s 
role as an upstream controller of cytokines that have been implicated in cardiometabolic 
diseases, considerable research on IL-1ß antagonism has been conducted. In an initial trial, 
70 T2D patients were randomised to receive daily doses of Anakinra™, an IL-1R antagonist, 
or placebo for 13 weeks218. At 13 weeks, the Anakinra™ group had significantly lower HbA1c, 
IL-6 and CRP levels and displayed improved ß-cell secretory function, assessed using the 
ratio of proinsulin to insulin, compared to placebo218. Participants were then followed for a 
further 39-weeks following Anakinra™ discontinuation219. Improved insulin secretion 
persisted, as did lowered inflammation, suggesting that this may be a possible therapeutic for 
T2D219. This proof-of-concept study paved the way for the larger Canakinumab™ anti-
inflammatory thrombosis outcomes study (CANTOS) trial consisting of 10,061 patients with 
previous myocardial infarction and CRP levels of more than 2mg/L220. Three doses of 
Canakinumab™ were compared to placebo: 50mg, 150mg and 300mg, each administered 
every 3 months220. The pre-specified primary endpoints of the trial were non-fatal myocardial 
infarction, non-fatal stroke or cardiovascular death220. Reductions in CRP level from baseline 
were observed in all Canakinumab™ groups, with the greatest reduction of 41% in the 300mg 
group220. The 150mg group had a 15% lower hazard for the primary cardiovascular endpoints 
compared to placebo220. This effect was also observed in the 300mg group, which had a 14% 
lower hazard for the primary cardiovascular endpoints compared to placebo, whereas the 
50mg group showed a 7% lower hazard220. However, only the 150mg dose met the 
prespecified multiple testing threshold for both the primary and secondary end points220. A 
secondary pre-specified analysis evaluated the efficacy of Canakinumab™ on incident T2D 
risk among participants with pre-diabetes at baseline221. Additionally, the effects of 
Canakinumab™ on fasting glucose and HbA1c levels in patients with and without prevalent 
T2D were also assessed221. However, Canakinumab™ did not significantly reduce the risk of 
incident diabetes in participants without diabetes at recruitment or improve glycaemia in 
participants with prevalent diabetes221. In summary, IL-1ß antagonism substantially reduced 
circulating inflammatory markers and proved effective in lowering the risk of recurrent 
cardiovascular events, independent of lowering lipid levels220. However, did not reduce the 
risk of new-onset diabetes in participants without diabetes at recruitment, or improve 
glycaemia in participants with diabetes221.  
 
There are several considerations regarding the suitability of the CANTOS trial for the 
evaluation Canakinumab™ to reduce the risk of incident T2D in the general population. Firstly, 
participants with previous myocardial infarction and high CRP levels were recruited, limiting 
the generalisability of the results. The trial was not designed to estimate the effect of 
Canakinumab™ in patients with established T2D, therefore, the effects of Canakinumab™ on 
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glucose control may not be representative221. Secondly, the trial noted a violation of the 
proportional hazards assumption, observing a reduction in the risk of incident T2D in the early 
phases of the trial while later estimates showed an increased risk of incident T2D221. Similarly, 
HbA1c was reduced in the first 6-9 months of the trial but was attenuated over time so that the 
overall effect was non-significant. The authors suggest that this may have been because 
lifestyle interventions and alterations in other anti-diabetic therapies were allowed during the 
course of the trial, which may have affected glycaemic control221.  
 
Inflammatory signalling is complex and involves considerable pathway crosstalk between 
constituent proteins to be effective. Therefore, it is unclear whether antagonism of single 
pathways, or combinations thereof, will have the best therapeutic potential. In addition, inter-
personal differences in inflammatory pathway may impact therapeutic efficacy9. The concern 
with immune antagonism is the potential for immunosuppression. However, considering that 
immunomodulation therapy is established for autoimmune and rheumatic disease, this may 
represent a possible area for drug repurposing. Finally, possible immunosuppression or 
adverse effects of immunomodulation can be estimated with minimal confounding using 
genetic data. As genetic effects represent life-long exposures, the effects thereof can be re-
scaled to represent the effect over short treatment durations, mimicking the effects of a trial222. 
 
In summary, inflammation is thought to be a potential mediator of obesity-related risk and 
cardiometabolic diseases, with a role in insulin resistance being suggested9,109,112,123,223. 
Evidence from small observational studies90,154,155,168,175,181,185,186,188–190,224,225 and clinical 
trials218,219 has suggested that lowering inflammation may confer protective benefits on 
glycaemic control, however, results vary. In addition, recent evidence from the CANTOS 
trial221,226 has challenged the findings of a protective effect in T2D. In light of this, several 
questions remain to establish their relevance in cardiometabolic diseases: 
1. The genetic determinants for the majority of inflammatory proteins are unknown, 
GWAS studies of proinflammatory cytokine levels have only recently been conducted 
in modest sample sizes227. 
2. It is unclear whether inflammation is causal for cardiometabolic diseases or whether it 
is a consequence of cardiometabolic diseases or their related risk factors. 
3. It is unclear which inflammatory proteins and biological pathways may be involved in 




Overview of the genetic architecture of IFNγ, IL-6, IL-8 and TNFα levels in population-
based studies 
Introduction 
This systematic search surveys the current genetic epidemiology knowledge of published 
GWAS studies of the four cytokines of interest in population-based studies. 
 
Methods 
To assess the literature surrounding the association of genetic variants with levels of the pro-
inflammatory cytokines (IFNγ, IL-6, IL-8 or TNFα), I performed a systematic literature search 
using the PubMed (MEDLINE) and GWAS catalogue databases. My search strategy focused 
on previous GWAS studies that have investigated the association of levels of at least one of 
the four cytokines of interest in population-based cohorts. I searched the databases for all 
clinical trials, journal articles and meta-analyses published in English between June 2007 (the 
year the WTCCC GWAS228 was published, considered as the inception of large-scale GWAS 
analyses) and 21 April 2020 using human participants only. The search strategy used is 
detailed in Table S1.1 and led to the inclusion of 8 full text articles in the review after using 
the exclusion criteria detailed in Figure 1.7. Briefly, studies were screened for their eligibility 
and were removed if the study was not a GWAS or if cytokine levels were measured in 




Figure 1.7: Schematic of the systematic literature review detailing the exclusion criteria 
and the number of articles excluded at each stage.  
Abbreviations: IFNγ, interferon-γ; IL-6, interleukin-6; IL-8, interleukin-8; TNFα, tumour necrosis factor-α. 
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Results and Discussion 
Throughout the GWAS era many studies have demonstrated that the associations of common 
genetic variants with common disease often have relatively small effect sizes, providing further 
support for the polygenicity of common disease228,235. However, the converse is also true as 
lower frequency variants tend to have larger effects on the phenotype236. This applies to 
protein traits too, however, often a single variant may have a disproportionately large effect 
on protein levels. This is often a cis-acting variant in the gene encoding the protein or a trans-
acting variant in the receptor of the respective protein. 
 
The initial systematic search identified a total of 2,311 articles which were narrowed down to 
8 full text articles (Table 1.2) after applying the exclusion criteria. The results of these studies 
identified variants that are robustly associated with circulating levels of IL-6 and TNFα. Two 
studies reported associations with TNFα levels and six reported associations with IL-6 levels 
(Table 1.3). Comparatively, none of the included studies found any significant associations 
with either IL-8 or IFNγ levels. Two studies227,229 examined the association of genetic variants 
with levels of IL-8 or IFNγ, however, no significant associations were found, which may be 
attributable to a lack of statistical power. 







LD EA EAF Beta P-value 
N, 
Population 
IL-6 233 6:133397598 
RP11-
314E23.1 
- T 0.01 -0.52a 8.6x10-9 
707, African 
Americans 
IL-6 234 rs657152 ABO 
1 
T 0.27 0.22b 2.1x10-29 
4,694, 
Sardinians 
IL-6 232 rs643434 ABO A 0.26 0.22b 5.8x10-27 
6,921, 
Sardinians 
IL-6 234 rs4129267 IL6R 
0.99 
T 0.26 0.11b 2.4x10-8 
4,694, 
Sardinians 
IL-6 232 rs12133641 IL6R G 0.26 0.12b 6.9x10-9 
6,921, 
Sardinians 
IL-6 235 rs4129267 IL6R T 0.37 0.69c 1.2x10-57 
1,200, 
Europeans 
IL-6 231 rs4129267 IL6R T 0.38 1.2d 1.6x10-265 
1,000, 
Europeans 
IL-6 230 rs4129267 IL6R T 0.40 1.11d 7.4x10-1101 
3,301, 
Europeans 
TNFα 229 rs17074575 DLEU1 - G 0.002 2.13d 2.7x10-9 
13,577 
Europeans 
TNFα 235 rs505922 ABO 
0.16 
N/Ae N/Ae N/Ae 6.8x10-40 
1,200, 
Europeans 
TNFα 235 rs8176746 ABO N/Ae N/Ae N/Ae 2.0x10-14 
1,200, 
Europeans 
Abbreviations: IL-6, Interleukin-6; TNFα, Tumour necrosis factor-α; SD, standard deviation; LD, Linkage 
disequilibrium; EA, Effect allele; EAF, Effect allele frequency; N, Number of participants.  
a. SD units of log10 transformed cytokine 
b. SD units of quantile-transformed cytokine 
c. SD units of ln-transformed cytokine 
d. SD units of inverse-normal transformed cytokine 
e. Estimates were not reported in the main text or supplementary information  
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Three loci have been found to be associated with IL-6 levels in population-based cohorts. 
Using a Sardinian founder population of 4,694 participants, rs657152 at the ABO locus was 
associated with lower IL-6 levels per G-allele234. This finding was later replicated in the same 
population using an additional 1,392 participants234 and by an independent, larger study using 
6,921 participants 2,120 of whom were whole genome sequenced232. An association signal 
for the T-allele of a non-coding variant outside of the HLA gene-region (chr6:133397598) at 
RP11-314E23.1 with IL-6 levels was found233. This was shown to lower IL-6 levels by 0.52 
standard deviation units of log10-transformed IL-6233. However, the sample size of 707 non-
diabetic African American participants is small thus replication of this result in a larger sample 
size is required. Several studies have identified association signals of genetic variants at the 
IL6R locus with higher IL-6 levels230–232,234,235. Two studies230,231 used the aptamer-based 
SOMAscan assay to quantify cytokine levels. Protein quantification is normalised to an internal 
standard, thus cytokine levels are relative abundances and poorly correlated with gold 
standard ELISA-based methods. However, studies using these assays do identify and 
replicate relevant hits. All variants found to be associated with IL-6 levels are in high LD (R2 > 
0.99) with a functional missense variant, rs2228145, in IL6R which mimics IL6R antagonism. 
Large-scale meta-analyses have shown that rs2228145 leads to 34.3% higher s-IL6R levels 
and 14.6% higher IL-6 levels160. The associated variants at the IL6R locus have also been 
found to be cis-acting eQTLs and pQTLs for IL-6 levels in large cohorts230,231,235. 
 
The largest available meta-analysis to-date of TNFα levels consisted of up to 13,577 
Europeans229. This study showed that a low frequency intergenic variant, rs17074575, nearby 
the deleted in lymphocytic leukaemia 1 (DLEU1) gene was associated with 2 SD higher TNFα 
levels229. Despite this considerably large effect, not much is known about how this region leads 
to higher TNFα levels. In addition to this, two independent trans-association signals, rs505922 
and rs8176746, in the pleiotropic ABO locus encoding the Histo-blood group ABO system 
transferase were found to be associated with TNFα levels in 1,200 European participants235. 
 
These results highlight the abundance of studies investigating the genetic determinants of IL-
6 and TNFα levels compared to the very few studies investigating IL-8 and IFNγ. Overall very 
few loci associated with cytokine levels were identified, this highlights an opportunity for larger, 
more powered studies to expand on the current knowledge. These results highlight the effects 
of established pleiotropic loci such as ABO on cytokine levels as well as the lack of specificity 
for the majority of results, aside from the association of IL6R with IL-6 levels. Critically, the 
lack of association between variants and levels of IL-8 and IFNγ highlights a gap in our 
knowledge that requires further investigation in large studies.  
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Chapter 2: Observational Analyses of Cytokine Levels with 
Cardiometabolic Diseases 
Contributions and collaborations 
Measurement of the cytokines and other blood-based biomarkers were performed by the 
laboratory team at the MRC Epidemiology Unit under the supervision of Deborah Lucarelli and 
Vasileios Kaimakis. Anthropometric and regional adiposity measurements were performed by 
members of the Fenland and EPIC-Norfolk study teams under the supervision of Emmanuela 
De Lucia Rolfe. The data related to these measures were collated and maintained by the data 
management team at the MRC Epidemiology Unit under the supervision of Adam Dickinson. 
Stephen J. Sharp provided statistical support for the setup of the Cox regression analyses. I 
designed the study, analysed the data and wrote the first draft of the report which was later 




Background: Previous studies have helped to establish the observational associations of IL-
6 and TNFα levels with cardiometabolic diseases and related risk factors, however, there is a 
significant gap in the knowledge surrounding the association of IFNγ and IL-8 levels with 
cardiometabolic traits.  
 
Aims: This chapter aims to characterise the observational associations between the levels of 
four cytokines IFNγ, IL-6, IL-8 and TNFα, and cardiometabolic traits measured in two large 
prospective population-based studies, EPIC-Norfolk and Fenland.  
 
Methods: Observational associations between levels of each cytokine and anthropometric, 
glycemic, lipid and regional adiposity traits from DEXA were estimated using multivariable 
linear regression adjusting for age and sex in up to 10,335 participants from the Fenland 
cohort. Next, the association between levels of each respective cytokine and incident T2D and 
CHD were estimated using multivariable cox regression adjusting for disease-specific 
covariates in up to 7,514 participants from the EPIC-Norfolk cohort. 
 
Findings: Levels of IFNγ, IL-6 and TNFα showed similar patterns of association with all 
measures of regional and overall adiposity, insulin and most lipid measures in the Fenland 
cohort, consistent with an adverse metabolic profile. However, adjustment for BMI attenuated 
the association estimates for the majority of traits, except for associations with lower HDL, 
higher triglycerides, waist-to-hip ratio (WHR) and fasting insulin levels. Comparatively, IL-8 
levels were associated with only two outcomes, namely higher WHR and HbA1c, which 
remained associated after BMI adjustment. In EPIC-Norfolk, only IL-6 and TNFα levels were 
significantly associated with incident T2D after extensive adjustment for cardiometabolic risk 
factors (HR per SD higher cytokine levels of 1.19; 95% CI: 1.07, 1.32; P = 0.002 and 1.16; 
95% CI: 1.04, 1.30; P = 0.008, respectively). The same was true for incident CHD (HR per SD 
higher cytokine levels of 1.16; 95% CI: 1.09, 1.24; P = 3x10-6 and 1.16; 95% CI: 1.09, 1.24; P 
= 4x10-6, respectively). 
 
Conclusion: This study demonstrates that IL-6 and TNFα levels are observationally 
associated with incident T2D and CHD and a wide variety of cardiometabolic risk factors but 
that associations with cardiometabolic traits are likely to be mediated by higher BMI. The 
evidence supporting the involvement of IFNγ and particularly IL-8 levels in cardiometabolic 




Obesity is hypothesised to be a major driver of chronic inflammation in cardiometabolic 
diseases, with obesity-mediated insulin resistance also thought to play a role94,111–
113,118,119,123,125,126,138. Due to their integral role in innate immunity, cytokine levels are subject to 
complex regulatory networks and feedback loops237. In addition, regulatory networks 
governing the levels of multiple cytokines often overlap and interdependent237.  
 
The observational association of cytokine levels with cardiometabolic diseases and related 
risk factors has been investigated in previous studies, often with inconsistent results (reviewed 
in Chapter 1). As outlined in Chapter 1, the levels of four pro-inflammatory cytokines are of 
interest to this study, namely IFNγ, IL-6, IL-8 and TNFα. Much of the previous work in this area 
has been conducted using comparatively small sample sizes155,174,175,183,186,225,238–240. While 
previous observational studies have examined the associations of IL-6 and TNFα levels with 
cardiometabolic traits90,155,168,175,181,183,185–187,189,190,238,239, there is a significant gap in the 
knowledge surrounding the relevance of IFNγ and IL-8 levels in cardiometabolic diseases. 
 
In this study, I sought to investigate the observational association of IFNγ, IL-6, IL-8 and TNFα 
levels with cardiometabolic diseases and related risk factors using two large population-based 
cohorts, Fenland and EPIC-Norfolk. 
2.2: Methods 
Study participants 
EPIC-Norfolk241, a constituent cohort of the European Prospective Investigation of Cancer 
(EPIC)242 study, is a prospective cohort of over 20,000 individuals aged between 40-79 years, 
living in Norfolk (a County of the UK) at time of baseline recruitment (1993-1997). Participants 
were recruited from general practice surgeries in the city of Norwich and surrounding areas241. 
A total of 77,630 participants were invited to take part in the study, 25,639 of whom attended 
a baseline visit243. Participants attended a baseline visit upon recruitment, during which 
standard anthropometric and dual energy X-ray absorptiometry (DEXA) measurements were 
taken, environmental and lifestyle factors were assessed, and blood sampling was done. 
Three follow-up consultations for monitoring and further sample collection were done: three, 
thirteen and twenty years after baseline assessment. A total of 15,786 participants attended 
the second follow-up visit243. Participants who attended a visit between 1998 and 2000 and 
had blood samples available for cytokine measurement were included. The date of cytokine 
measurement is taken as baseline for the purposes of this study. The study was approved by 
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the Norfolk Research Ethics Committee (ref. 05/Q0101/191) and all participants gave their 
written consent before entering the study. 
 
The Fenland study244 is a population-based study of 12,435 individuals without diabetes who 
were born between the years of 1950 and 1975 and recruited through general practice 
surgeries in Cambridge, Ely and Wisbech (in the Cambridgeshire County in the UK). An initial 
baseline visit in 2005-2015 for the purposes of metabolic phenotyping including DEXA 
measurements and DNA collection was done. Follow-up visits commenced in 2015 and are 
ongoing. Participants who attended the baseline visit and had available blood samples for 
cytokine measurement were included in this study. Ethical approval for the study was given 
by the Cambridge Local Ethics committee (ref. 04/Q0108/19) and all participants gave their 
written consent prior to entering the study. 
 
Cytokine measurement and phenotype generation  
Cytokine levels were measured in serum samples from fasted participants in Fenland244 and 
participants fasted ad libitum in EPIC-Norfolk241 using the Meso Scale Discovery® Human 
Pro-inflammatory Panel 1 multiplex kit (Rockville, MD, USA). Four pro-inflammatory cytokines 
(IFNγ, IL-6, IL-8 and TNFα) were measured using a 4-plex sandwich immunoassay.  Assays 
were provided in 96-well plates where each well was coated with cytokine-specific capture 
antibodies. Upon the addition of sample and buffer to the well, cytokines were conjugated to 
the capture antibodies on the well surface. Detection antibodies were added to the reaction 
binding to the analyte of interest which have coupled electrochemiluminescent labels (MSD 
SULFO-TAG™). Applying voltage to the plate electrodes caused the labels to emit light, the 
intensity of which provided a quantitative measure of the cytokine level as measured by the 
MSD Sector Imager 6000 instrument. To ensure result consistency, standards of known 
concentration were included on each plate along with 3 intra-plate duplicates of the samples 
to be measured. A pooled sample of serum from the study population was included on each 
plate as was a sample of stock, normal human serum (Millipore (UK) Ltd., UK). 
 
Quality control criteria were applied on a plate by plate basis to ensure measurement 
consistency. The following criteria were applied: the calculated concentration of standards, 
pooled and QC samples should fall within ±20% of the mean. Light intensity signals of the 
standards were checked for consistency with what was expected with coefficient of variation 
(CV) metrics of less than 20%. Calculated concentration CV of standards, QC and samples of 
interest should be less than 20%. Distribution parameters of plates should be within 30% of 
the overall value for at least two of the 25th, 50th and 75th percentiles. Plates that failed any of 
these criteria were not included in the final data. A standard curve was fitted using the 
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standards of known concentration with detection limits at 2.5 SD from the blank standard and 
0 SD from the highest standard as bounds.  
 
Any missing data points where measurement was not attempted or failed because of technical 
failure were set to missing. In cases where measurements were below the assay detection 
limit, data points were interpolated to random values between 0 and the lower limit of 
detection. Following this, two transformations were created: log transformed and inverse-rank 
normal transformed after the log-transformation. 
 
Anthropometric measurement and quantification of blood biochemical markers 
Fasting glucose, fasting insulin and HbA1c in Fenland244 were the values of circulating glucose 
(in mmol/L), insulin (log-transformed and expressed in log-pmol/L) and glycated haemoglobin 
(in %) measured in whole blood after overnight fasting. Two-hour glucose was the value of 
glucose (in mmol/L) measured in plasma two-hours after a 75-gram oral glucose challenge. 
Glucose was measured using the Dimension RxL Integrated Chemistry System (Siemens, 
Germany). In Fenland244 total cholesterol, high-density lipoprotein (HDL) cholesterol and 
triglyceride concentrations (in mmol/L) were measured using enzymatic assays (Siemens 
Healthcare). Low-density lipoprotein (LDL) cholesterol values were calculated using the 
Friedewald formula245. Weight was measured to the nearest 200 grams using a calibrated 
electronic scale (TANITA model BC-418 MA; Tanita, Tokyo, Japan). Height was measured to 
the nearest 0.1 cm with a wall-mounted stadiometer (SECA 240; Seca, Birmingham, United 
Kingdom). BMI (in kg/m2) was calculated as weight divided by height squared. Waist and hip 
circumferences were measured to the nearest 0.1 cm with a non-stretchable fibre-glass 
insertion tape (D loop tape; Chasmors Ltd, London, United Kingdom). Waist-to-hip ratio (WHR) 
was the ratio between the waist and hip circumferences. Average physical activity per week 
(in kJ/kg/day) was measured over seven days using a calibrated heart rate and movement 
sensor (Actiheart, CamNtech, Cambridge, UK). Measures for any participant that did not wear 
the sensor for more than 48 hours within the seven-day period were removed from the 
analysis.  
 
Overall and regional body fat mass in Fenland was quantified by dual-energy X-ray 
absorptiometry (DEXA) using a Lunar Prodigy advanced fan beam scanner (GE Healthcare, 
Bedford, UK), encore v14.10.022 and CoreScan® software (GE Healthcare, Bedford UK) a 
whole-body, low-intensity X-ray scan that precisely quantifies fat mass in different body 
regions. All body images were manually processed, and demarcations corrected following a 
standardized protocol. The trunk included neck, chest, abdominal and pelvic areas. The legs 
were defined as the region below the lower borders of the trunk. The abdomen was defined 
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as the portion of the trunk between ribs and pelvis, defined by the outline of the iliac crest. The 
gluteofemoral region included hips and upper thighs. Visceral abdominal fat mass was 
estimated using subcutaneous fat width and the anteroposterior thickness of the abdominal 
wall. These measurements were used to extrapolate abdominal subcutaneous fat mass. 
Visceral abdominal fat mass was calculated by subtracting the subcutaneous abdominal fat 
mass from the total abdominal fat mass. 
 
In EPIC-Norfolk241 total cholesterol and high-density lipoprotein (HDL) cholesterol 
concentrations (in mmol/L) were measured with the RA 1000 Tecnicon analyser (Bayer 
Diagnostics, Basingstoke, UK)246. Low-density lipoprotein (LDL) cholesterol values were 
calculated using the Friedewald formula246. 
 
Correlations between cytokine levels and cardiometabolic risk factors 
Pearson’s correlations were estimated between levels of the four cytokines (transformed as 
described above) and anthropometric, glycemic, lipid and regional adiposity traits from DEXA. 
Inverse-rank normal transformations were used for all variables to facilitate comparison across 
the four cytokines, to mitigate the effect of outliers and to minimise the effect of skewed 
variables.  
 
Associations between cytokine levels and cardiometabolic risk factors 
The associations between circulating levels of the four cytokines with various cardiometabolic 
risk-factors were estimated in the Fenland cohort244. Any participants with missing DEXA 
measures were excluded and participants where measurements for visceral fat mass were 
unable to be interpreted by the iDEXA software247 were interpolated between 0 and 1 gram. 
The following overall adiposity and DEXA traits were considered: WHR, BMI, body fat 
percentage, android fat mass, gynoid fat mass, leg fat mass, android to gynoid fat mass ratio, 
appendicular lean mass, peripheral fat mass, visceral adipose tissue and subcutaneous 
adipose tissue. The following glycaemic traits were considered: fasting glucose, 2-hour 
glucose and HbA1c and fasting insulin. The following fasted lipid measures were considered: 
high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and total triglycerides. 
Finally, a measure of physical activity energy expenditure in kJ/kg/day was used. An inverse-
rank normal transformation was then applied to the outcome variables to enable comparison 
across the four cytokines, to mitigate the effect of outliers and to minimise the effect of skewed 
variables. Insulin measures were log-transformed prior to inverse-rank normal transformation. 
The associations between adiposity, glycaemic, lipid and physical activity traits (outcomes) 
and cytokine levels (exposure; transformed as described above) were estimated per standard 
deviation (SD) higher cytokine levels using multivariable linear regression adjusted for age 
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and sex. Separate analyses adjusting for age, sex and BMI as well as a model additionally 
adjusting for fasting insulin levels were performed. A significance threshold of P<0.003 was 
used, accounting for 17 tests. All analyses were performed using STATA v14 (StataCorp, 
Texas, USA).  
 
 
Associations between cytokine levels and risk of incident CHD and T2D  
The association between inverse-rank normal transformed cytokine levels (exposure) and 
incident T2D or CHD (outcomes) was estimated using multivariable Cox regression models in 
the EPIC-Norfolk241 cohort. Inverse-rank normal transformed cytokine levels were used to 
facilitate comparison of effect sizes across the four cytokines regarding incident disease risk. 
Cytokine measurements were performed on blood samples collected at health check 2 in 
EPIC-Norfolk and therefore this serves as the study “baseline” for the purpose of this analysis.  
 
Incident T2D was defined as new-onset T2D in a participant without evidence of diabetes at 
health check 2 (when IL-6 levels were measured), defined on the basis of (a) a hospital 
admission record or mortality registry record of “type 2 diabetes mellitus” (International 
Statistical Classification of Diseases and Related Health Problems Tenth Revision [ICD-10] 
code E11); or (b) self-reported physician diagnosis of T2D during a follow-up visit; or (c) a 
value of HbA1c above 6.5% (48 mmol/mol) at a follow-up visit. Participants with T2D at the 
time of cytokine measurement were excluded. Incident CHD was defined as new-onset CHD 
in a participant without CHD at baseline based on an electronic health record consistent with 
ischemic heart disease (ICD-10 codes I20-25). The date of end of follow-up for these analyses 
was 31st of March 2016. Censoring criteria were either an incident disease event (disease 
cases) or the end of follow-up time (non-cases). Participants with confirmed prevalent disease 
at baseline or unavailable prevalent disease status were removed from these analyses.  
 
Associations with incident disease were estimated per 1 SD higher cytokine levels. Covariates 
included in a minimally adjusted model were age at baseline and sex. Extensively adjusted 
models for CHD included the following covariates: age at baseline, sex, BMI, WHR, education 
level, smoking status, average physical activity per week, systolic blood pressure, prevalent 
T2D, total cholesterol. Extensively adjusted models for T2D included the following covariates: 
age at baseline, sex, BMI, WHR, ethnicity, education level, family history of T2D, smoking 
status, units of alcohol per week, average physical activity per week. A significance threshold 
of P < 0.0125 was used, accounting for the four cytokines tested. Deciles of each cytokine 
were defined based on distribution of each cytokine in the non-case group. This was done to 
prevent skewing of the deciles by participants with incident disease, which were likely to have 
 
39 
higher cytokine levels. However, sensitivity analyses showed that the cut-offs between deciles 
were unaltered when considering the entire population. The association between deciles of 
each cytokine and incident disease were estimated as above, per 1 SD higher cytokine levels, 
relative to the lowest decile. The likelihood ratio test was used to test for departure from 
linearity when comparing treatments of the cytokine distribution as either a continuous or 
categorical measure. No departure from linearity was observed, therefore cytokine levels were 
treated as a continuous measure. 
 
A number of sensitivity analyses were conducted to contextualise the associations between 
cytokine levels and incident disease. Firstly, an established definition for incident T2D248 was 
used to validate the findings of the definition used above. This definition was based on a 
combination of primary and secondary care registers, self-report, medication use, hospital 
admissions, and mortality data248. The analysis was performed as described above, using a 
censor date of the 31st December 2007. Secondly, to estimate the effect of adjusting for 
correlated measures of overall (BMI) as well as regional (WHR) adiposity, a model adjusting 
for all covariates mentioned above was run without including either BMI or WHR. Subsequent 
models added BMI or WHR separately to the covariates to estimate their independent effects. 
Thirdly, to estimate the attenuation effect of adjusting for IL-6 and TNFα levels in the 
association of BMI, WHR or WHR adjusted for BMI (WHRadjBMI) with incident disease, a 
model adjusting for all covariates included in the main analysis was used without adjustment 
for BMI, WHR or WHRadjBMI. In subsequent models IL-6 and TNFα were then added 
iteratively to models to determine their attenuation effects. Lastly, to assess whether IL-6 and 
TNFα levels interact with either BMI or WHR in the association with incident disease, separate 
models adjusting for all covariates as in the main analysis were run within tertiles of the BMI 
and WHR distribution respectively, while including linear interaction terms for BMI and WHR. 




Study participants’ characteristics 
Characteristics of the participants included in the analyses are shown in Table 2.1. Compared 
to participants who attended the baseline health check in EPIC-Norfolk241, participants in this 
study were more likely to be older and female with a reduced likelihood of being a current 
smoker. Cytokine levels were measured at baseline in the Fenland study, therefore, participant 
characteristics were highly comparable to the wider study population249.  
Table 2.1: Participant characteristics for the Fenland and EPIC-Norfolk studies 
Study Fenland EPIC-Norfolk 
Participants, N 10,335 7,514 
Age at baseline, mean years (SD) 48 (7) 62 (9) 
Women, N (%) 5,491 (53) 4,598 (61) 
Men, N (%) 4,844 (47) 2,916 (39) 
Current smokers, N (%) 1,271 (12) 581 (8) 
BMI in kg/m2, mean (SD) 26.8 (4.9) 26.4 (3.8) 
Waist-to-hip ratio, mean (SD) 0.88 (0.09) 0.84 (0.09) 
Systolic blood pressure in mmHg, mean (SD) 123 (15) 134 (18) 
Diastolic blood pressure in mmHg, mean (SD) 74 (10) 81 (11) 
LDL cholesterol in mmol/L, mean (SD) 3.4 (0.9) 3.8 (1) 
HDL cholesterol in mmol/L, mean (SD) 1.5 (0.4) 1.5 (0.5) 
Triglycerides in mmol/L, median (IQR) 1 (0.7, 1.4) 1.6 (1.1, 2.2) 
IFNγ in pg/mL, median (IQR)a 2.83 (2.02, 4.26) 3.37 (2.35, 5.10) 
IL-6 in pg/mL, median (IQR) a 0.51 (0.34, 0.75) 0.59 (0.42, 0.85) 
IL-8 in pg/mL, median (IQR)b 9.69 (7.7, 12.19) 6.7 (5.09, 9.19) 
TNFα in pg/mL, median (IQR) a 1.56 (1.3, 1.88) 1.84 (1.53, 2.21) 
IFNγ in log-pg/mL, mean (SD) a 1.13 (0.77) 1.28 (0.74) 
IL-6 in log-pg/mL, mean (SD) a -0.77 (0.94) -0.55 (0.83) 
IL-8 in log-pg/mL, mean (SD)b 2.28 (0.39) 1.98 (0.61) 
TNFα in log-pg/mL, mean (SD) a 0.44 (0.32) 0.61 (0.33) 
Abbreviations: N/A, not available; N, number of participants; SD, standard deviation; BMI, body mass index; IFNγ, 
Interferon-gamma; IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor alpha; IQR, Interquartile 
range 
a. Participant numbers were the same for IFNγ, IL-6 and TNFα as they were measured from the start of the 
study 
b. IL-8 levels were measured in a subset of participants 
 
Cytokine measurement using the MSD platform 
Pro-inflammatory cytokine levels were measured in 10,335 people from the Fenland study and 
7,514 people from the EPIC-Norfolk study (Table 2.2). The distribution parameters and assay 
performance metric including the limits of detection and CVs for the MSD assay are shown in 
Table 2.2. Mean intra-plate CVs ranged from 3 to 7% in EPIC-Norfolk and from 4 to 8% for 
Fenland. Detection limits for the respective cytokines were largely comparable between 
Fenland and EPIC-Norfolk. Median levels of the four cytokines showed very little variability 
between the Fenland and EPIC-Norfolk studies (Table 2.1). 
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Cytokine IFNγ IL-6 IL-8 TNFα 
Total samples 9,966 7,292 10,335 7,420 10,335 7,514 10,068 7,447 
Samples in detection range (%) 97.64 99.00 78.68 89.78 87.87 99.92 99.83 99.92 
Samples below detection range (%) 1.71 0.89 18.55 9.99 0.02 0.04 0.06 0.05 
Samples below assay fit curve (%) 0.07 0.11 1.67 0.23 0 0.04 0.01 0.03 
Samples failed due to technical error (%)a 0.58 0 1.09 0 0.01 0 0.10 0 
Missing samples (%)b 0 0 0 0 12.10c 0 0 0 
Mean LLOD (pg/mL) 0.79 0.78 0.31 0.30 0.17 0.18 0.16 0.16 
Mean ULOD (pg/mL) 2,801.68 2,994.14 1,312.22 1,300.92 1,141.90 1,148.13 652.34 653.62 
Mean Intra-plate CV (%) 7 7 8 7 4 3 6 5 
Abbreviations: IFNγ, Interferon-gamma; IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor alpha; LLOD, Lower limit of detection; ULOD, Upper limit of detection; 
pg/mL, picograms per millilitre; CV, Cross-validation; %, percentage 
a. Samples which failed due to poor duplicate (intra-plate duplicates >20% difference in measures) or technical error 
b. Samples for which no measurement was available – not due to technical error 




Correlations and observational association between cytokine levels and 
cardiometabolic risk factors 
Correlation estimates showed that IL-6 and TNFα were strongly correlated with the majority 
of cardiometabolic risk factors whereas IFNγ and IL-8 were correlated with these to a lesser 
extent (Figure 2.1). HbA1c was estimated to be the trait with the strongest correlation with IL-
8 levels.  
 
Figure 2.1: Heatmap of the correlations between the four cytokines and cardiometabolic 
risk factors. All traits are unadjusted for BMI and clustered by correlation estimate similarity 
using hierarchical clustering. Abbreviations: BMI, Body mass index; WHR, Waist-to-hip ratio; HbA1c, 
Glycated haemoglobin; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; IFNγ, Interferon gamma, IL-6, 






































The association between cardiometabolic traits and cytokine levels were estimated in 10,335 
participants from the Fenland study (Figure 2.2). The association between cytokine levels and 
cardiometabolic traits was broadly consistent with the correlations presented above, in terms 
of estimate direction. Of the traits significantly associated with cytokine levels, only HDL and 
physical activity were shown to be significantly lowered by higher cytokine levels, all others 
were raised. Levels of IFNγ, IL-6 and TNFα showed broadly consistent directions of 
association with all measures of regional and overall adiposity, insulin and some lipid 
measures. However, the estimated strength of association with each trait was weaker for IFNγ 
levels compared to IL-6 and TNFα. 
 
In line with the hypothesis that inflammation in cardiometabolic diseases is likely to be driven 
by obesity, BMI adjustment led to the attenuation of the majority of association estimates. This 
effect was particularly evident for measures of regional adiposity. Levels of all four cytokines 
remained associated with WHR after BMI adjustment, despite a considerable attenuation in 
effect size. IFNγ, IL-6 and TNFα levels remained associated with body fat percentage and 
android fat mass, whereas only IL-6 and TNFα were associated with visceral fat mass. Only 
TNFα levels were associated with subcutaneous fat mass after BMI adjustment.  
 
Levels of IFNγ, IL-6 and TNFα also remained associated with lower HDL but higher WHR, 
fasting insulin and triglycerides following BMI adjustment, an effect consistent with an insulin 
resistance phenotype. Although adjusting the association between IFNγ, IL-6 and TNFα and 
these traits for both BMI and fasting insulin levels led to a minor attenuation in effect estimate 
strength, all associations remained significant (Figure S2.1). Compared to the other three 
cytokines, IL-8 levels were significantly associated with comparatively fewer traits overall. IL-
8 levels were associated with significantly higher WHR, body fat percentage, android fat mass, 





Figure 2.2: Associations of the four cytokines with cardiometabolic risk factors per 1 
SD higher cytokine levels. Risk factors are grouped into anthropometric, DEXA, glycaemic, 
lipid and physical activity categories. Traits adjusted for BMI are marked as such in the trait 
name. Traits that are significantly associated (P<0.003) with a respective cytokine are 
coloured in red, non-significant results are in black. Effect estimates are expressed per 1 SD 
higher cytokine levels.   
Abbreviations: BMI, Body mass index; adj., Adjusted for; WHR, Waist-to-hip ratio; mmol/L, millimoles per Litre; 
HbA1c, Glycated haemoglobin; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; g, Grams; Avg., 
Average; kJ, Kilojoules; Kg, Kilograms; IFNγ, Interferon gamma, IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, 
Tumour necrosis factor alpha. 
 
Associations of cytokine levels with incident cardiometabolic diseases 
In EPIC-Norfolk, the incidence rates of T2D and CHD were 3.3 cases per 1000 person-years 
and 11.6 cases per 1000 person-years respectively. IL-6 and TNFα levels were significantly 
associated with higher hazard of incident T2D with hazard ratios (HR) per SD higher cytokine 
levels of 1.19 (95% CI: 1.07, 1.32; P = 0.002) and 1.16 (95% CI: 1.04, 1.30; P = 0.008) 
respectively (Figure 2.3). IL-6 and TNFα levels were also significantly associated with higher 
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hazard of incident CHD (HR = 1.16; 95% CI: 1.09, 1.24; P = 3x10-6) and (HR = 1.16; 95% CI: 
1.09, 1.24; P = 4x10-6) respectively (Figure 2.3). The magnitude of the association between 
levels of these two cytokines and each cardiometabolic disease were highly comparable and 
directionally consistent. No significant associations between either IFNγ or IL-8 and either 
disease were found. Associations with log-transformed cytokine levels and incident 
cardiometabolic diseases are shown in Figure S2.2. Associations between the deciles of each 
cytokine and incident T2D and CHD are shown in Figures S2.3 and S2.4, respectively. No 
significant departures from linearity were observed for any of the four cytokines.  
Figure 2.3: Association of inverse-rank normal transformed cytokine levels with 
incident cardiometabolic diseases in EPIC-Norfolk. Results for T2D and CHD adjusted for 
age and sex only are shown in light blue and light orange respectively. Extensively adjusted 
results for T2D and CHD are shown in blue and orange respectively. T2D specific covariates: 
age, sex, BMI, WHR, ethnicity, education level, family history of diabetes, smoking status, 
units of alcohol per week and physical activity. CHD specific covariates: age, sex, BMI, 
WHR, education level, smoking status, physical activity, systolic blood pressure, prevalent 
diabetes and total cholesterol.  
Abbreviations: HR, Hazard ratio; SD, Standard deviation; BMI, Body mass index; WHR, Waist-to-hip ratio; T2D, 
Type 2 diabetes; CHD, Coronary heart disease; IFNγ, Interferon gamma, IL-6, Interleukin-6; IL-8, Interleukin-8; 
TNFα, Tumour necrosis factor alpha. 
 
Sensitivity analyses to validate the definition of incident T2D replicated the significant 
associations of IL-6 and TNFα levels with incident T2D as well as the non-significant 
association between IFNγ and incident T2D (Figure S2.5). While fewer incident cases were 
included in the analysis using this definition, the effect directions were consistent, and the 
strengths of the effect estimates were marginally stronger. In addition, a significant association 
between IL-8 levels and T2D was found (HR, 1.23; 95% CI, 1.09, 1.39; P=0.001). Sensitivity 
analyses estimating the effect of adjusting for BMI and WHR showed considerable attenuation 
of association effect estimates for each cytokine with incident disease when compared to 






IFNγ T2D 404 6,889
1.03 (0.93, 1.14) 0.54
0.99 (0.89, 1.10) 0.82
IL-6 T2D 411 7,010
1.40 (1.27, 1.54) 2x10-11
1.19 (1.07, 1.32) 0.002
IL-8 T2D 414 7,100
1.08 (0.98, 1.20) 0.11
1.06 (0.96, 1.17) 0.26
TNFα T2D 412 7,036
1.31 (1.18, 1.46) 6x10-7
1.16 (1.04, 1.30) 0.008
IFNγ CHD 1,220 6,048
1.05 (0.99, 1.11) 0.11
1.04 (0.98, 1.10) 0.22
IL-6 CHD 1,228 6,177
1.23 (1.16, 1.31) 5x10-12
1.16 (1.09, 1.24) 3x10-6
IL-8 CHD 1,246 6,252
1.09 (1.03, 1.16) 0.002
1.07 (1.01, 1.13) 0.02
TNFα CHD 1,231 6,201
1.21 (1.14, 1.29) 9x10-10
1.16 (1.09, 1.24) 4x10-6
1.8 1.2 1.4 1.6
HR(95% CI) for cardiometabolic disease 
per 1 SD higher cytokine levels
T2D: Age + sex adjusted
T2D: Extensively adjusted




models where BMI and WHR were not adjusted for, as expected (Figure S2.6). No association 
for IFNγ with either incident CHD or T2D was shown in unadjusted models. However, IL-8 was 
significantly associated with CHD in a model without either BMI or WHR adjustment. Similarly, 
adjustment for IL-6 and TNFα levels in the association of BMI, WHR and WHRadjBMI with 
incident CHD or T2D showed marginal attenuation of association estimates as a result of 
adjusting for cytokine levels (Figure S2.7). Association estimates for all three adiposity 
measures were smaller for CHD compared to those for T2D. All adiposity measures were 
significantly associated with incident CHD or T2D, except for WHRadjBMI with CHD (Figure 
S2.7). In addition, no significant interactions were found between cytokine levels and either 
BMI or WHR in the association of cytokine levels with incident cardiometabolic diseases 




This biomarker study supports the hypothesis that proinflammatory cytokine levels are 
associated with aetiology of cardiometabolic diseases. However, these results suggest that 
the impact of cytokine levels on disease risk in the general population is likely to be small and 
largely driven by higher BMI. This study is the first to investigate the associations between 
cytokine levels and measures of regional adiposity from DEXA scans and make use of them 
for extensive adjustment when estimating the association with incident cardiometabolic 
diseases. This study also represents an approximate 1.5 fold increase in sample size used to 
estimate these associations compared to previous studies155,174,175,183,186,225,238–240.  
 
IL-6 and TNFα levels were found to be significantly associated with incidence of both CHD 
and T2D, even with extensive adjustment for established cardiometabolic risk factors. The 
magnitude and direction of association for both cytokines with incident T2D was comparable 
to recent meta-analyses consisting of 4,480 incident cases and 19,709 non-cases from 10 
prospective studies of IL-6 levels186 and 2,780 incident cases and 10,078 non-cases from 5 
prospective studies of TNFα levels185. Similarly, associations of both cytokines with incident 
CHD were comparable to previous, smaller European studies189,190. This analysis showed that 
higher IFNγ levels were not significantly associated with either incident disease outcome, 
providing the first evidence that IFNγ levels are not associated with incident T2D. in addition, 
the results of this study replicate previous findings in a European cohort for incident CHD190 
consisting of 931 CHD cases and 971 controls.  
 
In comparison, in the main analysis IL-8 levels were not found to be associated with incidence 
of either CHD or T2D, results which are consistent with previous findings from smaller 
prospective studies175,183,187,188. However, results from a sensitivity analysis using an 
established definition of incident T2D248 showed an association between IL-8 levels and 
incident T2D. There are several explanations for this, 1) the main analysis used a definition 
that included HbA1c measures where participant HbA1c measures above 6.5% at a single 
timepoint would have led to the inclusion of these participants as incident cases, even if they 
were not strictly incident cases. This may therefore have contaminated the pool of participants 
used as incident cases, contributing to a higher incident case number while diluting any 
putative association of IL-8 levels with incident T2D. 2) The censor date in the main analysis 
was considerably longer than the sensitivity analysis, 31st March 2016 versus 31st December 
2007. Over the much longer interval, the effect of IL-8 levels on T2D incidence may have been 
less pronounced, which may also partly account for the reason why association estimates 
were stronger in the sensitivity analysis. Interpreting this within the context of findings from 
this study showing that IL-8 levels are associated with higher HbA1c levels, shows that HbA1c 
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levels may well mediate the effect of IL-8 on incident T2D risk. Together these results indicate 
that IFNγ levels are not associated with risk of incident cardiometabolic disease events, 
especially when compared to IL-6 and TNFα, despite being associated with several metabolic 
risk factors. The association between IL-8 levels and incident T2D will require validation in 
large, independent cohorts.    
 
Levels of IFNγ, IL-6 and TNFα were all found to be associated with higher overall and regional 
adiposity measures, fasting insulin levels, triglycerides and lower HDL levels. These 
associations with measures of regional adiposity reflect previous findings which demonstrate 
higher circulating cytokine levels in the plasma of obese human participants, as discussed in 
Chapter 1250–254. In line with previous findings, this study found associations between IFNγ, 
IL-6 and TNFα with fasting insulin. This is thought to be a result of compensatory increases in 
insulin production in the early stages of obesity-related insulin resistance111,174,181,255,256. Higher 
IFNγ, IL-6 and TNFα levels were associated with lower HDL cholesterol levels, even after 
adjusting for BMI, as has been previously shown190,257,258. Lower HDL and higher LDL levels 
are associated with increased CHD risk259–262. The anti-inflammatory capacity of HDL is 
thought to protect against CHD and T2D by controlling cytokine production through cholesterol 
efflux from macrophage foam cells and the concurrent inhibition of LDL oxidation259,263. 
Alternatively, this association may be secondary to the association with insulin resistance, of 
which lower HDL but higher triglycerides, WHR and fasting insulin levels are biomarkers259. 
However, adjusting the association between cytokine levels and these traits for both fasting 
insulin and BMI led to a marginal attenuation in effect estimates while remaining significantly 
associated. Future work using genetics to estimate the association between cytokine levels 
and these traits, as genetic estimates are robust to residual confounding61, will help to estimate 
whether obesity-mediated insulin resistance may be a potential driver of cytokine levels in 
cardiometabolic diseases. Similar association patterns were observed for IL-6 and TNFα in 
terms of estimated strength and direction for all associations except for LDL cholesterol and 
physical activity where no significant associations with TNFα were found.  
 
While IFNγ levels showed similar patterns of association to IL-6 and TNFα regarding measures 
of overall and regional adiposity, comparatively fewer associations with glycaemic traits were 
found. This is mirrored by the comparatively fewer traits found to be associated with IL-8 
levels. In fact, IL-8 levels were only found to be associated with higher WHR and HbA1c levels, 
which are in line with previous reports224,264,265. The association between IL-8 levels and higher 
HbA1c may be mediated via pathways independent of BMI, as BMI adjustment did not 
attenuate the association estimate. This may indicate that while IFNγ and IL-8 levels are raised 




The results of this study therefore suggest that many of the observed associations between 
cardiometabolic traits and cytokine levels, particularly IFNγ, IL-6 and TNFα, are likely to be 
mediated by higher BMI, in line with established findings168,174,189,224,266,267. This is evidenced 
by the attenuation of many significant associations with cardiometabolic traits when BMI was 
accounted for. Comparatively, the effects of IL-8 levels on cardiometabolic traits may be 
independent of BMI. 
 
There are limitations to this study. Firstly, in EPIC-Norfolk cytokine levels were measured at 
health check 2 and not at baseline. As only a subset of participants that attended the baseline 
assessment returned for the second heath check, this will have led to a marginal skewing of 
the baseline population characteristics. As a result, participants who returned for the second 
health check were older and more likely to be female than at baseline, therefore, it is possible 
that the estimates obtained in this study may be affected by selection bias. Secondly, the 
associations between cytokine levels and risk factors for cardiometabolic diseases were 
exploratory in nature and were therefore only adjusted for age, sex and BMI. This therefore 
does not rule out the possibility of residual confounding. Thirdly, as this work is observational 
in nature, definitive assessment of causality between cytokine levels and cardiometabolic 
diseases is not possible in this context. Finally, IL-8 levels had considerably higher 
missingness levels as IL-1β levels were measured initially. This may have led to decreased 
power for some of the analyses, particularly the Cox regression estimating the association of 
IL-8 levels with incident CHD, where IL-8 levels were close to the significance threshold. 
 
Future work could involve testing interactions between cytokine pairs on their respective 
associations with cardiometabolic risk factors, for example, testing the interaction between IL-
8 and IL-6 levels in their association with HbA1c, as IL-6 levels have been shown to be 
significantly correlated with IL-8 levels224. This would provide further insight into the biology of 
the inflammatory component that is present in cardiometabolic diseases and may show how 
cytokines act synergistically to influence phenotypes. Similarly, mediation analyses would aid 
our understanding of the extent to which inflammation contributes to established pathways for 
risk of cardiometabolic diseases. Finally, investigating whether the inflammation observed in 
cardiometabolic diseases predisposes patients to a worse prognosis or disease complications 
would be invaluable to improving the clinical treatment of patients with cardiometabolic 
diseases. 
 
This study showed that IL-6 and TNFα are associated with incident cardiometabolic diseases, 
however, the predictive value of a biomarker is dictated by the strength of its association with 
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incident disease268. Given the comparatively small estimates of association between cytokine 
levels and incident disease, it is unlikely that the measurement and consideration of IL-6 and 
TNFα will have more than an incremental effect in predicting incident cardiometabolic 
diseases above that of clinical risk factors. In this case, the predictive value of each cytokine 
may not be of primary importance but rather whether cytokine levels are causally associated 
with either disease. In the case where the levels of a particular cytokine are estimated to be 
causally relevant for cardiometabolic diseases, even relatively small changes in cytokine 
levels may be therapeutically targeted and bring about clinically relevant reductions in disease 
risk. Approaches using genetic variants such as Mendelian randomisation (MR) can try to 
address this question, as associations between variants and phenotypes of interest are less 
susceptible to the effects of confounding269. Causal inference is difficult in observational 
studies due to this confounding and the possibility for reverse causality72. Thus, further study 
into the genetics underpinning cytokine levels is critical to aid our wider understanding of 
inflammation but also to assess the causality of cytokine levels with cardiometabolic diseases 




Chapter 3: Discovery, Refinement and Characterisation of Loci 
Associated with Cytokine Levels 
Contributions and collaborations 
I designed the study, prepared phenotypes for GWAS and performed all analyses described 
in this chapter. Jian’an Luan provided statistical support when running the GWAS. I wrote the 





Background: To date, very few GWAS studies of cytokine levels have been conducted, most 
have been conducted in small sample sizes, identifying variants which are associated with IL-
6 and TNFα levels. No variants have been found to be associated with levels of IL-8 and IFNγ 
at genome-wide significance. 
 
Aims: To conduct a GWAS and meta-analysis of IFNγ, IL-6, IL-8 and TNFα levels in the 
Fenland and EPIC-Norfolk studies. 
 
Methods: GWAS was performed on levels of each cytokine in Fenland and EPIC-Norfolk 
separately, using multivariable linear regression. The results were then combined using 
inverse-variance weighted fixed effects meta-analysis. Variants were clumped into 2Mb loci, 
1Mb either side of the lead variant in each region. Secondary signals in each locus were then 
identified using a step-wise selection procedure in GCTA and conditional analysis, 
conditioning on the effects of the lead variant in each locus, was performed using multivariable 
linear regression. Bayesian fine mapping was then used to generate 99% credible sets at each 
locus. Next, SNP-based heritabilities and correlations between the four cytokines were 
estimated using LD score regression. Finally, the colocalisation between cytokine levels and 
T2D and CHD was estimated using a pairwise Bayesian colocalisation framework, COLOC. 
 
Findings: In up to 17,000 participants, the largest cytokine GWAS to date, 22 variant-cytokine 
associations were identified within 19 loci, 16 of which are novel associations with the 
corresponding cytokine and not in the HLA gene region. Six loci were associated with IFNγ 
levels, three with IL-6 levels, five with IL-8 levels and six with TNFα levels. An intronic variant 
in IL6R, rs4129267, in complete LD with a missense variant, rs2228145, was associated with 
0.11 SD higher IL-6 levels (95% CI, 0.08, 0.14; P = 3.5x10-38) per copy of rs4129267 was 
replicated. Variants residing in the receptors of IFNγ (IFNGR1), IL-6 (IL6R) and IL-8 (CXCR2, 
DARC) were found to be associated with each respective cytokine and explained the greatest 
proportion of variance in their respective levels. Of these, only the IL6R locus showed robust 
evidence of colocalisation with cardiometabolic diseases (PPcoloc with CHD = 0.98).  
 
Conclusion: This large cytokine GWAS further elucidates the genetic determinants of IL-6 
and TNFα but most importantly, provides the first genome-wide evidence of variants 





Evidence from observational studies and animal models points to a role for chronic 
inflammation in cardiometabolic disease pathophysiology109,112,123,154,155,184–186,189. Four key 
cytokines thought to play roles in chronic inflammation, atherosclerosis and insulin resistance 
are IFNγ, IL-6, IL-8 and TNFα9,94,123,138,162,223,270. In order to further our understanding of how 
these cytokines may affect cardiometabolic disease risk, I first need a better understanding of 
the genetics that underpin their levels. GWAS approaches systematically test the association 
between genetic variants and phenotypes of interest, highlighting loci of interest for follow-up. 
 
The systematic literature review conducted in Chapter 1 highlighted three loci associated with 
IL-6 levels ABO, IL6R and RP11-314E23.1 whereas two loci, DLEU1 and ABO, were 
associated with levels of TNFα. To-date, no significant loci have been shown to be associated 
with IL-8 or IFNγ levels in GWAS studies, despite both being investigated in a recent GWAS 
in Finnish participants227. To-date, the Finnish GWAS227 investigating the levels of 27 
cytokines and growth factors is the largest of its kind, as many previous GWAS efforts have 
been conducted in considerably smaller sample sizes. 
 
This chapter describes the results of GWAS for the levels of the four cytokines of interest in 
the largest GWAS to date. Using the loci estimated to be associated with cytokine levels, loci 
of interest were identified for further follow-up. Finally, the respective heritability and pairwise 
genetic correlations between the four cytokines were estimated.  
3.2: Methods 
Phenotype preparation 
Levels of IFNγ, IL-6, IL-8 and TNFα were measured in both EPIC-Norfolk241 and Fenland244 
respectively, using the method described previously. Any samples where measurement was 
attempted but measures were below the LLOD were imputed using a random value between 
0 and the LLOD. This imputation was done to retain statistical power.  Samples where 
measurement was not attempted or failed due to technical failure were set to missing. Cytokine 
measurements were normalised using an inverse-rank normal transformation and residuals 
were generated by regression of the normalised values using age, age2, sex and principal 
components as covariates. The generated residuals were then normalised using another 






GWAS for IFNγ, IL-6, IL-8 and TNFα levels 
Genome-wide genotyping in the Fenland cohort was performed in 3 sub-cohorts using either 
the Affymetrix genome-Wide Human variant Array 5.0, the Affymetrix UK Biobank Axiom Array 
or the Illumina CoreExome-24 v1 chip, with imputation to the Haplotype reference consortium 
v1.1271, the 1000 genomes project272 and the UK10K273 reference panels. Samples from EPIC-
Norfolk were genotyped using the Affymetrix UK Biobank Axiom Array and imputed to the 
same reference panels. GWAS analyses to estimate the association of genetic variants with 
cytokine levels were conducted in the Fenland and EPIC-Norfolk cohorts separately for IFNγ, 
IL-6, IL-8 and TNFα. variant associations were estimated using multivariable linear regression 
models in variantTEST274. Results were assessed for quality and consistency using several 
metrics. variants that had a minor allele count (MAC) lower than 10 were excluded along with 
those with evidence of deviation from Hardy Weinberg equilibrium (p<10-6). Variants with beta 
estimates with absolute values above 10 were removed. variants with standard errors larger 
than 10 or with a value of 0 due to model instability were removed. Imputation quality was 
assessed using the “INFO” metric assigned during imputation using Impute2275, where a value 
of 1 denotes perfect imputation or a directly genotyped variant. A cut-off value of 0.4 or above 
was used to retain variants of higher imputation quality. variants with sample sizes less than 
50% of the maximum sample size were excluded. 
 
Meta-analysis and quality control of GWAS analyses 
GWAS were conducted in EPIC-Norfolk and Fenland separately and results were combined 
using fixed-effects inverse-variance weighted meta-analysis in METAL276. Following this, any 
variant that was not successfully genotyped for more than half of the sample size was 
removed. variants available in only 1 sub-study were dropped. variants that had MAC counts 
of less than 20 were removed. Insertions and deletions were removed from the analyses along 
with tri-allelic sites along with any variants with highly variable effect allele frequencies and 
corresponding standard errors. Lead variants were defined as those with the lowest p-values 
in the regions and loci were then defined based on 2Mb windows around each of the lead 
variants (1Mb either side of the lead variant). Manhattan plots were drawn using the 
EasyStrata277 R-package under the R programming environment v3.3.1 (R core team 2017). 
A genome-wide significance threshold of p<5x10-8 was used. QQ-plots were drawn for quality 
control assessment of the meta-analysis using STATA v14 (StataCorp, Texas, USA). 
 
Regional association plots and independent signal selection 
Regional association plots were drawn around each of the lead variants using LocusZoom 
v1.2278 under the R programming environment v3.3.1 (R core team 2017) to examine the 
linkage disequilibrium (LD) structure within each 2Mb locus. LD structure was drawn from the 
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European populations of the 1000 Genomes Project272 and genomic coordinates from the 
human genome assembly GRCh37 (hg19). 
 
At each 2Mb locus defined around the lead variants, I sought to identify any independent 
secondary signals that met a locus-wide significance threshold of P < 1x10-5, corresponding 
to the approximate number of variants in each window and has been used in previous 
studies279,280. A 10Mb window was used for a locus on chromosome 12 locus significantly 
associated with TNFα, as the LD structure spanned a region greater than 2Mb (Figure S3.1). 
Initially, independent variants were identified using GCTA cojo-select281 which implemented a 
step-wise selection procedure, taking into account regional LD and the distance between 
genome-wide significant variants from GWAS summary data. At loci where there were multiple 
independent variants, association signals were decomposed using approximate conditional 
analysis using GCTA cojo-cond281 by including the other independent variants within the 
region as covariates in a regression model. The method applied by GCTA uses R2 LD metrics 
which capture the correlation between common variants well, however, do not perform well in 
scenarios where common and rare variants are correlated with one another. As a result of 
this, GCTA often found multiple independent variants at a locus, where one was common and 
the other rare. Given that the variants were often very rare and the p-values of were close to 
the significance threshold, a formal conditional analysis was used which was robust to the 
effects of rare variants and is not an approximation method.  
 
Multivariable linear regression models were used to condition the variants at each non-HLA 
locus on the lead variant by including the genotype of the lead variant as a covariate. 
Genotypes from the largest Fenland genotyping sub-cohort of over 8,000 participants were 
used. Any variants that remained significant at P< 1x10-5 were then added to the linear 
regression model as a further covariate. This process was repeated until no further variants 
were significant at the locus-wide threshold. All variants found to be significant at this threshold 
were considered secondary independent signals. Due to the extensive and complicated LD 
structure across the HLA region (chr6:28,477,797-33,448,354) signal decomposition and later 
fine mapping was not done in these regions. Following this, variants associated with levels of 
each respective cytokine were searched in the NHGRI-EBI GWAS catalog282, a repository of 
published GWAS results, to determine the number of novel association signals.  
 
Bayesian fine mapping 
Independent signals were refined with the aim of narrowing each association signal to a 
causative variant set or single variant. Fine mapping was performed using 1Mb windows 
around each independent variant in each locus, as posterior probabilities have been previously 
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shown to decay to basal levels 500Kb either side of the association signal283. Functionally 
unweighted credible sets were defined, using a model that assumed only a single causal 
variant at each locus. variants were ranked according to their posterior probability of causality 
and included in credible sets until a cumulative posterior probability of 0.99 was reached. A 
prior of W = 0.02 was used as in previous studies284 corresponding to the variance in allelic 
effects of standardised quantitative traits. Variant effect predictor (VEP) v96285 annotations 
were used to annotate the regional and functional consequences of each variant.  
 
Correlation between cytokines and variant-based heritability estimation 
Pearson’s correlations were estimated using the inverse-normal transformed residuals of the 
cytokine levels used to run the original GWAS. A correlation heat map was drawn using 
ggplot2286 under the R programming environment v3.3.1 (R core team 2017) to graphically 
represent the relationship between each pair of cytokines.  
 
LD-score regression287 (LDSC) was used to estimate the genetic correlations across the four 
cytokines and their respective variant-based heritabilities. Prior to implementing LDSC, 
variants that displayed effect sizes larger than χ2 > 80 (corresponding to a Z-score of 8.9) were 
removed, as these outliers may bias the regression. Variants within the HLA region were also 
removed due to the complex LD structure in the region. To retain high imputation quality (> 
0.9) the analysis was restricted to variants imputed to HapMap3, as these were considered to 
be well imputed across studies. A total of 1,217,312 variants were included in the LDSC 
regression, using European LD scores supplied with the LDSC package287. A second analysis 
without restricting the results to HapMap3 imputed variants was also conducted. Variant-
based heritability estimates were then compared to estimates of other circulating biomarkers 
using the LD-hub database288.  
 
False positive associations may arise in GWAS due to genetic confounding, generally driven 
by population stratification or unaccounted relatedness between participants. The genomic 
control lambda (λGC) has been traditionally used to provide a measure of test statistic inflation 
and serve as a correction factor to counteract this. Values below 1.1 were considered 
indicative of suitable control of genetic confounding. However, the method is unable to 
distinguish genetic confounding from polygenic trait architecture. Polygenicity, as is often 
observed in common disease, is the presence of many associations across the genome with 
comparatively small effect sizes that cumulatively contribute to higher disease risk. The LDSC 
regression intercept, however, is a robust measure of confounding because it does not inflate 
in the same way as λGC does with larger sample sizes in the presence of polygenicity287. This 
robustness lends increased power when correcting GWAS estimates with the LDSC 
 
57 
intercept287. To this end, I examined the λGC and LDSC intercept estimates from a model which 
did not restrict the variants included to those imputed to HapMap3 only. Values for the 
intercept below 1.5 were considered to adequately control for genetic confounding in this 
GWAS.  
 
Proportion of variance explained by variants associated with cytokine levels 
To determine if particular variants explained more variance in the levels of each cytokine, the 
proportion of variance explained by each variant was estimated using the following formula:  
𝑃𝑉𝐸 =  
2𝛽2𝑀𝐴𝐹(1 − 𝑀𝐴𝐹)
2𝛽2𝑀𝐴𝐹(1 − 𝑀𝐴𝐹) + (𝑆𝐸2)2𝑁𝑀𝐴𝐹(1 − 𝑀𝐴𝐹)
 
Where proportion of variance explained is denoted by PVE, β relates to the variant’s effect on 
cytokine levels, SE relates to the standard error of the variant, N represents the number of 
participants and MAF represents the minor allele frequency of the variant. Variants were 
ordered from greatest proportion of variance explained to smallest per cytokine and a stacked 
bar plot was drawn to show the incremental increases in variance explained by each additional 
variant. Analyses were conducted using R v3.6.0 and plots were drawn using the ggplot2 
package.   
 
Colocalisation of variants associated with cytokine levels and cardiometabolic 
diseases 
I employed a pairwise Bayesian genetic colocalisation framework to estimate whether variants 
explaining the greatest proportion of variance in cytokine levels were shared with either T2D 
or CHD. Using the above estimates, variants in IFNGR1, IL6R, DARC and LIPC explained the 
greatest proportion of variance in IFNγ, IL-6, IL-8 and TNFα levels respectively. The 1Mb 
regions either side of each variant were extracted from publicly available GWAS summary 
statistics for both diseases22,289 and the respective cytokine GWAS from this study. GWAS 
summary statistics were first aligned to the cytokine-raising allele and any indels were 
removed. Any variants with standard errors of “0” were also removed from the analysis. Only 
variants present in all datasets were considered. Bayesian colocalisation analysis was then 
conducted using the COLOC290 R package between each pair of traits using beta estimates 
and corresponding trait variances. Cytokine levels were treated as quantitative traits and both 
T2D and CHD were treated as case-control traits. The case proportion was used as input for 
case-control traits and standard deviations were used for quantitative traits. Colocalisation 
was done to estimate posterior probabilities (PPcoloc) denoting evidence of colocalisation: H0 
– no signal; H1 – signal unique to trait 1; H2 – signal unique to trait 2; H3 – two independent 
causal variants in the same locus driving the association signal for the respective traits and 
H4 – presence of a causal variant shared between two traits. The prior probability that a variant 
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is associated with trait 1, p1, was set to 1x10-4. The same settings were used for p2. I assigned 
a prior probability of 1x10-5 for p12, which relates to the prior probability that a single variant 
is associated with both traits. Pairwise PPcoloc estimates were considered significant if they 
met the following criteria: (H4 + H3 ≥ 0.9 & H4/H3 ≥ 3. All data analysis was performed using 






GWAS and meta-analysis for loci associated with cytokine levels 
Meta-analysis of the Fenland and EPIC-Norfolk cohorts resulted in a sample size of 
approximately 17,000 for each cytokine, with a mean of 16,248,771 variants analysed. Table 
S3.1 details the number of variants removed during meta-analysis quality control procedures. 
These meta-analyses identified 153, 131, 1,004 and 710 variants that were associated with 
circulating IFNγ, IL-6, IL-8 and TNFα levels respectively at genome-wide significance (P≤5x10-
8). Figure 3.1 shows the Manhattan plots for each of the meta-analyses and Figure S3.2 
shows the QQ-plots for each meta-analysis. Table 3.1 shows the lead variants of each 
association signal defined on the basis of distance-based pruning. This locus definition led to 
a total of 20 lead variants within 6 loci associated with IFNγ levels, 3 loci for IL-6, 5 loci for IL-
8 and 6 loci for TNFα. 
 
Table 3.1: Lead variants used for independent signal selection 
Trait Locus Variant Chr Pos EA EAF Beta (SE) p-value 
IFNγ 1 rs11754268 6 137540335 T 0.21 0.11 (0.013) 6.08x10-16 
IFNγ 2 rs76830965 3 159637678 A 0.12 0.13 (0.017) 1.17x10-14 
IFNγ 3 rs653178 12 112007756 T 0.53 -0.07 (0.011) 7.19x10-10 
IFNγ 4 rs2523609 6 31237255 A 0.62 0.07 (0.011) 1.11x10-09 
IFNγ 5 rs4492899 12 10598426 A 0.31 0.07 (0.012) 2.47x10-08 
IFNγ 6 rs2009581 2 111807677 A 0.27 -0.07 (0.012) 2.63x10-08 
IL-6 1 rs12730935 1 154419892 A 0.41 0.14 (0.011) 4.04x10-38 
IL-6 2 rs116457146 6 32578632 T 0.26 0.07 (0.012) 2.20x10-08 
IL-6 3 rs545129521 21 36823802 A 0.99 -0.71 (0.13) 4.27x10-08 
IL-8 1 rs12075 1 159175354 A 0.58 0.36 (0.011) 7.08x10-243 
IL-8 2 rs138840656 4 74567906 T 0.94 0.24 (0.024) 2.33x10-22 
IL-8 3 rs55799208 2 218999982 A 0.003 0.89 (0.118) 3.71x10-14 
IL-8 4 chr6:32634613:C>T 6 32634613 T 0.11 0.12 (0.02) 7.17x10-09 
IL-8 5 rs6503533 17 38184580 T 0.63 0.06 (0.011) 1.67x10-08 
TNFα 1 rs7161799 15 58770523 T 0.08 0.22 (0.018) 2.43x10-35 
TNFα 2a rs3184504 12 111884608 T 0.47 0.11 (0.011) 3.09x10-22 
TNFα 3 rs28611443 6 31341411 A 0.08 -0.15 (0.02) 1.01x10-14 
TNFα 4a rs11066320 12 112906415 A 0.42 0.08 (0.01) 2.95x10-13 
TNFα 5 rs146125856 15 50784990 T 0.90 0.12 (0.019) 8.83x10-10 
TNFα 6 rs66530140 4 187161211 T 0.49 0.07 (0.011) 1.77x10-09 
Abbreviations: IFNγ, Interferon-γ; IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor-α; Chr, 
Chromosome; Pos, Base-pair position; EAF, Effect allele frequency; EA, Effect allele; SE, Standard error. 





Figure 3.1: Manhattan plot for the meta-analysis of each cytokine. Relative base-pair 
positions of each variant are arranged by chromosome. The Y-axis depicts log
10
 P-values for 
each association with respective circulating cytokine levels. The red line denotes a genome-
wide significance threshold of P<5x10-8. The gene annotations for each lead variant from the 
























Independent signal selection using formal conditional analysis 
Independent variant selection identified 18 independent variants using a significance threshold 
of P<1x10-5. Table 3.2 shows 5 independent variants associated with IFNγ levels, 2 variants 
with IL-6 levels, 7 variants in 4 non-HLA loci with IL-8 levels and 4 variants with TNFα levels. 
Of the signals identified in this study, 16 were found to be novel associations with their 
corresponding cytokine as per the GWAS catalog282. Association estimates after having 
conditioned for other independent variants in the locus are presented.  
 
Bayesian fine mapping of independent association signals 
Bayesian fine mapping enabled the construction of credible sets that were highly likely to drive 
the observed association signals. Overall, the median number of variants and interquartile 
range (IQR) between the credible sets was 56 (4 – 135) variants. Median credible set size and 
IQR was 92,850 (8,221 – 247,015) base-pairs. In 13 of the 19 credible sets, the variant with 
the highest posterior probability was the same as the independent variant identified using 
conditional analysis (Table 3.3). Three 99% credible sets consisted of a single variant. At four 
loci a single variant accounted for more than 80% of the posterior probability, indicating high 
statistical evidence of causal association: Intronic variants in IFNGR1 and DARC and 
missense variants in LIPC and USP8. In other credible sets, posterior probabilities were 
comparatively smaller making it challenging to determine the variant that was likely to be 
driving the association. This was reflected in comparatively larger window sizes and an 
increased number of variants within these credible sets. Instances where several common 
variants are in high LD make determination of the causal variant challenging, as in the case 
of rs4129267 in IL6R where the posterior probability of causality is split evenly across several 












IFNγ 1 1 6 137540335 rs11754268 T 0.21 0.10 0.019 3.80x10-7 6.08x10-16 N Y 
IFNγ 2 1 3 159637678 rs76830965 A 0.12 0.14 0.024 3.63x10-9 1.17x10-14 N Y 
IFNγ 3 1 12 112007756 rs653178 C 0.47 0.06 0.016 7.32x10-5 7.19x10-10 N Y 
IFNγ 4 N/A 6 31237255 rs2523609 A 0.62 0.07 0.01 1.11X10-09 1.11x10-09 Y Y 
IFNγ 5 1 12 10598426 rs4492899 A 0.31 0.06 0.017 0.001 2.47x10-8 N Y 
IFNγ 6 1 2 111807677 rs2009581 G 0.73 0.07 0.018 2x10-4 2.63x10-8 N Y 
IL-6 1 1 1 154426264 rs4129267 T 0.41 0.11 0.016 1.10x10-12 3.52x10-38 N N 
IL-6 2 N/A 6 32578632 rs116457146 T 0.26 0.07 0.01 2.20X10-08 2.20x10-08 Y Y 
IL-6 3 1 21 36823802 rs545129521 T 0.01 0.75 0.173 1.62x10-5 4.86x10-8 N Y 
IL-8 1 1 1 159175354 rs12075 A 0.58 0.47 0.015 1.25x10-193 7.08x10-243 N Ne 
IL-8 2 1 4 74567906 rs138840656 G 0.06 0.28 0.036 1.37x10-14 2.33x10-22 N Y 
IL-8 2 2 4 74636009 rs7689435 G 0.43 0.09 0.016 2.35x10-8 2.33x10-22 N Y 
IL-8 2 3 4 74675215 rs141761385 G 0.01 0.84 0.160 1.61x10-7 2.33x10-22 N Y 
IL-8 3 1 2 218999982 rs55799208 A 0.002 0.91 0.182 5.62x10-7 3.71x10-14 N Y 
IL-8 3 2 2 219020958 rs114050631 T 0.01 0.43 0.092 3.47x10-6 3.71x10-14 N Y 
IL-8 4 N/A 6 32634613 chr6:32634613:C>T T 0.11 0.12 0.02 7.17x10-9 7.17x10-9 Y Y 
IL-8 5 1 17 38184580 rs6503533 T 0.63 0.07 0.016 4.18x10-5 1.67x10-8 N Y 
TNFα 1 1 15 58770523 rs7161799 T 0.08 0.27 0.030 1.90x10-20 9.00x10-37 N Y 
TNFα 3 N/A 6 31341411 rs28611443 C 0.92 0.15 0.02 1.01x10-14 1.01x10-14 Y Y 
TNFα 5 1 15 50784990 rs146125856 T 0.90 0.12 0.026 1.52x10-6 1.04x10-9 N Y 
TNFα 6 1 4 187163614 rs4253272 C 0.49 0.08 0.016 1.20x10-7 1.84x10-9 N Y 
TNFα 24c 1 12 111884608 rs3184504 T 0.47 0.10 0.016 1.43x10-10 4.72x10-22 N Y 
Abbreviations: IFNγ, Interferon-γ; IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor α; Chr, Chromosome; Pos, Position; EA, Effect allele; EAF, Effect allele frequency; 
SE, Standard error; N, No; Y, Yes 
a. The order that variants were selected in within each locus, after conditioning on other variants in the same locus. HLA variants were not included in this analysis 
b. Association statistics after conditioning 
c. 10Mb locus created when loci 2 and 4 were merged into one 
d. “Y” represents a novel association with levels of the corresponding cytokine in the GWAS catalog, “N” represents a previously identified signal 
e. Has been previously reported at just below the genome-wide significance threshold  
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Abbreviations: IFNγ, Interferon-γ; IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor α; Chr, Chromosome; Pos, Position 
a. Functional annotations from Variant Effect Predictor v96285 
b. P-value conditional on other variants in the locus  
  



























IFNγ 1 rs11754268 IFNGR1 Intronic 6 137540335 6.08x10-16 2 35 rs11754268 6.08x10-16 0.99 
IFNγ 2 rs76830965 3' of SCHIP1 Intergenic 3 159637678 1.17x10-14 4 34966 rs76830965 1.17x10-14 0.44 
IFNγ 3 rs653178 ATXN2 Intronic 12 112007756 7.19x10-10 9 225769 rs653178 7.19x10-10 0.37 
IFNγ 5 rs4492899 3’ of KLRC1 Intergenic 12 10598426 2.47x10-8 92 93172 rs4492899 2.47x10-8 0.12 
IFNγ 6 rs2009581 ACOXL Intronic 2 111807677 2.63x10-8 135 247015 rs2009581 2.63x10-8 0.39 
IL-6 1 rs4129267 IL6R Intronic 1 154426264 3.52x10-38 11 8221 rs4129267 3.52x10-38 0.16 
IL-6 3 rs545129521 RUNX1 Intronic 21 36823802 4.86x10-8 5,589 999854 rs545129521 4.86x10-8 0.33 
IL-8 1 rs12075 DARC Missense 1 159175354 7.08x10-243 1 0 rs12075 7.08x10-243 0.99 
IL-8 2 rs7689435 3' of IL8 Intergenic 4 74636009 2.35x10-8 b 80 97429 rs4279174 3.80x10-9 0.06 
IL-8 2 rs138840656 5' of IL8 Intergenic 4 74567906 1.37x10-14 b 92 45370 rs1951705 1.36x10-15 0.11 
IL-8 2 rs141761385 5’ of CXCL6 Intergenic 4 74675215 1.61x10-7 b 4,455 999513 rs55648028 2.95x10-7 0.03 
IL-8 3 rs55799208 CXCR2 Missense 2 218999982 5.62x10-7 b 4,585 999742 rs1346768 3.38x10-4 0.01 
IL-8 3 rs114050631 3' of CXCR1 Intergenic 2 219020958 3.47x10-6 b 3,695 999273 rs1126580 1.16x10-5 0.04 
IL-8 5 rs6503533 MED24 Intronic 17 38184580 1.67x10-8 135 92528 rs6503533 1.67x10-8 0.04 
TNFα 1 rs7161799 LIPC Intronic 15 58770523 9x10-37 1 0 rs7161799 9x10-37 0.99 
TNFα 5 rs146125856 USP8 Missense 15 50784990 1.04x10-9 1 0 rs146125856 1.04x10-9 0.99 
TNFα 6 rs4253272 KLKB1 Intronic 4 187163614 1.84x10-9 32 34744 rs4253272 1.84x10-9 0.06 
TNFα 24 rs3184504 SH2B3 Missense 12 111884608 4.72x10-22 5 142707 rs3184504 4.72x10-22 0.32 
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Correlation and variant-based heritability across the four cytokines 
Correlations between the four cytokines were measured on both a genetic and observational 
level. LDSC287, was used to estimate the genetic correlations and is robust to sample overlap 
as this inflates the model intercept and not the regression slope which is used to estimate the 
correlation291. Correlation estimates between the four cytokines are shown in Table 3.4. 
Table 3.4: Correlation estimates between the four cytokines 







IFNγ IL-6 0.002 (0.2) 0.99 0.24 (0.008) < 2.2x10-16 
IFNγ IL-8 -0.15 (0.14) 0.26 0.12 (0.008) < 2.2x10-16 
IFNγ TNFα 0.39 (0.18) 0.03 0.34 (0.007) < 2.2x10-16 
IL-6 IL-8 0.07 (0.16) 0.64 0.10 (0.008) < 2.2x10-16 
IL-6 TNFα 0.38 (0.2) 0.06 0.26 (0.007) < 2.2x10-16 
IL-8 TNFα -0.14 (0.14) 0.32 0.24 (0.008) < 2.2x10-16 
Abbreviations: IFNγ, Interferon-γ; IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor α;  
SE, Standard error 
a. Genetic correlation from LDSC – shown with its corresponding SE and p-value  
b. Pearson’s correlation coefficient – estimated using both EPIC-Norfolk and Fenland  
 
The four cytokines were significantly correlated with one another on an observational level, 
albeit with marginal estimates and were largely comparable to the genetic estimates. Although 
in the case of IFNγ and IL-8 levels, for example, directional inconsistencies were observed. 
Across both estimations, IFNγ levels were most correlated with TNFα levels, with both 
correlation estimates showing significance. IL-6 and TNFα levels were also correlated with 
one another, however, the genetic estimates were not significant despite having a higher 
estimate than the observational correlation.  
 
The variant-based heritabilities for each cytokine were calculated as part of the LDSC 
regression (Table 3.5). The regression intercept (Intercept < 1.5) and genomic control lambda 
(λGC < 1.1) did not show evidence of test statistic inflation due to bias or population stratification 
and that any inflation is likely to be due to polygenic architecture (Table 3.5). Heritability 
estimates were in line with those of other biomarkers from the LD-hub database288 such as 
LDL cholesterol from the global lipids consortium (GLGC): h2 = 0.13 (0.02) and HbA1c from 
the meta-analysis of glucose and insulin-related traits consortium (MAGIC): h2 = 0.07 (0.01). 
Table 3.5: Narrow-sense heritability estimates from LDSC 
Cytokine h2 SE λGC χ2 Intercept 
Number of 
variants 
IFNγ 0.11 0.03 1.02 1.03 0.99 1,179,881 
IL-6 0.06 0.02 1.02 1.02 0.99 1,179,857 
IL-8 0.21 0.04 1.03 1.05 0.98 1,179,832 
TNFα 0.09 0.03 1.03 1.04 1.00 1,179,873 
Abbreviations: IFNγ, Interferon-γ; IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor α; h2; 
Narrow-sense heritability; SE, Standard error; λGC, Genomic inflation factor; χ2, Chi-squared statistic  
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Incremental variance explained by variants associated with cytokine levels 
The proportion of variance explained for each variant associated with respective cytokine 
levels was estimated (Figure 3.2). Variants were ordered by their proportion of variance 
explained. Variants in IFNGR1, IL6R, DARC and LIPC explained the greatest proportion of 
variance in IFNγ, IL-6, IL-8 and TNFα levels respectively. In the case of IL6R and DARC 
variants, this was substantially greater than the remaining variants associated with the 
respective cytokine combined, 0.9% and 6.3% respectively.  
 
Figure 3.2: Stacked bar plot illustrating the incremental variance explained by each 
variant associated with cytokine levels. The four cytokines are shown along the X-axis and 
the proportion of variance explained by each variant in percent is shown on the Y-axis. 
Variants associated with each respective cytokine are ordered by their variance explained 
from largest (bottom of the bar) to smallest (top of the bar). Abbreviations: IFNγ, Interferon-γ; IL-6, 
Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor α; SNP, Single nucleotide polymorphism.  
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Colocalisation of cytokine variants with cardiometabolic diseases 
The genetic colocalisation between variants that explained the greatest proportion of variance 
in the respective cytokine levels and cardiometabolic diseases was estimated (Figure 3.3). 
T2D results for IFNγ, IL-6 and IL-8 robustly showed that cytokine and disease traits were 
driven by independent variants at the IFNGR1, IL6R and DARC loci, whereas only TNFα was 
estimated to have a significant association at the LIPC locus. Comparatively at the IFNGR1, 
DARC and LIPC loci, only IFNγ, IL-8 and TNFα were estimated to have significant association 
signals at the respective loci. In contrast, the IL6R locus showed robust evidence that IL-6 
levels and CHD colocalise (posterior probability of colocalisation, PPcoloc = 0.98).  
Figure 3.3: Heatmap of the pairwise colocalisation between cytokine levels and 
cardiometabolic diseases. A heatmap matrix depicting the largest pairwise colocalisation 
estimate between cytokine levels and both T2D and CHD. The 1Mb regions either side of the 
variant explaining the greatest proportion of variance in the levels of each cytokine was used. 
Each colocalisation hypothesis is coloured differently with the colour saturation showing the 
evidential strength. Trait-pairs with significant posterior probability estimates of colocalisation 
(H4 + H3 ≥ 0.9 & H4/H3 ≥ 3) were outlined in black. To discriminate between H1 and H2 
hypotheses, traits along the X-axis were used as “Trait 1” in the analysis and traits listed on 
the Y-axis were used as “Trait 2”. H0 – no signal; H1 – signal unique to trait 1; H2 – signal 
unique to trait 2; H3 – two independent causal variants in the same locus driving the 
association signal for the respective traits and H4 – presence of a causal variant shared 
between two traits. 
Abbreviations: H, Hypothesis; CHD, Coronary heart disease; T2D, Type 2 diabetes; IFNγ, Interferon-γ; IL-6, 






In what is the largest GWAS to date for cytokine levels, I identified 22 variant-cytokine 
associations within 19 loci, 16 of which are novel associations with the corresponding cytokine 
and not in the HLA gene region. This study also provides the first estimates of heritability which 
are comparable to estimates for other biomarkers. Genetic correlations between the four 
cytokines were also estimated and are in line with observational findings.  
 
Of the associations identified in this study, variants at the USP8, LIPC, DARC and IFNGR1 
loci were likely to be the causal variant for their respective association signals with TNFα 
(USP8 and LIPC), IL-8 (DARC) and IFNγ (IFNGR1) levels based on fine-mapping. The 
rs146125856 variant induces a missense L776P substitution within the ubiquitin carboxyl-
terminal hydrolase domain of USP8, responsible for the cleavage of conjugated ubiquitin 
chains. USP8 is a deubiquitinating enzyme thought to function in the turnover of endosomal 
transmembrane proteins and T-cell antigen receptor signalling292. While other members of the 
USP protein family have been shown to inhibit TNFα signalling, however, the role of USP8 is 
unclear293. The rs7161799 variant lies within an intronic region of the hepatic lipase C (LIPC) 
gene. Primarily expressed in the liver, LIPC functions as a triglyceride hydrolase that partially 
converts HDL to LDL and acts as a ligand for receptor-mediated lipoprotein absorption294. 
Previous work has shown that variants in LIPC are associated with HDL levels, however, 
contrasting effect directions have been reported295–297. However, none of the reported variants 
are in LD with rs7161799 (R2 < 0.05) suggesting that this represents a separate pathway that 
impacts TNFα levels. TNFα has previously been shown to interfere and regulate mechanisms 
that function in hepatic lipid homeostasis298,299 despite this, the impact of LIPC on TNFα 
expression is still unclear.  
 
A missense variant, rs12075 (G42D), was found to be associated with IL-8 levels at the Duffy 
antigen chemokine receptor (DARC) locus. The association with lower IL-8 levels at this locus 
has been previously described300. Previous studies have described associations with rs12075 
and MCP1 levels227. DARC encodes a non-specific, membrane bound chemokine reservoir 
that assimilates chemokines from inflamed tissue to maintain homeostasis and is central to 
monocyte and neutrophil infiltration301–304. The association of IL-8 levels in cardiovascular 
disease has long been established, however, contrasting results have been found regarding 
the direction of this association305. This difference may be due to the temporally distinct roles 
that IL-8 levels play in atherosclerosis306 and the fact that large-scale clinical trials have not 
been conducted. IL-8 levels function as a chemoattractant for circulating leukocytes and 
neutrophils to the vessel wall which initiate the atherosclerotic process306. In the later stages, 
DARC on the surface of erythrocytes functions as a regulator of local inflammatory processes 
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and aids in the clearance of IL-8 from circulation as high levels of IL-8 have been found to be 
bound to erythrocytes after myocardial infarction307. These results therefore replicate previous 
findings of the association between DARC and IL-8 levels and may point towards DARC 
assimilation and release of IL-8 being a mediator of the temporal association between IL-8 
levels and cardiovascular disease. 
 
The results highlight several associations of cytokines with their respective cellular receptors 
at the IFNGR1, IL6R and DARC/CXCR1/2 loci. The implications of this are intuitive, as variants 
affecting receptor expression or function will impact circulating levels of the respective 
cytokines. In addition, IFNGR1, IL6R and DARC explained the greatest proportion of variance 
in IFNγ, IL-6 and IL-8 levels respectively. The rs11754268 variant was found to lie within the 
promoter of IFNGR1 in a transcription factor binding site for RNA polymerase II and other 
transcription factors308. This may influence IFNGR1 protein expression and thereby contribute 
to higher IFNγ levels as IFNγ is not internalised. variants in the IFNGR1 gene have previously 
been found to be associated with higher BMI309, however, the variant identified in this study is 
independent of this signal (R2 < 0.05). At the IL6R locus, refinement of causality is challenging 
due to the LD structure and therefore posterior probabilities are shared between 11 variants. 
The lead variant rs4129267 is in high LD with rs2228145, described in Chapter 1. Considering 
the experimental evidence that rs2228145 is functional310, it is likely to be the variant driving 
the observed association. However, this presents a challenge to interpreting the causal 
association between variants leading to higher cytokine levels and risk of cardiometabolic 
diseases. It may seem intuitive to assume that the cytokine-raising allele would reflect higher 
inflammation mediated by an increase in cytokine levels. However, in the case of the IL6R 
locus (and possibly other loci found here), the opposite occurs where the missense variant 
rs2228145 leads to increased IL-6 levels but lower IL-6 mediated inflammation due to lower 
signalling through the IL-6 receptor310. Thus, combining cytokine-raising alleles that reflect 
opposing effect directions on downstream inflammation into a combined instrument may 
render the MR approach difficult to interpret and even invalid in some instances. In these 
instances, it may be more appropriate to interpret results of individual loci separately. 
 
IL-8 has three known cellular receptors namely CXCR1, CXCR2 and DARC/ACKR1311. This 
study identified independent associations of variants within or in close proximity to all three 
receptors with IL-8 levels. Of the identified variants, rs7689435 and rs138840656 have both 
been identified as expression quantitative trait loci (eQTL) that lead to significantly higher 
expression of the IL-8 gene (CXCL8) in blood312. C-X-C motif chemokine receptor 2 (CXCR2) 
is the receptor for all members of the IL-8 chemokine family and CXCR1 is a receptor for 
CXCL6-8311. CXCR2 mediates neutrophilic migration to sites of inflammation and many of the 
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angiogenic properties of IL-8311. Both CXCR1 and CXCR2 are G-protein coupled receptors, 
which make them attractive drug targets311. CXCR2 in particular, has been investigated as a 
possible therapeutic target for asthma and a number of related respiratory conditions including 
chronic obstructive pulmonary disease (COPD), clinical trials are ongoing311. The rare 
missense variant rs55799208 induces an R153H substitution in the second intracellular loop 
of CXCR2, an area crucial for G-protein interactions and receptor activation313. The 
rs114050631 variant downstream of CXCR1, the receptor for CXCL6-8311, lies within a STAT3 
transcription factor binding site and is an established eQTL for lower CXCR1 expression in 
blood312. Both of these variants have previously been associated with lower counts of several 
white blood cell types314. Neither the IL-8 polygenic score nor the individual IL-8 raising 
variants were associated with either disease outcome. Given that these variants reside in 
biologically plausible loci (including CXCL8) and their associations with IL-8 levels are 
statistically robust, this result reduces the likelihood that IL-8 levels have a strong causal effect 
in cardio-metabolic disease. This furthers our knowledge of the involvement of IL-8 in cardio-
metabolic disease as prior to this, increases in IL-8 levels have been demonstrated in CHD 
and T2D patients in isolated reports but the causal relevance of IL-8 to these diseases had 
yet to be assessed224. 
 
The pleiotropic ATXN2/SH2B3 locus on chromosome 12q24.1 was found to be associated 
with both IFNγ and TNFα levels respectively. The lead variants within each gene, rs653178 
and rs3184504 respectively, were found to be in high LD (R2 > 0.9) and both were within the 
99% credible set for each association signal. Ataxin-2 (ATXN2) plays a role in RNA processing 
and function and the formation of stress granules315. Under normal conditions, the SH2B 
adaptor protein 3 (SH2B3) protein negatively regulates TNFα signalling by modulating the 
activities of both PI3K and MAPK ERK1/2316. Interestingly, a recent study showed that SH2B3 
regulates adipose tissue expansion and activation of innate lymphoid cells, together these 
roles function to reduce the risk of T1D317. Loss of SH2B3 in a murine model led to adipose 
inflammation and glucose intolerance, however, this intolerance was not linked with 
concurrent impaired insulin secretion which is the hallmark of T1D, instead insulin resistance 
was noted which is more typical of T2D317. The rs3184504 variant, associated with TNFα 
levels, induces a R262W missense substitution within the pleckstrin homology domain of the 
SH2B3 protein which is crucial for protein translocation to the cell membrane and regulation 
of intracellular signalling318. This missense substitution is not predicted to induce a loss-of-
function phenotype by LoFtool319 therefore it is unlikely that carriers of rs3184504 would exhibit 
the phenotypes associated with loss of SH2B3 but given that the variant induces an amino 
acid substitution in a key domain, carriers may exhibit differential protein activity as a result. 
Both variants are associated with a number of autoimmune diseases including celiac 
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disease320,321 and Crohn’s disease322,323 and have also been associated with higher risk of both 
CHD289,324 and T1D325,326. A similar impact on IFNγ levels has been described using SH2B3-/- 
knockout in murine CD8+ T cells which lead to higher IFNγ secretion317,327. These results taken 
together with the complex LD structure at the ATXN2/SH2B3 locus (Figure S3.1) make the 
resolution of causality complex and illustrate some of the challenges in applying an MR 
framework using cytokine levels as risk factors. The association with CHD for both IFNγ and 
TNFα deserves two considerations. Firstly, the association at the SH2B3/ATXN2 locus may 
reflect horizontal pleiotropy in which case the locus would be an invalid instrument for MR71. 
Secondly, only some of the mechanisms which act in pathways leading to higher levels of 
these cytokines may be causally implicated in CHD.  Indeed, this locus is clearly highly 
pleiotropic and is associated with several anthropometric and lipid traits which contribute to 
cardiometabolic diseases via disparate pathways76. It is therefore likely that the 
ATXN2/SH2B3 locus is associated with both TNFα and IFNγ levels due to shared biology 
which may manifest via a shared regulatory mechanism, however, the exact mechanism and 
causal relationship underlying this mechanism is still not understood. 
 
There are several limitations to this study. Firstly, using an inverse-rank normal transformation 
of the cytokine levels limits the comparability of the association results of this study to those 
from previous studies that often use natural log transformations. However, this does facilitate 
direct comparison across the four cytokines as all effect estimates will be standardised to a 1 
SD increase and therefore risk of cardiometabolic diseases can be compared across the four 
cytokines. Secondly, the Bayesian fine mapping done here assumes only a single causal 
variant which may in some cases be an incorrect assumption of the underlying genetic 
architecture at a given locus. Methods that allow for multiple causal variants at the same locus 
may have produced different results at loci where complex LD structure hindered the 
resolution of the association signal to a single causal variant328,329. Thirdly, several factors 
prohibited the use of MR to estimate the causal relevance of cytokine levels to disease. The 
relatively low number of variants found to be associated with cytokine levels, compared to 
other biomarker traits such as triglyceride levels330, meant that such an approach would likely 
be underpowered and liable to bias by variants with large effects on the trait of interest. In 
addition, loci such as ATXN2-SH2B3 are established pleiotropic loci, invalidated one of the 
assumptions of MR as the locus is known to influence multiple traits through discrete 
pathways, characteristic of horizontal pleiotropy62. This study also identified associations 
between variants in cytokine receptors and levels of the respective cytokine. While variants 
such as rs2228145 in IL6R may not necessarily invalidate the assumptions of MR, they may 
hinder the interpretation of results through seemingly inverse associations between cytokine 
levels and disease, due to a lack of receptor mediated inflammatory signalling. Finally, this 
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study found that variants in cytokine receptors explain substantially greater proportion of 
variance in their respective cytokine levels compared to other variants. Colocalisation between 
these variants and cardiometabolic diseases may warrant further investigation on a single 
locus basis, however, for the majority of cytokines no colocalisation was observed with 
cardiometabolic diseases. The IL6R locus was the only region where robust colocalisation 
with cardiometabolic diseases was estimated, the relevance of this to cardiometabolic 




Chapter 4: Meta-analysis Investigating the Role of Interleukin-6 
Mediated Inflammation in Type 2 Diabetes 
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Background: Evidence from animal models and observational epidemiology points to a role 
for chronic inflammation, in which interleukin 6 (IL-6) is a key player, in the pathophysiology of 
type 2 diabetes (T2D). However, it is unknown whether IL-6 mediated inflammation is 
implicated in the pathophysiology of T2D.  
 
Methods: I performed a meta-analysis of 15 prospective studies to investigate associations 
between IL-6 levels and incident T2D including 5,421 cases and 31,562 non-cases. I also 
estimated the association of a loss-of-function missense variant (Asp358Ala) in the IL-6 
receptor gene (IL6R), previously shown to mimic the effects of IL-6R inhibition, in a large trans-
ethnic meta-analysis of six T2D case-control studies including 260,614 cases and 1,350,640 
controls. 
 
Findings: In a meta-analysis of 15 prospective studies, higher levels of IL-6 (per log pg/mL) 
were significantly associated with a higher risk of incident T2D (1·24 95% CI, 1·17, 1·32; 
P=1x10-12). In a trans-ethnic meta-analysis of 260,614 cases and 1,350,640 controls, the IL6R 
Asp358Ala missense variant was associated with lower odds of T2D (OR, 0·98; 95% CI, 0·97, 
0·99; P=2x10-7). This association was not due to diagnostic misclassification and was 
consistent across ethnic groups. IL-6 levels mediated up to 5% of the association between 
higher body mass index and T2D. 
 
Interpretation: Large-scale human prospective and genetic data provide evidence that IL-6 
mediated inflammation is implicated in the aetiology of T2D but suggest that the impact of this 
pathway on disease risk in the general population is likely to be small. 
 
Funding: The EPIC-Norfolk study has received funding from the Medical Research Council 
(MRC) (MR/N003284/1, MC-UU_12015/1 and MC_PC_13048) and Cancer Research UK 






Chronic inflammation, which is partly mediated via the interleukin 6 (IL-6) pathway, has been 
hypothesized to play a critical role in the pathophysiology of type 2 diabetes (T2D)112,123. In 
obesity, the enhanced production of IL-6 and other pro-inflammatory mediators as a result of 
higher BMI is associated with insulin resistance138,139,171 and with a higher risk of T2D154,186 and 
coronary heart disease189. In addition, evidence from animal models and observational 
epidemiology has linked chronic inflammation with metabolic disease risk factors including 
disruption of lipid metabolism,138,223 hypertension331–333 and impaired insulin 
secretion123,139,270,334. On this basis, it has been hypothesised that therapeutically targeting 
inflammatory pathways may reduce the risk of T2D or improve glycaemic control in people 
with diabetes9,112,186,335. 
 
While small scale clinical trials had provided initial supportive evidence of possible 
benefit,123,218 this notion has been strongly challenged by the negative findings of the 
Canakinumab™ Anti-inflammatory Thrombosis Outcome Study226,336 (CANTOS). In a pre-
specified secondary analysis of this trial of 10,061 people with previous myocardial infarction 
and high CRP, treatment with the interleukin-1β inhibitor Canakinumab™ substantially 
reduced circulating inflammatory markers, but did not significantly reduce risk of new-onset 
diabetes in participants without diabetes at recruitment, or improve glycaemia in participants 
with diabetes221.  
 
However, the possible therapeutic benefit on diabetes risk of directly inhibiting the IL-6 
pathway has not been directly evaluated in large trials. In cardiovascular medicine, biomarker 
studies showing associations of higher IL-6 levels with higher cardiovascular disease 
incidence89,90,189,190 and genetic studies88,160,337 showing robust associations of an 
experimentally-validated310 partial loss-of-function variant in the IL-6 receptor gene with 
protection against coronary disease have provided the evidence base for ongoing clinical trials 
that are evaluating the effects of IL-6 receptor inhibition in myocardial infarction. 
 
In this study, biomarker and human genetic data from large-scale population-based cohorts 
were combined to investigate the possible etiologic role of IL-6 and IL-6 receptor (IL-6R) 





Three sets of analyses were used to investigate the relationships between the IL-6 pathway 
and T2D (Table 4.1 and Figure 4.1). In stage 1, the associations between IL-6 levels, 
glycaemic and anthropometric traits, and risk of incident T2D were estimated in two 
population-based cohort studies and a meta-analysis of 15 prospective studies (Figure 4.1A, 
Table 4.1 and Table S4.1). In stage 2, the association of a missense variant (Asp358Ala) in 
the interleukin 6 receptor gene (IL6R) with T2D was estimated in a trans-ethnic meta-analysis 
of six case-control studies (Figure 4.1B, Table 4.1 and Table S4.1). In stage 3, the proportion 
of the association between body mass index (BMI) and risk of cardio-metabolic disease 
outcomes mediated by IL-6 levels was estimated in three population-based cohort studies 
(Figure S4.1, Table 4.1 and Table S4.1). All studies were approved by local institutional 
review boards and ethics committees and participants gave written informed consent. 
 
Table 4.1: Summary of the study design. 












Stage 1: Estimate 
the association of IL-
6 levels with incident 





level data); 14 
prospective studies 
(summary statistics) 
Risk ratio and 
95% CI 
P < .05  
Stage 2: Estimate 
the association of 
IL6R Asp358Ala with 









Suzuki et al.340 
(summary statistics)  
Odds ratio and 
95% CI 
P < .05 
Stage 3: Estimate 
the proportion of the 
associations 
between BMI and 
cardiometabolic 
diseases and BMI 
and fasting insulin 






















and 95% CI 
(%)  
Abbreviations: IL-6, interleukin 6; EPIC, European prospective investigation into cancer and nutrition; DIAMANTE; 
Diabetes meta-analysis of trans-ethnic association studies; MVP, Million veteran program; CI, confidence interval 
Data sources for secondary analyses are summarised in Table S4.1.  
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Figure 4.1: Study design. Panel A. Prospective association between IL-6 levels and risk of 
incident type 2 diabetes. Panel B. Mechanism by which IL6R Asp358Ala leads to dampened 
IL-6 mediated inflammation. Asp358Ala increases the proteolytic cleavage of the IL-6R, 
depicted with a pair of scissors, resulting in dampened classical IL-6 signalling. This is 
comparable to the effects of an IL-6R antagonist, shown at the bottom of the panel. 
Abbreviations: T2D, type 2 diabetes; IL-6, interleukin-6; IL-6R, interleukin 6 receptor (protein); Asp, 
aspartic acid; Ala, alanine; gp130, Glycoprotein 130.Modified from Servier Medical Art, licensed under 
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Studies and participants 
Participants from EPIC-Norfolk241 and Fenland244 are described in Chapter 2 and outlined in 
Table 1. UK Biobank66 (data collection: 2006-2019; Table 1) is a population-based cohort 
study of individuals recruited from 22 rural and urban recruitment centres in the United 
Kingdom. European ancestry participants with available genome-wide genotyping and 
phenotypic data were included in this study. Ethical approval for the UK Biobank study was 
given by the North West - Haydock Research Ethics Committee (16/NW/0274). This research 
was conducted using application 44448. Participants gave their electronic consent to use their 
anonymised data and samples for health-related research, to be re-contacted for further sub-
studies, and for access to their health-related records. 
 
The association of IL-6 levels with incident T2D was estimated in a meta-analysis of 
prospective studies including EPIC-Norfolk241 and 14 other studies186,225,239,240 (data collection: 
1998-2018) as described in Methods S4.1 and Tables S1-S4. Estimates from EPIC-Norfolk 
were generated as part of this study and contributed 8% of the total incident cases and 22% 
of the non-cases to the analysis. The association of IL6R Asp358Ala with prevalent T2D was 
estimated in a trans-ethnic meta-analysis of results from individual-level data in UK Biobank, 
and summary-level data from the European ancestry analysis of the Diabetes Meta-analysis 
of Trans-ethnic Association Studies22 (DIAMANTE; data collection: 2018-2019; Table S4.1), 
Million Veteran Program337,341 (MVP; data collection: 2011-2019; Table S4.1), Finngen338 
(Finngen; data collection: 1996-2016; Table S4.1), MyCode Study from the DiscovEHR 
Collaboration between Regeneron Genetics Center and Geisinger Health System339,342 
(Geisinger; data collection: 2007-2020; Table S4.1) and a recent Japanese meta-analysis340 
(Suzuki et al.; data collection: 2003-2012; Table S4.1). The association of IL6R Asp358Ala 
with prevalent type 1 diabetes was estimated in a meta-analysis of results from individual-level 
data in UK Biobank, and summary-level data from the Type 1 Diabetes Genetics consortium326 
(T1DGC; data collection: 2004-2019; Table S4.1) and MVP341 (data collection: 2011-2019; 
Table S4.1). Summary-level results from 10 previously published genome-wide association 
studies were used in different analyses of the study (Table S4.1).These included associations 
with BMI, BMI-adjusted waist-to-hip ratio (WHR), unadjusted WHR, waist- and hip-
circumference from a meta-analysis of Genetic Investigation of Anthropometric Traits343 
(GIANT) consortium and UK Biobank30, associations with fasting glucose, glucose at 2 hours 
after an oral glucose challenge and fasting insulin from the Meta-analyses of Glucose and 
Insulin-related Traits consortium344–346 (MAGIC).The association with HbA1c was estimated in 
a meta-analysis of UK Biobank66 and MAGIC347 (Table S4.1).The association with non-fasting 




Exposure and outcome variables 
In stage 1, the exposure variable was the circulating level of IL-6 (log-transformed and 
expressed in log-pg/mL), measured as described in Chapter 2. Log-transformed IL-6 
measures were preferred to inverse-rank normal transformed measures as in Chapter 2 as 
(1) I aimed to meta-analyse the EPIC-Norfolk estimates of the association between IL-6 levels 
and T2D with estimates previously reported in log-pg/mL, and (2) in Chapter 2 I aimed to 
compare association estimates across cytokines, whereas in this analysis only IL-6 levels 
were of interest.    
  
The outcome variable used in the meta-analysis was incident T2D from the EPIC-Norfolk 
study. Fasting glucose, glucose at 2 hours after an oral glucose challenge, HbA1c, fasting 
insulin, waist-to-hip ratio (WHR), BMI, iron, transferrin, ferritin, body fat percentage, abdominal 
fat mass, gluteofemoral fat mass, leg fat mass, abdominal to gluteofemoral fat mass ratio, 
peripheral fat mass, visceral fat mass and subcutaneous fat mass from the Fenland study 
were used in observational analyses. Incident T2D was defined as described in Chapter 2. 
Fasting glucose, two-hour glucose, fasting insulin, HbA1c, weight, height, BMI, waist and hip 
circumferences, WHR, and DEXA overall and compartmental fat masses were measured as 
described in Chapter 2 (Table S4.5). Iron (in µmol/L), transferrin (in g/L) and ferritin (in µg/L) 
were measured using the Dimension RxL Integrated Chemistry System (Siemens, Germany).  
 
In stage 2, the exposure variable was the genotype of rs2228145 (HUGO Gene Nomenclature 
Committee gene name, IL6R; transcript change, NCBI transcript identifier NM_000565.3 
c.1073A>C; protein change, Asp358Ala). The variant 358Ala protein (encoded by the minor 
allele C; allele frequency in European ancestry participants in the 1000 Genomes Project, 
36%) has been experimentally shown to be more susceptible to proteolytic cleavage by 
ADAM-proteases348, resulting in enhanced shedding of soluble IL-6R, reduced expression of 
the membrane-bound form of the receptor310 and impaired cellular responsiveness to IL-6310. 
On this basis, the variant allele has been hypothesized to impair signalling of the IL-6 receptor 
via its classical pathway in a way that mimics the effects of IL-6R inhibition using therapeutic 
monoclonal antibodies approved for the treatment of autoimmune conditions88,160. The pattern 
of association of this variant with a variety of intermediate traits and outcomes is highly 
consistent with the effects of IL-6R inhibitory drugs on those same traits in randomized clinical 
trials88,160. Hence, this variant has been used in several previous studies as a genetic 
instrument to study the likely consequences of pharmacological IL-6R inhibition. In UK 
Biobank, the variant genotype was obtained via imputation to the Haplotype Reference 
Consortium v1.1,271 UK10K273 and 1000 genomes phase 3349 reference panels as previously 
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described. The imputation quality score was 1 (i.e. the maximum possible score), indicating 
excellent imputation quality comparable with direct genotyping. 
 
The outcome variables were T2D in the primary analysis and type 1 diabetes, fasting glucose, 
2-hour glucose, non-fasted glucose, fasting insulin, HbA1c, BMI, WHR, BMI-adjusted WHR, 
waist and hip circumference in secondary analyses. In UK Biobank, binary definitions of 
prevalent disease and a case-control analytical design were used as previously described30. 
Participants were classified as cases of T2D if they had: (1) self-reported T2D diagnosis or (2) 
self-reported use of oral anti-diabetic medications at nurse interview or at digital questionnaire, 
or (3) an electronic health record consistent with T2D (ICD-10 code E11). Participants were 
classified as cases of type 1 diabetes if they had: (1) self-reported type 1 diabetes diagnosis 
or (2) self-reported use of insulin but not oral anti-diabetic medications at nurse interview or at 
digital questionnaire, or (3) an electronic health record consistent with type 1 diabetes (ICD-
10 code E10). Participants with evidence of diabetes but for whom the type of diabetes was 
unclear (e.g. participants reporting T2D but treated with insulin only or participants with 
electronic health records of both type 1 and T2D, code E10 in some electronic records but 
E11 in other records) were excluded. Controls were participants who (1) did not self-report a 
diagnosis of diabetes of any type, and (2) did not take any diabetes medications, and (3) did 
not have an electronic health record of diabetes of any type. Summary results for the 
association with glycaemic and anthropometric traits were extracted from the results of 
previous genome-wide association studies (Methods S4.2, Table S4.1 and Table S4.6). 
 
In stage 3, the exposure variables were BMI and a polygenic score for higher BMI. The latter 
was derived using 97 BMI-associated common variants from a previous genome-wide 
association study309 (Table S4.7). For each individual, the polygenic score was computed by 
adding the number of copies of each contributing genetic variant weighted by its association 
estimate in kg/m2 units of BMI per allele. 
 
The outcome variables were T2D, coronary heart disease and fasting insulin levels. T2D was 
defined as described above. In EPIC-Norfolk, incident coronary heart disease was defined as 
new-onset coronary heart disease in a participant without coronary heart disease at the time 
of IL-6 measurement based on an electronic health record consistent with ischemic heart 
disease (ICD-10 codes I20-25). Participants with coronary heart disease at the time of IL-6 
measurement were excluded. In UK Biobank, prevalent coronary heart disease was defined 
as either (1) myocardial infarction or coronary disease documented in the participant’s medical 
history at the time of enrolment by a trained nurse or (2) an electronic health record of acute 
myocardial infarction or its complications (ICD-10 codes I21-I23). Controls were participants 
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who did not meet any of these criteria. Summary-level results from MAGIC346 were used for 
fasting insulin levels. 
 
The mediator variable was the level of IL-6 in plasma measured by electrochemiluminescence 
as described above. 
 
Statistical analysis 
In stage 1, Cox regression models were used to estimate the association between IL-6 levels 
and T2D, as described in Chapter 2. Incident rates were calculated as number of incident 
cases divided by the total person-years of follow-up in people at risk. Absolute rate differences 
were obtained for each decile of the IL-6 distribution in EPIC-Norfolk relative to bottom decile 
(i.e. lowest IL-6 level) and 95% confidence intervals were calculated as ± 1.96 * √(number of 
incident cases in decile/(total follow-up in decile)2 + number of incident cases in bottom 
quantile/(total follow-up in bottom decile2)). The interaction between IL-6 levels and BMI on 
risk of incident type 2 diabetes was estimated by including an interaction term for BMI in the 
Cox regression model and adjusting for covariates as before, with the exclusion of BMI as a 
covariate. Estimates of association from the EPIC-Norfolk study and other 14 prospective 
studies186,225,239,240 were pooled using inverse-variance weighted fixed-effect meta-analysis, 
making the assumption that the study-specific estimates of association all approximated the 
relative risk. Linear regression models were used to estimate associations between IL-6 and 
glycaemic traits. Models were adjusted using three methods: (1) for age and sex, (2) for age, 
sex and DEXA-derived detailed anthropometric variables, (3) for age, sex, DEXA variables 
and iron variables (iron, ferritin and transferrin) to mitigate the effects of IL-6 levels on hepcidin 
and iron metabolism. 
  
In stage 2, the association between IL6R Asp358Ala and IL-6 levels in Fenland and EPIC-
Norfolk were estimated using linear regression adjusting for age, sex, genotyping platform and 
the first 10 genetic principal components.  The associations of IL6R Asp358Ala in UK Biobank 
were estimated using linear (continuous outcomes) or logistic (binary outcomes) regression. 
To minimize genetic confounding, association analyses were restricted to European ancestry 
individuals, identified by combining k-means clustering of genetic principal components with 
self-reported ancestry. To control for relatedness, analyses were either clustered using family 
structure data (third degree relatives) and adjusted for 40 genetic principal components or 
performed using linear mixed-effects models adjusting for a genomic kinship matrix. All 
analyses were adjusted for age, sex and genotyping array. Association estimates from UK 





Various secondary and sensitivity analyses, described below, were conducted to provide 
context for the association of IL6R Asp358Ala with T2D. In UK Biobank, the proportion of 
variance in T2D and coronary heart disease explained by the IL6R Asp358Ala variant was 
estimated as the difference in R2 between a regression model including Asp358Ala and 
covariates (age, sex, genotyping array and genetic principal components) and one including 
only the covariates. The heritability explained by the variant was estimated by rescaling the 
variance explained by the heritability in T2D and coronary heart disease estimated using 
linkage disequilibrium score regression287 (Methods S4.2). The association of Asp358Ala with 
T2D was also estimated while conditioning on an independent association signal upstream of 
Asp358Ala. 
 
To assess whether the association with T2D might be influenced by misclassification of cases 
of type 1 diabetes (i.e.an etiologic subtype of diabetes where immune pathways have an 
established causal role) as cases of T2D, the association of IL6R Asp358Ala with T2D was 
tested in individuals below the median value of a polygenic score for type 1 diabetes350. This 
approach has been shown to enable the exclusion of over 95% type 1 diabetes cases present 
in a dataset (sensitivity of values above the median to detect type 1 diabetes, 96%; false 
negative rate [i.e. type 1 diabetes cases left in individuals below the median], 4%)350. 
Simulations revealed that, when using this approach, only 46 (0.4%) misclassified cases out 
of over 11,000 cases of T2D would remain in the analysis, even in the extreme scenario that 
100% of type 1 diabetes cases in UK Biobank were misclassified as T2D (Methods S4.2). 
  
To assess whether genetic predisposition to lower IL-6R signalling due to IL6R Asp358Ala 
genotypes interact with genetic predisposition to known risk factors for T2D, the association 
of IL6R Asp358Ala with T2D was estimated in individuals above or below the median value 
for 10 polygenic scores capturing genetic predisposition to higher fasting glucose345,346, fasting 
insulin345,346, HbA1c via glycaemic-related mechanisms347, insulin resistance345,351, impaired 
insulin secretion351, BMI343, BMI-adjusted WHR30, BMI-adjusted WHR via lower gluteofemoral 
fat30, BMI-adjusted WHR via higher abdominal fat30 and lower BMI via a β-arrestin biased gain-
of-function variants in MC4R352 (Table S4.7). The analysis was then repeated using HbA1c 
levels in UK Biobank as the outcome and a polygenic score for higher BMI as the interaction 
variable. 
  
While both experimental310 and genetic88,160 association studies have shown that rs2228145-
C (358Ala) has phenotypic associations that mimic the effects of IL-6R inhibitory therapy, an 
association of this variant with lower risk of T2D does not necessarily mean that IL-6R 
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inhibitory therapy will produce clinically meaningful reduction in the risk of T2D. Even when 
assuming that the effects of a genetic variant and that of a drug on the target are qualitatively 
the same, two differences remain. The first is that genetic variants are usually associated with 
small differences in the activity of the target gene, while drugs usually have large effects on 
target activity. The second is that the small differences in target gene activity associated with 
a genetic variant are lifelong, while the effect of drugs is usually assessed in trials of short 
duration. Statistical approaches have been proposed to model these differences and formulate 
approximate projections of a range of possible effects of drug treatment on the basis of the 
magnitude of genetic associations222,353. In this study, a projected range of possible effects for 
IL-6R blocking therapy on incident T2D in a primary prevention setting were formulated using 
(a) the genetic association of IL6R Asp358Ala with diabetes in this study, (b) the genetic 
association of IL6R Asp358Ala with C-reactive protein (used as biomarker of IL-6R mediated 
inflammation) in this and other studies88 and (c) the effects of IL-6R blocking therapy on C-
reactive protein (the most-widely used biomarker of target engagement for IL-6R blocking 
therapy) in randomized clinical trials160. Assumptions and details of the methods employed in 
these calculations are in Methods S4.2. 
  
In stage 3, two mediation models were utilized (Figure S4.1). The first estimated the 
proportion of the association between measured BMI and cardio-metabolic disease outcomes 
mediated by IL-6 levels (observational mediation). The second estimated the proportion of the 
association between genetic predisposition to higher BMI and cardio-metabolic disease 
outcomes mediated by IL-6 levels (genetic mediation). The genetic analysis was also repeated 
using fasting insulin levels as the outcome. As genetic associations are robust to non-genetic 
forms of confounding, I hypothesized that the second model would be more conservative in 
estimating the role of IL-6 levels as a possible mediator. 
  
The proportion of association mediated by IL-6 was estimated using the Baron-Kenny354 
method. To obtain a 95% confidence interval for this proportion, 80% of individuals from each 
sample population used in each step of the mediation analysis were randomly sampled and 
the respective analyses were performed with 1000 iterations per arm of the framework. 
Sampled individuals were replaced prior to the next iteration. Mediation estimates were 
calculated for the 1000 iterations and the 2.5th and 97.5th percentile mediation estimates 
respectively were used as the lower and upper bounds of the 95% confidence interval. 
P-values <.05, or the Bonferroni correction corresponding to P<.05 for each analysis of the 
study with multiple exposures or outcomes, were considered statistically significant. All 
reported P-values were from 2-tailed statistical tests. Statistical analyses were performed 
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using STATA v14.2 (StataCorp, College Station, Texas 77845 USA), R v3.2.2 (The R 




IL-6 levels, anthropometric and glycaemic measures and risk of T2D 
Among 7,421 participants of the EPIC-Norfolk cohort, median levels of IL-6 were 0.59 pg/mL 
(interquartile range [IQR], 0.42, 0.85 pg/mL; Table 4.2).  
Table 4.2: Study participants 
Study Fenland EPIC-Norfolk UK Biobank 
Participants, N 10,344 7,421 447,491 
Age at baseline, mean years (SD) 48 (8) 62 (9) 57 (8) 
Women, N (%) 5,528 (53) 4,536 (61) 243,114 (54) 
Men, N (%) 4,816 (47) 2,885 (39) 204,377 (46) 
Current smokers, N (%) 1,236 (12) 574 (8) 46,459 (10) 
BMI in kg/m2, mean (SD) 26.7 (4.5) 26.4 (3.8) 27.4 (4.7) 
Waist-to-hip ratio, mean (SD) 0.88 (0.09) 0.84 (0.09) 0.87 (0.09) 
Systolic blood pressure in mmHg, mean 
(SD) 
122 (15) 134 (18) 138 (19) 
Diastolic blood pressure in mmHg, mean 
(SD) 
74 (10) 81 (11) 82 (10) 






IL-6 in log-pg/mL, mean (SD) -0.77 (0.94) -0.55 (0.83) N/A 
In UK Biobank genotyping was performed using the Affymetrix 500K and Affymetrix UK BiLEVE genotyping chips 
and imputation was performed using the Haplotype Reference Consortium v1.1, UK10K and 1000 Genomes phase 
3 reference panels. IL-6 levels were not measured in UK Biobank. 
Abbreviations: N/A, not available; N, number of participants; SD, standard deviation; BMI, body mass index; IL-6, 
Interleukin-6; IQR, Interquartile range   
 
A total of 411 incident cases of T2D occurred over 122,115 person-years of follow-up 
(incidence rate, 3.4 per 1000 person-years). Higher levels of IL-6 were associated with higher 
incidence of T2D (hazard ratio [HR] per log-pg/mL higher IL-6 levels, 1.25; 95% CI, 1.10, 1.41; 
P<.001), with participants in the top decile of IL-6 levels having approximately 2-fold higher 
hazard compared to the bottom decile (HR, 2.14; 95% CI, 1.21, 3.81; P=.009; absolute rate 
difference in incident cases per 1000 person-years, 4.2; 95% CI, 2.8, 5.7; Figure S4.3). The 
difference between these results and those presented in Chapter 2 is that these are natural 
log transformed, whereas those in Chapter 2 were inverse-rank normal transformed to enable 
comparison across cytokines. For comparison, participants in the top decile of BMI had 
approximately 6-fold higher hazard compared to those in the bottom decile (HR, 5.64; 95% 
CI, 2.77, 11.49; P=2x10-6; Figure S4.4). No evidence of an interaction between IL-6 levels 
and BMI was found on incident type 2 diabetes risk (Pinteraction=0.86). A meta-analysis of 15 
prospective studies including 5,421 incident cases and 31,562 non-cases showed a robust 
association between higher IL-6 levels and higher incident T2D, with a pooled hazard ratio 
that was approximately the same as that of the EPIC-Norfolk analysis (Figure 4.2A). In 
sensitivity analyses, no evidence of publication bias or bias induced via differing IL-6 
quantitation methods used between studies was found (PEgger = 0.44; Methods S4.1). In 
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10,344 participants of the Fenland cohort, IL-6 levels were positively correlated with DEXA-
measures of overall adiposity and abdominal fat distribution, which accounted for 9% of the 
variance in IL-6 levels (Table S4.8). After extensive adjustment for adiposity measures, higher 
IL-6 levels remained associated with higher HbA1c levels, but not with fasting glucose, 2-hour 
glucose or fasting insulin (Figures 4.2B and 4.2C). This remained after further adjustment for 
iron-related traits to mitigate the effects of IL-6 on hepcidin and iron metabolism (beta in % per 
log-pg/mL higher IL-6 levels, 0.04; 95% CI, 0.03, 0.05; P=<.001).   
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Figure 4.2: Association of IL-6 levels with type 2 diabetes and glycaemic traits. Panel 
A. Association between higher IL-6 levels and type 2 diabetes in 15 prospective studies. The 
study-specific estimates of association (here labelled “Relative Risk” (RR)) and their 95% 
confidence intervals are shown per log-pg/mL higher IL-6 levels. Thorand et al., 2007 is 
depicted with sex-stratified estimates as different IL-6 quantitation methods were used in men 
and women. Panel B. Association between IL-6 levels and glycaemic traits in the Fenland 
study. Estimates are presented in standard deviation and clinical units of continuous outcome 
per log-pg/mL higher IL-6 levels. Panel C. Association between IL-6 levels (in deciles) and 
HbA1c.Estimates are shown for a given decile compared to the bottom decile (reference 
group) and are adjusted for age, sex, DEXA adiposity measures and iron-related traits. 
Abbreviations: RR, risk ratio; CI, confidence interval; F, females; M, males; pg, picograms; mL, millilitres; L, litres, 
mmol; millimoles; pmol, picomoles; HbA1c, glycated haemoglobin; DEXA, dual-energy X-ray absorptiometry; IQR, 
inter-quartile range; SD, standard deviation.  
Overall  
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0.01 (0.002, 0.02) 0.020.02 (0.004, 0.04)
Beta (95% CI)
in SD units
Age and sex adjusted




0-.1 .1 .2 .3 .4 .5 .6
Beta (95% CI) in SD units of HbA1c 





2 0.700.01 (-0.03, 0.04) 0.01 (-0.06, 0.09)0.33 (0.30-0.36)
3 0.400.01 (-0.02, 0.05) 0.03 (-0.04, 0.11)0.41 (0.40-0.43)
4 0.570.01 (-0.02, 0.04) 0.02 (-0.05, 0.10)0.48 (0.47-0.50)
5 0.770.01 (-0.03, 0.04) 0.01 (-0.06, 0.09)0.55 (0.53-0.57)
6 0.330.02 (-0.02, 0.05) 0.04 (-0.04, 0.12)0.63 (0.61-0.65)
7 0.020.04 (0.01, 0.08) 0.10 (0.02, 0.18)0.73 (0.70-0.76)
8 1 x 10-40.07 (0.04, 0.11) 0.16 (0.08, 0.24)0.85 (0.82-0.89)
9 5 x 10-120.13 (0.10, 0.17) 0.29 (0.21, 0.37)1.07 (1.00-1.16)
10 9 x 10-150.15 (0.11, 0.19) 0.33 (0.25, 0.41)1.73 (1.43-2.63)
IL6 in pg/mL, 
median (IQR)
1 ReferenceReference Reference0.16 (0.09-0.23)
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Genetically impaired IL6R signalling and T2D risk 
In 14,528 participants from the Fenland and EPIC-Norfolk cohorts, each copy of the 358Ala 
partial loss-of-function variant in IL6R was associated with 0.11 log-pg/mL (95% CI, 0.09, 0.13; 
P<.001) higher IL-6 levels. In 260,614 cases and 1,350,640 controls, each copy of the 358Ala 
partial loss-of-function variant in IL6R was associated with an odds ratio for T2D of 0.98 (95% 
CI, 0.97, 0.99; P<.001; Figure 4.3A). In UK Biobank, the odds of T2D was lowest in carriers 
of two copies of the 358Ala allele (OR compared with non-carriers, 0.92; 95% CI, 0.89, 0.96; 
P<.001; Figure S4.5), with no statistical evidence of deviation from an additive association 
(Pnon-linearity=0.13; Figure S4.5). In the UK Biobank study, estimates of association with T2D for 
Asp358Ala were comparable in odds ratio, variance explained and heritability to those for 
coronary heart disease (Figure S4.5 and Table S4.9). The association of Asp358Ala with 
diabetes was conditionally independent of an association peak for T2D led by rs2481065, 
which is located 115,059 base pairs upstream of the Asp358Ala variant (OR per copy of 
358Ala conditioned on rs2481065, 0.97; 95% CI, 0.95, 0.99; P=.007; Table S4.10). The 
association with T2D of the Asp358Ala variant was not the consequence of case-admixture 
(diagnostic misclassification) between type 1 and T2D. First, in an analysis including 24,209 
cases and 758,240 controls, each copy of the 358Ala allele was associated with an odds ratio 
for type 1 diabetes of 0.97 (95% CI, 0.95, 0.99; P=.007; Figure S4.6). Given the ~10-fold 
higher prevalence of type 2 vs type 1 diabetes in the general population350 and similar 
magnitude of association, only very high levels of misclassification might lead to a spurious 
association with T2D (Figure S4.7). To further address this, a sensitivity analysis was 
conducted in UK Biobank where possible cases of type 1 diabetes were excluded on the basis 
of a cut-off of a polygenic score for type 1 diabetes (sensitivity to detect type 1 diabetes cases 
for exclusion >95%)350. In this analysis, estimates of the association with T2D were 
approximately the same as those in the main analysis (OR for T2D, 0.96; 95% CI, 0.94, 0.99; 
P=.008; Figure 4.3B). 
 
In continuous metabolic trait analyses, the 358Ala allele was associated with lower HbA1c 
(beta in SD units per copy of 358Ala, -0.007; 95% CI, -0.012, -0.003; P=.002; Figure S4.8) 
and numerically lower BMI-adjusted WHR (beta in SD units per copy of 358Ala, -0.004; 95% 
CI, -0.008, 0; P=.03; Figure S4.8). The latter association was not statistically significant after 





Figure 4.3: Association of IL6R Asp358Ala with type 2 diabetes, glycaemic and 
anthropometric traits. Panel A. Odds ratios and their 95% confidence intervals for type 2 
diabetes are presented per copy of 358Ala. Panel B. Association of Asp358Ala with type 2 
diabetes in UK Biobank before and after excluding participants based on the values of a type 
1 diabetes polygenic risk score. Both cases and controls were excluded if the type 1 diabetes 
score was above the median of the value among diabetes cases. Abbreviations: DIAMANTE, 
Diabetes meta-analysis of trans-ethnic association studies; UKBB, United Kingdom biobank; MVP, Million veteran 
program OR, odds ratio; CI, confidence interval; Asp, aspartic acid; Ala, alanine; T2D, type 2 diabetes; T1D, type 
1 diabetes. 
 
The association of Asp358Ala genotype was similar in people above or below the median of 
9 polygenic scores for T2D risk factors, with no evidence of interaction (Figure S4.9A). There 
was, however, evidence of a significant interaction between Asp358Ala genotype and a 
polygenic score for higher BMI on HbA1c levels (Pinteraction=0.009; Figure S4.9B).  Projections 
of the range of possible effects of IL-6R inhibition therapy in the primary prevention of T2D 
were generated based on results from genetic studies and biomarker data from trials. These 







Controls OR (95% CI) P-value
Main 22,182 424,361 0.96 (0.95, 0.98) 3x10-4
T2D cases and controls 
excluded if T1D score 
above median
11,450 222,238 0.96 (0.94, 0.99) 0.008
1.93 .94 .95 .96 .97 .98 .99
OR (95% CI) for type 2 diabetes 








Controls OR (95% CI) P-value
UKBB 22,182 424,361 0.96 (0.95, 0.98) 3x10-4
DIAMANTE 55,005 400,308 0.99 (0.97, 1.01) 0.18
Geisinger 26,616 64,558 0.99 (0.96, 1.01) 0.33
Suzuki, 2019 36,614 155,150 0.98 (0.96, 1.00) 0.02
MVP 109,191 223,608 0.98 (0.97, 0.99) 6x10-3
Finngen 11,006 82,655 0.98 (0.94, 1.01) 0.15
1.94 .96 .98 1.02
Overall  
(I2 = 0%, p = 0.55)
0.98 (0.97, 0.99) 2x10-7260,614 1,350,640
OR (95% CI) for type 2 diabetes 
per copy of 358Ala
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corresponding to a relative risk of 0.90, only when assuming long-term treatment duration with 
high dose inhibitors (Figure S4.10). 
 
Mediation by the IL-6 pathway of cardio-metabolic disease risk associated with higher 
adiposity  
Both higher measured BMI or genetic predisposition to higher BMI via a 97-variant polygenic 
score were associated with higher circulating IL-6 levels (0.14 log-pg/mL higher IL-6 levels per 
4.8 kg/m2 [corresponding to one standard deviation] higher measured BMI; 95% CI, 0.12, 0.16; 
P<.001; 0.13 log-pg/mL higher IL-6 levels per 4.8 kg/m2 higher BMI due to the polygenic score; 
95% CI, 0.05, 0.21; P=.001). The percentage of the BMI/T2D association mediated by IL-6 
was estimated to be 4% (95% CI, 3, 5%) in observational analyses and 3% (95% CI, 2, 5%) 
in genetic analyses. The percentage of the BMI/cardio-metabolic disease association 
mediated by IL-6 was estimated to be 18% (95% CI, 14, 25%) in observational analyses and 
10% (95% CI, 7, 15%) in genetic analyses. The percentage of the association between BMI 





This large genetic and biomarker study supports the hypothesis that IL-6 mediated 
inflammation plays a role in the aetiology of T2D, but it also suggests that the impact of this 
pathway on disease risk in the general population may be small. Early evidence of a possible 
role of inflammation in metabolic disease dates back to over 25 years ago139. Findings of an 
inflammatory response accompanying obesity109,138,223,356, insulin resistance138,223,270 and 
diabetes109,223,334,356, and the support of experimental results from cellular and animal models 
have led to the hypothesis that T2D may be viewed as an “inflammatory disease”123. 
 
This study provides large-scale human genetics evidence that supports the role of chronic 
inflammation via the IL-6 pathway in T2D. It also shows that IL-6 mediates in small part the 
links between obesity, insulin resistance and cardio-metabolic diseases, which has been a 
prevalent hypothesis in the field due to the evidence that the adipose tissue of insulin-resistant 
obese people is infiltrated with inflammatory cells137,138 and displays an enhanced secretion of 
IL-6, tumour necrosis factor alpha and other pro-inflammatory mediators109,270,356. 
Biomarker89,90,189,190 and human genetic88,160,337 results with similar strength to those of this 
study have formed part of the evidence basis for efforts to re-purpose IL-6R inhibitory therapy 
in cardiovascular disease (e.g. clinicaltrials.gov registered trials number NCT03004703, 
NCT01491074, or NCT02419937).  
 
However, several findings from this study suggest that the impact of the IL-6 pathway on risk 
of T2D in the general population may be small. Firstly, people in the top decile of IL-6 levels 
had a 2-fold (hazard ratio, 2.14) higher risk of incident T2D than people in the bottom decile. 
This is approximately three times smaller than the relative risk associated with being in the top 
decile of BMI in this study (hazard ratio, 5.64). While the association between Asp358Ala and 
lower T2D risk was statistically robust, consistent across studies and ancestries and was 
unaffected by possible misclassification of type 1 diabetes cases, the odds ratio of 0.98 for 
disease risk was lower for carriers of one copy and the odds ratio of 0.92 was lower for carriers 
of two copies of this partial loss-of-function allele compared to non-carriers. Finally, the 
proportion of BMI-associated risk of diabetes mediated by IL-6 levels was below 5%, ~3-4 
times smaller than for coronary disease. In line with this, the proportion of the association 
between BMI and fasting insulin levels mediated by IL-6 was around 3%. Taken together, 
these results suggest that removing inflammation via this pathway may not substantially 
impact on diabetic risk in obesity but still represents a biologically significant effect. 
  
This study has limitations. First, as this study is based on observational epidemiology findings 
and not randomised controlled trial data, it cannot definitively establish causality. Second, this 
 
91 
study did not exclude patients with pre-existing inflammatory conditions or acute infections at 
baseline. Although I cannot exclude the possibility that IL-6 levels may have been impacted 
by acute infections at baseline, to affect the observational results presented, IL-6 levels would 
have to differ significantly at the time of prospective type 2 diabetes diagnosis to have an 
effect. In addition, the study design included follow-up of these observational analyses with 
genetic analyses which are robust to this type of confounding. Despite these efforts to mitigate 
this potential confounding, capturing infection-mediated inflammation in observational studies 
is challenging and is therefore a limitation of this study. Third, some of the findings of this study 
assume that the IL6R Asp358Ala variant mimics the effects of IL-6R inhibition. While the in 
vitro consequences310 and the pattern of association88,160 of this variant with a variety of 
phenotypes have been shown to be consistent with the effects of IL-6R inhibitory drugs, 
differences cannot be excluded which could affect some of the estimates reported here. Using 
re-scaling methods to project the possible efficacy of IL-6R blocking therapy in primary 
prevention based on estimates of lifelong genetic associations, the projected relative risk 
reduction was below 10% in most simulated scenarios. In comparison, relatively safe and 
inexpensive lifestyle interventions28, metformin28 or other hypoglycaemic drugs357 have been 
associated with reductions in the incidence of diabetes ranging from 30% to 70% in previous 
primary prevention trials. However, due to the underlying assumptions, this estimate is likely 
to be conservative and may underestimate the effect of IL-6R antagonists, which profoundly 
inhibit the pathway. In contrast to pharmacological antagonism, the IL6R Asp358Ala variant 
results in a partial loss of IL-6 mediated signalling and may therefore not be the most 
informative model to estimate the possible effects IL-6R blockade on glucose metabolism 
achieved through complete or near-complete pharmacological inhibition of this pathway. In 
addition, IL-6 is a pleiotropic cytokine that has established pro- and anti-inflammatory effects 
that act via the classical and trans signalling pathways358. It is therefore conceivable that the 
Asp358Ala variant acts upon the anti-inflammatory effects of IL-6 signalling and may have 
impacted upon the results of this study. Fourth, while some of the results from this study 
suggest that IL-6R inhibition might have limited efficacy for the primary prevention of T2D, 
these findings focus on first occurrence of disease in people from the general population. 
Hence, these findings do not exclude that IL-6R inhibition may yield clinically significant 
benefits on glucose metabolism in groups of people at risk for T2D, or on glycaemic levels and 
risk of complications in patients with T2D. In fact, in a post-hoc meta-analysis of three 
randomized controlled trials of the IL-6R inhibitor sarilumab including 1,982 patients with 
rheumatoid arthritis, Genovese and colleagues showed statistically-significant improvements 
in HbA1c in patients randomized to sarilumab as opposed to placebo (least squares mean 
difference in HbA1c ranging from −0.21% to −0.69%), which were more pronounced at higher 
dosages and in patients who also had diabetes212. This finding is further reinforced by results 
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demonstrating a significant 0.4% reduction in HbA1c in 67 rheumatoid arthritis patients treated 
with tocilizumab359. Therefore, it is possible that IL-6R inhibition may yield clinically meaningful 
changes in glycaemia in people with inflammatory or immune conditions which are linked with 
diabetes. Results from the interaction analysis between Asp358Ala and BMI on HbA1c levels 
suggest that reductions in HbA1c may be more pronounced in individuals below the median 
of the BMI polygenic score. However, as this result was estimated in a population-based 
cohort, this requires validation in a cohort selected for participants with existing inflammatory 
conditions. Finally, while the associations observed in this study are statistically robust and 
despite a growing body of research in the topic, the molecular mechanisms linking the IL-6 
inflammatory pathway with glucose metabolism remain only partly understood. In this study, 
IL-6 levels and the IL6R Asp358Ala variant were more strongly associated with HbA1c, which 
reflects average glycaemic levels in the three months prior to measurement, than with other 
glycaemic traits. Infection and other inflammatory challenges are associated with reactive 
hyperglycaemia360, which may be aggravated in people with higher IL-6 levels361. It is possible 
that enhanced glycaemic response to inflammatory stimuli may explain part of the associations 
between higher IL-6 mediated inflammation and higher diabetes risk observed in this study. 
 
In conclusion, this large human genetics and biomarker study supports the hypothesis that IL-
6 mediated inflammation is implicated in the pathophysiology of T2D but suggests that the 





Chapter 5: Estimating the Inflammatory Proteins and Pathways 
Implicated in Cardiometabolic diseases: A Multi ‘Omics Approach 
Contributions and collaborations 
I designed the study, collated all input datasets and performed all analyses described in this 
chapter aside from the GWAS for each of the protein targets covered by the SomaLogic v4 
assay. The SomaLogic GWAS formed part of a larger effort to characterise the role of 
circulating proteins on diverse health outcomes which is being led by Dr. Eleanor Wheeler. 
Both Dr. Wheeler and Dr. Maik Pietzner provided methodological support during this work. I 






Background: Evidence from in vitro studies, animal models and observational epidemiology 
points to an inflammatory component in the aetiology of cardiometabolic diseases. However, 
the proteins and pathways involved are sparsely characterised and the direction of effect is a 
matter of debate, i.e. it is unclear whether inflammation is causal for or a result of disease. 
Methods: Using a combination of GO terms and reciprocal lookup, inflammatory proteins with 
suggestive evidence (P≤1x10-5) of a genetic association with cardiometabolic diseases were 
identified. Next, the colocalisation between all identified proteins and cardiometabolic 
diseases was estimated using HyPrColoc, a Bayesian multi-trait colocalisation framework. 
Following this, the levels of proteins which colocalised with cardiometabolic diseases were 
tested for association with polygenic scores for established risk factors for cardiometabolic 
diseases using multivariable linear regression. Finally, gene set enrichment analysis was 
performed to estimate whether inflammatory proteins which colocalised with cardiometabolic 
diseases were enriched in particular pathways.  
Findings: A total of 3,214 human proteins were identified using GO terms, of which 1,358 
were captured by the SOMAscan v4 assay. Reciprocal lookup of sentinel variants for disease 
and inflammatory protein levels in GWAS summary statistics resulted in 335 inflammatory 
proteins with at least suggestive evidence of an association with either of the two diseases. A 
total of 10 and 18 loci were identified where inflammatory proteins colocalised with T2D and 
CHD, respectively. T2D was estimated to colocalise with a total of 164 inflammatory proteins 
whereas CHD colocalised with 181 proteins. However, closer examination showed that 95% 
and 85% of proteins which colocalised with T2D and CHD colocalised at a minimum of one 
established pleiotropic locus. In addition, 42% and 36% of proteins which colocalised with T2D 
and CHD respectively were associated with at least one polygenic score (PGS) for an 
established cardiometabolic risk factor, with triglyceride-PGS associated with the levels of the 
most proteins in each case. Finally, gene set enrichment analysis showed that inflammatory 
proteins which colocalised with cardiometabolic diseases were significantly enriched in the 
human complement cascade.  
Conclusion: This study identified multiple loci where inflammatory proteins colocalised with 
cardiometabolic diseases, however, this was largely at pleiotropic loci. The strong association 
of PGS for established cardiometabolic risk factors with many candidate proteins suggests 
that inflammation may be resultant of the genetic predisposition to either the disease or its 
associated risk factors. Therefore, the inflammatory component of cardiometabolic diseases 
is unlikely to be an independent causal risk factor for disease and is likely to be resultant of a 




Modern technologies have facilitated the simultaneous, large scale quantification of many 
biomarker levels. This has increased interest in their relevance to disease as putative drug 
targets and how they may be used to predict disease risk68. The inflammatory component of 
cardiometabolic diseases is a central aspect of the aetiology of cardiometabolic diseases that 
is still yet to be fully elucidated4,109,112,123,125,223,268. As outlined in Chapter 1, evidence from in 
vitro studies111,137–139, animal models123,223,270 and observational epidemiology94,154,155,168,181 has 
pointed to a role for chronic inflammation in cardiometabolic diseases. However, whether this 
is causal or is a result of either the disease itself or related risk factors is yet to be established. 
Related to this, the proteins that function in the inflammatory component of cardiometabolic 
diseases as well as the putative pathways through which they act to modulate disease risk 
are largely unknown. 
 
GWAS studies have led to the identification of thousands of genetic loci that are associated 
with clinical endpoints and phenotypes of interest284,362. However, identifying the underlying 
causal variant and the molecular basis of these associations is challenging. One method of 
addressing this problem is by testing whether genetic associations are shared between traits, 
an approach known as genetic colocalisation284. The presence of a shared variant increases 
the likelihood that the traits share a common causal mechanism or pathway284. This approach 
uses a Bayesian framework to estimate the likelihood of a causal variant underlying a genetic 
association being shared between pairs of traits284. However, this method only estimates 
whether the genetic association is likely to be shared between two traits and does not refine 
this to a single candidate causal variant. Secondly, this approach can quickly become 
inefficient when considering hundreds of traits as independent pairwise analyses would need 
to be conducted per locus to enumerate all possible trait combinations.  
 
Recent methodological extensions to this method362,363 enable the rapid enumeration of 
colocalisation across multiple traits. In particular, HyPrColoc362 uses a Bayesian framework to 
estimate clusters of traits which share a genetic association and refines this to distinct causal 
variants by employing a fine mapping approach (described in Chapter 3). This is therefore an 
efficient and powerful method of identifying shared loci across traits while estimating the likely 
causal variant underlying the association for future follow-up. Application of such a 
framework362 in this setting helps to elucidate and contextualise the role of inflammation in 
cardiometabolic diseases by providing information on two levels. Firstly, the method362 is able 
to fine map shared association signals between traits to single candidate variants and provide 
empirical estimates of the likelihood that the candidate variant is shared between traits of 
interest. This is of interest as these candidate variants tag biological pathways that may 
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explain how they affect disease risk. Secondly, the proteins which are estimated to colocalise 
with disease are of interest as they highlight shared aetiology and therefore provide biological 
context surrounding the role of inflammatory proteins in the aetiology of cardiometabolic 
diseases. 
 
In this study, I aimed to characterise the genetics underlying the inflammatory component of 
cardiometabolic diseases and infer the biological pathways. I leveraged large-scale aptamer-
based proteomic data in a multi-trait colocalisation framework to identify loci where clusters of 
inflammatory proteins, cardiometabolic diseases and risk factors colocalise at shared causal 
variants. I then further characterise these protein clusters by estimating their association with 
established cardiometabolic risk factors and estimating the effects of pleiotropic loci on 




This work made use of GWAS summary statistics that formed part of a larger effort to study 
the genetic underpinnings of plasma protein levels and how these relate to diseases. The 
methods are described briefly in the following section. 
 
Profiling of the plasma proteome 
Fasted EDTA-plasma samples from 12,084 participants from the Fenland244 study (described 
in Chapter 2) were subjected to proteomic profiling by SomaLogic Inc. (Boulder, US) using an 
aptamer-based technology (SOMAscan v4). The relative abundances of 4,775 human 
proteins were measured using 4,979 SOMAmers, as previously described364. To account for 
within run hybridisation variability, control probes were used to generate a scaling factor for 
each sample. Differences in total signal between samples as a result of variation in overall 
protein concentration or technical variability such as reagent concentration, pipetting or assay 
timing, were accounted for using the ratio between each SOMAmer's measured value and a 
reference value. The median of these ratios was computed for each dilution set (40%, 1% and 
0.005%) and applied to each dilution set. Samples were removed if they failed SomaLogic QC 
measures or did not meet the acceptance criteria of between 0.25-4 for all scaling factors. A 
total of 10,078 samples had available genotype data and were used in this study. Aptamer 
target annotations and mapping to UniProt accession numbers as well as gene identifiers were 
provided by SomaLogic.  
 
GWAS and meta-analysis of human plasma protein levels 
Genotyping and imputation in the Fenland study were performed as described in Chapter 2. 
Related individuals and ancestry outliers were removed, leaving 10,708 participants with both 
protein measures and genetic data for association testing (OMICS=8,350, Core-
Exome=1,026, GWAS=1,332). Prior to GWAS, relative abundances of each SOMAmer were 
transformed within each genotyping subset using the rank-based inverse normal 
transformation. These were then regressed on age, sex, sample collection site and 10 
principal components to generate residuals. GWAS was performed using BGENIE (v1.3), 
assuming an additive model. Variants with minor allele frequency < 0.001, imputation quality 
< 0.4 or Hardy Weinberg Equilibrium p < 1x10-7 in any of the genotyping subsets were 
excluded from further analyses. Results from the three genotyping subsets were later 
combined in a fixed-effects meta-analysis using METAL276. Only variants present in the largest 
genotyping subset were taken forward for further analysis, variants specific to either of the 
smaller subsets were not considered.  
 
Locus definition and cis/trans annotation 
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A genome-wide significance threshold of P<1x10-11 was used, adjusting the conventional 
genome-wide significance threshold to account for 5,000 tests. Non-overlapping loci were 
defined as 500Kb regions either side of all genome-wide significant variants, any overlapping 
regions were merged. The MHC region (chr6:25.5–34.0Mb) was treated as a single region. 
Within each region, sentinel variants were defined as the variant with the lowest P-value in the 
region. Variants were classified as cis-acting pQTLs if the variant was less than 500Kb from 
the respective protein encoding gene.  
 
Conditional analysis 
Conditional analysis was performed as described in Chapter 3, independently for each 
aptamer. As an additional quality control measure, all variants identified by GCTA365 in a given 
region were jointly modelled using individual level data from the largest available genotyping 
subset. Any variants that were no longer genome-wide significant were not taken forward. 
 
Inflammatory protein identification 
To identify proteins which play a role in inflammation, defined as the response of the immune 
system to an exogenous or endogenous stimulus, gene ontology (GO)366,367 terms were used. 
GO terms366,367, accessed via the Amigo2 browser368, have a tree hierarchical structure split 
into three main classes: biological processes, cellular components and molecular functions. 
In order to obtain the broadest and most comprehensive list, all human proteins annotated to 
function under the biological process annotation “immune system process” were selected. 
Proteins were then filtered to retain only human proteins; any micro RNA or long non-coding 
RNA annotations were removed. Finally, the list of identified proteins was searched by Uniprot 
ID in the SomaLogic dataset to identify inflammatory proteins of interest. This process yielded 
a total of 1,358 candidate protein targets. 
 
Genetic correlation between inflammatory proteins and cardiometabolic traits 
Using the inflammatory proteins identified above, pairwise genetic correlation was estimated 
between the proteins and cardiometabolic traits of interest using LDSC v1.0.0287,291. Prior to 
implementing LDSC, variants within the HLA region as well as those that displayed effect sizes 
larger than χ2 > 80 (corresponding to a Z-score of 8.9) were removed, as described in Chapter 
3.To retain high imputation quality (> 0.9) the analysis was restricted to variants imputed to 
HapMap3, as these were considered to be well imputed across studies. The cardiometabolic 
traits considered were BMI, WHRadjBMI, T2D, CHD, HbA1c, fasting insulin, fasting glucose, 
2-hour glucose, HDL, LDL and triglycerides. Fasting insulin, glucose and 2-hour glucose were 
all adjusted for BMI. Several autoimmune diseases were included as comparators with the 
aim of delineating inflammatory proteins more correlated with autoimmune disease, these 
 
99 
included rheumatoid arthritis, Crohn’s disease, ulcerative colitis and inflammatory bowel 
disease. Details of the included studies can be found in Table 5.1.  
Firstly, heatmaps were drawn to illustrate the pairwise correlations between cardiometabolic 
traits and diseases using the pheatmap package in R v3.6.3. Next, a second heatmap 
illustrating the pairwise correlation between cardiometabolic traits and inflammatory proteins 
was drawn. Inflammatory proteins that were significantly correlated with at least one 
cardiometabolic trait were included. P-values smaller than P<1.4x10-4, accounting for the 350 
traits tested, were considered statistically significant.   
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 Abbreviations: N, Number of participants; HbA1c; Glycated haemoglobin; BMI; Body mass index; DIAMANTE, 
Diabetes meta-analysis of trans-ethnic association studies; MAGIC, Meta-Analyses of glucose and insulin-related 
traits consortium; EPIC, European prospective investigation of cancer; GLGC, Global lipid genetics consortium 
a. Traits are continuous unless otherwise stated as a disease or a polygenic score  
Table 5.1: Summary of the included traits and their data sources 










number of variants 
(for polygenic 
scores) overall, N 
Participating study 




Type 2 diabetes 74,124 824,006 DIAMANTE 30297969 





BMI  738,628 
GIANT, UK Biobank 25673413; 25826379 
WHRadjBMI  636,282 
Glycaemic 
HbA1c  451,782 UK Biobank; InterAct 25826379 




Fasting glucose adjBMI  190,384 
2-hour glucose adjBMI  62,183 
Lipid 
HDL  450,957 
UK Biobank; InterAct 25826379 LDL  375,774 
Triglycerides  450,625 
Cytokines 
IFNγ  17,030 
EPIC-Norfolk; Fenland Chapters 2 and 3 
IL-6  17,318 
IL-8  16,353 
TNFα  17,330 
Autoimmune 
disease 
Rheumatoid arthritis 29,880 73,758 
Meta-analysis of 26 
studies 
24390342 
Crohn's disease 12,194 28,072 
Cambridge MREC; 
26192919 




Plasma proteins 4,979 proteins  10,708 Fenland 27841877 
Polygenic 
scores 
T2D   386 
DIAMANTE 30297969 
T2DadjBMI  191 




BMI  96 GIANT 25673413 
Hip  22 
UK Biobank; GIANT 30575882 
Waist  36 
WHR  202 
HipadjBMI  22 
Waist adjBMI  36 
WHRadjBMI  202 
Insulin resistance  53 MAGIC; GLGC 27841877 





Reciprocal lookup of independent variants in inflammatory protein targets and 
cardiometabolic disease GWAS summary statistics 
Next, I aimed to determine whether established T2D and CHD loci are protein quantitative trait 
loci (pQTLs) for inflammatory proteins and vice versa, whether pQTLs for inflammatory 
proteins were associated with disease risk. To do this, a reciprocal lookup approach was used. 
Firstly, using published GWAS summary statistics for T2D22 and CHD289, the independent 
variants associated with disease risk were extracted from the GWAS summary statistics of 
each inflammatory protein. Similarly, independent variants associated with levels of 
inflammatory proteins were extracted from GWAS summary statistics for each cardiometabolic 
disease. In cases where the independent variant itself was unable to be found in the reciprocal 
GWAS, proxy variants in LD (R2 > 0.8) with the variant of interest were used. Following this, 
independent variants associated with disease (P<5x10-8) were prioritised to take forward any 
variant with at least suggestive evidence of an association with protein levels (P<1x10-5). 
Similarly, only independent variants associated with inflammatory protein levels (P<5x10-8) 
that were within or near the protein-coding gene (cis variants) were prioritised to take forward 
any variant with at least suggestive evidence of an association with disease (P<1x10-5). This 
was done to facilitate biological interpretation of the effects of the variant. Loci were then 
defined, as described in Chapter 3, as 500Kb regions either side of the variant with the lowest 
P-value in the region. Any overlapping loci were merged into a single locus, yielding 85 loci in 
total. 
 
Multi-trait colocalisation between inflammatory proteins and cardiometabolic traits 
I used multi-trait colocalisation (HyPrColoc)362 within each of the loci defined above to identify 
inflammatory proteins which share a common causal variant with cardiometabolic diseases. 
In short, HyPrColoc employs a Bayesian framework to estimate whether multiple traits 
colocalise within a single locus at a shared genetic signal and creates clusters of traits which 
colocalise around distinct causal variants in the region. HyPrColoc was run using a variant-
specific prior configuration where default settings were as follows 1) the prior probability that 
a variant is associated with a single trait, prior 1, was set at 1x10-4, and 2) prior 2, the prior 
probability that a variant is associated with an additional trait, given that it is already associated 
with one trait, was set at 0.02369. A regional threshold of 0.5 was used, denoting the probability 
that all traits share an association with one or more variants in the region. Related to this, an 
alignment threshold of 0.5 was also used, relating to the probability that all traits align and 
share a single causal variant.  
 
The 500Kb regions either side of the lead variant at each locus were extracted from GWAS 
summary statistics for the 335 inflammatory protein targets with suggestive evidence of an 
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association with a disease, 4 cytokines and 11 cardiometabolic traits of interest. The 
cardiometabolic traits consisted of disease outcomes, anthropometric traits, lipids and 
glycaemic measures as previously outlined. 
 
To assess sensitivity in the number and size of clusters identified to the specification of 
algorithm parameters, increasingly stringent prior and threshold configurations were used. The 
values of prior 2 considered were 0.02 and 0.01, threshold values of 0.5, 0.6, 0.7, 0.8 and 0.9 
were considered. Heatmaps based on similarity matrices were drawn to illustrate how often 
trait pairs were clustered together across all algorithm parameter choices. This protocol is 
notably stringent therefore results that passed thresholds such as these have robust evidence 
for colocalisation. Only variants present in all included traits were considered for each 
respective locus and any variants with a reported standard error of 0 were removed. T2D and 
CHD were considered as binary case-control traits whereas all others were considered 
quantitative. To estimate the posterior probability that the candidate variant is the causal 
variant (PPcausal), I multiplied the PP for colocalisation (PPcoloc) by the PP explained by the 
candidate variant (PPexplained). 
 
In order to prioritise high confidence clusters of inflammatory proteins and cardiometabolic 
traits, several prioritisation criteria were used, 1) only clusters where inflammatory proteins 
colocalised with a cardiometabolic disease were considered, 2) clusters were retained if they 
showed sufficient evidence for colocalisation with disease i.e. PPcoloc ≥ 0.5 and regional 
posterior probability (PPregional) ≥ 0.8. Gene and consequence information for each candidate 
variant were annotated using VEP v99285.  
 
Diverse traits colocalising at a given locus do not necessarily imply a common casual 
mechanism. I therefore established a classification system for each of the proteins to 
characterise the levels of specificity. Pleiotropic loci were defined based on the literature370–
373 as any of APOE, GCKR, TM6SF2, ABO and SH2B3, all of which have been associated 
with diverse outcomes. Non-pleiotropic loci were considered as none of the above genes. In 
detail, proteins only colocalising at well-known pleiotropic loci, as defined, were classified as 
pleiotropic. Those colocalising at pleiotropic and non-pleiotropic loci were classified as 
“mixed”, and most notably, proteins colocalising at specific loci were classified as non-
pleiotropic. In order to assess the contribution of pleiotropic loci to the colocalisation between 
inflammatory proteins and cardiometabolic diseases, the number of proteins that colocalised 
at non-pleiotropic, pleiotropic and a mixture of non- and pleiotropic loci were counted. 




Association of candidate variants with all human proteins 
For candidate variants of interest arising from the HyPrColoc analysis, the association of the 
variant and all 4,979 human proteins on the SOMAscan v4 platform was estimated using 
multivariable linear regression adjusting for age, sex, sample collection site and the first ten 
genetic principal components. Test site refers to the testing centre where blood samples were 
taken from participants. As sample processing and storage protocols varied by test site, 
internal quality control testing showed that protein levels varied by test site as well. Thus, to 
avoid spurious associations, this was included as a covariate. Volcano plots to illustrate the 
association of the variant with each protein were drawn using the ggplot2 R package. All data 
analysis was performed using R version 3.6.3. 
 
Association between polygenic scores for cardiometabolic traits and inflammatory 
protein levels 
It is currently unclear whether the inflammation observed in cardiometabolic diseases is 
resultant of the disease itself or its related risk factors. To estimate whether cardiometabolic 
risk factors and disease endpoints are associated with inflammatory protein levels and may 
therefore be mediating the observed inflammation in cardiometabolic diseases, the 
associations between polygenic scores for 12 cardiometabolic traits (Table 5.1) and levels of 
the inflammatory proteins were estimated. The four cytokines of interest were also included in 
the list of inflammatory proteins. 
 
Firstly, the variants and weighting for each score was extracted from the respective publication 
(Table 5.1), except for the CHD score, which was accessed using the ieugwasr R package 
(ID: ebi-a-GCST005195). Each score was then depleted for variants within 200Kb either side 
of a pQTL for one of the inflammatory proteins. This was done to avoid spurious associations 
between scores and inflammatory protein levels resulting from variants that affect both traits. 
Following this, genotype dosages for each of the remaining variants were extracted in Fenland 
participants genotyped using the Affymetrix UK Biobank Axiom Array, the largest genotyping 
sub-cohort. Dosages were aligned to the score-raising allele and weighted by their effect on 
the respective cardiometabolic trait. A score for each cardiometabolic trait was generated per 
individual by summing the respective weighted variants contributing to the score. Finally, 
inflammatory protein levels were inverse-rank normal transformed so that each protein had a 
mean of 0 and a standard deviation of 1. The association between the polygenic score and 
inflammatory protein levels was estimated using multivariable linear regression adjusted for 




Volcano plots were used to visualise the associations between polygenic scores and 
inflammatory protein levels. These were coloured according to their colocalisation with 
cardiometabolic diseases and whether this colocalisation was estimated to be driven by known 
pleiotropic loci (APOE, GCKR, TM6SF2, SH2B3 or ABO)370–373. A Bonferroni significance 
threshold of P<1.5x10-4 was used to account for 339 tests, corresponding to 335 inflammatory 
proteins with suggestive evidence of an association with cardiometabolic diseases and the 
four cytokines of interest. All data analysis was performed using R version 3.6.3. 
 
Gene-set enrichment analysis 
In order to estimate whether the proteins which colocalised with T2D and CHD were enriched 
in terms of their pathway involvement, gene-set enrichment analyses were conducted for each 
disease independently. Enrichment analysis was conducted using the functional mapping and 
annotation (FUMA) v1.3.6a374 web application GENE2FUNC process. Curated gene sets for 
testing enrichment were downloaded from the molecular signatures database (MSigDB) v7375. 
As pathway annotations are notably database specific, MSigDB combines data from several 
sources including KEGG, reactome and Biocarta to circumvent this. In this analysis, gene-set 
enrichments were only considered significant if the same gene set from at least two databases 
was significant.  
 
The protein-encoding gene for each protein which colocalised with disease were used as 
input. The genes for all cytokines and inflammatory proteins present in the SomaLogic dataset 
that were identified using GO terms were used as the background for the analysis. Only gene-
sets consisting of more than 2 genes were included. Significant overlap between input genes 
and gene-sets was performed using linear regression376. Multiple testing correction using the 




A total of 3,214 human proteins were identified using GO terms as playing a role in an “immune 
system process”. Of these, 1,358 proteins (42%) were covered by the SomaLogic v4 assay. 
The median number of variants estimated to be significantly associated with protein levels was 
2 (IQR: 1-4). Genetic correlation estimates between autoimmune diseases and 
cardiometabolic traits showed a clear cluster of cardiometabolic traits which was separate 
from a cluster of autoimmune diseases (Figure S5.1). Genetic correlation estimates showed 
that autoimmune diseases and cardiometabolic traits were significantly correlated with levels 
of 68 proteins (Figure 5.1). However, no clear delineation in the correlation of inflammatory 
proteins with autoimmune diseases and cardiometabolic traits was observed. Total 
triglycerides were significantly correlated with levels 38 of these proteins (56% of the 
significant proteins; 3% of the total), the most of any trait, whereas T2D and CHD were 
significantly correlated with levels of 24 and 18 proteins, respectively. The most significant 
correlation with both T2D and CHD was transforming growth factor beta receptor 3 (TGF-b R 
III) with comparable correlation estimates of 0.37 (genetic correlation estimate (rg)=-0.37; 95% 
CI, -0.47, -0.26; P=1.6x10-12) and 0.36 (rg=-0.36; 95% CI, -0.47, -0.26; P=2.3x10-11), 
respectively. However, the strongest correlation with T2D was insulin like growth factor binding 
protein 2 (IGFBP-2) (rg=-0.65; 95% CI, -0.87, -0.44; P=2.1x10-9). The strongest positive 
correlation with T2D was with leptin levels (rg=0.53; 95% CI, 0.36, 0.69; P=1.1x10-10), a 
correlation that was also the strongest for BMI. The strongest positive correlation with CHD 
was with IL-6 levels (rg=0.37; 95% CI, 0.18, 0.55; P=1.1x10-4), IL-6 levels were also strongly 
correlated with T2D and were ranked second only to leptin in terms of correlation strength 
(rg=0.43; 95% CI, 0.24, 0.62; P=8.9x10-6). However, while genetic correlation estimates 
provide insight into common genetic architecture between traits, the direction of effect is 
unable to be inferred.  
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Figure 5.1: Correlation heatmap illustrating the pairwise genetic correlation of 
autoimmune diseases and cardiometabolic traits with inflammatory protein levels. Only 
proteins that are significantly correlated with one autoimmune or cardiometabolic trait below a 
Bonferroni significance threshold of P< 1.4 x10-4 are shown. The data sources of each trait 
are outlined in Table 5.1. Positive correlations are shown in red whereas inverse correlations 
are shown in blue. Colour saturation denotes the strength of the correlation between traits. 
Significant correlations at a nominal significance threshold of P< 0.05 are shown with a single 
asterisk “*”, whereas correlations significant at a Bonferroni significance threshold are shown 
with a double asterisk “**”. 
Abbreviations: BMI, Body mass index; HbA1c, Glycated haemoglobin; T2D, Type 2 diabetes; CHD, Coronary heart 
disease; HDL, High density lipoprotein; LDL, Low-density lipoprotein; RA, Rheumatoid arthritis; UC, Ulcerative 
colitis; IBD, Inflammatory bowel disease.  
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Reciprocal lookup of cardiometabolic and inflammatory GWAS sentinels 
A total of 386 and 118 independent variants for T2D and CHD, respectively, were extracted 
from the GWAS summary statistics for each of the 1,358 inflammatory proteins. Following this, 
2,067 unique pQTLs associated with inflammatory protein levels were extracted from GWAS 
summary statistics for the two diseases. Once results were filtered to retain variants with P-
values less than P<1x10-5, 290 and 280 of the T2D and CHD variants met this threshold in the 
inflammatory protein GWAS. Comparatively fewer inflammatory sentinel variants were 
retained in the disease GWASs, of the 2,067 variants, only 73 and 94 variants were found in 
the T2D and CHD GWAS results, respectively. This was reduced to 11 variants extracted from 
each disease GWAS once only cis variants were considered. Only proteins with suggestive 
evidence (P<1x10-5) of an association with cardiometabolic diseases were retained, resulting 
in 335 inflammatory proteins of interest (Table S5.1). Finally, a total of 85 1Mb loci were 
defined and taken forward for multi-trait colocalisation analysis (Table S5.2).   
 
Multi-trait colocalisation between inflammatory proteins and cardiometabolic traits 
Multi-trait colocalisation was conducted at each of the 85 loci (Table S5.2) to estimate whether 
subsets of inflammatory proteins colocalised with cardiometabolic diseases. Across the 85 
loci, a median of 2,717 (IQR: 3,665 – 2,153) variants were included. At 10 and 18 loci, 
respectively, T2D and CHD were estimated to colocalise with at least one inflammatory protein 
where PPcoloc ≥ 0.5 and PPregional ≥ 0.8 (Table 5.2 and Table 5.3). T2D was estimated to 
colocalise with a total of 164 inflammatory proteins whereas CHD colocalised with 181 
proteins. At 6 (60%) and 13 (72%) loci for T2D and CHD respectively, the candidate variant 
was estimated to explain more than 80% of the posterior probability (PPexplained > 0.8). 
Interestingly, inflammatory proteins were not estimated to colocalise with disease at any of the 
inflammatory sentinels, i.e. protein-encoding genes, included in the analysis, except for those 
that were already established disease sentinels.  
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Table 5.2: Loci where T2D colocalised with inflammatory proteins 











Thresh Gene Consequence 
rs7412 6 HERC5, CRP, ARGI1, GGT2, MMP-8, T2D, HbA1c, WHRadjBMI 0.97 rs429358 1 2,771 0.98 0.9 APOE Missense 
rs72802342 11 
REG1B, DLL4, TLR4:MD-2 complex, GIB, GRN, Trypsin 2, IL-1 sRI, T2D, HbA1c, 
Fasting Glucose adjBMI 
0.68 rs72802342 1 3,401 0.98 0.8 CTRB2 Downstream 
rs1260326 16 
LRRK2, IgA, SELS, CD59, GEM, HERC5, WNT5A, B4GT1, PXDN, GRB14, M-CSF R, 
KIF3A, Ephrin-A2, EFNB2, C1QR1, RNF8, GAS-6, SAP3, ABP1, CD248, RBP, 
SPLC2, PACAP, Alpha-1B-glycoprotein, FADD, SDC3, SEM4A, L-plastin, CD46, 
CRIP1, CEAM8, ARF1, UB2D3, SP-D, TIMP-2, Apo E, Myeloperoxidase, Cystatin C, 
gp130, soluble, suPAR, EMAP-2, GDF-11/8, Fibrinogen, Lipocalin 2, DAN, TNFSF15, 
MBL, C9, IL-18 BPa, TNF sR-II, Coagulation Factor VII, CD109, CD48, DLL4, FCG3B, 
TSP4, FSTL3, b2-Microglobulin, TAFI, Adiponectin, a1-Antitrypsin, Angiostatin, 
Thrombin, IGF-I sR, NCAM-L1, MSP, NCAM-120, sL-Selectin, Epithelial cell kinase, 
Coactosin-like protein, C1QBP, TSG-6, DAF, ILT-2, ILT-4, JAG1, Notch 1, SLAF6, 
DLL1, Fas, soluble, sLeptin R, DR6, ALCAM, FGL1, LEAP2, SEM4D, PTPRS, CECR1, 
GGT2, LIRA3, GP116, CPN2, MFAP5, FAIM3, HBD-1, DRB3, Semaphorin-7A, LRC32, 
LIRA5, ROR2, CRTAM, NKp46, IGFBP-2, Leptin, NR1H2, CATF, C1RL1, GGH, C4b-
binding protein alpha chain, LPLC1, VEGF-D, Gelsolin, ENPP2, BT3A3, TLR5, Apo A-
I, TGF-b R III, ADAM 9, CLM6, TCCR, PGRP-L, NPFF, CM35H, FCRL1, EMBP, BMI, 
LDL, T2D, HbA1c, HDL, Triglycerides, 2hr Glucose adjBMI, Fasting Glucose adjBMI, 
Fasting Insulin adjBMI 
0.65 rs1260326 1 1,570 0.98 0.8 GCKR 
Missense; 
splice region 
rs1050362 58 Hexosaminidase B, Angiostatin, Haptoglobin, Mixed Type, Galectin-3, T2D 0.78 rs217181 1 2,297 0.98 0.8 HPR Downstream 
rs8107974 35 
WNT5A, NEUR1, Hexosaminidase B, BGLR, CRIP1, Apo E, Apo B, Angiostatin, CATZ, 
Cathepsin D, prosaposin, GGT2, LIRB4, Cathepsin B, CATF, CREG1, GGH, ADAM 9, 
MIP-3b, LDL, T2D, CHD, HbA1c, HDL, Triglycerides, WHRadjBMI 
0.73 rs58542926 0.99 1,934 0.98 0.8 TM6SF2 Missense 
rs507666 24 
PSP, IL-1 sRII, REG3G, Complement receptor type 2, SPLC2, REG1B, Complement 
receptor type 1, 6Ckine, suPAR, Calpain I, AIF1, Midkine, MBL, DC-SIGN, sL-Selectin, 
GRN, TR, NFASC, LRC32, IL-1F6, T2D 
0.68 rs529565 0.83 3,161 0.98 0.8 ABO Intron 
rs10882101 2 FCG3B, T2D 0.94 rs12219514 0.66 2,365 0.98 0.5 Y RNA Downstream 
rs2972144 4 
cIAP-1, CLC4G, WNT5A, C1QBP, PTPRS, LDL, T2D, CHD, HbA1c, Triglycerides, 2hr 
Glucose adjBMI, Fasting Glucose adjBMI, Fasting Insulin adjBMI 
0.68 rs2943646 0.56 2,347 0.98 0.8 3’ of IRS1 Intergenic 
rs2072633 47 Osteocalcin, T2D 0.86 rs7382085 0.30 4604 0.98 0.6 HLA-DRA Downstream 
rs2268382 85 Leptin, T2D, HbA1c 0.84 rs61462211 0.28 2,195 0.98 0.8 5’ of KLF14 Intergenic 
Abbreviations: Coloc, Colocalisation; BMI, Body mass index; HbA1c, Glycated haemoglobin; T2D, Type 2 diabetes; CHD, Coronary heart disease; HDL, High density lipoprotein; LDL, Low-density 
lipoprotein. 
1. Gene names coloured in red are known pleiotropic loci 





Table 5.3: Loci where CHD colocalised with inflammatory proteins 











Thresh Gene Consequence 
rs11591147 14 CRIP1, Apo B, PAFAH, LDL, CHD, HDL 0.80 rs11591147 1 3,203 0.98 0.5 PCSK9 Missense 
rs55730499 1 CRIP1, PAFAH, SLAF6, PTPRS, EMBP, LDL, CHD, HDL 0.78 rs10455872 1 2,906 0.98 0.8 LPA Intron 
rs7412 6 
cIAP-1, CLC4G, LRRK2, GRB14, SDC3, HO-1, Syntenin 1, CRIP1, gpIIbIIIa, TECK, Apo B, b2-
Microglobulin, C1QBP, PAFAH, SLAF6, PSME1, FAIM3, TR, C1RL1, PGM1, KMT2C, TIGIT, BT3A3, 
MLF1, UB2D2, ihh, Sonic Hedgehog, CD5L, ADAM 9, NPFF, STOM, NR1H4, p15-INK4b, LAG-3, LDL, 
CHD, HDL 
0.78 rs7412 1 2,771 0.98 0.7 APOE Missense 
rs4845625 30 Fibrinogen, CRP, Trypsin 2, LIRB4, Cathepsin B, SAA, IL-6 sRa, CHD, HbA1c, HDL, IL6 0.74 rs2228145 1 1,934 0.98 0.8 IL6R Missense 
rs964184 36 
LRRK2, SELS, WNT5A, B4GT1, GRB14, GAS-6, LL-37, SPLC2, HO-1, CRIP1, UB2D3, gpIIbIIIa, Apo E, 
EMAP-2, Apo B, C1QBP, PAFAH, DR6, GGT2, MMP-8, IFIT2, TIGIT, GBP2, Apo A-I, STOM, LDL, CHD, 
HbA1c, Triglycerides 





M-CSF R, IL-1 sRII, GAS-6, LL-37, SPLC2, gpIIbIIIa, Cystatin C, TECK, GDF-11/8, Apo B, C9, FSTL3, sE-
Selectin, TAFI, CPN2, HBD-1, GGH, TLR5, Apo A-I, Galectin-3, BMI, LDL, CHD, HbA1c, HDL, 
Triglycerides 
0.67 rs28601761 1 2,390 0.98 0.8 3’ of TRIB1 Intergenic 
rs507666 24 
ACE, CLC4G, SECTM1, M-CSF R, EFNB2, CD8A, BGLR, HD-5, HO-1, CD46, gp130, soluble, TECK, Apo 
B, CCL28, SARP-2, LRP8, CD30 Ligand, sE-Selectin, GNS, TLR4:MD-2 complex, VEGF sR2, HSP 70, P-
Selectin, IGF-I sR, NCAM-L1, sICAM-1, GIB, PAFAH, DAF, ILT-2, MO2R1, OX2G, sICAM-5, sICAM-2, 
SEM4D, Cripto, MANBA, GP116, ICAM4, DRB3, S100A13, GPNMB, Uromodulin, CATE, TLR5, MICA, 
PIGR, LGMN, IL-1 R4, CLM6, CM35H, FCRL1, Sema E, AT1B2, BTNL8, CRIP2, SCF, LDL, CHD, HDL, 
Triglycerides, 2hr Glucose adjBMI, Fasting Glucose adjBMI 
0.66 rs507666 1 3,161 0.98 0.8 ABO Intron 
rs6905288 52 SPLC2, BMI, LDL, CHD, HbA1c, Triglycerides, WHRadjBMI, 2hr Glucose adjBMI, Fasting Insulin adjBMI 0.59 rs998584 1 2,426 0.98 0.5 VEGFA Downstream 
rs3184504 8 
CO1A1, CARD9, TPSN, SECTM1, B4GT1, M-CSF R, C1QR1, CD8A, BGLR, Complement receptor type 2, 
SEM4A, Complement receptor type 1, TIMP-2, GDF-11/8, Fibrinogen, Midkine, DAN, DC-SIGN, IL-18 BPa, 
CD48, FCG3B, granzyme A, b2-Microglobulin, P-Selectin, NCAM-L1, sL-Selectin, IgD, DAF, sICAM-5, 
sICAM-2, SEM4D, PTPRS, CECR1, MFAP5, FAIM3, Semaphorin-7A, NKp46, IL-23, STAT1, KI2S2, CD7, 
VEGF-D, Gelsolin, RAB4A, KI2L3, BT3A3, Collagen Type III, CXCL16, soluble, VCAM-1, IL-1 sRI, TGF-b 
R III, I-TAC, CD5L, CLC4K, Cathepsin V, Kallikrein 7, Thrombopoietin Receptor, GCP-2, Lymphotoxin 
a1/b2, IP-10, C1-Esterase Inhibitor, GP1BA, CLM6, COLEC12, TRML2, Epo, Sema E, CRIP2, AZGP1, 
LAG-3, LDL, CHD, HbA1c, IFNg, TNFa, Triglycerides, WHRadjBMI, Fasting Insulin adjBMI 
0.68 rs7310615 0.99 1,056 0.98 0.8 SH2B3 Intron 
rs8107974 35 
WNT5A, NEUR1, Hexosaminidase B, BGLR, CRIP1, Apo E, Apo B, Angiostatin, CATZ, Cathepsin D, 
prosaposin, GGT2, LIRB4, Cathepsin B, CATF, CREG1, GGH, ADAM 9, MIP-3b, LDL, T2D, CHD, HbA1c, 
HDL, Triglycerides, WHRadjBMI 
0.73 rs58542926 0.99 1,934 0.98 0.8 TM6SF2 Missense 
rs10512861 72 6Ckine, CHD 0.89 rs11925382 0.99 2,854 0.98 0.8 DNAJC13 Intron 
rs2814993 53 DR6, GPNMB, LDL, CHD, HDL 0.85 rs76967117 0.99 2,371 0.98 0.8 ILRUN Intron 
rs15285 41 CRIP1, GGT2, LDL, CHD, HbA1c, WHRadjBMI 0.53 rs3208305 0.82 3,665 0.98 0.5 LPL 3’ UTR 
rs2246942 17 prosaposin, LGMN, CHD 0.97 rs1412444 0.60 3,060 0.98 0.5 LIPA Intron 
rs668948 29 Apo B, CHD, HDL 0.93 rs541041 0.60 2,294 0.98 0.8 5’ of APOB Intergenic 
rs2972144 4 
cIAP-1, CLC4G, WNT5A, C1QBP, PTPRS, LDL, T2D, CHD, HbA1c, Triglycerides, 2hr Glucose adjBMI, 
Fasting Glucose adjBMI, Fasting Insulin adjBMI 
0.68 rs2943646 0.56 2,347 0.98 0.8 3’ of IRS1 Intergenic 
rs34855406 51 LGP2, CHD 0.98 rs2074164 0.45 1,297 0.98 0.7 KAT2A/MLX Intron 
rs6511720 5 Apo B, CHD 0.94 rs56289821 0.30 2,255 0.98 0.9 5’ of LDLR Intergenic 
Abbreviations: BMI, Body mass index; HbA1c, Glycated haemoglobin; T2D, Type 2 diabetes; CHD, Coronary heart disease; HDL, High density lipoprotein; LDL, Low-density lipoprotein. 
1. Gene names coloured in red are known pleiotropic loci 
2. The causal gene for rs964184 has been refined to APOA5 using eQTL data in other studies362 
3. Loci are reported at the lowest prior 2 and threshold configuration where PPcoloc ≥ 0.5 and PPexplained ≥ 0.8, clusters may alter with more stringent prior and threshold configurations 




A total of four loci (APOE, TM6SF2, ABO and IRS1) were shared between T2D and CHD, of 
these, both diseases colocalised with inflammatory proteins at the same candidate variant at 
TM6SF2 and IRS1. At ABO the LD between rs529565 and rs507666 was moderate (R2=0.39). 
Comparatively, at APOE the LD between the respective candidate variants rs429358 and 
rs7412 was negligible (R2=0.01), indicating that the two variants are independent of one 
another. Interestingly, T2D was estimated to colocalise with inflammatory proteins at rs429358 
whereas CHD colocalised with inflammatory proteins at rs7412 (Tables 5.2 and 5.3), 
suggesting independent mechanisms of action at each variant. Closer examination of the 
effects of both variants on all inflammatory proteins estimated to colocalise with T2D and CHD 
at APOE, showed a clear delineation in the effects of each variant with respect to the proteins 
they are estimated to colocalise with (Figure 5.2). 
Figure 5.2: Scatterplot illustrating the effects of rs7412 and rs429358 on the set of 
inflammatory proteins which colocalised with T2D and CHD in APOE. The Z-score of the 
association between each variant and the inflammatory proteins are plotted. Proteins 
colocalising with T2D at rs429358 are shown in blue whereas proteins colocalising with CHD 
at rs7412 are shown in red. Any protein with an absolute Z-score greater than 10 with one of 
the variants is labelled. A clear delineation in the effects of each variant on the subset of 
proteins estimated to colocalise with T2D or CHD at either variant can be seen.  
Abbreviations: CHD, Coronary heart disease; T2D, Type 2 diabetes; Apo B; Apolipoprotein B; PAFAH, Platelet-
activating factor acetylhydrolase; CRIP1, Cysteine-rich protein 1; MMP-8, Matrix metalloproteinase-8; TIGIT, T-cell 
immunoreceptor with Ig and ITIM domains; PGM1, Phosphoglucomutase-1; UB2D2; Ubiquitin-conjugating enzyme 
E2 D2; HO-1, Heme oxygenase 1; ihh, Indian hedgehog protein; KMT2C, Histone-lysine N-methyltransferase 2C; 
NPFF, Pro-FMRFamide-related neuropeptide FF; gpIIbIIIa, Integrin alpha-IIb: beta-3 complex; CRP, C-reactive 




Of the 18 loci where CHD was estimated to colocalise with inflammatory proteins, candidate 
variants at 11 loci (61%) are in or nearby genes with diverse functions in lipid metabolism and 
homeostasis (PCSK9, LPA, APOE, ZNF259 [APOA5], TRIB1, TM6SF2, LPL, LIPA, APOB, 
LDLR, ILRUN). At each of these genes aside from LDLR and LIPA, CHD colocalised with at 
least one lipid measure, further highlighting their involvement in the regulation of lipid levels. 
Recent evidence372,377 has suggested that two of these genes, ZNF259 (APOA5) and TRIB1 
have pleiotropic associations with several metabolic traits ranging from body fat distribution377 
to lipid levels372. In addition to these, the candidate variants at APOE, GCKR, TM6SF2, ABO 
and SH2B3 are established pleiotropic loci because of their associations with many diverse 
traits370–373. Closer examination of the number of proteins that colocalise with T2D and CHD 
highlighted that the majority of proteins, 95% and 85% respectively, colocalised with both 
diseases at a minimum of one pleiotropic locus (mixed + pleiotropic loci; Table 5.4). Only 5% 
and 15% of all proteins colocalise with T2D and CHD at non-pleiotropic loci. 
Table 5.4: Number of proteins which colocalise with disease at the 3 pleiotropy classes 
Disease 
Number of proteins 
which colocalise at 
non-pleiotropic loci, 
 (%) 
Number of proteins 
which colocalise at 
mixed loci, 








T2D 8 (5%) 11 (7%) 145 (88%) 164 
CHD 28 (15%) 34 (19%) 119 (66%) 181 
Abbreviations: T2D, Type 2 diabetes; CHD, Coronary heart disease 
a. Proteins which colocalise at mixed loci do so at a combination of non-pleiotropic and pleiotropic loci. 
These proteins are not double counted in the other two groupings 
b. APOE, GCKR, TM6SF2, ABO and SH2B3 are pleiotropic loci 
 
CHD was estimated to colocalise with inflammatory proteins at rs2228145 (Asp358Ala), the 
missense variant in IL6R (PPcoloc = 0.74; PPexplained = 1). As outlined in Chapter 4, this variant 
is associated with HbA1c levels. These results demonstrate that HbA1c colocalises with IL-6 
levels at Asp358Ala, providing further evidence of the link between IL-6 and HbA1c levels. 
Examining the wider associations of Asp358Ala with all 4,979 human proteins highlighted the 
specificity of Asp358Ala for IL-6R levels and showed associations with levels of galectin-3 
binding protein (LG3BP), S100 Calcium Binding Protein A7 (S100A7), Calcium/Calmodulin 
Dependent Protein Kinase I (CAMK1) and Mannose-binding lectin (Figure 5.3). Only 
mannose-binding lectin was included as an inflammatory protein in this analysis but was not 
estimated to colocalise with CHD at rs2228145 (Table 5.3). Consistent with an effect of 
reduced IL6R-mediated inflammation, Asp358Ala was associated with -0.11 SD lower CRP 





Figure 5.3: Volcano plot of the association between the IL6R missense variant 
(Asp358Ala; rs2228145) and all 4,979 human proteins from the SOMAscan v4 platform. 
Due to the large association of Asp358Ala with higher IL-6 sRa levels, the axes are broken to 
facilitate its display. Marker size for each protein is relative to its absolute effect size (beta) of 
Asp358Ala on levels of the respective protein. Proteins are coloured according to their 
significance with Asp358Ala. Proteins coloured in blue are significant at a Bonferroni 
significance threshold of P < 1x10-5, denoted by the dashed line. All significant associations 
with Asp358Ala are labelled as well as any inflammatory proteins which were estimated to 
colocalise with CHD at Asp358Ala (Table 5.3). 
Abbreviations: IL-6 sRa, Interleukin-6 receptor subunit alpha; LIRB4, Leukocyte Immunoglobulin Like Receptor B4; 
CAMK1, Calcium/calmodulin-dependent protein kinase type 1; LG3BP, Galectin-3-binding protein; SAA, Serum 





































Association of polygenic scores for cardiometabolic traits with inflammatory protein 
levels 
The association of 13 polygenic scores for cardiometabolic risk factors and disease outcomes 
with inflammatory protein levels were estimated in up to 7,959 participants from Fenland. 
Overall, the polygenic scores were significantly associated (P<1.5x10-4) with the levels of 100 
inflammatory proteins, 29% of the total 339 proteins investigated. Of the 164 proteins which 
colocalised with T2D (Table 5.2), the levels of 69 proteins (42% of the total) were associated 
with at least one polygenic score (Figure 5.4). Of the proteins not significantly associated with 
any score, only Galectin-3, IL-1 receptor type 1 (IL-1 sR1), Osteocalcin, Trypsin-2, 
phospholipase A2 (GIB) and the TLR4:MD-2 complex colocalised with T2D at a non-
pleiotropic locus. Thus, 94% of proteins not associated with any polygenic score colocalised 
with T2D at a minimum of one pleiotropic locus. The TLR4:MD-2 complex and GIB colocalised 










Figure 5.4: Volcano plots illustrating the association of polygenic scores for 13 
cardiometabolic traits with levels of the 335 inflammatory proteins and four cytokines. 
The number of proteins significantly associated (P<1.5x10-4) with each polygenic score is 
shown. Markers for each protein are sized according to their association with the respective 
polygenic score and coloured according to their colocalisation with T2D. Proteins that do not 
colocalise with T2D are shown as open grey circles, those that colocalise with T2D at non-
pleiotropic loci are shown in blue, those that colocalise with T2D at both pleiotropic and non-
pleiotropic loci are deemed “mixed” and shown in gold and those that colocalise with T2D at 
pleiotropic loci (APOE, GCKR, TM6SF2 or ABO) are shown in red. The top 10 proteins 
significantly associated with each score are labelled as well as any proteins significantly 
associated with the polygenic score that also colocalised with T2D at a non-pleiotropic locus. 
Abbreviations: Coloc, Colocalisation; SD, Standard deviation; T2D, Type 2 diabetes 
 
The scores significantly associated with the levels of the largest number of proteins were the 
triglycerides, WHR and WHRadjBMI scores. The triglycerides score was significantly 
associated with the levels of 80 of the 339 inflammatory proteins, 24% of the total and the 
most of any score. Of these, 58 proteins colocalised with T2D, 96% of which colocalised at 
pleiotropic loci. The triglycerides score was significantly associated with levels of Haptoglobin 
(mixed type) and Baculoviral IAP repeat-containing protein 2 (cIAP-1), two out of eight proteins 
which colocalised with T2D at non-pleiotropic loci (Figure S5.2). Thus, the triglycerides score 
was significantly associated with 35% of the proteins estimated to colocalise with T2D. 
Similarly, the WHRadjBMI score was associated with the levels of 31 proteins, the second-




Thus, the WHRadjBMI score was significantly associated with 18% of the proteins estimated 
to colocalise with T2D. 
 
Of the 181 proteins which colocalised with CHD (Table 5.3), the levels of 67 proteins (36% of 
the total) were associated with at least one polygenic score (Figure 5.5). Of the proteins not 
significantly associated with any score, 9 colocalised with CHD at non-pleiotropic loci. Thus, 
92% of proteins not associated with any polygenic score colocalised with CHD at a minimum 
of one pleiotropic locus. Similar to the T2D results and in line with the finding that a 
considerable proportion of the loci identified by colocalisation with CHD are involved in lipid 
metabolism, the triglycerides score was significantly associated with levels of 54 (30%) of the 
proteins that colocalised with CHD, the most of any score (Figure 5.5). Indeed, the 
triglycerides score was significantly associated with 16 (57%) of the 28 proteins which 
colocalised with CHD at non-pleiotropic loci (Figure S5.3). In line with the T2D results, the 
WHR and WHRadjBMI scores were associated with levels of the second-highest number of 









Figure 5.5: Volcano plots illustrating the association of polygenic scores for 13 
cardiometabolic traits with levels of the 335 inflammatory proteins and four cytokines. 
The number of proteins significantly associated (P<1.5x10-4) with each polygenic score is 
shown. Markers for each protein are sized according to their association with the respective 
polygenic score and coloured according to their colocalisation with CHD. Proteins that do not 
colocalise with CHD are shown as open grey circles, those that colocalise with CHD at non-
pleiotropic loci are shown in blue, those that colocalise with CHD at both pleiotropic and non-
pleiotropic loci are deemed “mixed” and shown in gold and those that colocalise with CHD at 
pleiotropic loci (APOE, SH2B3, TM6SF2 or ABO) are shown in red. The top 10 proteins 
significantly associated with each score are labelled as well as any proteins significantly 
associated with the polygenic score that also colocalised with CHD at a non-pleiotropic locus. 
Abbreviations: Coloc, Colocalisation; SD, Standard deviation; CHD, Coronary heart disease 
 
Gene-set enrichment analysis 
Proteins that colocalised with T2D were significantly enriched in 22 gene-sets across 8 
categories (Figure 5.6 and Table S5.3). The most significant of these was blood protein levels 
in GWAS catalog (overlap = 19%; adjusted P = 1.5x10-5). This significant enrichment was also 
shared by proteins which colocalised with CHD with a greater degree of overlap (overlap = 
23%; adjusted P = 7.3x10-8; Table S5.4). Proteins that colocalised with T2D were significantly 
enriched in gene-sets related to liver development and function (Cairo liver development DN: 
overlap = 38%; adjusted P = 0.002; HSIAO Liver specific genes: overlap = 33%; adjusted P = 
0.01) were significantly enriched. Interestingly, proteins that colocalised with both diseases 




T2D and CHD showed significant enrichment in the human complement system gene-set from 
Wikipathways (Table S5.3 and S5.4), overlapping the gene-set by 30% and 36% respectively 
(T2D adjusted P = 0.03; CHD adjusted P = 0.002). Proteins colocalising with T2D were also 
significantly enriched in the KEGG complement and coagulation cascade gene-set (overlap = 
39%; adjusted P = 0.01) whereas CHD proteins were enriched in the Hallmark complement 




Figure 5.6: Bar plot showing the gene-sets that were significantly enriched in proteins 
that colocalised with either T2D or CHD. T2D results are shown in the top panel whereas 
CHD results are shown in the lower panel. The percentage overlap of the colocalised proteins 
with the total genes in each respective gene-set is shown above each bar. Colours correspond 
to the database each gene-set originated from.  
Abbreviations: GO, Gene ontology terms; BP, Biological processes; CC, Cellular compartment; MF, Molecular 
function; KEGG, Kyoto Encyclopaedia of Genes and Genomes; ECM, Extracellular matrix; T2D, Type 2 diabetes; 






To estimate whether there was evidence for a shared genetic basis underlying the 
inflammatory component of cardiometabolic diseases, this study used large-scale proteomic 
data for up to 1,358 inflammatory proteins within a Bayesian multi-trait colocalisation 
framework. The benefit of such an analysis is that trait colocalisation is fine mapped to a 
putative causal variant which may therefore tag an aetiologically relevant pathway362. Finally, 
the association of inflammatory proteins with polygenic scores for established cardiometabolic 
risk factors was estimated to determine whether risk factors were associated with levels of 
inflammatory proteins, thus mitigating the likelihood that inflammatory proteins levels are 
independent risk factors for cardiometabolic diseases. 
 
The vast majority of loci with evidence for colocalisation between inflammatory proteins and 
cardiometabolic diseases were well-known pleiotropic loci, such as APOE, ABO, TM6SF2, 
SH2B3 or GCKR and have been shown to associate with a wide of metabolic and other 
phenotypes, including anthropometric and lipid traits370–373,377. This pleiotropic effect is 
exemplified by the finding that the majority of proteins which colocalise with T2D and CHD did 
so at established pleiotropic loci.  
 
Interestingly, the results of this study show that T2D and CHD colocalise with inflammatory 
proteins with robust evidence for colocalisation at rs429358 and rs7412, two independent 
missense variants (R2 = 0.01) in apolipoprotein E (APOE). Allelic combinations of these two 
variants constitute the three main alleles of the APOE gene (ԑ2, ԑ3 and ԑ4), each of which 
have differential risk for diverse diseases378. The ԑ4 allele represents the C,C genotype for 
both variants and is associated with the highest APOE protein levels and concurrent 15-fold 
higher risk of Alzheimer’s disease378. Phenome-wide analyses have demonstrated that the ԑ4 
genotype is associated with higher hypercholesterolaemia and CHD risk, consistent with an 
effect of APOE on lipid levels378. In contrast, the same analysis demonstrated a significant 
protective effect of the ԑ4 genotype on both T2D and obesity378. This finding is interesting in 
the context of the results of this study as the two variants that make up the ԑ4 genotype may 
mediate disease risk via distinct pathways. It is likely that T2D risk is lowered due to the effect 
of ԑ4 on obesity risk while CHD risk is raised due to the effect of ԑ4 on lipid levels, however, 
more thorough investigations are required to fully assess this relationship. Taking this into 
consideration and as outlined in Chapter 1, the pleiotropic effects of these loci hinder the 
straight-forward interpretation of their effects on single traits as the locus may affect the 
phenotype of interest via many diverse pathways62,73. These findings do, however, suggest 
that a considerable proportion of the inflammatory response in cardiometabolic diseases may 




The findings of this study show that the majority of proteins colocalise with cardiometabolic 
diseases at pleiotropic loci and a proportion are also associated with established risk factors. 
Therefore, the emphasis from a drug target identification standpoint must be on those proteins 
which colocalise at non-pleiotropic loci and are not associated with established 
cardiometabolic risk factors. The results of this study show that only 6 and 10 proteins, 4% 
and 5% of all proteins which colocalised with T2D and CHD respectively, fell into this category. 
Of these, galectin-3, has been highlighted as a potential therapeutic target secreted by 
macrophages that links inflammation and insulin resistance that may be used to improve 
insulin sensitivity379,380. Galectin-3 colocalised with T2D and CHD at variants downstream of 
HPR and TRIB1, respectively. Studies have shown that haptoglobin-related protein, the 
protein product of HPR is a circulating ligand of galectin-3381. Galectin-3 levels have been 
shown to induce macrophage chemotaxis and are significantly higher in obese individuals 
when compared to lean individuals and are positively correlated with both BMI and HOMA-
IR379. Consistent with an effect on insulin resistance, galectin-3 was shown to inhibit insulin-
stimulated glucose transport in in vitro experiments in myocytes and adipocytes379. In addition, 
experiments in murine hepatocytes showed that galectin-3 blocked the actions of glucagon on 
hepatic glucose output379. Further in vitro experimentation showed that galectin-3 induces 
insulin desensitisation through insulin receptor binding, leading to abolished signalling. In vitro 
knockout experiments demonstrated lower pro-inflammatory gene expression in adipose 
tissue and improved glucose tolerance in obesity379. While this evidence suggests that 
galectin-3 may be a useful target to simultaneously lower inflammation and improve insulin 
resistance in obesity, it remains to be determined whether haptoglobin-related protein is the 
major ligand of galectin-3 and how this relationship may mediate T2D and CHD risk.   
 
Of particular interest to this thesis, the missense variant, Asp358Ala (rs2228145), in IL6R was 
highlighted as a candidate variant where inflammatory proteins robustly colocalise with CHD. 
In line with previous results, Asp358Ala is associated with lower CHD risk88 and, as presented 
in Chapter 4, is associated with HbA1c levels. In contrast to the findings in Chapter 4, T2D 
was not estimated to colocalise with IL-6 levels at Asp358Ala. However, closer examination 
of the magnitude of the meta-analysis effect estimate between Asp358Ala and T2D in Chapter 
4 shows that estimate (OR = 0.98) is comparatively small, thus requiring the very large sample 
size (260,614 cases and 1,350,640 controls) used to detect the association. As described in 
Chapter 3, P≤1x10-4 is a commonly used prior probability that a variant is associated with trait 
of interest and is therefore sufficiently powered for use in colocalisation analyses. In the T2D 
dataset used in this study, the Asp358Ala variant was associated with T2D risk at a nominal 
significance threshold (OR = 0.99; 95% CI, 0.97, 1; P = 0.02). Therefore, the apparent lack of 




than a biological mechanism. This study also showed that CHD was estimated to colocalise 
with HDL levels at Asp358Ala. This is line with results of previous studies showing an 
association between Asp358Ala and higher HDL levels330, an effect consistent with lower CHD 
risk382. Consistent with an effect on lower IL-6R mediated inflammation, Asp358Ala was 
associated with lower CRP, serum amyloid A (SAA and SAA2) 383,384, and fibrinogen88,160 
levels. SAA is secreted as part of the acute phase response where it replaces ApoA1 as the 
predominating apolipoprotein on HDL particles385. Inflammation lowers HDL levels and 
suppresses cholesterol efflux, the process by which cholesterol is removed from cells such as 
macrophages and excreted via the liver386. The presence of SAA is thought to contribute to 
this by lowering HDL cholesterol efflux capacity386 thereby raising cardiovascular risk387. 
Overall, the inflammatory proteins which colocalise with CHD at Asp358Ala provide greater 
insight into the mechanisms underlying the role of IL-6 levels in CHD.  
 
While considering the candidate variants where cardiometabolic diseases and inflammatory 
proteins are estimated to colocalise is valuable to identify pathways of interest, closer 
examination of the association between inflammatory proteins and established 
cardiometabolic risk factors can contextualise the inflammatory response within the aetiology 
of cardiometabolic diseases. The results of this study show that of the proteins that colocalise 
with T2D and CHD, 38% and 33% respectively were associated with at least one polygenic 
score for a cardiometabolic risk factor. Polygenic scores for triglycerides, WHR and 
WHRadjBMI were estimated to be associated with the levels of the greatest number of 
inflammatory proteins. Recent evidence from genetic studies has suggested that this is 
consistent with an insulin resistance phenotype244,351,388,389 which is associated with higher 
adiposity, partly mediating the link between obesity and cardiometabolic diseases244. The 
hallmarks of an insulin resistant phenotype are higher fasting insulin adjusted for BMI346, 
higher triglyceride levels and lower HDL levels33,345,390. In line with this, polygenic scores for 
insulin resistance and fasting insulin adjusted for BMI were associated with the levels of some 
inflammatory proteins, although not as many as the triglycerides and WHRadjBMI scores. 
These results therefore suggest that the levels of a proportion of the inflammatory proteins 
which colocalise with cardiometabolic diseases are governed by established cardiometabolic 
risk factors. As a result, these inflammatory proteins cannot be considered as independent 
risk factors for cardiometabolic diseases and are therefore not suitable to be used in an MR 
setting as they would invalidate the instrumental variable assumptions62,73.   
 
Overall, the results of gene-set enrichment analyses showed that inflammatory proteins which 
colocalised with cardiometabolic diseases were significantly enriched in proteins involved in 




immune system which is activated via three distinct pathways namely the classical, alternative 
and lectin pathways each of which lead to the formation of the membrane attack complex 
(MAC)391. Prospective observational epidemiological studies have shown that levels of 
complement component C3, the major component of the complement system, are associated 
with incident T2D and CHD, insulin resistance, abdominal obesity, lower HDL levels and 
higher fasting and 2-hour glucose levels in obesity392–394. As yet, the activation pathway 
mediating the higher levels of C3 in both T2D and CHD is unknown. Future investigation using 
genetic methods robust to reverse causality and residual confounding may help to elucidate 
the role of the complement cascade in cardiometabolic diseases. 
 
In summary, several lines of evidence indicate that inflammatory proteins are unlikely to be 
independent causal risk factors for cardiometabolic diseases. Firstly, inflammatory proteins 
only colocalised with cardiometabolic diseases at loci which were already established T2D 
and CHD sentinels. Secondly, established cardiometabolic risk factors were associated with 
levels of approximately a third of all proteins which colocalised with T2D and CHD. Therefore, 
the levels of these proteins likely to be mediated by cardiometabolic risk factors instead of the 
proteins being independent risk factors for disease. Finally, the vast majority of inflammatory 
proteins colocalised with cardiometabolic diseases at established pleiotropic loci, thus making 
it difficult to pinpoint the pathways through-which these proteins act to modulate risk of 
cardiometabolic diseases. 
 
This study has limitations. Firstly, the liberal selection criteria for the inclusion of proteins 
involved in “immune-related processes” likely led to the inclusion of proteins which function in 
the immune system but may not be involved in inflammation per se. This may have contributed 
noise to the analysis. Secondly, while only including cis-acting pQTLs for inflammatory 
proteins in the analysis may have aided the interpretability of the results, this may have come 
at the expense of missing potentially important loci where cardiometabolic diseases may have 
colocalised with inflammatory proteins. However, the reason for focussing the analysis on cis 
variants was based on proximal biology, i.e. having a high prior for the biological pathway 
involved. The interpretation of the biological pathways tagged by trans-pQTLs would have 
been much less clear, as they may affect protein levels and disease risk through different 
mechanisms. In addition, there are very few trans-pQTLs which are specific for protein levels 
that may have provided further insights, only those encoding known ligands, binding partners 
or receptors of inflammatory proteins may have provided further insights. In addition, the use 
of a permissive locus inclusion threshold of P≤1x10-5 suggests that only trans-pQTLs or loci 
which showed weak evidence (P>1x10-5) for association with the disease of interest may have 




and cardiometabolic traits, any variants with very large effect estimates were removed from 
the analysis. This was done to prevent variants such as these having a disproportionate 
influence on the LD score regression estimates287, therefore biasing the result. However, as 
is the case with many molecular biomarkers, a single cis-acting variant (often in the protein 
encoding gene itself) may have a disproportionately large effect on levels of the protein. 
Exclusion of such variants may lead to underestimation of the trait heritability thereby also 
underestimating the true correlation between this protein and other traits. Fourth, the 
HyPrColoc method assumes a single causal variant in a given region362, a limitation of most 
colocalisation methods290. While this study investigated comparatively small genomic regions, 
this assumption is more likely to be violated as the number of included traits increases. 
However, simulations using HyPrColoc have demonstrated that multiple independent variants 
in a region rarely invalidate the results, as long as the secondary variants do not explain more 
trait variation than the sentinel variant362. Future work could, however, make use of summary 
statistics conditioned on other independent signals within a locus to aid the estimation of the 
causal variant. Fifth, while HyPrColoc is able to consider an LD matrix to help resolve putative 
candidate variants in regions with complex LD, one was not provided. When using an LD 
matrix, a matrix of pairwise phenotypic correlation as well as a matrix of sample overlap must 
also be supplied362. As GWAS summary statistics from publicly available datasets were used, 
the estimation of pairwise phenotypic correlations was not possible. Finally, this analysis 
classified loci as pleiotropic based on published literature and was not based on a strict 
definition, as such a definition is still debated. Instead, only loci that are hallmark pleiotropic 
loci were considered as such, a potentially conservative approach. This does not rule out the 
possibility that loci such as TRIB1, which is associated with many lipid species and 




Chapter 6: Incretins and the incretin effect 
Contributions and collaborations 
The work in outlined in this chapter is all my own aside from the systematic literature search 
for genetic variants associated with incretin levels. This formed part of the work done by Robert 
Hansford, who’s Wellcome Trust PhD rotation I helped supervise. However, all discussion of 




6.1: The physiological roles of incretins and their alterations in obesity 
and T2D 
The physiological roles of incretins 
Until recently, our knowledge of glucose homeostasis was based upon the discoveries of 
insulin and glucagon. Insulin, secreted by β-cells in the pancreatic islet of Langerhans, has a 
hypoglycaemic effect on glucose levels after a meal399,400. Not long afterwards, glucagon 
secretion from the α-cells of the islet of Langerhans was discovered to reverse this effect, 
thereby raising glucose levels between meals401. Together, these hormones coordinate to 
maintain glucose homeostasis402.  
 
Following this, experimental evidence showed that plasma insulin levels were significantly 
higher upon the ingestion of glucose, compared to intravenous administration in humans403,404. 
This suggested that the source of this insulin potentiation was unlikely to be of pancreatic 
origin but rather secreted from the gut405. Glucose-dependent insulinotropic polypeptide (GIP) 
was the first of the incretins to be discovered406–408. Shortly afterwards a second incretin was 
discovered, glucagon-like peptide-1 (GLP-1), due to its structural similarities with 
glucagon409,410. The coordinated actions of GIP and GLP-1 on glucose-dependent insulin 
potentiation is now known as the “incretin effect”, defined as the difference in pancreatic β-cell 
insulin secretion between oral and intravenously delivered glucose411–413. 
 
The absorption of glucose by sodium-dependent glucose transporter (SGLT) receptors on 
epithelial cells in the small intestine triggers GLP-1 and GIP secretion from L- and K-cells 
respectively (Figure 6.1)402.  GLP-1 and GIP bind to their respective receptors, GLP-1R and 
GIPR, on pancreatic β-cells amplifying insulin secretion and contributing to the maintenance 
of glucose homeostasis402. GLP-1R expression is widely expressed in the pancreatic β-cells, 
central nervous system (CNS), kidneys liver, heart and gut414. Similarly, GIPR expression is 
much more ubiquitous, and is  found in the CNS, stomach, heart and adipose tissue, as well 





Figure 6.1: Overview of insulin potentiation by GIP and GLP-1. Glucose is absorbed by 
SGLT transporters on the surface of epithelial cells of the small intestine, resulting in elevated 
plasma glucose concentrations. This leads to higher Calcium2+ concentrations in pancreatic 
β-cells, triggering insulin secretion. Glucose detection and absorption by SGLT transporters 
on K cells or L cells triggers GIP and GLP-1 secretion respectively. Binding of GIP and GLP-
1 to their respective receptors initiates a signalling cascade that leads to higher intracellular 
cAMP, triggering the amplification of the insulin secretion signal. Figure taken from402. 
Abbreviations: SGLT1, Sodium-dependent glucose transporter 1; GIP, Gastric inhibitory polypeptide; GLP-1, 
Glucagon-like peptide-1; GIPR, GIP receptor; GLP-1R, GLP-1 receptor; Ca2+, Calcium2+; cAMP, Cyclic adenosine 
monophosphate; β-cell, pancreatic β-cell 
 
Incretin proteins are initially expressed as prohormones requiring enzymatic cleavage to 
liberate their active forms414. Proglucagon cleavage by prohormone convertase-1 liberates the 
more abundant GLP-17-36 amide isoform as well as the equipotent GLP-17-37 isoform416. Pro-
GIP cleavage by the same enzyme liberates active GIP1-42417. Both GLP-1 and GIP contain an 
alanine at position 2 in the peptide, making them ideal substrates for are rapid degradation by 
dipeptidyl peptidase IV (DPP4), resulting in a half-life of less than two minutes for GLP-1 and 
approximately seven minutes for GIP414,418. This rapid degradation facilitates fine-scale control 
over insulin-potentiating action and therefore glucose homeostasis. However, due to the 
physiological mechanism of incretins, their fasting levels are relatively low – making them 
challenging to measure, often requiring measurement during OGTT – this, coupled with their 






The incretin effect in health and T2D 
In healthy individuals, the magnitude of the incretin effect is glucose-dependent419–421 and 
estimated to be between 50-70% of postprandial insulin response412,422. GIP levels have been 
shown to mediate a substantially greater proportion of the incretin effect in individuals with 
normal glucose tolerance423,424, whereas GLP-1 mediates approximately 32-55%425–427. 
However, the incretin effect has been shown to be diminished in patients with T2D, with around 
half the C-peptide production (150mM) per mM higher plasma glucose observed419,420,428,429. 
GLP-1 levels have been reported to be reduced in T2D430–433, whereas postprandial GIP levels 
have been reported to be either normal or higher in T2D433–437. Later experiments showed that 
the insulinotropic effect of GIP was dampened in T2D, whereas the effects of GLP-1 were 
largely unaffected433,438,439. Contrastingly in obese participants without T2D, the insulinotropic 
effect of GIP was unaltered440. Later studies established that the diminished effect of GIP 
relative to GLP-1 was not exclusive to T2D but was common to monogenic diabetes, diabetic 
chronic pancreatitis and latent autoimmune diabetes patients441,442. On the basis of these 
findings, it was posited that impaired β-cell response to glucose, rather than defects in GIP 
signalling, was the likely cause of the diminished incretin effect in diabetes441,442, suggesting 
that impairment of the incretin effect occurs in the early stages of diabetes pathogenesis443.  
 
Critical to the maintenance of glucose homeostasis, is the effect of incretins on glucagon 
secretion, as this may facilitate improved glycaemic control. In healthy individuals, studies 
have demonstrated that while GLP-1 stimulates insulin levels, it has a dose-dependent, 
suppressive effect on glucagon levels444–447. Conversely, GIP levels have been shown 
glucose-dependent glucagon secretion in healthy participants and T2D patients421,429,448,449.  
 
The role of GLP-1 in satiety, food consumption and weight loss 
Aside from their effects on insulin secretion, both GLP-1 and GIP have diverse physiological 
actions on metabolically active tissues422. In clinical studies, higher GLP-1 levels have been 
shown to reduce appetite and as a result, food consumption450. The mechanism behind this is 
unclear, however, it is thought that the presence of the GLP-1R in the CNS414,451 may be 
central to this effect452. Linked with this, GLP-1 levels have also been shown to decrease the 
rate of gastric emptying to the small intestine through the inhibition of gastrointestinal motility, 
an effect linked to satiety451, in both healthy participants425,453 and T2D patients454. Of specific 
relevance to cardiometabolic diseases, GLP-1 levels have been demonstrated to modulate 
body weight in both healthy participants and T2D patients455–457.  
 
GLP-1 mediated weight loss has been demonstrated in a RCT using liraglutide, a once-daily 




weight during an initial low-calorie diet were randomised to receive either 3mg liraglutide or 
placebo for 56 weeks. The study aimed to assess whether GLP-1 maintained weight loss 
through caloric restriction and induced further weight loss458. Treatment with liraglutide led to 
further weight loss from the mean of 6.2% lost during caloric restriction, amounting to a total 
of 12.2% loss over the study duration. In addition, 81.4% of participants in the liraglutide group 
maintained the weight lost during caloric restriction, indicating that GLP-1 levels aided both 
weight maintenance and loss in obese participants458. The capacity to induce weight loss using 
GLP-1 agonists makes them attractive therapeutic targets for the treatment of obesity, coupled 
with their insulinotropic properties, GLP-1 agonists represent a viable therapeutic for T2D as 
well.  
 
The role of GIP in obesity, dyslipidaemia and risk of T2D 
Aside from the established role for GIP in modulating insulin and glucagon levels, studies 
conducted in human subcutaneous adipose tissue and in vitro studies of adipocytes have 
suggested a role in dietary fat metabolism and lipid storage in adipose tissue459. In vitro studies 
have suggested that GIP stimulates lipoprotein lipase (LPL) thereby promoting triacylglycerol 
(TAG) uptake into cells459. Findings from animal models have been varied459–473 and highly 
dependent on experimental design415. Studies in obese humans have concluded that GIP 
does not influence food intake474. Findings from an observational cross-sectional study in 
1,405 individuals across the spectrum of T2D risk, showed that doubled fasting GIP levels 
were associated with lower subcutaneous fat but higher visceral fat, waist-to-hip ratio, waist 
circumference and BMI in men475. Interestingly, in women the opposite was found, as high 
GIP levels were associated with 1.2% lower body fat percentage as well as lower BMI and 
waist circumferences475. In summary, interpretation of the available data from clinical studies 
is challenging due to the difficulty of estimating the effects of GIP independently of its 
insulinotropic effects. Taken together, the available evidence supports a role for GIP in rodent 
lipid metabolism, whereas its role in human lipid metabolism may be sex-specific and 
influenced by insulin levels, sensitivity, and BMI, thus making its role unclear415,476.  
 
As a result of the challenges surrounding incretin measurement in large epidemiological 
cohorts (outlined in the previous section), a considerable proportion of our knowledge of 
incretin physiology is based on experiments conducted in animal and in vitro models or from 
clinical studies in small cohorts. While there are many clinical studies investigating this, the 
findings are often in opposition or inconclusive. Despite this, the findings outlined in this 
section constitute the evidence base, upon which, both GIPR agonists and antagonists are 




6.2: The role of incretin levels in cardiovascular disease 
Obesity and T2D, as outlined above, have been associated with raised CVD risk15 as well as 
earlier onset16 and greater severity17 of CVD events. Recent evidence has suggested that the 
role of GIP in dietary lipid metabolism and adipose blood flow, coupled with GIPR expression 
in both adipocytes and cardiomyocytes415, may implicate GIP in CVD pathogenesis479,480. 
Recent evidence from a meta-analysis of two large population-based cohort studies totalling 
8,044 participants estimated the associations between fasting and post-challenge GIP levels 
with both total and cardiovascular mortality481. Higher fasting GIP levels were associated with 
higher hazard for both total and cardiovascular mortality (Hazard ratio [HR] per SD GIP, 1.22; 
95% CI, 1.11, 1.35; P =4.5×10−5) and (HR, 1.30; 95% CI, 1.11, 1.52; P = 0.001) in models 
extensively adjusted for age, sex and relevant cardiovascular risk factors481. Post-challenge 
GIP levels were not associated with either outcome481. Interestingly, neither fasting or post-
challenge GLP-1 were associated with either outcome, suggesting that only GIP-mediated 
pathways  may be implicated in raising cardiovascular risk481.  
 
These findings were somewhat reinforced by 2-sample MR estimates using a missense 
variant in GIPR, rs1800437 which encodes a substitution of glutamic acid for glutamine at 
position 354 of the GIPR peptide, as an IV for fasting GIP levels481. Estimates showed that 
genetically-predicted fasting GIP levels were associated with higher odds of CHD in both 
CARDIoGRAMplusC4D and UK Biobank (OR per copy of rs1800437, 1.67; 95% CI, 1.34, 
1.99; P = 0.002) and (OR, 1.52; 95% CI, 1.27, 1.77; P = 0.001) respectively, as well as 
myocardial infarction (OR, 1.58; 95% CI, 1.22, 1.95; P = 0.01)481. In line with this, estimates in 
the reverse direction showed no significant effect of CHD on fasting GIP levels, suggesting 
that fasting GIP levels raise the risk of both CHD and myocardial infarction481. These estimates 
should be interpreted with caution, however, as (1) they represent the effect of a single variant 
on cardiovascular risk and do not model the effects of other variants in the region which may 
dampen or modulate this effect, (2) these estimates do not take into account that the 
association with CHD may be the result of LD between this variant and the true causative 
variant driving the association with CHD. 
 
Similarly, genetic studies482 using a low frequency missense variant in GLP1R (Ala316Thr; 
rs10305492) replicated the observational findings for GLP-1481. This variant was associated 
with lower fasting glucose (beta in SD per copy of rs10305492, -0.51; 95% CI, -0.20, -0.11; 
P=2.6x10-10) T2D risk (OR, 0.83; 95% CI, 0.76, 0.91; P=9.4x10-5) and CHD risk (OR, 0.93; 





Evidence from smaller clinical studies have demonstrated raised heart rate and differences in 
blood pressure during GIP infusions448,483, however, while GIP’s effects on heart rate appeared 
to be independent of its insulinotropic capacity, its effects on blood pressure were dependent 
on prevailing glycaemia. These effects should be interpreted with caution, however, as neither 
heart rate or blood pressure were predefined outcomes of the study, plus these effects are 
likely to be transient, as trends towards normalisation after 90 minutes of GIP infusion were 
noted479. This also does not rule out the possibility that postprandial GIP levels lead to spikes 
in heart rate that rapidly normalise following the degradation of active GIP by DPP-4. Studies 
using in vitro cellular models have suggested that these effects on blood pressure may be 
mediated by secretion of endothelin-1 (ET-1), a vasoconstrictor stimulated by signalling 
cascades upon binding of GIP to GIPR484. ET-1 has been shown to stimulate secretion of 
osteopontin (OPN), an inflammatory protein that facilitates leukocyte cell adhesion and 
migration that acts in atherogenic pathways, eventually leading to vascular remodelling and 
stiffening485,486. While these findings are in line with evidence suggesting that GIP raised 
cardiovascular risk, further evidence in larger epidemiological cohorts is required to confirm 
this455,487.  
6.3: Incretin-based therapies for cardiometabolic diseases 
The discovery of GIP and the elucidation of its physiological role led to great enthusiasm about 
its potential as a possible therapeutic for T2D488. However, evidence of a reduced 
insulinotropic capacity in T2D419,420,428,429, coupled with raised adipose deposition459 and 
glucagon secretory responses421,448 in non-diabetic participants dampened this interest. 
Added to this, a suitable treatment strategy for GIP was unclear due to evidence from animal 
models suggesting that both agonism and antagonism of GIPR could protect against dietary-
induced obesity460,466,489. It has been suggested that chronically raised GIP levels, mimicking 
receptor agonism, may lead to reductions in GIPR expression, thereby leading to 
desensitisation to GIP’s effects490. Other studies have suggested that naturally occurring end-
products of endogenous GIP degradation may antagonise the GIPR491. Finally, human and 
murine GIPR share only 81% amino acid sequence homology492. These subtle differences 
coupled with differential responses to antagonists493,494 have complicated the extrapolation of 
findings from animal studies into clinically meaningful evidence in humans. 
 
Attention was soon diverted from GIP with the discovery of GLP-1 and evidence of its 
metabolically favourable effects on satiety450 and glucagon suppression444. As postprandial 
GIP levels are consistent between healthy participants and T2D patients433–436 and GLP-1 




using GLP-1R agonism as a possible treatment. The effects of one such agonist, liraglutide, 
were assessed in a 20 week double-blind, placebo-controlled trial in 564 obese participants 
using orlistat, a lipase inhibitor, as a comparator495. Participants were randomised to one of 
four liraglutide doses, orlistat or placebo and were subjected to a 500 kcal per day restricted 
diet and physical activity regimen throughout the trial495. Participants in the liraglutide group 
lost significantly more weight than either comparator, mean weight loss for the four liraglutide 
doses estimated to be 4.8 kg, 5.5 kg, 6.3 kg, and 7.2 kg respectively, compared to 2.8 kg for 
placebo and 4.1 kg for orlistat. Of note, 76% of participants in the highest liraglutide group lost 
more than 5% of their baseline weight, compared to 30% and 44% on placebo and orlistat 
respectively495. Additionally, liraglutide was found to lower blood pressure and reduce the 
prevalence of pre-diabetes at most doses495. However, the most common adverse effects of 
liraglutide treatment were transient nausea and vomiting495. Overall, liraglutide treatment had 
a metabolically favourable, dose-dependent effect on weight as well as a protective effect 
against pre-diabetes, however, adverse effects such as nausea may impact upon its use as a 
chronic therapeutic495. 
 
In a 30 week trial of a second GLP-1R agonist, exenatide, in 295 T2D patients, once weekly 
administration of exenatide significantly lowered HbA1c and led to a greater proportion of 
patients achieving target HbA1c levels of 7% or less496. In addition, exenatide treatment was 
not shown to increase the risk of hypoglycaemia and replicated the beneficial effects on weight 
loss, however, nausea was again reported as a significant adverse event496. As mentioned 
previously, cardiovascular disease prevalence is higher in T2D patients15. Considering the 
metabolically favourable effects of GLP-1R agonists, investigations have assessed the 
cardioprotective efficacy of both lixisenatide497 and exenatide498. Both studies included T2D 
patients with previous cardiovascular events, however, no significant differences were 
observed in the rate of cardiovascular events between GLP-1R agonist treatment and 
placebo497,498.  
 
Recently, evidence suggesting that the insulinotropic effect of GIP is raised in T2D patients 
receiving insulin treatment when near-normal glycaemic levels are achieved, has reignited 
interest in the therapeutic potential of GIPR agonism421,428,499. Studies in these patients have 
noted that GIP enhanced the glucose stimulated insulin response and that glucagon secretion 
was only stimulated when glucose levels were low421,428,499. This is beneficial, as glucagon 
secretion is regulated effectively, thus buffering against hypoglycaemia through hepatic 
glucose production421. However, the requirement of re-establishing near normo-glycaemia 
suggests that GIP needs to be administered in tandem with an additional glucose-lowering 




1R-GIPR co-agonists428,501–503 which exert additive metabolically favourable effects as well as 
normalising adverse effects of single agonism such as nausea489,500. The first of these, 
NNC0090-2746, displays balanced agonistic effects at both receptors504. In a 12-week 
randomised, double-blind, placebo-controlled phase 2a trial, 108 T2D patients with poorly 
controlled glucose tolerance received daily 1.8mg doses of the dual agonist or placebo504. 
Escalating doses of liraglutide to a maximum of 1.8mg were used as an open-label 
comparator504. The dual agonist significantly lowered HbA1c levels by up to 1.04% and fasting 
plasma glucose compared to placebo over the 12 week period504. In line with GLP-1R 
agonism, significant weight loss up to 1.87% from baseline were noted, with continued 
reductions in body weight over the study duration504. Additionally, total cholesterol and leptin 
levels were significantly lowered compared to placebo and reduced the occurrence of adverse 
events such as nausea504. 
 
The efficacy of a second dual agonist, tirzepatide, was assessed in a double-blinded, 
randomised phase 2 trial where 316 T2D patients with poorly controlled glycaemia were 
randomised to one of four tirzepatide doses or placebo for 26 weeks503. Tirzepatide displayed 
unbalanced agonism at the two receptors, displaying greater affinity for the GIPR503. 
Treatment group assignment was stratified by baseline HbA1c, metformin use and BMI503. A 
dose-dependent effect of tirzepatide on HbA1c was observed, with mean reductions from 
baseline 1.06%, 1.73%, 1∙89% and 1.94% respectively503. At the end of the trial, up to 90% of 
patients in the tirzepatide group achieved HbA1c levels of less than 7%503. In line with findings 
for other dual agonists, similar reductions in fasting plasma glucose, weight and total 
cholesterol were observed503. 
 
Taken together, these results suggest that while single GLP-1R or GIPR agonists may display 
metabolically beneficial effects, the use of dual agonists lead to dose-dependent additive 
effects on weight loss, glycaemic control and total cholesterol levels while lowering the 
incidence of adverse effects such as nausea. It should be noted that triple agonists targeting 
the GIPR, GLP-1R, and glucagon receptor are in development, however, their efficacy in 
large-scale human trials are yet to be assessed489,500. In addition, the cardiovascular risks of 
dual agonists have not yet been assessed. While pharmaceutical development has focussed 
on agonism as the favourable treatment strategy, further research into the clinical safety and 
efficacy of dual agonists is required to facilitate their establishment as a putative treatment for 




6.4: Overview of the genetic architecture underpinning incretin levels 
Introduction 
As outlined above, incretins have become the focus of significant attention as putative targets 
for pharmacological modulation in T2D415,489,505. However, considering the often-contradictory 
clinical findings in the published literature it is unclear whether agonism or antagonism of their 
effects is the preferable treatment modality. As outlined previously, genetic analyses are 
robust to residual confounding and are therefore useful tools to predict the effect of 
pharmacological manipulation of this pathway in disease56,57,506. I therefore aimed to survey 
the current knowledge of genetic variants associated with incretin levels in healthy participants 




The published literature was systematically searched using the PubMed (MEDLINE) database 
to identify studies describing associations between genetic variants and circulating levels of 
incretins. The search strategy was focussed on human studies conducted in population-based 
cohorts investigating genetic associations with at least one incretin and was not limited to 
GWAS. My search included for all clinical trials, journal articles and meta-analyses published 
in English between June 2007 (the year the WTCCC GWAS228 was published, considered as 
the inception of large-scale GWAS analyses) and 4 November 2019. The search strategy is 
outlined in Table S6.1 and led to the inclusion of 2 full text articles in the review after using 





Figure 6.2: Schematic of the systematic literature search. The exclusion criteria and the 
number of articles excluded at each stage are detailed.  
Abbreviations: GWAS, Genome-wide association study; CGS, Candidate-gene study 
 
Results and discussion 
The systematic search identified a total of 495 articles that were then prioritised to 2 full text 
articles507,508 (Table 6.1) for review after applying the exclusion criteria summarised in Figure 
6.2. The GWAS was conducted using participants derived from two prospective Scandinavian 
population-based cohorts – the Malmö Diet Cancer Cardiovascular Cohort (MDC) in Malmö, 
Sweden (n=3,344) and the Prevalence, Prediction and Prevention of Diabetes Botnia (PPP-
Botnia) cohort, a population-based cohort in Western Finland (n=5,208)508. The CGS was 
conducted on 171 nondiabetic individuals509. All studies followed a standard 75g OGTT 
protocol in fasted participants and measured levels of GIP and GLP-1 at fasting and 2 hours 








(1 GWAS, 6 CGS)
Final results
1 GWAS, 1 CGS
437 non-specific studies 
removed for: using non-
human participants, 
inappropriate study 
design, not investigating 
genetic associations
51 studies removed 
because they were not 
conducted in healthy 
participants, did not 
investigate incretin levels 
etc.
5 results with insufficient 
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Abbreviations: GWAS, Genome-wide association study; CGS, Candidate-gene study; MDC, Malmӧ diet and 
Cancer; PPP-Botnia, Prevalence prediction and prevention of diabetes in Botnia; GLP-1, Glucagon-like peptide-1; 
GIP, Gastric inhibitory polypeptide 
 
Together, the two studies identified 12 variants associated with circulating levels of GLP-1 
and GIP (Table 6.2). No associations with other incretins were reported in suitably powered 
studies. This not only highlights a deficit in our knowledge of the genetic underpinnings of 
other incretin levels but also illustrates how few studies have investigated the genetics of 
incretins. The variant identified by the CGS507 was associated with 30-minute measures of 
both GLP-1 and GIP but was not associated with fasting or 2-hour measures of either 
incretin. Furthermore, the association of this variant with levels of GLP-1 and GIP was not 
replicated by the GWAS, thus its relevance is currently unknown.  
 
Of the variants identified by the GWAS508, seven were missense variants and some, such as 
rs1800437 in the GIP receptor gene (GIPR), were associated with incretin measures at 
multiple timepoints. Several of the reported variants were in high LD (R2 > 0.8) with one 
another, such as those at the GIPR, ABO and SLC5A1 loci, effectively representing the same 
association signal. A total of four variants at the pleiotropic ABO locus, all in high LD (R2 = 
0.83) with one another, were associated with levels of GIP and GLP-1. This is unsurprising as 
this locus has previously been shown to be associated with levels of cytokines232,234,235 (as 
described in Chapter 1), blood proteins513, cholesterol514, HbA1c347, T2D279, and risk of CHD 
and large artery stroke515. Given that the ABO locus was associated with lower 2-hour and not 
fasting GIP levels508, it may be speculated that the ABO locus may impact upon levels of DPP-







Table 6.2: Genetic variants associated with levels of GIP and GLP-1 in published studies 












rs17681684 GLP2R chr17:9792768 - A/G Missense 7,826 0.055 (0.009) 1.4×10-9 
rs1800437 GIPR chr19:46181392 
0.89 
G/C Missense 7,825 0.076 (0.010) 4.1×10-15 
rs2287019 GIPR chr19:46202172 T/C Intron 7,828 -0.066 (0.010) 4.0×10-11 
30 min 
GIP 
rs151290b KCNQ1 chr11:2821615 - A/C Intron 1,578 3c 0.004 
2hr GIP 
rs1800437 GIPR chr19:46181392 
0.89 
G/C Missense 7,448 0.072 (0.009) 1.6×10-17 
rs2287019 GIPR chr19:46202172 T/C Intron 7,450 -0.066 (0.009) 4.0×10-14 
rs150112597 HOXD1 chr2:177054181 - C/G Missense 7,443 -0.280 (0.049) 1.6×10-8 
rs927332 F13A1 chr6:6331873 - T/C Intergenic 7,442 0.040 (0.007) 4.1×10-8 
rs635634 ABO chr9:136155000 
0.83 
T/C Upstream 7,446 -0.070 (0.009) 7.4×10-14 
rs507666 ABO chr9:136149399 A/G Intron 7,450 -0.069 (0.009) 8.9×10-14 
rs651007 ABO chr9:136153875 T/C Upstream 7,449 -0.063 (0.009) 2.9×10-12 
rs579459 ABO chr9:136154168 C/T Upstream 7,450 -0.062 (0.009) 3.4×10-12 
rs17683430 SLC5A1 chr22:32487700 
1 
A/G Missense 7,450 0.120 (0.014) 3.0×10-18 
rs17683011 SLC5A1 chr22:32445946 G/A Missense 7,450 0.120 (0.014) 3.2×10-18 
30 min 
GLP-1 
rs151290b KCNQ1 chr11:2821615 - A/C Intron 1,578 5c 0.02 
2hr GLP-1 rs17683011 SLC5A1 chr22:32445946 - G/A Missense 3,849 0.091 (0.017) 4.2×10-8 
Abbreviations: variant, Single nucleotide polymorphism; LD, Linkage disequilibrium; EA, Effect allele; OA, Other 
allele; N, Number of participants; SE, Standard error; GWAS, Genome-wide association study; GIP, Gastric 
inhibitory polypeptide; GLP-1, Glucagon-like polypeptide-1; Min, Minutes; Chr, Chromosome 
a. LD is only reported for variants on the same chromosome 
b. Variant was reported in the candidate gene study507 
c. Variant effects were reported as fold changes relative to wild-type alleles  
 
The results of the GWAS508 also showed an association of GIPR variants with both fasting and 
two-hour GIP levels. The LD between these two variants, rs1800437 and rs2287019, is high 
(R2 = 0.89; Table 6.2). Interestingly, an intronic variant, rs10423928, in perfect LD with the 
GIPR missense variant rs1800437 was initially discovered in a GWAS344 of 2-hour glucose 
levels in up to 15,234 non-diabetic participants. The association of this variant with both 2-
hour glucose levels344 as well as fasting and 2-hour GIP levels508 fits well with the role of GIP 
in insulin potentiation and glucose homeostasis. In line with results from observational 
studies475, previous studies have shown that the GIP decreasing alleles of the two variants at 
the GIPR locus, rs1800437 and rs2287019, are associated with lower BMI516 and waist-to-hip 
ratio517. Interestingly, lower rs1800437-mediated GIP levels have also been shown to be 
associated with higher T2D risk (OR, 1.06; 95% CI, 1.04, 1.08; P = 3x10-14) when adjusted for 
BMI in 74,124 T2D European cases and 824,006 controls22. This suggests that this raised 
T2D risk is not mediated by obesity-related pathways but is instead resultant of the diminished 




Of interest to this thesis was rs1800437, a missense variant in GIPR. It was chosen for further 
characterisation because (i) rs1800437 has translational consequences inducing the 
substitution of glutamic acid for glutamine at position 354 of the GIPR peptide (E354Q)518. (ii) 
the G allele (E354; frequency ~0.74) is associated with both higher fasting and 2-hour GIP 
levels of 0.076 and 0.072 log (pmol/L) higher fasting GIP levels per copy of E354 respectively 
(Table 6.2). (iii) this general increase in GIP signalling508 mimics the effect of GIPR agonism 
therefore the functional consequences of E354 are of particular interest for the development 





Chapter 7: Genetically predicted glucose-dependent insulinotropic 
polypeptide (GIP) levels and cardiovascular disease risk are driven 
by independent mechanisms at the GIPR 
Contributions and collaborations 
I designed the study, analysed the data and wrote the first draft of the manuscript. Claudia 
Langenberg, Nicholas J. Wareham, Pallav Bhatnagar, Matthew Coghlan, Fiona Gribble and 
Frank Reimann supervised the study. I performed the 2SMR analyses and analysed the data 
with the help of Robert Hansford. Christopher N. Foley provided statistical support. Victoria 
Au Yeung conducted the partial correlation analysis and created the Gaussian Graphical 
Model. Stephen Burgess, Aslan M. Erzurumluoglu, Isobel D. Stewart, Eleanor Wheeler and 
Maik Pietzner assisted me with data collation and contributed to the data analysis. All authors 






Background: There is significant interest in pharmacological agonism of the glucose-
dependent insulinotropic polypeptide (GIP) receptor as a therapeutic for type 2 diabetes (T2D) 
and obesity. Evidence from in vitro and animal models as well as acute clinical studies has 
implicated higher fasting GIP levels in raising cardiovascular disease risk, a safety concern 
threatening the use of these therapies. Recent genetic epidemiological evidence also 
suggests that higher GIPR-mediated GIP levels are associated with elevated risk for 
cardiovascular disease. 
Methods: I integrated large-scale genomic data for 24 different cardiometabolic diseases, as 
well as anthropometric, glycaemic, lipid and ~6,000 ‘omics biomarkers (metabolomic and 
aptamer-based plasma proteomic measures) to systematically characterise the clinical 
consequences of the GIPR missense variant rs1800437 (G allele; E354 henceforth). Bayesian 
multi-trait colocalisation was applied to define distinct clusters of traits driven by a shared 
causal variant. Conditional analyses were used to identify variants contributing to associations 
between the GIPR locus and traits of interest. 
Findings: I identified E354 as the putatively causal variant shared between fasting GIP levels 
(higher), diabetes-related (protective) and adiposity-related (adverse) traits (posterior 
probability for colocalisation, PPColoc>0.97; PPexplained=0.99; PPcausal=0.96). In unconditional 
analyses, each copy of E354 was significantly associated with an increased risk of CHD, albeit 
with an odds ratio (OR) of 1.03 (95% CI, 1.02,1.05; P=2x10-6), in line with associations 
observed for lipids, anthropometric traits and other known cardiovascular risk factors. I 
identified robust evidence of colocalisation at a distinct signal for associations with CHD and 
lipids (LDL, HDL, total cholesterol, lipoprotein A and ApoB) driven by a known independent 
missense variant (rs7412; distance to E354 ~770Kb) in APOE (PPcoloc>0.99; PPexplained=1; 
PPcausal=0.99). However, the low LD between rs7412 and E354 (R2=0.004) and results from 
conditional analyses showed that this signal was not responsible for the association between 
E354 and CHD (OR for E354 after adjustment for rs7412: 1.03 (95% CI, 1.02,1.04; P=0.003). 
However, E354’s effect on CHD was completely attenuated when conditioned on an additional 
established CHD signal, rs1964272, (R2 with E354=0.27), an intronic variant in SNRPD2 (OR 
for E354 after adjustment for rs1964272: 1.01; 95% CI, 0.99, 1.03; P=0.06). 
Interpretation: I demonstrate that associations of glycaemic and adiposity traits versus CHD 
and lipid traits in the GIPR region are driven by distinct genetic signals. This study provides 
evidence that inclusion of GIPR agonists in dual agonists could potentiate the protective effect 






As outlined in Chapter 6, the incretin hormones glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like peptide-1 (GLP-1) are well known for their insulinotropic activity412,422, 
which is diminished in type 2 diabetes (T2D)419,420,428,429. This has prompted significant 
therapeutic interest in the agonism of their respective receptors, GIPR and GLP-1R, to rescue 
their insulinotropic effects489,500. Moreover, preclinical and clinical data demonstrate that dual 
agonism of the GIPR and GLP-1R deliver superior glycaemic and weight control efficacy 
compared to selective GLP-1R agonism503,519,520. Clinical proof-of-concept for the superiority 
of tirzepatide, a dual GIP/GLP-1R agonist, versus GLP-1R agonism alone was established in 
a 6-month dose range finding Phase 2b trial in subjects with type 2 diabetes503. Post hoc 
analysis of the tirzepatide phase 2b trial reported a beneficial impact on cardiovascular risk 
biomarkers compared to the blinded GLP-1R agonist included in the trial521. 
 
There exists little direct preclinical experimental physiologic or pharmacologic evidence for 
GIPR agonism contributing to cardiovascular risk480,522. GIP exhibits largely anti-atherogenic 
effects on vascular endothelial cells523 with the exception that it has been reported to stimulate 
expression of osteopontin in the vasculature in an endothelin-1 dependent manner484. 
However, recent evidence from a meta-analysis481 of two large population-based cohort 
studies suggests that higher fasting but not post-challenge GIP levels were associated with 
higher hazard for cardiovascular mortality in models adjusted for age, sex and relevant 
cardiovascular risk factors (HR, 1.30; 95% CI, 1.11, 1.52; P=0.001). Neither fasting nor post-
challenge GLP-1 were associated with cardiovascular mortality, suggesting that only GIP-
mediated pathways are implicated in raising cardiovascular risk481, a finding corroborated by 
both clinical trial data524–527 and genetic evidence482.  
 
Genetic studies using two-sample Mendelian randomisation (2SMR) have reinforced 
suggestions that higher GIP levels raise cardiovascular risk481. A missense variant in GIPR, 
rs1800437 (E354Q), encoding a substitution of glutamic acid for glutamine at position 354 of 
the GIPR peptide, was used as an instrumental variable for fasting GIP levels481. This variant 
has previously been associated with higher 2-hour glucose528, BMI529 and fasting and 2-hour 
GIP levels508. Estimates showed that genetically-predicted higher fasting GIP levels were 
associated with higher odds of both coronary heart disease (CHD) and myocardial infarction 
(MI)481. In line with a predicted causal direction from fasting GIP levels to CHD risk, estimates 




genetic estimates should be interpreted with caution, however, as (1) they represent the effect 
of a single variant on cardiovascular risk and do not model the effects of other variants in the 
region which may dampen or modulate this effect, and (2) they do not take into account that 
the association between E354 and CHD may be entirely synthetic due to LD between this 
variant and the true CHD causal variant. 
 
Considering the pharmacological interest in modulating this pathway as a potential T2D 
therapeutic, increases in cardiovascular risk would represent a major concern with regard to 
the safety and continued development of these therapies. To quantitatively assess the GIPR-
mediated cardiovascular risk, I used a three-stage study design. Firstly, I integrated large-
scale genomic data for cardiometabolic diseases as well as anthropometric, glycaemic, lipid, 
metabolomic and proteomic traits to characterise the association of E354 with clinical 
biomarkers. Secondly, I used a Bayesian multi-trait colocalisation method to formally test 
whether the genetic signal at the GIPR locus mediating a protective effect on T2D is the same 
signal driving cardiovascular disease risk. Lastly, results from statistical colocalisation were 
confirmed using conditional analysis to identify independent variants for each trait and account 






Three sets of genetic analyses were used to investigate the relationships between the GIPR 
and cardiovascular risk. Firstly, the association of a missense variant (E354Q) in the GIP 
receptor gene (GIPR) with CHD and 23 different cardiometabolic diseases, as well as 
anthropometric, glycaemic, lipid and ~6,000 ‘omics biomarkers was estimated using univariate 
2SMR (Table S7.1). Secondly, using the traits significantly associated with E354, Bayesian 
multi-trait colocalisation was applied in the GIPR region to define distinct clusters of traits 
driven by a shared causal variant. Finally, conditional analyses were used to identify 
independent variants contributing to associations between the GIPR locus and traits of 
interest. All studies were approved by local institutional review boards and ethics committees 
and participants gave written informed consent. 
 
Study participants 
EPIC-Norfolk241 (Table 7.1) is a population-based prospective cohort of individuals aged 
between 40-79 years and living in Norfolk (a county of the United Kingdom) at the time of 
recruitment from primary-care outpatient clinics in the city of Norwich and surrounding areas. 
The study was approved by the Norfolk Research Ethics Committee (ref. 05/Q0101/191) and 
all participants gave their written consent before entering the study. 
Fenland244 (Table 7.1) is a population-based cohort study of individuals without diabetes who 
were born between the years of 1950 and 1975 and recruited through population-based 
general practice registers in Cambridge, Ely and Wisbech (Cambridgeshire county, United 
Kingdom). Ethical approval for the study was given by the Cambridge Local Ethics committee 
(ref. 04/Q0108/19) and all participants gave their written consent prior to entering the study. 
UK Biobank66 (Table 7.1) is a population-based cohort study of individuals recruited from 22 
rural and urban recruitment centres in the United Kingdom. European ancestry participants 
with available genome-wide genotyping and phenotypic data were included in this study. 
Ethical approval for the UK Biobank study was given by the North West - Haydock Research 
Ethics Committee (16/NW/0274). This research was conducted using application 44448. 
Participants gave their electronic consent to use their anonymised data and samples for 
health-related research, to be re-contacted for further sub-studies, and for access to their 




Table 7.1: Study participants 
Study Fenland EPIC-Norfolk UK Biobank 
Participants, N 10,708 11,539 452,197 
Age at baseline, mean years (SD) 49 (7) 60 (9) 57 (8) 
Women, N (%) 5,714 (53) 6,198 (54) 245,277 (54) 
Men, N (%) 4,994 (47) 5,341 (46) 206,883 (46) 
BMI in kg/m2, mean (SD) 26.9 (4.9) 26.2 (3.7) 27.4 (4.8) 
Waist-to-hip ratio, mean (SD) 0.74 (0.08) 0.86 (0.09) 0.87 (0.09) 
Systolic blood pressure in mmHg, mean (SD) 123 (15) 136 (18) 138 (19) 
Diastolic blood pressure in mmHg, mean (SD) 74 (10) 82 (11) 82 (10) 
Fasting glucose in log-pg/mL, median (IQR) a 1.57 (1.50, 1.63) N/A N/A 
2-hr glucose in log-pg/mL, median (IQR) a 1.63 (1.44, 1.79) N/A N/A 
Fasting insulin in log-pg/mL, median (IQR) a 3.66 (3.29, 4.06) N/A N/A 
Abbreviations: N/A, not available; N, number of participants; SD, standard deviation; BMI, body mass index; mmHg; 
Millimetres Mercury; pg; Picograms; mL, Millilitres; IQR, Interquartile range 
a. Glycaemic measures from Epic-Norfolk and UK Biobank were not used in this study   
 
Genotyping and imputation 
Genome-wide genotyping in the Fenland cohort was performed in 3 sub-cohorts using either 
the Affymetrix genome-wide Human variant Array 5.0, the Affymetrix UK Biobank Axiom Array 
or the Illumina CoreExome-24 v1 chip, with imputation to the Haplotype reference consortium 
v1.1271, the 1000 genomes project272 and the UK10K273 reference panels. Samples from EPIC-
Norfolk and UK Biobank were genotyped using the Affymetrix UK Biobank Axiom Array and 
imputed to the same reference panels. 
 
Profiling of the plasma proteome 
Fasted EDTA plasma samples from 12,084 participants from the Fenland244 study were 
subjected to proteomic profiling by SomaLogic Inc. (Boulder, US) using an aptamer-based 
technology (SOMAscan v4). The relative abundances of 4,775 human proteins were 
measured using 4,979 SOMAmers, as previously described364. To account for within run 
hybridisation variability, control probes were used to generate a scaling factor for each sample. 
Differences in total signal between samples as a result of variation in overall protein 
concentration or technical variability such as reagent concentration, pipetting or assay timing, 
were accounted for using the ratio between each SOMAmer's measured value and a reference 
value. The median of these ratios was computed for each dilution set (40%, 1% and 0.005%) 
and applied to each dilution set. Samples were removed if they failed SomaLogic QC 
measures or did not meet the acceptance criteria of between 0.25-4 for all scaling factors. A 
total of 10,078 samples had available genotype data and were used in this study. Aptamer 
target annotations and mapping to UniProt accession numbers as well as gene identifiers were 





Plasma metabolomic profiling 
The EPIC-Norfolk population-based cohort241 (described previously) consists of two sub-
cohorts, a T2D case-cohort and a quasi-random selection of participants from the larger 
EPIC242,530 study. The levels of up to 1,504 metabolites were measured in three batches using 
the Metabolon DiscoveryHD4 platform531 (Metabolon, Inc., Durham, USA), in citrate plasma 
samples collected at baseline. Measurements were made in approximately 12,000 samples, 
in two sets of approximately 6000 quasi-randomly selected samples, which were preceded by 
measurements in an incident T2D case-cohort (N= 1503; 857 in the sub-cohort). 
 
Briefly, raw data were extracted, peaks were identified and assessed for quality by Metabolon. 
Metabolite identification was done by comparing measures to a curated library containing the 
retention time, mass to charge ratio and chromatographic data of known metabolites. Each 
metabolite was then quantified using an area-under-the-curve method and the data were 
normalised to correct for instrument tuning variations across run-days. Data normalisation for 
each run-day set the median value for each metabolite to 1, normalising each measurement 




GWAS of plasma proteins 
Prior to GWAS, relative abundances of each SOMAmer were transformed within each 
genotyping subset using the rank-based inverse normal transformation. These were then 
regressed on age, sex, sample collection site and 10 principal components to generate 
residuals. GWAS was then performed using BGENIE (v1.3), assuming an additive model. 
Variants with minor allele frequency < 0.001, imputation quality < 0.4 or Hardy Weinberg 
Equilibrium p < 1x10-7 in any of the genotyping subsets were excluded from further analyses. 
Results from the three genotyping subsets were later combined in a fixed-effects meta-
analysis using METAL. Only variants present in the largest genotyping subset were taken 
forward for further analysis, variants specific to either of the smaller subsets were not 
considered.  
 
Two SOMAmers were used to target circulating GIP, namely 16292-288 and 5755-29. 
SOMAmer 16292-288 was selected against amino acids 1-93 of the precursor protein, 
corresponding to the signal peptide, first propeptide and GIP peptide in Uniprot532. Overlapping 
this region, 5755-29 targeted amino acids 22-153 which corresponded to the first propeptide, 




underlying genetics at GIPR were comparable between the relative abundance SOMAmers 
and absolute quantitation techniques such as enzyme-linked immunosorbent assays (ELISA), 
I performed pairwise genetic colocalisation analyses between GIP measures and 
cardiometabolic traits (Methods S7.1). 
 
GWAS of plasma metabolites 
Metabolite quantitation was performed for a total of 1,008 metabolites across 8 metabolite 
classes and as yet unidentified metabolites, measured in up to 11,539 individuals. GWAS was 
performed in 2 sets, for all metabolites present in at least 100 individuals in both sets. The first 
set consisted of up to 5,841 individuals from both the T2D sub-cohort and the first batch of 
quasi-randomly selected samples. The second set consisted of up to 5,698 individuals from 
the second batch of quasi-randomly selected samples. Metabolite levels were then natural 
log-transformed and winsorised to five SDs. Residuals were calculated, adjusting for age, sex 
(and measurement batch where appropriate) and standardised (mean =0, SD =1). Genotyping 
and imputation were performed as described above. Following imputation, variants with 
imputation quality INFO < 0.4 or minor allele account (MAC) of <= 2 within EPIC-Norfolk were 
excluded. 
 
GWAS were performed using mixed linear models in BOLT-LMM533 v2.2. In instances where 
BOLT-LMM533 failed, related individuals were excluded (identity by descent > 0.185) and linear 
regression models were run using variant SNPTEST274 v2.4.1, while also adjusting for the top 
4 principal components. Variants with evidence of deviation from Hardy Weinberg equilibrium 
(p<10-6), as well as associations with effect estimates with absolute values above 10 or 
standard errors less than 0 or above 10 were removed. Variants with MAF <0.0001 or 
imputation quality scores lower than 0.3 were excluded. An inverse variance weighted meta-
analysis was performed to pool associations from the 2 GWAS sets, using METAL276. This 
included a minor allele count filter of 10 for each individual contributing GWAS, so that these 
associations did not contribute to the meta-analysis.  
 
Association between E354, cardiometabolic and molecular traits 
This work leveraged GWAS summary statistics from in-house studies and publicly available 
data. All phenotypes included in this study, along with details of their respective studies can 
be found in Table S7.1. Only self-reported, white European participants were included.  
 
The exposure variable for this study was the genotype of rs1800437 (HUGO Gene 
Nomenclature Committee gene name, GIPR; transcript change, NCBI transcript identifier 




allele and has an allele frequency in European ancestry participants in the 1000 Genomes 
Project of 79%. Fasting and 2-hour GIP levels used as outcomes in this study were taken from 
a recent GWAS meta-analysis including up to 7,828 Scandinavian participants508. 
 
The disease outcomes investigated in this study included GWAS summary statistics of T2D22, 
T2D adjusted for BMI22 and CHD289 (a meta-analysis of UK Biobank66 and 
CARDIoGRAMplusC4D534). In addition to these broader cardiometabolic disease outcomes, 
summary statistics from cardiovascular disease and stroke sub-types were used. I included 
summary statistics from 16 cardiovascular disease subtypes defined in UK Biobank535 and a 
total of five stroke subtypes from the MEGASTROKE536 consortium.  
 
I gathered genome-wide summary statistics for the following glycaemic traits from different 
resources. Firstly, published measures of fasting glucose, 2-hour glucose, fasting insulin and 
corrected insulin response from the MAGIC344,346,537 consortium were used. GWAS summary 
statistics for fasting glucose, 2-hour glucose and fasting insulin were all adjusted for BMI344,346. 
Measures of HbA1c and non-fasted plasma glucose levels will be described along with the 
other biomarkers measured in UK Biobank66 and InterAct538. 
 
Summary statistics for each of the 19 biomarkers included in this study (Table S7.1) were 
taken from a meta-analysis of UK Biobank66 and InterAct538 data. All biomarkers in InterAct, 
except HbA1c, were measured using a Cobas® (Roche Diagnostics, Mannheim, Germany) 
assay on a Roche Hitachi Modular P analyser. HbA1c was measured on erythrocyte samples 
using a Tosoh (HLC-723G8) assay on a Tosoh G8 analyser. All traits were then regressed on 
age, age2, sex, and centre using multivariable linear regression to generate residuals. These 
residuals were then rank-based inverse normal transformed. The top 10 genetic principal 
components were included in the final linear regression model. Traits measured in UK Biobank 
were also rank-based inverse normal transformed within each respective aliquot. In the final 
model, all traits were adjusted for age, age2, sex, aliquot, genotyping chip, lipid lowering 
medication and the top 40 principal components using a multivariable linear mixed model. 
GWAS were performed using a linear mixed model implemented in BOLT-LMM533 to account 
for cryptic population structure and relatedness. Results from both GWAS analyses were then 
meta-analysed using METAL276.  
 
The anthropometric outcomes included in this study were estimated in a meta-analysis of 
Genetic Investigation of Anthropometric Traits (GIANT)343,539 and UK Biobank data66. In UK 
Biobank66, weight was measured using a calibrated electronic scale (TANITA model BC-418 




202; Seca, Birmingham, United Kingdom). BMI (in kg/m2) was calculated as weight divided 
by height squared. Waist and hip circumferences were measured with a non-stretchable 
sprung tape measure (Wessex tape, London, United Kingdom). WHR was the ratio between 
the waist and hip circumferences. Residuals were then generated by regressing each outcome 
against age, age2, study-specific covariates and BMI (if applicable). Residuals were estimated 
for each sex independently and transformed using a rank-based inverse normal 
transformation prior to association testing using multivariable linear regression. Results from 
UK Biobank GWAS analyses were then meta-analysed with results from GIANT343,539 using 
METAL.   
 
Bio-impedance measurements were performed in UK Biobank66 using the Tanita BC418MA 
body composition analyser (Amsterdam, The Netherlands). All bio-impedance traits were 
natural log transformed and adjusted for age (and total fat mass or height2 – if adjusted) in 
each sex separately to generate residuals. As before, the residuals were rank-based inverse 
normal transformed. Each trait was then tested for association with genetic variants using a 
linear mixed model in BOLT-LMM533, adjusting for age, sex, genotyping chip, and the top 40 
principal components.  
 
I performed two-sample univariate MR analyses using the Wald ratio method540 to estimate 
the potential causal effect of fasting GIP levels on various cardiometabolic and molecular traits 
(Table S7.1). Genetically predicted fasting GIP levels were used as the exposure and E354 
was used as the instrumental variable. Associations of E354 with each of the cardiometabolic 
and molecular traits listed above were extracted from GWAS summary statistics and used as 
outcomes. All summary statistics were aligned to the fasting GIP raising allele (G) of E354. 
Estimates of the association of E354 with disease outcomes were expressed as odds ratios 
per copy of E354. Associations with all other traits were expressed as SD unit increase in trait 
(beta) per copy of E354. A nominal significance threshold of P<0.05 was used to ascertain 
statistical significance for all outcomes aside from cardiovascular disease subtypes, protein 
and metabolite levels, where Bonferroni significance thresholds accounting for the number of 
disease subtypes, proteins or metabolites were used. All data analysis was performed using 
R version 3.6.3. 
 
Multi-trait colocalisation across cardiometabolic traits 
I used multi-trait colocalisation (HyPrColoc)362 at the GIPR locus to 1) identify cardiometabolic 
traits that share a common causal variant, and 2) identify distinct clusters of cardiometabolic 
traits driven by distinct causal variants. The same prior configurations and thresholds as 





All variants within 1Mb either side of E354 were extracted from GWAS summary statistics for 
26 cardiometabolic traits of interest. The GIP measures considered were fasting GIP as 
measured by SOMAmers X16292_288 and 5755-29, as well as fasting and 2-hr GIP measures 
from the Malmö Diet and Cancer (MDC) sub-cohort of Almgren et al. 2017508. MDC measures 
were preferred to those from either PPP-Botnia or the meta-analysis of the two cohorts as the 
MDC genotyping platform had better variant coverage than PPP-Botnia, despite PPP-Botnia 
having a larger sample size. In addition, the variant coverage of the meta-analysis was limited 
to variants present in both genotyping subsets, effectively limiting the variant coverage to that 
of PPP-Botnia. The anthropometric traits included were BMI, WHR, and hip and waist 
circumferences. Anthropometric traits adjusted and unadjusted for BMI were included, where 
applicable. T2D and CHD were included as disease outcomes of interest. Glycaemic 
measures included non-fasted glucose, HbA1c, 2-hr glucose adjusted for BMI, fasting glucose 
adjusted for BMI and fasting insulin adjusted for BMI. Finally, lipid traits of interest were LDL, 
HDL, total cholesterol, triglycerides, lipoprotein A, apolipoprotein A1 and apolipoprotein B. 
Summary statistics used for fasting and 2-hour glucose as well as fasting insulin were not the 
same as those used to characterise the association of E354 with cardiometabolic traits. 
Despite these summary statistics being well-powered to detect associations at E354, their 
imputation to older reference panels led to poor variant coverage, which made them unsuitable 
for use in a colocalisation setting. To address this, I carried out separate GWASs for these 
three traits in the densely imputed Fenland cohort (Methods S7.2) and used these summary 
statistics for HyPrColoc. 
 
Sensitivity analyses were run as described in Chapter 5. The MDC cohort was genotyped 
using an exome-wide platform (Illumina Infinium OmniExpressExome v1.0), thus limiting the 
variant coverage especially in intergenic regions. To address this and provide greater genomic 
context, I ran a sensitivity analysis using the same configuration and sensitivity assessments 
as above, while excluding the GIP traits measured in MDC. 
 
Finally, heatmaps based on similarity matrices estimating how often trait pairs were clustered 
together across all algorithm parameter choices were drawn. In addition, stacked regional 
association plots were drawn for each cluster of traits using the gassocplot R package. LD 
data used to plot the correlation between the candidate variant and other variants in the locus 







Conditional analysis at the GIPR locus 
To determine whether the association between E354 and CHD was due to LD between E354 
and other CHD lead variants in the GIPR region, I performed conditional analysis using 
GCTA542 v1.93.1. Using GWAS summary statistics for CHD289, I implemented a step-wise 
selection based on regional LD to identify independent variants associated with CHD on 
chromosome 19. Selection was performed using a selection threshold of P< 1x10-5, a 
threshold for collinearity between variants of 0.05 and a minor allele frequency threshold of 
1%. An LD reference panel from the EPIC-Norfolk cohort imputed as described above was 
used for selection. Using the identified independent variants, the association between E354 
and CHD was conditioned on each respective variant to estimate whether the association was 
attenuated. Attenuation of the association would imply that the association between E354 and 
CHD was due to the residual LD between E354 and one of the independent variants, rather 
than being driven by a separate mechanism. This procedure was repeated for all traits 
associated with E354. If E354 (or a proxy variant in complete LD with E354) was identified as 
one of the independent variants, conditional analysis was not performed. Following this, 
regional association plots were generated to visualise the association of E354 with CHD, 
before and after conditioning using LocusZoom v1.2. I also extracted the estimates for other 
variants previously found to be associated with fasting GIP levels508 from the CHD summary 
statistics289. This was done to ascertain whether any other loci showed overlapping 






Characterisation of a missense variant E354Q (rs1800437) in the GIPR 
T2D and related glycaemic outcomes 
Among the cardiometabolic disease outcomes examined, higher E354-mediated fasting GIP 
levels were associated with lower T2D risk (OR per copy of E354, 0.97; 95% CI, 0.96, 0.99; 
P=7×10-5; Figure 7.1A), an effect which strengthened following BMI adjustment (0.93; 95% 
CI, 0.91, 0.95; P=3×10-14). In line with this, lower 2-hour glucose levels were observed (2-hour 
glucose in mmol/L per copy of E354, -0.09; 95% CI, -0.11, -0.07; P=2×10-15; Figure 7.1B). 
Additionally, HbA1c levels were shown to be 0.01 SD units lower per copy of E354. I observed 
no association with either of the insulin outcomes. 
 
Cardiovascular outcomes and related risk factors 
In contrast to the T2D association, E354 was associated with higher CHD risk (OR per copy 
of E354, 1.03; 95% CI, 1.02, 1.05; P=2x10-6; Figure 7.1A). This was coupled with higher levels 
of several cardiovascular lipid risk factors including apolipoprotein A1, apolipoprotein B, HDL, 
low-density lipoprotein and total cholesterol (Figure 7.1B). In contrast to the other lipid traits, 
E354 was associated with lower triglyceride levels. Across stroke sub-types, no significant 
associations between E354 and stroke were observed aside from a lower risk of small vessel 
stroke (OR per copy of E354, 0.93; 95% CI, 0.87, 0.98; P=0.009; Figure 7.1A). E354 was not 
significantly associated with other cardiovascular disease subtypes in UKBB, however, a 
suggestive association with abdominal aortic aneurysm was observed (Figure S7.1).  
 
Anthropometric outcomes 
Each copy of E354 was associated with 0.03 SD higher BMI (95% CI, 0.03, 0.04; P=3×10-59; 
Figure 7.1B). This was coupled with similar associations between E354 and higher regional 
anthropometric measures such as hip and waist circumferences and waist-to-hip ratio. In line 
with this, significant associations were found with all regional adiposity measures from a large 
GWAS based on bio-impedance data (Figure S7.2). 
 
Biomarker outcomes 
Of the 19 biomarkers investigated, E354 was significantly associated with lower levels of only 
two, namely albumin and creatinine (beta in SD units per copy of E354, -0.01; 95% CI, -0.02, 





Figure 7.1: Associations between E354 (rs1800437) and cardiometabolic diseases, 
glycaemic traits, cardiovascular risk factors and lipids, anthropometric traits and 
biomarkers. Panel A. Associations with cardiometabolic diseases are shown in blue and are 
represented as odds ratios (95% CI) for each disease per copy of rs1800437. Panel B. 
Associations with glycaemic traits are shown in orange, cardiovascular and lipid traits in green, 
anthropometric traits and biomarkers are shown in yellow and purple respectively. Estimates 
are represented as beta (95% CI) for each outcome per copy of rs1800437. All traits are in 
SD units aside from fasting and 2-hour glucose which are in mmol/L, fasting insulin in log 
(pmol/L) and HbA1c in mmol/mol. Fold change insulin represents the fold change in insulin 
levels between fasting to 2-hour measures. 
Abbreviations: OR, Odds ratio; CI, Confidence interval; N, Number; BMI, Body mass index; adj., Adjusted; HbA1c, 
Glycated haemoglobin; ApoA1, Apolipoprotein A1; ApoB, Apolipoprotein B; HDL, High-density lipoprotein; LDL, 
Low-density lipoprotein; γ, Gamma.  
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Associations of E354 with plasma protein and metabolite levels  
Next, I estimated the association of E354 with the fasting levels 4,979 human proteins from 
the SOMAscan® v4 system. Significant associations with the levels of three proteins were 
found (Figure S7.3), one of these being 0.08 SD higher fasting GIP levels (95% CI, 0.05, 0.11; 
P=4×10-6) as measured by SOMAmer 16292-288. Interestingly, this analysis did not find a 
significant association between the other GIP SOMAmer, 5755-29, and E354. Lower levels of 
secretoglobin family 3A member 1 (SCGB3A1) and glutaminyl-peptide cyclotransferase-like 
protein (QPCTL) were also found to be associated with E354. In contrast with a previous 
report484, no association between E354 and osteopontin was found. 
 
Lower levels of a single metabolite were found to be significantly associated with E354, an 
unidentified metabolite named X-12283 (beta in SD units per copy of E354, -0.08; 95% CI, -
0.12, -0.05; P=2×10-5; Figure S7.4) which was detectable in 8,278 participants. To elucidate 
the metabolite class and putative function of X-12283, partial correlations were estimated in 
11,966 participants between X-12283 and 883 metabolites with less than 50% missingness 
(Methods S7.3). A total of 11 metabolites were significantly correlated with X-12283, of these, 
five showed a correlation estimate with X-12283 greater than 0.1 (Figure S7.5). In addition to 
significant correlations with unknown metabolites, X-12283 was most significantly correlated 
with the known amino acid indolepropionate (correlation estimate = 0.23; P= 2.14x10-51; 
Figure S7.5).  
 
Multi-trait colocalisation across cardiometabolic traits 
Multi-trait colocalisation between several cardiometabolic risk factors and disease outcomes 
was run at the GIPR locus in the 1Mb regions either side of E354. A total of 425 variants were 
included in the main analysis, which was limited due to the inclusion of fasting and 2-hour GIP 
measures from MDC508, whereas 5,016 were included in the sensitivity analysis (Table 7.2). 
Using a default prior and threshold configuration, 5 distinct trait clusters were identified, 3 of 
which were shared by both the main and sensitivity analyses (Table 7.2). Cluster similarity 
across all prior and threshold permutations for the two analyses are summarised in heatmaps 
Figure 7.2. Results for all permutations for both the main and sensitivity analyses can be 
found in Tables S7.2 and S7.3 respectively.  
 
Of the clusters identified, two distinct clusters were of interest. The first, driven by rs7412 a 
missense variant in the apolipoprotein E gene (APOE), contained CHD and lipid traits – many 
of which are established cardiovascular risk factors. Both the PPcoloc and PPcausal were 
estimated to be 1 in the two analyses, demonstrating robust evidence for colocalisation (Table 




identified when using more stringent values for the prior probability of colocalisation (Figure 
7.2, Tables S7.2 and S7.3).A second cluster consisting of GIP traits, anthropometric traits 
and 2-hour glucose was driven by rs11672660, which is in perfect LD with rs1800437 (E354; 
R2 = 1) (Table 7.2 and Figure S7.7). The PPcoloc for both analyses showed robust evidence 
for colocalisation (PPcoloc>0.9; PPexplained=0.99; PPcausal=0.96), making it highly likely that 
rs11672660 was the causal variant. Due to the LD between rs1800437 and rs11672660, the 
cluster of BMI and waist circumference identified in the sensitivity analysis form part of the 
cluster with the fasting GIP levels. This is evidenced by the clear association signal across all 
traits led by rs11672660 (Figure S7.7).  
 
Critically, these results replicate my findings using pairwise-trait colocalisation at this locus, 
showing that fasting GIP levels and cardiovascular risk are driven by independent variants (R2 
between rs11672660 and rs7412 = 0.004) (Table 7.2; Figures S7.6-S7.8; Figure 7.2). 
Additionally, both colocalisation analyses demonstrate that the underlying genetics at GIPR 
are comparable between the relative abundance GIP levels measured by SOMAmer 16292-
288 and the absolute quantitation methods of previous analyses508. Together these results 
robustly demonstrate that the GIP-raising and cardiovascular risk increasing effects at this 
locus are distinct (Tables S7.2 and S7.3).  
 
A third cluster including a mixture of glycaemic, anthropometric traits and ApoA1 levels were 
estimated to colocalise at rs4420638 which was in LD with rs429358 (R2 = 0.69), a missense 
variant in APOE. In the sensitivity analysis, rs429358 was identified as the candidate variant 
and T2D was estimated to colocalise with the traits mentioned above. As the sensitivity 
analysis included more variants and therefore had greater genomic context, rs429358 is likely 
to be the candidate variant at which these traits colocalise. Supporting this, rs429358 was not 
present in the main analysis, as this was limited to variants present in all datasets, including 
fasting GIP measures from MDC which included only exome-wide variants. At default settings, 
non-fasted glucose was estimated to be part of the cluster, however, at more stringent prior 
and threshold configurations it was removed, thus replicating the cluster identified in the 
sensitivity analysis (Figure 7.2A and Table S7.2). Again, the high PPcoloc demonstrated robust 
evidence for colocalisation between these traits at rs429358. ApoA1 was estimated to 
colocalise at rs429358, an independent variant in APOE, unlike the other lipid traits which 
colocalised with CHD at rs7412 (R2 = 0.69) (Table 7.2).  
 
Finally, a cluster between T2D and hip circumference adjusted for BMI was identified in the 
main analysis, however, was not replicated in the sensitivity (Table 7.2). Instead, a cluster 




analysis, driven by an independent variant rs5117 (R2 with rs10408179 = 0.001) (Table 7.2). 
This discrepancy is likely to be resultant of the low number of variants present in the main 
analysis. When provided with more genomic context, triglycerides were estimated to 
colocalise with hip circumference adjusted for BMI instead of T2D. Supporting this, rs5117 
was not present in the main analysis, as this was limited to variants present in the summary 





Table 7.2: Clusters of colocalised traits identified by the main and sensitivity analyses at default settings 























LDL, CHD, HDL, Total 
Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 
LDL, CHD, HDL, Total 
Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5,016 
GIPR 0.69 
Glucose, HbA1c, ApoA1, 
WHRadjBMI, Waist 
circumference adjBMI, WHR 





0.85 rs429358 1 5,016 
GIPR 1 
GIP SOMAmer 16292_288, 
Fasting GIP, 2hr GIP, BMI, 
Hip circumference, Waist 
circumference, 2hr Glucose 
adjBMI 





0.90 rs11672660 0.99 5,016 
GIPR 1b      BMI, Waist circumferenceb 0.99 rs1800437 0.68 5,016 
GIPR NA 
T2D, Hip circumference 
adjBMI 
0.97 rs10408179 1 425      
GIPR NA      
Triglycerides, Hip 
circumference adjBMI 
0.98 rs5117 0.93 5,016 
Abbreviations: GIPR, Glucose-dependent insulinotropic polypeptide receptor; LD, Linkage disequilibrium; PP, Posterior probability; coloc, Colocalisation; N, Number; variants, 
Single nucleotide polymorphisms; LDL, Low-density lipoprotein; CHD, Coronary heart disease; HDL, High-density lipoprotein; ApoB, Apolipoprotein B; Glucose, Non-fasted 
glucose; ApoA1, Apolipoprotein A1; adj., Adjusted for; WHR, Waist-to-hip ratio; BMI, Body mass index; T2D, Type 2 diabetes 
a. Traits are reported at default settings for Hyprcoloc: Prior 2 = 0.02; regional and alignment thresholds = 0.5; thus, the posterior probabilities will vary dependent on the 
prior configuration 
b. The rs1800437 and rs11672660 variants are in perfect LD (R2 = 1) meaning that the BMI + WC cluster at the GIPR locus, reported separately in the sensitivity analysis, 
forms part of the larger cluster with the fasting GIP traits as in the main analysis. The BMI + WC cluster has therefore not been counted as an independent cluster in 
results 
c. Blank rows for either analysis indicate a cluster not identified in the respective analysis 





Figure 7.2: Similarity heatmap for each cluster at the GIPR locus across prior and 
threshold permutations. Traits that were estimated to colocalise are clustered together. 
Darker colours represent traits which were estimated to colocalise more often across prior and 
threshold permutations. Panel A. Main analysis. Panel B. Sensitivity analysis 
Abbreviations: LDL, Low-density lipoprotein; CHD, Coronary heart disease; HDL, High-density lipoprotein; ApoB, 
Apolipoprotein B; Glucose, Non-fasted glucose; ApoA1, Apolipoprotein A1; adj., Adjusted for; WHR, Waist-to-hip 









































































































































































































































































































































































































































Conditional analysis at the GIPR locus 
The univariate two-sample MR results showed that E354 was associated with a total of 20 
traits at a nominal significance threshold (Figure 7.1). Independent signal selection showed 
that E354, or proxy variants in high LD (R2 > 0.9) with E354, were identified as independent 
signals for fasting GIP, 2-hour glucose, total cholesterol levels, BMI and X-12283 levels. 
Independent signal selection identified a total of 24 variants independently associated with 
CHD on chromosome 19, four of which were in the 1Mb regions either side of E354 at the 
GIPR locus (Table 7.3). Conditioning the association between E354 and CHD on the residual 
LD between E354 and rs7412, the variant estimated to drive the cluster with CHD, showed a 
slight attenuation of this association (OR per copy of E354 after adjustment 1.03; 95% CI, 
1.02, 1.04; P=0.003), however, the association remained significant. Of the independent 
variants identified, rs1964272 an intronic variant in small nuclear ribonucleoprotein D2 
polypeptide (SNRPD2), was estimated to be in the strongest LD with E354 (R2=0.27) (Figure 
7.3 and Figure S7.9). The association between E354 and CHD risk was attenuated when 
conditioned on rs1964272 (OR per copy of E354 after adjustment, 1.01; 95% CI, 0.99, 1.03; 
P = 0.06) (Table S7.4). In line with this, the association between E354 and small vessel stroke 
was also attenuated when conditioning on rs1964272 (Table S7.4), however, the association 
of E354 with non-fasted glucose remained nominally significant (P=0.05). None of the other 
loci previously reported as associated with fasting GIP levels were found to be associated with 
CHD (Table S7.5). Interestingly, rs1964272 was also shown to be associated with levels of 
the proteins QPCTL and SCGB3A1 indicating confounding by LD for the proteomics data as 
well (Figure S7.10). In accordance with this, the association between E354 and levels of 
QPCTL was also attenuated to non-significance when conditioned on rs1964272 (beta QPCTL 
per copy of E354 after adjustment, 0.01; 95% CI, -0.02, 0.04; P=0.48). The association 
between E354 and SCGB3A1 levels was attenuated when conditioned on rs61703905 but 
remained significant (Table S7.4).  
 
Table 7.3: Independent CHD variants identified using approximate conditional analysis. 
Variant a Chr:pos EA EAF 
Marginal 










rs429358 19:45411941 T 0.85 -0.09 (0.008) 2.86x10-27 -0.08 (0.008) 5.87x10-23 286,423 0.001 
rs7412 19:45412079 T 0.08 -0.14 (0.011) 1.66x10-35 -0.12 (0.011) 1.58x10-28 275,803 0.004 
rs11673093 19:45742094 A 0.26 0.04 (0.007) 4.11x10-11 0.04 (0.007) 3.09x10-10 300,789 0 
rs1964272 19:46190268 A 0.48 -0.03 (0.006) 9.65x10-9 -0.03 (0.006) 1.87x10-7 299,519 0.27 
Abbreviations: Chr, Chromosome; pos, Position; EA, Effect allele; EAF, Effect allele frequency; SE, Standard error; 
N, Number of participants; R2, Linkage disequilibrium estimate 
a. The independent CHD variants in the 1Mb region either side of E354 are shown 
b. Log odds ratios from the original GWAS summary statistics 




Much like the CHD association, conditioning the associations between E354 and lipid traits on 
rs7412 did show partial attenuation for ApoB and LDL, however, these associations remained 
significant (Table S7.4). In line with this, conditioning the association of E354 with triglycerides 
on rs4803936, an intronic variant in protein phosphatase 5 catalytic subunit (PPP5C), also 
remained significant, suggesting that E354 has independent effects on lipid metabolism. 
Interestingly, the same was not true for the associations of E354 with ApoA1 and HDL when 
conditioning on rs2238689, an intronic variant in GIPR (R2 with E354=0.36), as these 




Figure 7.3: Regional association plots depicting CHD lead variants in the GIPR region. 
Panel A. The independent CHD lead variants in the GIPR region are labelled and their 
respective associations with CHD are shown before conditional analysis. The region around 
rs1800437 (E354) is expanded in the red insert to show the LD and proximity of rs1964272 to 
rs1800437. Panel B. The associations of variants in the GIPR region after conditioning on 
rs1964272. The region around rs1800437 (E354) is expanded in the red insert to show the 





7.4: Discussion  
Recently, evidence linking higher fasting GIP levels with increased CVD risk481,484 has led to 
safety concerns surrounding GIPR agonism via either selective GIPR agonists or dual-GIPR 
and GLP-1R agonists481. As new T2D therapies cannot confer clinically significant increases 
in CVD risk543, these findings may be considered detrimental to therapeutics targeting this 
pathway.  
 
In this study, I applied Bayesian multi-trait colocalisation and conditional analysis to gain 
greater resolution into the underlying genetic architecture of CHD and its relation to fasting 
GIP levels at the GIPR locus. Results from multi-trait colocalisation robustly partitioned the 
colocalisation of CHD and lipid traits to a cluster at APOE that was independent from a cluster 
of fasting and 2-hour GIP, glycaemic and anthropometric traits driven by E354. Several factors 
highlight the robust partitioning of these two distinct clusters of colocalised metabolic traits at 
the GIPR locus, (1) colocalisation analyses were consistent between the main and sensitivity 
analyses, (2) the same variant was identified as putatively causal in each analysis, and (3) 
traits included in each cluster were stable at increasingly stringent prior and threshold 
configurations. The clustering of these traits at independent variants, is likely to represent 
independent biological mechanisms. APOE has a central role in lipid metabolism and transport 
in blood544 and APOE is an established gene associated with both plasma lipid levels396 and 
CHD risk534. In contrast, the traits clustering at GIPR have all been associated with E354 
previously and are in line with the established functions of GIP508,528,529. Results from 
conditional analysis demonstrated a robust attenuation of the E354 association with CHD, 
small vessel stroke and QPCTL levels when adjusted for rs1964272, an intronic variant in 
SNRPD2. This, together with the multi-trait colocalisation results, demonstrates that these 
association signals for CVD at GIPR are not mediated by an independent effect of GIPR 
variants on CVD risk but are instead the result of low-level LD between E354 and rs1964272. 
This variant lies within an established CHD risk locus289,534 and functions as part of a 
spliceosomal complex mediating pre-mRNA splicing534, however, its role in CHD 
pathophysiology is unclear.  
 
The conditional analysis results also highlighted the effects of E354 on lipid metabolism and 
BMI. E354 is an established variant associated with higher BMI529 and was identified as an 
independent variant in this analysis. Studies in animal models have posited a role for fasting 
GIP in lipid metabolism, suggesting that the effects of GIP on lipid deposition479,480 may 
contribute towards weight gain and higher BMI481. The conditional analysis results 




conditioning on rs7412 in APOE, the association remains significant. This suggests that GIPR-
mediated higher fasting GIP levels have an independent effect on some lipid levels.   
 
Taken together, these findings demonstrate the specificity of E354’s effects on fasting GIP 
levels and crucially demonstrate that higher E354-mediated fasting GIP levels are not 
associated with CVD risk. I therefore provide evidence that the inclusion of GIPR agonists in 
dual agonists simultaneously targeting GIPR and GLP-1R could potentiate the protective 
effect of GLP-1 agonists on diabetes without undue cardiovascular risk, an aspect which has 
yet to be assessed in clinical trials. In addition, results from clinical trials of dual agonists have 
shown that the effects of GIP on weight gain are counteracted by GLP-1, as significant weight 
loss was demonstrated, while potentiating improved glycaemic control and protection against 
T2D503,504. Many studies have shown that GLP-1R agonism achieved through chronic 
pharmacologic therapy, or genetic gain of function, is associated with improved cardiovascular 
outcomes482,524–527. Hence, the totality of available evidence suggests that dual agonism of 
these receptors may exploit the metabolically favourable combined pharmacology of these 
incretins without undue CVD risk. However, this proposition requires formal assessment in 
clinical trials such as the recently initiated SURPASS cardiovascular outcomes trial of the 
novel GIP/GLP-1R dual agonist tirzepatide (clinicaltrials.gov registered trials number 
NCT04255433). 
 
This study has potential limitations. Firstly, this analysis focuses on a single locus associated 
with both fasting GIP levels and CHD. In doing so, this assumes that the GIPR locus is a 
suitable proxy for fasting GIP levels within which to partition the associations of these two 
complex traits. Considering that the association with 2-hour glucose is statistically robust and 
in line with the established function of GIP, this is a reasonable assumption. In addition, no 
other locus has been reported to be associated with both fasting GIP and CHD, therefore, this 
is likely to be the only locus where these traits overlap. Examining the association of other 
variants found to be associated with fasting GIP levels508 showed no association of any of 
these variants with CHD289. This does not, however, exclude the possibility that other variants 
that have not yet been shown to be associated with GIP levels, do not contribute to CVD risk. 
Secondly, this analysis made use of fasting GIP measures from aptamer-based technology, 
which used two SOMAmers to target overlapping portions of the GIP precursor peptide which 
are present in the active GIP peptide. To enable fine-scale control of insulin potentiation, active 
GIP is rapidly degraded by dipeptidyl peptidase 4 (DPP-4), cleaving the first two amino acids 
from active GIP(1-42) to create GIP(3-42), which has been shown to antagonise GIPR418,489. 
Due to the nature of the technology it is unable to discriminate between active and degraded 




techniques508. Thirdly, protein abundances were measured in plasma samples, where protein 
function and abundance may differ from that measured intracellularly and is likely to include 
purposefully secreted as well as leaked proteins.  
This study highlights the specificity of E354 for fasting GIP levels and robustly demonstrates 
that CVD risk and fasting GIP levels are driven by independent causal variants in the region 
surrounding GIPR. I also demonstrate that GIPR-mediated cardiovascular risk is in fact the 
result of low-level LD between E354 and rs1964272 and not the result of independent effects 
of GIPR variants on CVD risk. Taken together, these findings are promising for the 
development of therapeutics designed to pharmacologically modulate this pathway in T2D 






Chapter 8: Concluding Discussion 
8.1: Summary of the findings 
This PhD thesis set out to identify the aetiological pathways underpinning the roles of 
inflammatory biomarkers and incretins, two areas of considerable pharmacological interest, in 
cardiometabolic diseases. This was based on the integration of large-scale genetic data in 
deeply phenotyped cohorts with multiple ‘omics datasets to further our understanding of the 
molecular underpinnings of T2D and CHD. 
 
Studies have shown that obesity is accompanied with an inflammatory response109,138,223,356 
which has been shown to be associated with insulin resistance138,223,270, diabetes109,223,334,356 
and atherosclerosis4,90,155,160,383. In Chapter 2, the observational associations of four 
proinflammatory cytokines IFNγ, IL-6, IL-8 and TNFα with cardiometabolic diseases and 
related risk factors were estimated. Levels of IFNγ, IL-6 and TNFα were associated with all 
measures of adiposity that were considered and most lipid levels, whereas IL-8 levels were 
only associated with WHR and HbA1c. In line with the hypothesis that higher BMI is a major 
driver of inflammation in cardiometabolic diseases94,112,123,223,545, adjustment for BMI 
attenuated the majority of these associations. IL-6, TNFα and to a lesser extent IFNγ, 
remained associated with lower HDL but higher triglycerides, fasting insulin, HbA1c and WHR, 
hallmarks of an insulin resistance phenotype33,345,346,390. Similarly, IL-6 and TNFα were shown 
to be associated with both incident T2D and CHD, despite extensive adjustment for 
established cardiometabolic risk factors.  
 
Next, to gain a better understanding of the genetics underpinning the levels of these four 
cytokines, I conducted a GWAS in approximately 17,000 individuals, the largest cytokine 
GWAS to date. A total of 22 variant-cytokine associations were identified in 19 loci, 16 of which 
were novel and outside the MHC gene region. Six of these were associated with IFNγ levels, 
three with IL-6 levels, five with IL-8 levels and six with TNFα levels. Missense variants in the 
receptors for the respective cytokines were identified: DARC (IL-8), IL6R (IL-6), CXCR1/2 (IL-
8) and IFNGR1 (IFNγ), making them ideal candidates for follow-up. While these variants 
explained the greatest proportion of variance in levels of the respective cytokines, only the 
IL6R region showed strong evidence of a shared signal underlying cytokine levels and 





In a meta-analysis of 15 prospective studies higher IL-6 levels were associated with incident 
T2D risk. Closer examination of the Asp358Ala variant in a large trans-ethnic meta-analysis 
showed an association with lower odds of T2D. This was conditionally independent of a nearby 
association peak for T2D, consistent across ethnic groups, and unlikely to be influenced by 
potential diagnostic misclassification. In line with the observational findings, the 358Ala allele 
was associated with lower HbA1c levels and showed a significant interaction with higher BMI 
on HbA1c levels. Mediation analyses showed that IL-6 levels mediated up to 5% of the 
association between higher BMI and T2D, this was 3-4 times smaller than for CHD. This, 
together with rescaled projections of IL-6R antagonism in T2D of below 10% risk reduction, 
suggested that while IL-6 mediated inflammation plays a role in the aetiology of T2D, the 
impact of this pathway on disease risk in the general population may be small. 
 
Next, I integrated large-scale genomic and aptamer-based proteomics data in a Bayesian 
multi-trait colocalisation framework to systematically identify inflammatory proteins and 
pathways associated with cardiometabolic diseases. Considering cis genetic association data 
for 335 inflammatory proteins, a total of 164 and 181 showed strong evidence of a shared 
signal with T2D and CHD, respectively. The candidate variant at 95% and 85% of the regions 
shared between inflammatory proteins and either T2D or CHD, respectively, was an 
established pleiotropic locus. In addition, 42% and 36% of inflammatory proteins which shared 
a signal with T2D and CHD, respectively, were estimated to be driven by established risk 
factors for cardiometabolic diseases. Consistent with an insulin resistance phenotype, the 
triglycerides and WHRadjBMI scores were associated with levels of the greatest number of 
proteins for both diseases.  
 
Finally, recent observational and genetic epidemiological studies using a missense variant in 
GIPR, E354, suggested an association between higher GIPR-mediated fasting GIP levels and 
CHD risk481, a concern for therapeutic development targeting GIPR agonism in T2D. Using a 
Bayesian multi-trait colocalisation framework in the region around GIPR, I showed that GIP, 
adiposity and glycaemic traits shared a signal at E354, a missense variant in GIPR, whereas 
CHD and lipid traits shared an independent signal at rs7412, a missense variant in APOE. 
However, the low LD between rs7412 and E354 was estimated not to be driving the 
association of E354 with CHD. Instead, the association of E354 with CHD was completely 






In this final chapter, I will discuss the strengths and limitations of the research presented in 
this thesis and how this may have impacted the findings. Next, I will consider the implications 





To my knowledge, the work presented in this thesis represents the most comprehensive and 
systematic investigation of the role of inflammation in the aetiology of T2D and CHD. This work 
leveraged large-scale genomic data in deeply phenotyped cohorts such as UK Biobank and 
integrated this with large, publically available datasets to ensure that all analyses were suitably 
powered. This work examined the role of inflammation on both a locus and global perspective 
to identify and characterise the inflammatory proteins and pathways involved in the aetiology 
of cardiometabolic diseases. My work on cytokine levels used a systematic evidence-based 
approach resulting in the largest GWAS of cytokine levels to date, further elucidating the 
genetic determinants of IL-6 and TNFα but most importantly, providing evidence of the first 
genome-wide evidence of variants associated with IL-8 and IFNγ levels. I also conducted the 
most comprehensive epidemiological and human genetics study to date on the association 
between IL-6 mediated inflammation and the risk of T2D. This work integrated trans-ethnic 
genetic data from UK Biobank and publically available datasets to demonstrate a consistent 
effect of this pathway across ancestries that is not due to diagnostic misclassification with type 
1 diabetes. I provide the first human genetics evidence supporting the long-standing 
hypothesis of a role for chronic inflammation in T2D and used this evidence to project the 
effects of IL-6 antagonism in T2D, an area not yet addressed by RCTs.  
 
Later, this was expanded to identify inflammatory proteins and pathways involved in the 
aetiology of cardiometabolic diseases by integrating genomic data with large-scale aptamer-
based proteomics data. This work used contemporary genetic methods to address several 
important aetiological questions. Firstly, this work identified inflammatory proteins which may 
be involved in T2D and CHD risk and highlighted loci underpinning inflammation in 
cardiometabolic disease risk. Secondly, using polygenic scores, an approach robust to 
reverse causality, I demonstrated that inflammation in cardiometabolic diseases is likely to be 
driven by both pleiotropy and established cardiometabolic risk factors. 
 
The work on GIP presented in this thesis illustrates how genetics may be used to partition the 
effects of variants to assess the safety of a therapeutic target. Genomic, metabolomic and 
proteomic data were integrated to investigate the relationship between GIPR signalling and 
CHD risk, using E354 as an instrument for GIPR agonism. Integrating these biological layers 
helped to characterise the molecular effects of GIPR agonism on the proteomic and 
metabolomic profile, highlighting the specificity of therapeutically targeting this pathway in 
T2D. This work had several advantages over previous efforts. Firstly, the entire genomic 
region surrounding GIPR was considered facilitating a comprehensive investigation into the 




Secondly, this facilitated an in-depth assessment of the LD in the region to determine whether 
the association between E354 and CHD risk was an entirely synthetic effect. This work has 
promising implications for pharmacological modulation of this pathway. I showed that GIP, 
anthropometric and glycaemic traits are driven by a variant that is distinct from a variant driving 
CHD risk in the GIPR region. Finally, using conditional analysis I demonstrated that 
cardiovascular risk was not estimated to be mediated via GIPR, suggesting that therapeutics 






Approximation of pharmacological agonism or antagonism using genetic variants 
In Chapter 4 and Chapter 6 of this thesis, missense variants, Asp358Ala and E354Q, were 
used as genetic instruments for pharmacological antagonism and agonism of the IL-6R and 
GIPR, respectively. Experimental evidence310 has demonstrated that the 358Ala allele is a 
major determinant of soluble IL-6R levels, leading to a reduction in IL-6R cell surface 
expression and impaired cellular responsiveness to IL-6. Similar functional evidence490 has 
indicated that the GIPR missense variant 354Q results in an exaggerated reduction in GIPR 
expression on the plasma membrane following GIP stimulation, coupled with a delayed 
recovery in GIP sensitivity after GIP stimulation, mimicking pharmacological antagonism. The 
work presented in Chapter 7 used the other allele of this variant, E354 as an instrument for 
GIPR agonism. However, there are several key differences between pharmacological 
modulation of these receptors compared to the effects of naturally occurring genetic variants 
which mean that genetic variants may not accurately approximate the effects of 
pharmacological modulation.  
 
Firstly, unlike pharmacological antagonism or agonism which may be complete or incomplete, 
the alleles of these common variants represent partial loss- and gain-of-function respectively. 
In addition, genetic variants are usually associated with small differences in the activity of the 
target gene, while drugs typically have larger effects on target activity222,353. It should therefore 
be noted that the effects of these variants are likely to differ with respect to the effects of 
pharmacological antagonism or agonism of these receptors. Using these variants as proxies 
for pharmacological modulation of these receptors is likely to have resulted in an 
underestimation of the potential pharmacological effects of targeting these receptors. This 
may mean that smaller, potentially detrimental effects were overlooked, thus this approach 
cannot be used to definitively rule out safety concerns of therapeutically targeting a pathway.  
 
Second, these genetic variants represent a lifelong chronic exposure to antagonism and 
agonism respectively, which is not reflective of the comparatively shorter, higher dosage acute 
administrations of pharmacological therapy. As shown in Chapter 4, this limitation can be 
accounted for by re-scaling genetic effect estimates to be comparable to the effects of 
pharmacological antagonism of IL-6R estimated in clinical trials222,353, where these are 
available, thus estimating the potential effect of IL-6R antagonism in T2D. However, the fact 
remains that 358Ala is representative of partial loss-of-function, therefore, the projections of 
potential pharmacological efficacy of IL-6R antagonism in T2D are likely to be underestimated. 
With respect to the E354 GIPR variant, re-scaling the estimate to predict the potential 




agonists are not available, as therapeutic development has focussed instead on GLP-1R 
mono agonists458,495,498 or dual GLP-1R/GIPR agonism503,504,520,521. Overall, this approach 
enables the estimation of an association between pharmacologically modulating a pathway 
and a beneficial effect on an outcome of interest, in a framework that is robust to non-genetic 
confounding. This is therefore not an accurate estimate of the potential effect size of a 
pharmacological intervention. 
 
Finally, the projections of therapeutic efficacy in Chapter 4 assume additive risk of the IL-6 
pathway on type 2 diabetes risk, which is in line with assumptions of genetic association 
studies of common variants and previously used Mendelian randomization approaches in this 
and other settings. However, the therapeutic efficacy may be non-linear and vary with time62, 
an effect which was not tested for. Projections of therapeutic efficacy in scenarios where the 
association between the exposure and outcome is non-linear and/or time-dependent may lead 
to inaccurate estimates. 
 
Limitations to causal inference 
In Chapter 5 of this thesis, I used Bayesian multi-trait colocalisation to systematically assess 
cis-acting genetic regulation shared between inflammatory proteins and cardiometabolic 
diseases. The aim being to identify inflammatory proteins that are potentially involved in 
cardiometabolic diseases and thereby explore the inflammatory pathways which participate in 
the aetiology of cardiometabolic diseases. In this case using a multivariable MR framework 
would have provided an empirical estimate of the causal relevance of each identified protein 
with disease, adjusted for established cardiometabolic risk factors74, however, this was not 
possible for several reasons. Firstly, comparatively few variants were found to be associated 
with levels of the inflammatory proteins considered in the study, an issue common to the 
cytokine analyses in Chapter 3. In practice, MR analyses require sufficient numbers of 
variants to reliably estimate the causal relevance of the exposure for the outcome, which was 
not possible for these analyses. Secondly, a single cis-acting variant, either in the protein 
encoding gene or in the protein’s receptor, often has a disproportionately large effect on 
protein levels. This disproportionally large effect may lead to biased causal estimates, 
particularly when few variants are associated with levels of the protein61. An example of this 
was shown in Chapter 3 where a single cis-acting variant in the receptor for the respective 
cytokine explained the greatest proportion of variance in cytokine levels. Inclusion of these 
variants in an MR model made lead to biased estimates, purely driven by these variants of 
large effect. Third, the analysis showed that some of the variants underlying protein levels 
were pleiotropic. As described in Chapter 1, horizontal pleiotropy invalidates the instrumental 




would therefore need to be removed in an MR analysis74. Considering the low numbers of 
variants associated with inflammatory protein levels, this would decrease the number of 
variants further. Fourth, variants in the MHC gene region are often removed from MR analyses 
due to the complex LD in the region. This particularly impacts inflammatory proteins as often 
variants in the MHC region are associated with their levels. Despite this, in Chapter 5, I was 
able to estimate the association of polygenic scores for cardiometabolic risk factors with 
inflammatory protein levels, the reverse causal direction. This analysis showed that the levels 
of a proportion of inflammatory protein levels are associated with established cardiometabolic 
risk factors, effectively ruling them out as independent risk factors for cardiometabolic 
diseases. 
 
Colocalisation analyses assume a single causal variant 
In this thesis, Bayesian pairwise284 and multi-trait colocalisation362 analyses were used in 
Chapters 3, 5 and 6. While these methods enable the identification of shared genetic signals 
between traits or trait-sets, both methods share a common limitation where only a single 
independent causal variant is assumed to be present in a region of interest284,362. This study 
used relatively small regions of interest (1Mb-2Mb) to reduce the likelihood of this assumption 
being violated, however, it is possible that this may have been violated despite taking this into 
consideration. The likelihood of violating this assumption increases with an increasing number 
of traits362. Considering that in Chapter 5, a total of 341 traits (2 disease traits and 339 
inflammatory proteins) were included in the multi-trait colocalisation model for each of the 85 
loci considered, the likelihood of violating this assumption for at least one of the traits is 
considerable. For this reason, sensitivity analyses were conducted where the colocalisation 
model was run over increasingly stringent prior and threshold configurations. In addition, 
simulations using HyPrColoc have demonstrated that multiple independent variants in a region 
rarely invalidate the results, so long as secondary variants in the same region do not explain 
more trait variance than the sentinel variant362. To that end, the proportion of variance 
explained was estimated for both sentinels and secondary signals, only the ABO locus was 
deemed to have potentially violated this assumption, thus estimates need to be interpreted 
with caution. 
 
Associations between genetic variants and phenotypes may be false positives, biased 
or study-specific 
Genetic variants which reach genome-wide significance for an association with a phenotype 
of interest may not be truly associated with the trait due to chance, study-specific effects, 
confounding by LD or bias. One of the most challenging aspects of GWAS is refining 




were applied in the cytokine GWAS presented in Chapter 3, there were some loci where it 
was challenging to resolve the association signal to a single variant. Therefore, it may be that 
some of the results are confounded by LD. However, the approach used in Chapter 7 
overcame the limitations of previous analyses481 by using conditional analyses to conclude 
that CHD risk was not mediated via GIPR. Throughout this study, every effort has been made 
to mitigate the possibility of LD confounding.  
 
Many GWAS studies adopt a widely used a Bonferroni genome-wide significance threshold of 
P≤5x10-8. This threshold was first used in 2005, the advent of early GWAS studies546, and is 
based on the estimated number of common (MAF > 5%), independent variants that distinguish 
haplotypes throughout the genome547. This threshold has subsequently been used to limit the 
chance of false positive findings (Type 1 error) to a tolerable proportion of 5%. However, with 
the development of denser imputation reference panels that are widely adopted in 
contemporary GWAS, several studies547 have advocated for a revision of this threshold to 
ensure that the false positive rate remains constrained at 5%. The converse is also true, 
meaning that variants which are truly associated with a trait, may be deemed to be non-
significant (Type 2 error). In order to limit the impact of Type 2 error, the largest sample sizes 
were used where possible. Throughout this study, Bonferroni thresholds have been used to 
ensure that the Type 1 error is limited to 5%. In Chapter 3 of this thesis, the conventional 
genome-wide significance threshold of P≤5x10-8 was used. Despite this some of the loci 
estimated to be associated with cytokine levels may have reached significance by chance and 
may therefore be false positives. To ensure that their findings are truly associated with the 
phenotype of interest, many GWAS studies typically use a two-stage discovery and replication 
study design548,549. This also ensures that the genetic variants’ effects replicate across several 
studies, limiting the chances of identifying a study-specific effect. In Chapter 3, variants 
associated with cytokine levels were identified in EPIC-Norfolk and Fenland, however, as no 
studies with a sufficiently large sample size were available, replication of these findings was 
not possible. However, consistency in the effect size and direction was observed between the 
two studies, minimising the likelihood of these findings being study-specific or due to chance. 
 
This thesis used participants from three population-based studies: UK Biobank66, EPIC-
Norfolk241 and Fenland244. A commonly observed phenomenon in population-based studies is 
the healthy volunteer effect, whereby individuals who are generally healthier and of better 
socioeconomic status relative to the general population are more likely to participate in 
studies550. In the case of UK Biobank there is evidence for this effect, study participants were 
leaner, less likely to smoke and drink alcohol on a daily basis and were comparatively of better 




Fenland or EPIC-Norfolk relative to the general population are currently available, however, it 
must be assumed that this is a likely limitation243. Where possible, publically available datasets 
from large consortium-based efforts were used to ensure the generalisability and specificity of 
results. These have the advantage of being highly powered due to large sample sizes and use 
strict disease definitions and inclusion criteria to ensure specificity. 
 
The field of human genetics is heavily biased towards sampling participants of predominately 
European ancestry552–554. This bias has led to a systematic underrepresentation of participants 
from non-European ancestry, limiting the generalisability of scientific research findings67. For 
example, it is currently unknown whether IL-6R antagonism or GIPR agonism exhibit ethnicity- 
or sex-specific effects. Clinical trials of these therapies have included participants of different 
ethnicities503,555–557, however, this was comparatively fewer than the number of white European 
participants included. The efficacy of these therapeutics was demonstrated in these trials, 
however, due to the low numbers of participants from other ethnicities included, the trial may 
not have been sufficiently powered to detect differences in drug efficacy between ethnicities.  
Given that drug metabolism varies with ethnicity558 and sex559, this is an important 
consideration for ongoing research. However, ethnicity and sex specific GWAS analyses are 
rarely conducted and were unavailable for this study. Therefore, this needs to be considered 
for future work to ensure the generalisability of these findings. Genetic research stands to 
benefit greatly from the greater inclusion of participants from diverse ancestral backgrounds 
for several key reasons. Firstly, GWAS studies have identified many common variants which 
are associated with disease; however, these explain a fraction of disease heritability. 
Therefore, the effects of rare variants are believed to be increasingly important67,553 and these 
variants are likely to be specific to particular populations. In addition, variant allele frequencies 
vary according to ancestry, thus inclusion of participants from diverse ancestral backgrounds 
provides greater statistical power to discover variants associated with phenotypes of 
interest552. Secondly, as a result of homologous recombination events, the size of LD blocks 
also vary with ancestry560. This property is extremely beneficial for the fine-mapping of 
association signals to identify causal variants if they are shared between ancestries67.  
 
From an ethical standpoint the lack of ancestral diversity in genetic studies is a barrier to the 
generalisability to therapeutic development and efficacy561. Developing therapeutics on the 
basis of research conducted solely in Europeans does not guarantee therapeutic efficacy 
when administered in individuals of other ancestries552. This form of sampling bias also hinders 
our understanding of the aetiology of cardiometabolic diseases and risk factors, as these are 
well established for European populations but less so for individuals of African or South-Asian 




Therefore, expanding the ancestral diversity of genetic and biomedical research in general is 
key to facilitating a better understanding of the aetiology of cardiometabolic diseases. 
 
Statistical uncertainty 
Statistical error in epidemiology refers to the random, uncorrelated error which may arise 
during phenotypic measurement within and between studies. In large cohort studies such as 
UK Biobank66, every effort is made to adhere to standardised, rigorous protocols for 
phenotypic assessment to minimise sources and magnitude of error. Error in epidemiology is 
inversely related to sample size, therefore, increasing sample sizes tends to minimise error, 
thereby also increasing statistical power of the study562. In this thesis, meta-analysis was 
performed using inverse-variance weighting, ensuring that cohorts were weighted according 
to their sample size and therefore minimising the contribution of random error to the final 
standard error reported for each effect estimate. Where applicable, formal heterogeneity 
assessments were undertaken to ensure that estimates were directly comparable across 
studies or cohorts. Finally, results from the largest available dataset for each phenotype of 




8.4: Directions for future research and clinical implications  
The need for larger GWAS to facilitate the discovery of further variants associated with 
biomarkers 
Biomarkers such as inflammatory proteins and incretins are quantifiable intermediate traits 
which often lie on the causal pathway between established risk factors and disease outcomes 
and may therefore mediate some of the risk between exposures and disease563. The results 
presented in Chapter 5 suggest that this is likely to be the case for a proportion of inflammatory 
proteins which colocalise with T2D and CHD, levels of which were shown to be affected by 
established cardiometabolic risk factors. However, in order to gain a better understanding of 
the genetics underpinning biomarker levels, larger and better powered GWAS studies are 
required. Statistical power in GWAS is directly related to the sample size used564, therefore 
larger sample sizes are required to enable discovery of additional variants associated with 
biomarker levels. One of the biggest challenges faced throughout the work outlined in this 
thesis was the comparatively few genetic variants that have been found to be associated with 
biomarker levels. This, coupled with the finding that a considerable proportion of the identified 
loci were pleiotropic, hindered the capacity to empirically estimate their causal relevance for 
cardiometabolic diseases using an MR framework.  
 
The cytokine GWAS presented in Chapter 3 had a sample size of approximately 17,000 
participants across the four cytokines, the largest sample size used to date. Despite this, a 
maximum of six loci were estimated to be associated with levels of IFNγ and TNFα. The same 
is true for variants associated with incretin levels, the largest study to date had a sample size 
of up to 7,828 participants and found a total of two variants associated with fasting GIP levels, 
five associated with 2-hr GIP levels and one associated with 2-hr GLP-1 levels. It is 
conceivable that cytokine and incretin levels may be governed by relatively few variants, some 
of which (e.g. missense variants in cytokine receptors) may have large effects on the trait, but 
it is also likely that studies simply do not have sufficient power to discover all variants 
associated with their levels. The contrast in participant numbers is particularly stark when 
considering the number of individuals included in GWAS studies of anthropometric traits 
present in large biobanks such as UK Biobank66 for example BMI565 or WHRadjBMI30. 
However, this discrepancy can be easily explained when considering the ease, speed and 
negligible cost of measuring anthropometric traits compared to biomarker measurements 
which require trained staff for blood extraction, laboratory equipment for blood processing and 
storage as well as expensive assays for quantification.  
 
Ideally measurement of these biomarkers in large multinational, trans-ethic biobanks using 




further variants associated with biomarker levels, however, in reality this would be extremely 
expensive and time consuming. It should also be considered whether plasma is the best tissue 
to study (discussed in detail below). Another option would be to leverage large-scale proteomic 
profiling methods that simultaneously quantify the levels of thousands of proteins, such as that 
used in this study, in large trans-ethnic biobanks. This would afford greater statistical power 
to discover variants associated with biomarker levels. However, this would require the 
normalisation of protein levels to an internal standard, therefore protein levels represent 
relative abundances which are incomparable across studies. In addition, questions 
surrounding the specificity of the technology in comparison to gold-standard assays such as 
ELISA need to be considered. Nevertheless, biomarker quantification in large sample sizes is 
necessary to facilitate thorough investigations of the genetics governing their levels and 
characterisation of the molecular pathways through which biomarkers act to mediate 
cardiometabolic risk.  
 
Expanding the scope to include different tissues 
Obesity is thought to be one of the main drivers for inflammation in cardiometabolic 
diseases109,138,223,356. Inflammation, is therefore hypothesised to partly mediate obesity-related 
risk in cardiometabolic diseases, as shown in Chapter 4. Logically and of direct relevance to 
cardiometabolic diseases, many epidemiological studies have focussed their attention on 
inflammatory proteins produced by adipose tissue such as IL-690,155,175,181,186,189 and 
TNFα168,174,175,189,190. While the liver has previously been considered to be a non-immunological 
organ, accumulating evidence suggest that inflammatory and metabolic processes converge 
and interact here, influencing the regulation of many inflammatory protein levels566. It is 
currently unclear how hepatic cross-talk may affect metabolic and inflammatory pathways and 
how this interaction may relate to risk of cardiometabolic diseases.  
 
Most studies have investigated the role of the liver in cardiometabolic diseases within the 
context of non-alcoholic fatty liver disease (NAFLD) and how hepatic lipid accumulation may 
influence this phenotype567–574. It would be of interest to investigate the influence of NAFLD 
and other metabolic dysregulations on inflammatory protein levels and estimate the causal 
relevance of NAFLD for levels of inflammatory proteins. This work could leverage the release 
of liver MRI data in UK Biobank66, combined with ultrasonography data in Fenland to create a 
score of liver fat for use in GWAS. Using variants associated with this phenotype, one could 
then leverage the availability of large-scale aptamer based proteomic data from SomaLogic in 
Fenland to estimate the causal relevance of hepatic lipid accumulation for inflammatory protein 
levels. Additionally, one could estimate the colocalisation between inflammatory protein levels 




between NAFLD and inflammatory proteins. However, while expanding this work to other 
metabolically relevant tissues will help to contextualise the role of inflammation in 
cardiometabolic diseases, investigations into the role of biomarkers in other diseases should 
also be conducted.  
 
Consideration of other diseases 
One of the most advantageous aspects of investigating biomarkers as a phenotype is that 
they represent intermediate traits for many diseases and are readily druggable55. It is this 
property which makes biomarkers attractive drug targets for a range of diseases and presents 
interesting drug re-purposing opportunities outside the scope of the original drug indication575. 
Relevant examples include the re-positioning of IL-1Ra, IL-6R and TNFα receptor monoclonal 
antibody antagonists for use in rheumatoid arthritis patients555,576,577. Recently the CANTOS 
trial has investigated the use of canakinumab, an IL-1β antagonist, in both CHD226 and T2D221. 
Many diseases are deemed to have a chronic inflammation component to their aetiology, for 
example type 1 diabetes, asthma and inflammatory bowel disease94. It would be possible to 
apply similar multi-trait colocalisation methods to those used in Chapter 5 to estimate the 
colocalisation between inflammatory proteins and autoimmune diseases. This work could also 
leverage summary statistics conditioned on other independent signals within a locus to aid the 
estimation of causal variants in colocalisation analyses. Therefore, expanding this research to 
autoimmune conditions may further elucidate the underpinnings of chronic inflammation, 
highlight whether the genetic loci identified are different from those identified to play a role in 
cardiometabolic diseases. Furthermore, the inclusion of type 1 diabetes in colocalisation 
analyses with T2D would elucidate inflammatory pathways common to both diseases while 
also highlighting distinct aetiological pathways. Such cross-disease approaches may be 
conducted efficiently using genetics and may highlight aetiological pathways shared between 
cardiometabolic and autoimmune conditions while also discriminating between pathways 
specific to each disease type.  
 
Investigation of incretins within the context of metabolic disease as a whole 
Incretins have been shown to play a role in glucose stimulated insulin potentiation412,422 and 
are therefore a promising pharmacological target for T2D489,500. In Chapter 6 of this thesis I 
investigated the association between GIPR variants and cardiovascular risk. Experimental 
evidence has pointed to a role for GIP in triglyceride storage and adipose expansion, 
suggesting that GIP has more diverse metabolic functions than just insulin 
potentiation459,578,579. In addition, the effects of both GIP and GLP-1 have been shown to be 
associated with reduced body weight455–457,471,475,580. On balance, and considering the results 




metabolic phenotypes and may therefore be suitable targets for the generalised improvement 
of metabolic health. However, our results suggest that GIPR agonism may lead to higher BMI. 
On this basis, further characterisation of the effects of variants associated with higher GIP and 
GLP-1 levels respectively on diverse metabolic traits would be of interest, specifically their 
effects on lipid profile and BMI. Therapeutic development in this field has shifted from 
designing mono-agonists for GIPR and GLP1R towards dual GIPR/GLP1R 
agonism503,504,520,521. In light of this, using genetics to investigate the possible interaction 
between GIP and GLP-1 levels on lipid profile and BMI as well as T2D and CHD risk would 
be of substantial interest. This work may provide estimates of the potential efficacy of dual 
agonism in both diseases and help to characterise the molecular effects of dual agonism with 
respect to how these relate to disease risk.  
 
A focus on the in-depth characterisation of genetic loci 
Throughout the history of GWAS for complex traits, a significant focus has been placed on 
ever-expanding sample sizes to achieve greater statistical power to detect variants associated 
with phenotypes of interest91. While I have advocated for this in the sections above, GWAS 
has already led to the identification of many thousands of loci associated with diverse traits91. 
However, the biological mechanism underlying many of these variant-trait associations are 
still yet to be elucidated. Indeed, in the case of anthropometric traits such as obesity, it could 
be argued that increasingly larger GWAS efforts are likely to lead to marginal gains in 
biological understanding over and above what is already known. For example, increasing the 
sample size for a GWAS of protein levels mainly leads to an increase in the number of trans-
acting variants discovered. Therefore, while increasing sample sizes is beneficial, this should 
be balanced with emphasis on characterising the molecular effects of established loci.  
 
To that end, the cytokine GWAS presented in Chapter 3 highlighted variants in genes such 
as CXCR1-CXCR2 and IFNGR1 that are associated with IL-8 and IFNγ levels respectively. 
Further characterisation of the rs55799208 variant, in particular, at the CXCR1-CXCR2 locus 
would be of interest as this is a missense variant in a receptor specific for IL-8, making this an 
ideal candidate for further follow-up. In light of the observational results presented in Chapter 
2, using this variant to further characterise the association between IL-8 and HbA1c levels 
would be of interest, particularly when considering that IL-8 levels was not found to be 






The work presented in this thesis integrated large-scale genetic data on cardiometabolic traits 
with multiple ‘omics datasets to investigate the role of inflammatory biomarkers and incretins 
in the aetiology of cardiometabolic diseases. The observational findings of this study highlight 
that IL-6 and TNFα levels are associated with a wide variety of risk factors for cardiometabolic 
diseases as well as incident T2D and CHD. Expanding on these findings using genetics to 
further investigate the role of IL-6R-mediated inflammation in T2D demonstrated that IL-6 
levels were associated with prevalent T2D. However, while IL-6 mediated inflammation plays 
a role in the aetiology of T2D, several lines of evidence suggest that the impact of this pathway 
on disease risk in the general population may be small. Firstly, people in the top decile of IL-
6 levels had a 2-fold higher risk of incident T2D than people in the bottom decile. This is 
approximately three times smaller than the relative risk associated with being in the top decile 
of BMI in our study. While the association between Asp358Ala and lower T2D risk was 
statistically robust, consistent across studies and ancestries and was unaffected by possible 
misclassification of type 1 diabetes cases, the odds ratio of 0.98 for disease risk was a 
marginal reduction in disease risk compared to non-carriers. In addition, rescaled projections 
of IL-6R antagonism in T2D estimate risk reductions of below 10% in most simulated 
scenarios. In comparison, relatively safe and inexpensive lifestyle interventions28, metformin28 
or other hypoglycaemic drugs357 have been associated with reductions in the incidence of 
diabetes ranging from 30% to 70% in previous primary prevention trials. Finally, the proportion 
of BMI-associated risk of diabetes mediated by IL-6 levels was below 5%, ~3-4 times smaller 
than for coronary disease. Taken together, these results suggest that targeting inflammation 
via this pathway may not substantially impact on diabetic risk in obesity but still represents a 
biologically significant effect. While these results suggest that IL-6R antagonism may have 
limited efficacy for the primary prevention of T2D, these findings do not exclude that IL-6R 
inhibition may yield greater benefits on glucose metabolism in groups of people at risk for T2D. 
Results from observational and genetic analyses demonstrated that IL-6 levels were 
associated with HbA1c levels with genetic analyses showing a significant interaction between 
IL-6 levels and higher BMI on HbA1c levels. In line with this, evidence from clinical trials212,359 
has shown a statistically-significant improvement in HbA1c in rheumatoid arthritis patients 
randomized to IL-6R antagonists as opposed to placebo. Therefore, it is possible that IL-6R 
inhibition may yield clinically meaningful changes in glycaemia in people with inflammatory or 
immune conditions which are linked with diabetes and that reductions in HbA1c may be more 
pronounced in individuals below the median of the BMI polygenic score. 
 
The GIP pathway has been highlighted as a potential therapeutic for use in T2D and therapies 




that these therapies offer promising metabolic benefits such as improved insulin potentiation, 
lipid profile and weight management in T2D patients503,504,520. However, recent epidemiological 
evidence has suggested that agonism of GIPR may raise CHD risk481. This work used a 
genetic framework to investigate the relationship between higher GIPR-mediated GIP levels 
and CHD risk. The results showed that fasting GIP levels and CHD risk were driven by 
independent variants. In addition, the association between GIP levels and CHD risk was found 
to be the result of residual LD between E354, a missense variant in GIPR, and rs1964272, an 
intronic variant in SNRPD2. As a result, these results have positive implications for the 
development of dual GIPR/GLP1R agonists targeting this pathway, as these are not estimated 
to unduly raise CHD risk.  
8.5: Conclusion 
The work presented in this PhD integrates large-scale genetic data with multiple ‘omics 
datasets to investigate the role of inflammatory biomarkers and incretins in the aetiology of 
cardiometabolic diseases, two areas that are of considerable pharmacological interest. The 
role of inflammation in cardiometabolic diseases was examined on both a locus-level and 
global perspective. Overall, the results of this study suggest that chronic inflammation in 
cardiometabolic diseases is largely driven by a combination of pleiotropic effects and 
established risk factors for cardiometabolic diseases. This work closely examined the 
aetiological role of proinflammatory cytokines in cardiometabolic diseases. In the largest 
GWAS of cytokine levels to date, I provide the first genetic variants associated with IL-8 and 
IFNγ at a genome-wide significance level and expand the knowledge of the genetic 
determinants underpinning IL-6 and TNFα levels. Evidence from observational and genetic 
analyses suggest that IL-6 and TNFα levels are more relevant for both incident and prevalent 
cardiometabolic diseases compared to IFNγ or IL-8. Further examination of the role of IL-6 
mediated inflammation in T2D provided the first human genetics evidence supporting the long-
standing hypothesis of a role for chronic inflammation in T2D. However, the results suggested 
that the impact of this pathway on T2D risk in the general population is likely to be small. 
 
In this PhD thesis I also used a genetic framework to investigate the role of GIPR agonism, a 
pathway of considerable pharmacological promise for T2D, in raising CHD risk. I provide 
evidence that GIP, anthropometric and glycaemic traits are driven by distinct variants from 
those raising CHD risk and lipids in the GIPR region. I also demonstrate that raised CHD risk 
in the GIPR region is not driven by GIPR but instead by SNRPD2, a nearby CHD risk locus. 
This result holds considerable promise for continued therapeutic research targeting this 
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Methods S4.1. Additional methods for observational epidemiology analyses. 
Systematic review and meta-analysis of prospective studies investigating the association of 
IL-6 levels with incident type 2 diabetes 
A systematic review and meta-analysis of studies investigating the association of IL-6 levels 
with incident type 2 diabetes in population-based cohorts was conducted. A previous meta-
analysis had been performed by Wang et al186 for studies with a publication date up to 10 
February 2012. In addition to studies identified by Wang et al186, novel results from the EPIC-
Norfolk study and from studies identified with a new and updated systematic search were 
included in the meta-analysis reported in this manuscript. A review protocol has not previously 
been published and will be described in detail in this section. EPIC-Norfolk constitutes the 
largest study to date and the one with the longest duration of follow-up (Table S4.2). A search 
of the PubMed electronic database was performed to identify studies investigating the 
association of IL-6 levels with incident type 2 diabetes. Prospective studies published between 
10 February 2012 and 30 October 2018 were considered. A full list of search terms can be 
found in Table S4.3. Studies focusing on prevalent type 2 diabetes, type 1 diabetes or 
gestational diabetes were excluded as were review articles and animal studies. Additionally, 
studies were excluded if they included cohorts that overlapped those already included in the 
meta-analysis by Wang and colleagues. The initial database search yielded 379 recent 
publications, the titles of which were initially screened using the above-mentioned criteria. Two 
of the authors (NB and RLS) independently screened the titles of the identified publications 
and conferred to ensure consistency. Following this, 14 relevant publications were identified, 
and their abstracts were further screened by the same authors to ensure consistency. Overall, 
three recently published studies225,239,240 were identified and their results were included in the 
meta-analysis, which included 15 studies overall. Quality ratings for the 15 selected studies 
were adjudicated based on criteria evaluating study size and representativeness, reliability of 
exposure measurement, reliability of type 2 diabetes ascertainment, and adjustment for 
possible confounders (Table S4.4). 
 
Estimates of association (risk ratios, odds ratios, hazard ratios – all assumed to approximate 
the hazard ratio) with type 2 diabetes were calculated per 1 log pg/mL higher IL-6 levels for 
studies included in the Wang et al186 analysis. In the case of the three newly identified studies, 
only the results of Koloverou et al239 were presented per 1 log pg/mL higher IL-6 levels. The 
results of Dallmeier et al240 and Marques-Vidal et al225 were originally presented per 1 SD 
higher log IL-6 levels. These estimates were converted to units per 1 log pg/mL higher IL-6 
levels using a conversion factor of 0.8 (corresponding to the SD of log IL-6 levels in the EPIC-
Norfolk study). Study characteristics and relative risks for the included studies are summarised 
in Table S4.2. Fixed-effects meta-analysis was conducted including all 15 available studies 
consisting of a total of 5,421 incident type 2 diabetes cases and 31,562 non-cases. The 
combined hazard ratio was reported per 1 log pg/mL higher IL-6 levels. The I2 heterogeneity 
statistic was used to estimate significant heterogeneity between study effect estimates. 
 
To assess potential publication bias, the Egger test581 was used. Furthermore, funnel plots 
illustrating the relationship between the hazard ratio and standard error of each study were 
drawn (Figure S4.11). No significant evidence of publication bias was found (P = 0.44). The 
funnel plot showed that two studies were on the contour line and could potentially bias the 
overall estimate (Figure S4.11). Subgroup analysis excluding these two studies demonstrated 
no change in the overall estimate (1.24; 95% CI, 1.17, 1.32; P=1x10-12). We also sought to 
estimate potential bias induced via differing IL-6 measurement methods between studies. 




methods such as ELISA were excluded. The remaining prospective studies were meta-
analysed, resulting in the same effect estimate as the main analysis (HR 1.24; 95% CI, 1.16, 
1.33; P = 1x10-10). Differential IL-6 measurements between studies were therefore ruled out 
as a potential source of bias. 
 
 
DEXA protocol in Fenland. 
In the Fenland study overall and regional body fat mass was quantified by dual-energy X-ray 
absorptiometry (DEXA) using a Lunar Prodigy advanced fan beam scanner (GE Healthcare, 
Bedford, UK), encore v14.10.022 and CoreScan® software (GE Healthcare, Bedford UK). All 
body images were manually processed, and demarcations corrected following a standardized 
protocol. The trunk included neck, chest, abdominal and pelvic areas. The legs were defined 
as the region below the lower borders of the trunk. The abdomen was defined as the portion 
of the trunk between ribs and pelvis, defined by the outline of the iliac crest. The gluteofemoral 
region included hips and upper thighs. Visceral abdominal fat mass was estimated using 
subcutaneous fat width and the anteroposterior thickness of the abdominal wall. These 
measurements were used to extrapolate abdominal subcutaneous fat mass. Visceral 
abdominal fat mass was calculated by subtracting the subcutaneous abdominal fat mass from 
the total abdominal fat mass.  
 
Methods S4.2. Additional methods for genetic association analyses. 
Re-scaling the association estimates of IL6R Asp358Ala with continuous metabolic traits 
To aid the interpretation of association estimates with different continuous metabolic traits 
(e.g. HbA1c or fasting insulin), the associations were reported in both clinical and standardized 
units of each trait per copy of the IL6R 358Ala allele. Clinical units aid interpretation of the 
association results, while standard deviation units enable comparison of association estimates 
across outcomes. Estimates from summary-level results were converted to standardized units 
or to clinical units using the standard deviation (SD) in the Fenland or in the UK Biobank as 
summarized in Table S4.6. 
In these analyses, individuals carrying the IL6R 358Ala allele had numerically lower WHR 
adjusted for BMI, a risk factor for type 2 diabetes30 However, the difference in WHR adjusted 
for BMI observed for the IL6R 358Ala allele is unlikely to explain its association with lower risk 
of type 2 diabetes. From previous analyses, a 1-SD increase in WHR adjusted for BMI is 
associated with an odds ratio for type 2 diabetes of 1.7930 On the basis of this estimate, given 
that each copy of IL6R 358Ala is associated with 0.004 SD lower BMI-adjusted WHR, the 
expected odds ratio for type 2 diabetes would be 0.998 (i.e. a very small estimated effect size) 
if the association of the IL6R 358Ala allele was entirely due to BMI-adjusted WHR. Since the 
95% confidence interval estimated for the association between the IL6R 358Ala allele and 
type 2 diabetes excludes 0.998 (i.e. odds ratio per allele from 0.970 to 0.989), it is unlikely that 
the association of this variant with diabetes is only due to an association with more favourable 
fat distribution.  
 
Estimation of heritability and variance in the risk for type 2 diabetes and coronary disease 
explained by the IL6R 358Ala allele 
In stage 2, estimates of heritability for type 2 diabetes and coronary heart disease were 
obtained using linkage disequilibrium score regression287 in UK Biobank using the HapMap3 
European ancestry CEU population as reference panel (Table S4.9). Variants included in the 
regression model were restricted to those present in the reference panel with minor allele 
frequency above 5% to retain only common variants. Type 2 diabetes and coronary heart 
disease prevalence in the general population were assumed to be equivalent to the prevalence 
in UK Biobank, 5.51% and 5.50% respectively. The heritability in these conditions explained 
by the IL6R 358Ala allele was estimated by dividing the heritability of the disease by the 
variance explained by the genetic variant. 
 




To assess whether the association with type 2 diabetes of IL6R 358Ala might be affected by 
misclassification of cases of type 1 diabetes as type 2 diabetes, an approach based on a 29-
variant polygenic risk score350 for type 1 diabetes was used. Using individual-level data from 
UK Biobank, this polygenic score was calculated for each participants by adding the number 
of copies of each contributing variant weighted by its per allele association estimate with type 
1 diabetes as previously described350.  
 
Individuals with values of the polygenic score below the median in people with diabetes (type 
1 and type 2 combined; value in UK Biobank, 13.04) have been shown to be highly unlikely to 
have type 1 diabetes (sensitivity to detect type 1 diabetes cases for exclusion, 96%; false 
negative rate, 4%)350 This means that if one were to restrict an analysis to people below that 
value, only 4% of type 1 diabetes cases originally included would remain in the analysis. This 
restriction does not bias the association of the IL6R 358Ala allele as the IL6R locus is not 
included in the type 1 diabetes genetic score and therefore is in linkage equilibrium with (i.e. 
inherited randomly regarding) the loci included in the score. 
 
Given that type 1 diabetes accounts for ~10% of diabetes in the general population, one would 
expect that amongst the approximately 22,000 cases of type 2 diabetes included in this 
analysis, cases of type 1 diabetes erroneously classified as type 2 diabetes would be 2,200 if 
there were a 100% misclassification. Even in the extreme scenario of 100% misclassification, 
restricting to only people with polygenic score for type 1 diabetes below the median would 
lower the number of type 1 diabetes present in the analysis to just 44 (0.4% of overall diabetes 
cases; corresponding to 1,100 misclassified cases left in the halved sample size multiplied by 
4% false negatives). More likely scenarios of a lower misclassification rate yield numbers of 
misclassified type 1 diabetes cases left in the sensitivity analysis in the single digits (Figures 
S4.7B and S4.7C). On this basis, the association with type 2 diabetes was estimated after 
restricting for participants below the median of the type 1 diabetes polygenic score.  
 
Projection of the potential benefit of IL6R blocking therapy on the risk of type 2 diabetes. 
Both experimental310 and genetic88,160 association studies have shown that rs2228145-C 
(358Ala) closely mimics some of the effects of IL-6R inhibitory therapy. However, an 
association of this variant with lower risk of type 2 diabetes, as shown in this study, does not 
necessarily mean that IL-6R inhibitory therapy will produce clinically meaningful reduction in 
the risk of type 2 diabetes. Even if the effects of a genetic variant and that of a drug on the 
target were qualitatively the same, two differences between genetic variant and treatment with 
the drug in randomized clinical trials would remain. First, genetic variants are usually 
associated with small differences in the activity of the target gene, while drugs usually have 
large effects on target activity (different effect size)222,353. Second, differences in target gene 
activity associated with a genetic variant are lifelong, while the effect of drugs is usually 
assessed in trials of short duration (duration of exposure). With several assumptions, these 
differences can sometimes be modelled to formulate projections of the likely efficacy of drug 
treatment based on association magnitude of genetic variants that mimic that drug treatment.  
 
In this study, projections of potential benefit of IL-6R blocking therapy on the risk of type 2 
diabetes in a primary prevention setting were formulated using (a) the genetic association of 
IL6R 358Ala with type 2 diabetes from this study, (b) the genetic association of IL6R 358Ala 
with C-reactive protein (CRP; used as biomarker of target engagement for IL-6R) in this and 
other studies160 and (c) the effects of IL-6R blocking therapy on CRP (the most-widely used 
biomarker of target engagement for IL-6R blocking therapy) in randomized clinical trials of 
tocilizumab, an IL-6R inhibitor88.  
 
First, to model the different effect size, ratios between the absolute differences in CRP levels 
for the Asp358Ala variant and for IL-6R inhibitory therapy were obtained. Estimates of the 
absolute difference in CRP between IL-6R inhibitory therapy (tocilizumab 4 or 8 mg/kg) and 




Estimates of the absolute difference in CRP per copy of the 358Ala allele  were obtained on 
the basis of previously-published genetic association studies160. Because CRP was loge-
transformed in these studies, the reported estimate reflected the percentage rather than the 
absolute difference (i.e., 7.5% lower CRP per allele). To obtain an absolute difference 
comparable to the one reported in the trials (which were conducted in people with autoimmune 
disease and hence high average CRP levels), the 7.5% difference was applied to the mean 
CRP level of individuals contributing to the trial estimate (i.e., mean CRP in trial participants, 
26 mg/L; absolute difference per copy of 358Ala, -1.9 mg/L). This assumes that the percentage 
difference in CRP due to the 358Ala allele stays the same at different starting levels of CRP. 
To assess this, conditional quantile regression (CQR) and subsequent meta-regression were 
performed in 14,695 individuals from EPIC-Norfolk. Using the CQR model, the association of 
358Ala with ln-CRP was estimated at every 5th percentile of the ln-CRP distribution. Standard 
errors were calculated using bootstrapping with 200 replicates. CQR models were adjusted 
for age, sex and the first four genetic principal components. Meta-regression across the CQR 
estimates per quantile was performed to estimate the difference in ln-CRP per copy of 358Ala 
across the quantiles of ln-CRP. The meta-regression model was adjusted using the same 
covariates as the CQR. This meta-regression model did not show evidence that the variant 
association estimates vary at different ln-CRP levels (P=0.81; Figure S4.2). Therefore, ratios 
between the absolute differences in CRP levels for the 358Ala allele and IL-6R inhibitory 
therapy were estimated (i.e. 4.7 for tocilizumab 4 mg/kg / 358Ala and 10.9 for tocilizumab 8 
mg/kg / 358Ala). These ratios were used to re-scale the estimate of association with type 2 
diabetes from genetic association studies of Asp358Ala while accounting for the larger 
absolute effect of IL-6R inhibitory therapy on CRP. This re-scaling makes the critical 
assumption that the effects of IL-6R inhibition on diabetes risk estimated by a small difference 
due to the genetic variant will scale linearly even for large (~5-10 fold) differences between 
variant and treatment effects.  
 
This estimate attempts to correct for the different effect size of genetic variant vs drug but still 
does not correct for the duration of exposure. To account for that, it was assumed that the 
rescaled estimate represented the projected effect of the drug on diabetes risk for a lifelong-
exposure (or a long-term exposure of several decades as genetic association studies used for 
these estimates were conducted in people with an average age of ~59 years). Projections for 
shorter exposure were obtained by re-scaling the life-long estimate for increasing numbers 
representing the ratio of exposure between lifelong and a given shorter exposure. Estimates 
are reported for ratios ranging from 1 to 10, to capture a range of hypothetical durations of 
treatment. This projection assumes a constant additive risk of the IL-6 pathway on type 2 
diabetes risk, which is in line with assumptions of genetic association studies of common 
variants and previously used Mendelian randomization approaches in this and other settings. 
These projections are relative to primary occurrence of type 2 diabetes in a general population 
setting and do not reflect the likely efficacy of treatment in people with high diabetes risk or 





Methods S7.1. Fenland glycaemic traits GWAS 
Fasting glucose and fasting insulin in Fenland244 (Table 7.1) were the values of circulating 
glucose (in mmol/L), insulin (natural log-transformed and expressed in log-pmol/L) measured 
in whole blood after overnight fasting. Two-hour glucose was the value of glucose (in mmol/L) 
measured in plasma two-hours after a 75-gram oral glucose challenge (Table 7.1). Glucose 
levels were quantified using the Dimension RxL Integrated Chemistry System (Siemens, 
Germany). Insulin levels were quantified using the 1235 AutoDELFIA automatic immunoassay 
system using a two-step time resolved fluorometric assay (Kit No. B080-101, Perkin Elmer, 
USA). Individuals were excluded if they had prevalent type 1 or type 2 diabetes (defined by 
physician diagnosis); reported use of diabetes medication(s); or had fasting glucose levels 
>=7 mmol/L, 2-hr glucose levels >=11.1mmol/L, or HbA1c >= 6.5%. A total of 8,729, 7,428 
and 8,619 participants were included in the analysis for fasting glucose, fasting insulin and 2-
hour glucose respectively. 
 
Fenland244 genotyping and imputation were performed as described in the main text. Only 
samples genotyped using the Affymetrix UK Biobank Axiom Array were included. Samples 
with low call rates < 95%, extreme heterozygosity, gender mismatch with X chromosome 
variants, duplicates, first- or second-degree relatives or outlying ethnic ancestry were removed 
prior to association testing. Following sample QC, we applied variant QC thresholds for call 
rate (< 95%), Hardy-Weinberg Equilibrium (HWE) P<1x10-6, imputation quality < 0.4 and minor 
allele frequency (MAF) < 1%. Association testing for 2-hour glucose was performed under an 
additive model adjusting for age, sex, BMI and the first 10 principal components using 
SNPTEST v2.4.1. Association testing for fasting glucose and insulin was performed in the 
same manner while including age2 as an additional covariate. Following this, additional 
variants were excluded if they were tri-allelic; had a minor allele count (MAC)<3; demonstrated 
a standard error ≥10; or were missing an effect estimate, standard error, or imputation quality. 
 
Methods S7.2. Pairwise colocalisation of GIP levels with cardiometabolic traits and 
disease endpoints 
The SOMAscan® 4K system (SomaLogic, Boulder, Colorado, USA) used two SOMAmers to 
quantify GIP levels, namely X16292_288 and X5755_29, that targeted different portions of the 
GIP precursor protein. As GIP levels measured by SOMAmers represented relative 
abundances, we aimed to assess whether the underlying genetics at GIPR were comparable 
to those of absolute quantitation Methods S7.uch as ELISA. In addition, we aimed to determine 
which of the SOMAmers represented the best fasting GIP measure available in our cohort. 
 
To address this, we employed a pairwise Bayesian genetic colocalisation framework to 
estimate whether the associations with cardiometabolic traits at the GIPR locus were shared 
between the two GIP SOMAmers and the Almgren et al. 2017508 GIP measures. As an 
association with 2-hr GIP levels was also found at the GIPR locus, this trait was also included. 
To contextualise the analysis, we included T2D, CHD, BMI, 2-hour glucose adjusted for BMI 
(2-hr glucose adjBMI) and LDL as cardiometabolic traits of interest, the data sources of each 
are described in (Table S7.1). Summary statistics from the Fenland 2-hr glucose adjBMI 
GWAS were preferred to those from previous efforts344, as outlined in the main text. The details 
of this GWAS are described in Methods S7.1. Using GWAS summary statistics for each trait, 
the 1Mb regions either side of E354 were extracted. Insertions and deletions as well as any 
variants with a standard error of 0 were removed from the analysis and only variants present 
in all datasets were considered. All traits were then aligned to the GIP-raising alleles for 
consistency. Bayesian colocalisation analysis was then conducted using the COLOC290 R 
package between each pair of traits using beta estimates and corresponding trait variances 
as well as either the case proportion for case-control traits or trait standard deviations for 
quantitative traits. This was done to estimate posterior probabilities (PPcoloc) denoting evidence 
of colocalisation: H0 – no signal; H1 – signal unique to trait 1; H2 – signal unique to trait 2; H3 
– two independent causal variants in the same locus driving the association signal for the 




probability that a variant is associated with trait 1, p1, was set to 1x10-4, hence the prior 
probability that any variant is associated with trait 1 is 1 in 10,000. The same settings were 
used for p2. We assigned a prior probability of 1x10-5 for p12, which equates to a prior 
probability of 1 in 100,000 that a single variant is associated with both traits. T2D and CHD 
were treated as case-control traits and all other traits as quantitative. Pairwise PPcoloc 
estimates were considered significant if they met the following criteria: (H4 + H3 ≥ 0.9 & H4/H3 
≥ 3. All data analysis was performed using R version 3.6.3. 
 
Methods S7.3. Partial correlations between X-12283 and known metabolites 
To attempt to find an indication of the metabolite class and putative functional pathway of X-
12283, we estimated partial correlations between X-12283 levels and the levels of other 
metabolites measured using the Metabolon platform among EPIC-Norfolk participants. Briefly, 
a partial correlation estimates the pairwise correlation between two metabolites A and B, while 
adjusting this estimate for all other metabolites correlated with each metabolite of interest. We 
performed this analysis using measures from 11,966 individuals, from the two measurement 
sets of each approximately 6000 quasi-randomly selected individuals. In order to retain 
sufficient statistical power, we considered only the 883 metabolites with less than 50% 
missingness within both of the two measurement sets. 
 
First, missing metabolite measures were imputed within each measurement set, using 
multivariate imputation by chained equations (MICE) 582 with the R package “mice”583 version 
3.6.0. Prior to imputation, metabolite levels were natural log-transformed, winsorised to five 
SDs, and residuals taken by regressing out the effects of age and sex. Imputation was 
repeated a total of 20 times, generating 20 sets of fully imputed results. Following imputation, 
measures were standardised (mean = 0, SD =1). For each imputation, partial correlations 
between metabolite pairs were calculated using the R package “GeneNet”584–586 version 
1.2.14. Partial correlation estimates were transformed using Fisher’s z transformation and the 
R package “psych”587 version 1.9.12.31, and then pooled across the 20 imputations for each 
measurement set, using Rubin’s rules588. Estimates for the two measurement sets were then 
meta-analysed, using a fixed effect, inverse variance weighted method and R package 
“meta”589 version 4.12-0, and finally back transformed to correlation estimates.  
 
Partial correlation estimates of more than 0.1 were then used to draw a gaussian graphical 
model (GGM) to visualise the correlation network, using X-12283 as the central node. Partial 
correlations were considered significant at a Bonferroni significance threshold of P≤ 1.28x10-
7, accounting for the 389,403 metabolite pairs tested. All data analysis was performed using 







Table S1.1: The search strategy used for the systematic literature review. The search 
was limited to: Clinical trials, journal articles, meta-analyses in English on PubMed in human 
populations without any disease after June 2007 = First large-scale GWAS (WTCCC) 
 
Search strategy used: 
1. Cytokine* AND genome-wide association 
2. Cytokine* AND GWAS 
3. Cytokine* AND Varia* 
4. Cytokine* AND SNP 
5. Cytokine* AND Association 
6. Cytokine* AND Associat* 
7. Inflammat* AND genome-wide association 
8. Inflammat* AND GWAS 
9. Inflammat* AND Varia* 
10. Inflammat* AND SNP 
11. Inflammat* AND Association 
12. Inflammat* AND GWAS 
13. Inflammat* AND Associat* 
14. Interleukin* AND genome-wide association 
15. Interleukin* AND GWAS 
16. Interleukin* AND Varia* 
17. Interleukin* AND SNP 
18. Interleukin* AND Association 
19. Interleukin* AND GWAS 
20. Interleukin* AND Associat* 
21. IL* AND genome-wide association 
22. IL* AND GWAS 
23. IL* AND Varia* 
24. IL* AND SNP 
25. IL* AND Association 
26. IL* AND GWAS 
27. IL* AND Associat* 
28. Interferon* AND genome-wide association 
29. Interferon* AND GWAS 
30. Interferon* AND Varia* 
31. Interferon* AND SNP 
32. Interferon* AND Association 
33. Interferon* AND GWAS 
34. Interferon* AND Associat* 
35. IFN* AND genome-wide association 
36. IFN* AND GWAS 
37. IFN* AND Varia* 
38. IFN* AND SNP 
39. IFN* AND Association 
40. IFN* AND GWAS 
41. IFN* AND Associat* 
42. Tumour Necrosis Factor* AND genome-
wide association 
43. Tumour Necrosis Factor* AND GWAS 
44. Tumour Necrosis Factor* AND Varia* 
45. Tumour Necrosis Factor* AND SNP 
46. Tumour Necrosis Factor* AND Association 
47. Tumour Necrosis Factor* AND GWAS 
48. Tumour Necrosis Factor* AND Associat* 
49. TNF* AND genome-wide association 
50. TNF* AND GWAS 
51. TNF* AND Varia* 
52. TNF* AND SNP 
53. TNF* AND Association 
54. TNF* AND GWAS 




Table S3.1: Number of variants removed from each cytokine meta-analysis at each 
quality control step.  
Abbreviations: QC, Quality control; IFNγ, Interferon-γ; IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour 
necrosis factor-α; MAC, Minor allele count; Indels, Insertions and deletions; SE, Standard error; minfreq, Minimum 
frequency; maxfreq, Maximum frequency 
a. Minimum frequency observed for a particular SNP across the 4 studies sub-studies included in each meta-
analysis 
b. Maximum frequency observed for a particular SNP across the 4 studies sub-studies included in each 
meta-analysis 
c. The total number of genome-wide significant SNPs for each meta-analysis 
 
QC filter IFNγ IL-6 IL-8 TNFα 
Number of SNPs before QC 20,889,287 21,005,838 20,792,591 20,991,893 
Drop if less than 50% sample size 
genotyped 
2,861,949 2,886,839 2,728,592 2,868,406 
Drop if number studies < 2 per SNP 0 0 0 0 
MAC <20 0 0 0 0 
Indels 1,791,026 1,796,779 1,793,926 1,797,320 
Tri-allelic SNPs 22,290 22,472 22,370 22,520 
Frequency SE > 0.1 9 9 9 9 
Drop if minfreqa <0.05 & maxfreqb >0.5 0 0 0 0 
Drop if maxfreq >0.95 & minfreq <0.5 0 0 0 0 
Number of SNPs After QC 16,214,013 16,229,739 16,247,694 16,303,638 









































Fasting glucose - 10,344 
HbA1c - 10,331 
Fasting insulin - 8,428 
DEXA traits - 10,344 
Iron - 8,980 
Transferrin - 8,988 
Ferritin - 8,958 
2 
Type 2 diabetes 





55,005 400,308 DIAMANTE 30297969 N/A 
36,614 155,150 Suzuki et al. 30718926 http://jenger.riken.jp/en/result 
11,006 82,655 Finngen NA https://www.finngen.fi/en 
26,616 64,558 Geisinger 26866580 https://www.geisinger.org/mycode 
Type 1 diabetes 






UK Biobank 25826379 http://www.ukbiobank.ac.uk/ 






























https://www.magicinvestigators.org/ 2-hour glucose - 42,854 
Fasting insulin - 108,557 







Non-fasted glucose - 355,817 UK Biobank 25826379 http://www.ukbiobank.ac.uk 








Hip circumference - 604,143 
Waist circumference - 615,305 
Waist-to-hip ratio adjusted for BMI - 625,123 
Waist-to-hip ratio unadjusted - 602,940 
3 b 
Type 2 diabetes (observational 
association) 
411 7,010 
EPIC-Norfolk 10466767 http://www.srl.cam.ac.uk/epic/ 
Coronary heart disease 
(observational association) 
1,123 5,917 
Type 2 diabetes 
(genetic association) 
17,006 330,572 
UK Biobank 25826379 http://www.ukbiobank.ac.uk/ 
Coronary heart disease 
(genetic association) 
18,770 333,247 
Abbreviations: N, Number of participants; HbA1c; Glycated haemoglobin; BMI; Body mass index; EPIC, European prospective investigation of cancer; 
DIAMANTE, Diabetes meta-analysis of trans-ethnic association studies; MAGIC, Meta-Analyses of glucose and insulin-related traits consortium; T1DGC, 
Type 1 diabetes genetics consortium. 
a. Traits are continuous unless otherwise stated as a disease or a polygenic score 
b. EPIC-Norfolk contributed to both the observational and genetic mediation analyses whereas UK Biobank contributed to only the genetic 




























Pradhan et al. 
2001 (US) 





Self-report based on ADA 







Age, FH of diabetes, smoking, 
physical activity, alcohol, PMT, 
fasting status, BMI, and FI 
a 
Duncan et al. 
2003 (US) 




1. Reported physician 
diagnosis; 
2. use of anti-diabetes 
medications; 
3. FG ≥7.0 mmol/L; 







Age, centre, sex, ethnicity, FH 
of diabetes, hypertension, BMI, 
WHR, FG, and FI 
a 
Krakoff et al. 
2003 (US) 




4.6 WHO criteria 
ELISA (Quantikine 
High Sensitivity; R&D 
Systems, Oxon, U.K.) 
0.75 
(0.45-1.25) 
Age, WC, FPG, PG2h, HbA1c, 
and FI 
a 
Spranger et al. 
2003 
(Germany) 





Self-report with cases 
validated using a 
questionnaire completed by 






Age, sex, sporting activities, 
smoking, alcohol, educational 
attainment, BMI, WHR, and 
HbA1c 
a 
Hu et al. 2004 
(US) 





Unconfirmed self-report of one 
of: 
1. Classic symptoms plus 
elevated glucose levels; 
2. two elevated plasma 
glucose if no symptoms; 
3. treatment with agents or 
insulin, ADA criteria for cases 
after 1998 
ELISA (Quantikine 
HS Immunoassay kit) 
1.52 
(1.18-1.96) 
Age, race, time at blood drawn, 
alcohol, physical activity, 
smoking, FH of diabetes, PMT, 
MP, diet score, fasting status, 
and BMI 
a 
Liu et al. 2007 
(US) 









Age, race, clinic, time of blood 
draw, BMI, alcohol, physical 
activity, smoking, PMT, FH of 
diabetes, and FG 
a 
Thorand et al. 
2007 F 
(Germany) 




Self-report with cases 
validated using a 
questionnaire mailed to the 
treating physician or by 









Age, survey, smoking, alcohol, 
physical activity, SBP, total-to-
HDL cholesterol ratio, BMI, and 
FH of diabetes 
a 
Thorand et al. 
2007 M 
(Germany) 




Self-report with cases 
validated using a 
questionnaire mailed to the 
treating physician or by 
medical chart review 
High sensitivity 
immunoradiometric 
assay (IRMA) (men 
aged 45–64 years) or 
a high-sensitivity latex 
enhanced 
nephelometric assay 
on a BN II analyser 




Age, survey, smoking, alcohol, 
physical activity, SBP, total-to-
HDL cholesterol ratio, BMI, and 































et al. 2007 (UK) 
108 3599 0 Cohort 5 
Self-report confirmed via 





Age, social class, physical 
activity, smoking, alcohol, use 
of statins, CHD or stroke, SBP, 
treatment for hypertension, 
BMI, and HOMA-IR 
a 
Ley et al. 2008 
(Canada) 
86 406 58 Cohort 10 
1. FG ≥7.0 mmol/L or PG2h 
≥11.1 mmol/L; 
2. current use of insulin or oral 
hypoglycaemic agents; 







Age, sex, TG, HDL-C, 
hypertension, WC, and IGT 
a 
Bertoni et al. 
2010 (US) 
410 5161 53 Cohort 4.7 
Using hypoglycaemic 
medication or FG ≥7 mmol/L 
ELISA (Quantikine 





Age, sex, race, education, site, 
alcohol, smoking, exercise, 
SBP, antihypertensive 
medication, HOMA-IR, and 
BMI 
a 
Dallmeier et al., 
2012 (USA) 
162 2476 56 Cohort 6.6 
Fasting glucose level ≥126 
mg/dL or use of insulin or oral 







Age, sex, cohort, BMI, FG, 
SBP, HDL-C, TG, and smoking 
b 
Marques-Vidal 
et al., 2012 
(Switzerland) 
208 3634 56.7 Cohort 5.5 
Fasting plasma glucose ≥7.0 
mmol/L and/or presence of 
oral hypoglycaemic or insulin 
treatment 
Multiplexed particle-




Age, FH of type 2 diabetes, 
height, WC, resting heart rate, 
presence of hypertension, 






160 1094 51 Cohort 10 
Unconfirmed self-report or 
ADA criteria i.e. use of 
antidiabetic medication 
(hypoglycaemic drugs and/or 
insulin use) or fasting plasma 




Age, sex, FH of diabetes, 
smoking, adherence to the 







411 7010 61 Cohort 16.7 
1. WHO criteria (HbA1c >6.5% 
(48mmol/mol)) 
2. Electronic health records 
(ICD 10: E11) 
3. Self-report 
Electrochemiluminesc




Age, sex, BMI, WHR, ethnicity, 
education level, FH of type 2 
diabetes, smoking status, 
average units of alcohol per 
week and average physical 
activity per week 
c 
Abbreviations: ADA, American Diabetes Association; BMI, body mass index; CHD, coronary heart disease; FG, fasting glucose; FH, family history; FI, fasting insulin; FPG, fasting 
plasma glucose; HDL-C, HDL cholesterol; IGT, impaired glucose tolerance; MP, menopausal; PG2h, 2-h plasma glucose; PMT, postmenopausal with hormone replacement 
therapy; SBP, systolic blood pressure; TG, triglycerides; WHO, World Health Organization; WHR, waist-to-hip ratio. 
Sources: 
a. Wang et al., 2013186 
b. Systematic search 




Table S4.3: Systematic literature review search terms. The following terms were searched 
in the PubMed database to identify prospective studies that have investigated the association 
between IL-6 levels and incident type 2 diabetes.  
 Search Terms 
#5 #1 AND #2 AND #3 AND #4 
#4  "2012/02/10"[Date - Publication]: "2018/10/30"[Date - Publication] 
#3  "Cohort Studies"[MeSH] OR Cohort Study OR Studies, Cohort OR Study, Cohort 
OR Studies, Historical Cohort OR Cohort Studies, Historical Cohort Study, 
Historical OR Historical Cohort Study OR Study, Historical OR Analysis, Cohort 
OR Analyses, Cohort OR Cohort Analyses OR Cohort Analysis OR Incidence 
Studies OR Incidence Study OR Studies, Incidence OR Study, Incidence OR 
"Incidence"[MeSH] OR "Cohort Studies"[MeSH] OR Case-cohort study OR 
Nested case-control study OR Survey 
#2  Diabetes Mellitus, Type 2[MeSH] OR NIDDM OR Maturity-Onset Diabetes OR 
Diabetes Mellitus, Noninsulin-Dependent OR Diabetes Mellitus, Adult-Onset OR 
Adult-Onset Diabetes Mellitus OR Diabetes Mellitus, Adult Onset OR Diabetes 
Mellitus, Ketosis-Resistant OR Diabetes Mellitus, Ketosis Resistant OR Ketosis-
Resistant Diabetes Mellitus OR Diabetes Mellitus, Maturity-Onset OR Diabetes 
Mellitus, Maturity Onset OR Diabetes Mellitus, Non-Insulin Dependent OR 
Diabetes Mellitus, Non-Insulin-Dependent OR Non-Insulin-Dependent Diabetes 
Mellitus OR Diabetes Mellitus, Noninsulin Dependent OR Diabetes Mellitus, Slow-
Onset OR Diabetes Mellitus, Slow Onset OR Slow-Onset Diabetes Mellitus OR 
Diabetes Mellitus, Stable OR Stable Diabetes Mellitus OR Diabetes Mellitus, Type 
II OR Maturity-Onset Diabetes Mellitus OR Maturity Onset Diabetes Mellitus OR 
MODY OR Type 2 Diabetes Mellitus OR Noninsulin-Dependent Diabetes Mellitus 
OR T2D OR T2DM OR Type 2 Diabetes[tiab] OR Type 2 diabetes mellitus OR 
diabetes[ti] 
#1  Interleukin-6[MeSH] OR Interleukin 6 OR IL6 OR B-Cell Stimulatory Factor 2 OR 
B-Cell Stimulatory Factor-2 OR Differentiation Factor-2, B-Cell OR Differentiation 
Factor 2, B Cell OR B-Cell Differentiation Factor-2 OR B Cell Differentiation 
Factor 2 OR BSF-2 OR Hybridoma Growth Factor OR Growth Factor, Hybridoma 
OR IFN-beta 2 OR Plasmacytoma Growth Factor OR Growth Factor, 
Plasmacytoma OR Hepatocyte-Stimulating Factor OR Hepatocyte Stimulating 
Factor OR MGI-2 OR Myeloid Differentiation-Inducing Protein OR Differentiation-
Inducing Protein, Myeloid OR Myeloid Differentiation Inducing Protein OR B-Cell 
Differentiation Factor OR B Cell Differentiation Factor OR Differentiation Factor, 
B-Cell OR Differentiation Factor, B Cell OR IL-6 OR Interferon beta-2 OR 
Interferon beta 2 OR beta-2, Interferon OR B Cell Stimulatory Factor-2 OR B Cell 


















Pradhan et al. 2001 1 1 1 2 5 
Duncan et al. 2003 1 1 1 1 4 
Krakoff et al. 2003 0 1 1 1 3 
Spranger et al. 2003 1 1 1 1 4 
Hu et al. 2004 1 1 0 2 4 
Liu et al. 2007 1 1 0 1 3 
Thorand et al. 2007 M a 1 0 1 2 4 
Thorand et al. 2007 F a 1 0 1 2 4 
Wannamethee et al. 2007 1 1 1 1 4 
Ley et al. 2008 0 1 1 1 3 
Bertoni et al. 2010 1 1 1 1 4 
Dallmeier et al. 2012 1 1 1 1 4 
Marques-Vidal et al. 2012 1 1 1 1 4 
Koloverou et al. 2018 1 1 1 2 5 
EPIC-Norfolk, 2018 1 1 2 2 6 
Abbreviations: M, Males; F, Females; EPIC, European prospective investigation of cancer 
a. IL-6 levels were measured differently between males aged 45-64 years compared to males aged 35-44 years and all females in the study therefore estimates were 
analysed separately. 
Each study received up to 6 points based on the criteria below: 
1. Size and representativeness: the study sample was representative of participants (i.e. sample size was more than 500, or more than 80% of eligible participants were 
invited, or more than 80% agreed to participate). [1 point] 
2. Reliably measured exposure (ELISA = 1, Electrochemiluminescent assay = 1, particle-based flow cytometry = 1, light-scatter based methods other than flow 
cytometry = 0). [1 point] 
3. The study reliably assessed outcome (Only self-reported = 0, objective glycaemic measures = +1 point to score, use of health records = +1 point to score). [2 points] 
4. Adjustment for possible confounders (Adjusted only for age and sex = 0, Adjusted for age, sex and self-reported risk factors = 1, additionally adjusted for 
anthropometry = 2, adjusted for glycaemic measures = -1 point from score) [2 points] 




Table S4.5: Fenland participant DEXA and glycemic measures. 
Variable Value 
Country United Kingdom 
Number of participants 10,344 
Baseline age, mean years (SD) 48 (8) 
Female sex, N (%) 5,528 (53) 
Arms fat mass, median (IQR) in grams 2,516 (2,046-3,099) 
Trunk fat mass, median (IQR) in grams 13,142 (9,570-17,268) 
Abdominal fat mass total, median (IQR) in grams 2,145 (1,435-2,991) 
Subcutaneous abdominal fat mass, median (IQR) in grams 1,239 (921-1,667) 
Visceral abdominal fat mass, median (IQR) in grams 766 (317-1,409) 
Gluteofemoral fat mass, median (IQR) in grams 4,124 (3,298-5,174) 
Leg fat mass, median (IQR) in grams 8,285 (6,652-10,446) 
Fasting glucose, mean (SD) in mmol/L 4.83 (0.66) 
2-hour glucose, mean (SD) in mmol/L 5.29 (1.70) 
HbA1c, mean (SD) in % 5.54 (0.46) 
Fasting insulin, median (IQR) in pmol/L 38.3 (26.5-57.2) 
Abbreviations: SD, Standard deviation; N, Number of participants; IQR, Interquartile range; mmol/L, millimoles per 





Table S4.6: Standard deviation values used to convert estimates for continuous 
metabolic traits between clinical and standardized units and their source. 
Metabolic trait Clinical units Standard deviation Source study 
2-hour glucose mmol/L 1.7 Fenland 
Fasting plasma glucose mmol/L 0.66 Fenland 
HbA1c % 0.49 Fenland 
Fasting insulin Log (pmol/L) 0.60 Fenland 
Non-fasted glucose mmol/L 0.87 UK Biobank 
BMI kg/m2 4.8 UK Biobank 
Hip circumference cm 9.2 UK Biobank 
Waist circumference cm 13.5 UK Biobank 
WHRadjBMI ratio 0.056 UK Biobank 
WHR ratio 0.09 UK Biobank 
Abbreviations: BMI, Body mass index; WHR, Waist-to-hip ratio; WHRadjBMI, WHR adjusted for BMI; mmol, 
millimoles; L, Litre; pmol, picomoles; Kg, Kilograms; m, meters; cm, centimetres 





Table S4.7: Polygenic risk scores used in Stage 2 and their sources. 
Phenotype SNP ID EA a Beta PMID 
BMI rs543874 A 0.205 
25673413309 
BMI rs3101336 T 0.395 
BMI rs12566985 G 0.450 
BMI rs17024393 T 0.026 
BMI rs657452 A 0.399 
BMI rs11165643 C 0.419 
BMI rs12401738 G 0.366 
BMI rs2820292 A 0.441 
BMI rs11583200 C 0.399 
BMI rs977747 T 0.426 
BMI rs7903146 C 0.290 
BMI rs17094222 T 0.209 
BMI rs11191560 T 0.081 
BMI rs7899106 A 0.051 
BMI rs11030104 A 0.203 
BMI rs3817334 C 0.402 
BMI rs12286929 A 0.476 
BMI rs4256980 C 0.354 
BMI rs2176598 T 0.248 
BMI rs7138803 G 0.365 
BMI rs11057405 G 0.100 
BMI rs12429545 G 0.130 
BMI rs9581854 C 0.175 
BMI rs1441264 G 0.402 
BMI rs9540493 A 0.461 
BMI rs7141420 C 0.481 
BMI rs10132280 C 0.303 
BMI rs12885454 C 0.352 
BMI rs11847697 C 0.051 
BMI rs16951275 T 0.235 
BMI rs7164727 C 0.343 
BMI rs3736485 A 0.468 
BMI rs1558902 T 0.394 
BMI rs3888190 C 0.390 
BMI rs12446632 G 0.138 
BMI rs758747 C 0.287 
BMI rs9925964 A 0.354 
BMI rs2650492 G 0.288 
BMI rs2080454 C 0.390 
BMI rs4787491 A 0.465 
BMI rs12940622 G 0.439 
BMI rs1000940 A 0.305 
BMI rs9914578 C 0.213 
BMI rs6567160 T 0.235 
BMI rs7239883 G 0.377 
BMI rs7243357 T 0.178 
BMI rs1808579 C 0.482 
BMI rs2287019 C 0.181 
BMI rs3810291 G 0.342 
BMI rs2075650 A 0.144 
BMI rs29941 A 0.326 
BMI rs17724992 A 0.270 
BMI rs13021737 A 0.169 
BMI rs10182181 A 0.493 
BMI rs1016287 T 0.295 
BMI rs7599312 G 0.266 
BMI rs11126666 G 0.258 
BMI rs492400 C 0.429 
BMI rs2176040 A 0.348 
BMI rs1528435 C 0.378 
BMI rs11688816 G 0.457 
BMI rs2121279 C 0.121 
BMI rs17203016 A 0.196 
BMI rs1460676 T 0.159 
BMI rs6091540 C 0.295 
BMI rs2836754 T 0.377 
BMI rs1516725 T 0.138 
BMI rs13078960 T 0.195 




Phenotype SNP ID EA a Beta PMID 
BMI rs16851483 G 0.067 
BMI rs6804842 A 0.432 
BMI rs3849570 C 0.350 
BMI rs10938397 A 0.429 
BMI rs13107325 C 0.072 
BMI rs17001654 C 0.148 
BMI rs11727676 T 0.093 
BMI rs2112347 T 0.368 
BMI rs7715256 G 0.430 
BMI rs2207139 A 0.169 
BMI rs205262 A 0.275 
BMI rs13191362 A 0.122 
BMI rs751414 G 0.283 
BMI rs9400239 T 0.309 
BMI rs9374842 C 0.231 
BMI rs13201877 A 0.130 
BMI rs9641123 G 0.399 
BMI rs1167827 A 0.431 
BMI rs2245368 C 0.176 
BMI rs6465468 G 0.299 
BMI rs17405819 T 0.295 
BMI rs16907751 C 0.099 
BMI rs2033732 T 0.252 
BMI rs10968576 A 0.315 
BMI rs1928295 T 0.430 
BMI rs4740619 T 0.453 
BMI rs10733682 A 0.473 
BMI rs6477694 C 0.359 
WHRadjBMI rs998584 A 0.05 
3057588230 
WHRadjBMI rs1936805 T 0.041 
WHRadjBMI rs7133378 G 0.039 
WHRadjBMI rs2371767 G 0.04 
WHRadjBMI rs2791550 G 0.037 
WHRadjBMI rs10923724 T 0.035 
WHRadjBMI rs10195252 T 0.031 
WHRadjBMI rs1294410 C 0.031 
WHRadjBMI rs718314 G 0.034 
WHRadjBMI rs3786897 G 0.03 
WHRadjBMI rs10919388 C 0.033 
WHRadjBMI rs714515 G 0.028 
WHRadjBMI rs17451107 T 0.029 
WHRadjBMI rs2236519 A 0.03 
WHRadjBMI rs6861681 A 0.029 
WHRadjBMI rs1443512 A 0.031 
WHRadjBMI rs9837325 C 0.034 
WHRadjBMI rs459193 A 0.029 
WHRadjBMI rs2167750 T 0.027 
WHRadjBMI rs12608504 A 0.026 
WHRadjBMI rs2145272 G 0.026 
WHRadjBMI rs2294239 A 0.025 
WHRadjBMI rs797486 A 0.037 
WHRadjBMI rs1055144 T 0.03 
WHRadjBMI rs605203 A 0.025 
WHRadjBMI rs12214804 C 0.045 
WHRadjBMI rs4738141 G 0.028 
WHRadjBMI rs2276824 C 0.024 
WHRadjBMI rs17819328 G 0.023 
WHRadjBMI rs634869 T 0.023 
WHRadjBMI rs2925979 T 0.024 
WHRadjBMI rs905938 T 0.025 
WHRadjBMI rs8066985 A 0.022 
WHRadjBMI rs10502148 C 0.023 
WHRadjBMI rs1569135 A 0.021 
WHRadjBMI rs7492628 G 0.024 
WHRadjBMI rs6556301 T 0.022 
WHRadjBMI rs9792666 A 0.057 
WHRadjBMI rs2845885 C 0.045 
WHRadjBMI rs3810068 T 0.023 
WHRadjBMI rs7801581 T 0.023 




Phenotype SNP ID EA a Beta PMID 
WHRadjBMI rs3747577 C 0.023 
WHRadjBMI rs757608 A 0.02 
WHRadjBMI rs143384 A 0.02 
WHRadjBMI rs951252 G 0.019 
WHRadjBMI rs2428549 G 0.021 
WHRadjBMI rs2073267 G 0.025 
WHRadjBMI rs601339 A 0.025 
WHRadjBMI rs910382 G 0.019 
WHRadjBMI rs711869 G 0.019 
WHRadjBMI rs1051921 G 0.023 
WHRadjBMI rs11263432 T 0.02 
WHRadjBMI rs7598832 C 0.019 
WHRadjBMI rs6719672 G 0.025 
WHRadjBMI rs780159 G 0.018 
WHRadjBMI rs6688233 T 0.022 
WHRadjBMI rs622217 T 0.019 
WHRadjBMI rs16891532 A 0.034 
WHRadjBMI rs9644033 A 0.022 
WHRadjBMI rs10264590 A 0.018 
WHRadjBMI rs6446204 C 0.02 
WHRadjBMI rs10462028 A 0.019 
WHRadjBMI rs8030605 A 0.026 
WHRadjBMI rs10992408 G 0.024 
WHRadjBMI rs4779526 A 0.021 
WHRadjBMI rs4727695 A 0.029 
WHRadjBMI rs6853254 T 0.019 
WHRadjBMI rs9388766 C 0.018 
WHRadjBMI rs6581662 T 0.02 
WHRadjBMI rs3741378 C 0.024 
WHRadjBMI rs13256367 A 0.018 
WHRadjBMI rs2993481 T 0.021 
WHRadjBMI rs11724804 G 0.017 
WHRadjBMI rs4420638 A 0.022 
WHRadjBMI rs1045241 C 0.018 
WHRadjBMI rs4450871 A 0.018 
WHRadjBMI rs7589318 G 0.017 
WHRadjBMI rs2836179 G 0.017 
WHRadjBMI rs11592754 C 0.023 
WHRadjBMI rs303084 A 0.019 
WHRadjBMI rs9844972 C 0.033 
WHRadjBMI rs2047937 C 0.016 
WHRadjBMI rs3764002 C 0.018 
WHRadjBMI rs727428 T 0.016 
WHRadjBMI rs10980802 G 0.016 
WHRadjBMI rs11747001 A 0.018 
WHRadjBMI rs2222543 G 0.016 
WHRadjBMI rs39312 C 0.016 
WHRadjBMI rs7235010 A 0.018 
WHRadjBMI rs9362097 G 0.016 
WHRadjBMI rs9583489 C 0.017 
WHRadjBMI rs1805741 C 0.017 
WHRadjBMI rs2254069 A 0.024 
WHRadjBMI rs2235529 C 0.021 
WHRadjBMI rs17041868 C 0.03 
WHRadjBMI rs13154197 G 0.027 
WHRadjBMI rs2298632 C 0.015 
WHRadjBMI rs1876829 C 0.019 
WHRadjBMI rs1440372 C 0.016 
WHRadjBMI rs4902632 A 0.021 
WHRadjBMI rs6433219 A 0.017 
WHRadjBMI rs7122422 C 0.015 
WHRadjBMI rs2444770 T 0.021 
WHRadjBMI rs10512606 C 0.027 
WHRadjBMI rs11079041 A 0.016 
WHRadjBMI rs4849294 T 0.015 
WHRadjBMI rs1316979 T 0.029 
WHRadjBMI rs4851221 G 0.019 
WHRadjBMI rs1144 C 0.015 
WHRadjBMI rs3851294 G 0.025 




Phenotype SNP ID EA a Beta PMID 
WHRadjBMI rs11051005 A 0.016 
WHRadjBMI rs6920788 T 0.016 
WHRadjBMI rs7680787 T 0.014 
WHRadjBMI rs12459350 A 0.014 
WHRadjBMI rs4704389 A 0.014 
WHRadjBMI rs6932767 T 0.017 
WHRadjBMI rs1474921 A 0.015 
WHRadjBMI rs380654 G 0.014 
WHRadjBMI rs8055190 C 0.034 
WHRadjBMI rs9647379 G 0.014 
WHRadjBMI rs2398893 A 0.015 
WHRadjBMI rs2821391 A 0.015 
WHRadjBMI rs998749 A 0.013 
WHRadjBMI rs12828318 A 0.018 
WHRadjBMI rs10844642 A 0.014 
WHRadjBMI rs1328757 T 0.014 
WHRadjBMI rs1053593 G 0.014 
WHRadjBMI rs1498126 C 0.017 
WHRadjBMI rs1190982 T 0.015 
WHRadjBMI rs12774134 C 0.02 
WHRadjBMI rs11726981 C 0.015 
WHRadjBMI rs7800072 G 0.014 
WHRadjBMI rs10880321 G 0.014 
WHRadjBMI rs7823561 A 0.014 
WHRadjBMI rs4751628 G 0.014 
WHRadjBMI rs7242873 G 0.024 
WHRadjBMI rs2061705 G 0.013 
WHRadjBMI rs17326656 T 0.015 
WHRadjBMI rs13406302 C 0.014 
WHRadjBMI rs2452877 A 0.013 
WHRadjBMI rs7114403 A 0.013 
WHRadjBMI rs2283847 T 0.013 
WHRadjBMI rs11187537 C 0.015 
WHRadjBMI rs6752964 C 0.02 
WHRadjBMI rs3789615 C 0.012 
WHRadjBMI rs11893688 T 0.014 
WHRadjBMI rs332105 G 0.013 
WHRadjBMI rs8030277 T 0.013 
WHRadjBMI rs10963067 C 0.022 
WHRadjBMI rs174829 G 0.014 
WHRadjBMI rs2057869 A 0.014 
WHRadjBMI rs421168 G 0.013 
WHRadjBMI rs10745659 G 0.012 
WHRadjBMI rs7612999 A 0.014 
WHRadjBMI rs6449133 T 0.013 
WHRadjBMI rs2595004 C 0.016 
WHRadjBMI rs7919055 C 0.032 
WHRadjBMI rs2066107 T 0.013 
WHRadjBMI rs2058914 G 0.013 
WHRadjBMI rs2333496 T 0.012 
WHRadjBMI rs10887759 A 0.016 
WHRadjBMI rs12684047 T 0.016 
WHRadjBMI rs4239275 T 0.012 
WHRadjBMI rs6486060 G 0.012 
WHRadjBMI rs2320125 T 0.012 
WHRadjBMI rs807067 T 0.011 
WHRadjBMI rs17167945 G 0.015 
WHRadjBMI rs36232 G 0.015 
WHRadjBMI rs9750952 C 0.014 
WHRadjBMI rs710122 G 0.012 
WHRadjBMI rs9896963 C 0.014 
WHRadjBMI rs9305545 G 0.016 
WHRadjBMI rs747249 A 0.012 
WHRadjBMI rs6874524 T 0.013 
WHRadjBMI rs676556 G 0.014 
WHRadjBMI rs6908042 A 0.011 
WHRadjBMI rs2701523 A 0.012 
WHRadjBMI rs1360485 T 0.011 
WHRadjBMI rs544668 T 0.011 




Phenotype SNP ID EA a Beta PMID 
WHRadjBMI rs1979527 A 0.013 
WHRadjBMI rs1278493 G 0.011 
WHRadjBMI rs12631066 C 0.013 
WHRadjBMI rs2823096 A 0.014 
WHRadjBMI rs10891483 T 0.017 
WHRadjBMI rs362275 C 0.011 
WHRadjBMI rs6496127 G 0.01 
WHRadjBMI rs7235891 C 0.011 
WHRadjBMI rs1156979 A 0.011 
WHRadjBMI rs505102 C 0.013 
WHRadjBMI rs10507524 C 0.018 
WHRadjBMI rs13028903 T 0.011 
WHRadjBMI rs12440695 C 0.01 
WHRadjBMI rs2590440 G 0.013 
WHRadjBMI rs2240328 T 0.014 
WHRadjBMI rs3758938 T 0.011 
WHRadjBMI rs4454603 C 0.01 
WHRadjBMI rs1328369 T 0.01 
WHRadjBMI rs12186798 G 0.013 
WHRadjBMI rs15285 C 0.011 
Hip-specific score for higher WHR rs10195252 T 0.031 
Hip-specific score for higher WHR rs9837325 C 0.034 
Hip-specific score for higher WHR rs2167750 T 0.027 
Hip-specific score for higher WHR rs2145272 G 0.026 
Hip-specific score for higher WHR rs605203 A 0.025 
Hip-specific score for higher WHR rs2845885 C 0.045 
Hip-specific score for higher WHR rs12936587 G 0.02 
Hip-specific score for higher WHR rs3747577 C 0.023 
Hip-specific score for higher WHR rs601339 A 0.025 
Hip-specific score for higher WHR rs10992408 G 0.024 
Hip-specific score for higher WHR rs4450871 A 0.018 
Hip-specific score for higher WHR rs11592754 C 0.023 
Hip-specific score for higher WHR rs727428 T 0.016 
Hip-specific score for higher WHR rs2235529 C 0.021 
Hip-specific score for higher WHR rs13154197 G 0.027 
Hip-specific score for higher WHR rs7122422 C 0.015 
Hip-specific score for higher WHR rs1316979 T 0.029 
Hip-specific score for higher WHR rs6920788 T 0.016 
Hip-specific score for higher WHR rs12459350 A 0.014 
Hip-specific score for higher WHR rs4704389 A 0.014 
Hip-specific score for higher WHR rs2061705 G 0.013 
Hip-specific score for higher WHR rs2320125 T 0.012 
Waist-specific score for higher WHR rs17451107 T 0.029 
Waist-specific score for higher WHR rs1055144 T 0.03 
Waist-specific score for higher WHR rs1569135 A 0.021 
Waist-specific score for higher WHR rs757608 A 0.02 
Waist-specific score for higher WHR rs7598832 C 0.019 
Waist-specific score for higher WHR rs6719672 G 0.025 
Waist-specific score for higher WHR rs11724804 G 0.017 
Waist-specific score for higher WHR rs11747001 A 0.018 
Waist-specific score for higher WHR rs39312 C 0.016 
Waist-specific score for higher WHR rs9362097 G 0.016 
Waist-specific score for higher WHR rs11079041 A 0.016 
Waist-specific score for higher WHR rs4849294 T 0.015 
Waist-specific score for higher WHR rs6932767 T 0.017 
Waist-specific score for higher WHR rs9647379 G 0.014 
Waist-specific score for higher WHR rs998749 A 0.013 
Waist-specific score for higher WHR rs10844642 A 0.014 
Waist-specific score for higher WHR rs17326656 T 0.015 
Waist-specific score for higher WHR rs6752964 C 0.02 
Waist-specific score for higher WHR rs11893688 T 0.014 
Waist-specific score for higher WHR rs332105 G 0.013 
Waist-specific score for higher WHR rs10963067 C 0.022 
Waist-specific score for higher WHR rs2058914 G 0.013 
Waist-specific score for higher WHR rs710122 G 0.012 
Waist-specific score for higher WHR rs9305545 G 0.016 
Waist-specific score for higher WHR rs676556 G 0.014 
Waist-specific score for higher WHR rs6908042 A 0.011 
Waist-specific score for higher WHR rs544668 T 0.011 




Phenotype SNP ID EA a Beta PMID 
Waist-specific score for higher WHR rs2823096 A 0.014 
Waist-specific score for higher WHR rs10891483 T 0.017 
Waist-specific score for higher WHR rs362275 C 0.011 
Waist-specific score for higher WHR rs13028903 T 0.011 
Waist-specific score for higher WHR rs2590440 G 0.013 
Waist-specific score for higher WHR rs2240328 T 0.014 
Waist-specific score for higher WHR rs4454603 C 0.01 
Waist-specific score for higher WHR rs1328369 T 0.01 
HbA1c via glycemic mechanisms rs560887 C 0.0284 
28898252347 
HbA1c via glycemic mechanisms rs11708067 A 0.0132 
HbA1c via glycemic mechanisms rs8192675 T 0.0112 
HbA1c via glycemic mechanisms rs13134327 A 0.0131 
HbA1c via glycemic mechanisms rs7756992 G 0.0123 
HbA1c via glycemic mechanisms rs4607517 A 0.0306 
HbA1c via glycemic mechanisms rs11558471 A 0.015 
HbA1c via glycemic mechanisms rs2383208 A 0.0142 
HbA1c via glycemic mechanisms rs579459 C 0.0107 
HbA1c via glycemic mechanisms rs17747324 C 0.0149 
HbA1c via glycemic mechanisms rs11603334 G 0.012 
HbA1c via glycemic mechanisms rs10830963 G 0.0196 
Fasting plasma glucose rs10438234 C 0.013 
22581228346; 22885924345; 
24947364351 
Fasting plasma glucose rs10747083 A 0.013 
Fasting plasma glucose rs10811661 T 0.024 
Fasting plasma glucose rs10814916 C 0.016 
Fasting plasma glucose rs10830963 G 0.078 
Fasting plasma glucose rs11039149 A 0.025 
Fasting plasma glucose rs11558471 A 0.029 
Fasting plasma glucose rs11603334 G 0.019 
Fasting plasma glucose rs11607883 G 0.021 
Fasting plasma glucose rs11619319 G 0.02 
Fasting plasma glucose rs11708067 A 0.023 
Fasting plasma glucose rs1280 T 0.026 
Fasting plasma glucose rs1334577 A 0.013 
Fasting plasma glucose rs16913693 T 0.043 
Fasting plasma glucose rs17264369 A 0.017 
Fasting plasma glucose rs174576 C 0.02 
Fasting plasma glucose rs2191348 T 0.029 
Fasting plasma glucose rs2302593 C 0.014 
Fasting plasma glucose rs2657879 G 0.012 
Fasting plasma glucose rs340874 C 0.013 
Fasting plasma glucose rs3829109 G 0.017 
Fasting plasma glucose rs4258313 G 0.035 
Fasting plasma glucose rs4502156 T 0.022 
Fasting plasma glucose rs4869272 T 0.018 
Fasting plasma glucose rs573225 A 0.063 
Fasting plasma glucose rs576674 G 0.017 
Fasting plasma glucose rs6113722 G 0.035 
Fasting plasma glucose rs6943153 T 0.015 
Fasting plasma glucose rs730497 A 0.057 
Fasting plasma glucose rs7651090 G 0.013 
Fasting plasma glucose rs7708285 G 0.011 
Fasting plasma glucose rs7756992 G 0.014 
Fasting plasma glucose rs780093 C 0.028 
Fasting plasma glucose rs7903146 T 0.022 
Fasting plasma glucose rs9814873 A 0.0098 
Fasting plasma glucose rs983309 T 0.026 
Fasting plasma glucose rs10305492 G 0.071 
Fasting plasma glucose rs651007 A 0.0099 
Impaired insulin secretion rs10811661 T 0.083 
Impaired insulin secretion rs10830963 G 0.076 
Impaired insulin secretion rs10946398 C 0.061 
Impaired insulin secretion rs11603334 G 0.051 
Impaired insulin secretion rs11605924 A 0.069 
Impaired insulin secretion rs11672660 T 0.13 
Impaired insulin secretion rs12686676 G 0.015 
Impaired insulin secretion rs12779790 G 0.068 
Impaired insulin secretion rs13266634 C 0.041 
Impaired insulin secretion rs174550 T 0.031 
Impaired insulin secretion rs4502156 T 0.05 




Phenotype SNP ID EA a Beta PMID 
Impaired insulin secretion rs5015480 C 0.061 
Impaired insulin secretion rs5219 T 0.038 
Impaired insulin secretion rs560887 T 0.047 
Impaired insulin secretion rs7903146 T 0.06 
Impaired insulin secretion rs7957197 T 0.062 
Impaired insulin secretion rs933360 T 0.079 
Insulin resistance Scott rs10195252 T 0.017 
Insulin resistance Scott rs17036328 T 0.021 
Insulin resistance Scott rs2745353 T 0.011 
Insulin resistance Scott rs2943645 T 0.019 
Insulin resistance Scott rs3822072 A 0.012 
Insulin resistance Scott rs459193 G 0.015 
Insulin resistance Scott rs4846565 G 0.013 
Insulin resistance Scott rs4865796 A 0.015 
Insulin resistance Scott rs6536208 A 0.017 
Insulin resistance Scott rs731839 G 0.015 
Insulin resistance rs9425291 A 1 
Insulin resistance rs7973683 C 1 
Insulin resistance rs2745353 T 1 
Insulin resistance rs2943645 T 1 
Insulin resistance rs1045241 C 1 
Insulin resistance rs8032586 C 1 
Insulin resistance rs6937438 A 1 
Insulin resistance rs4865796 A 1 
Insulin resistance rs11231693 A 1 
Insulin resistance rs10195252 T 1 
Insulin resistance rs4738141 G 1 
Insulin resistance rs3822072 A 1 
Insulin resistance rs492400 T 1 
Insulin resistance rs6066149 G 1 
Insulin resistance rs966544 G 1 
Insulin resistance rs17386142 C 1 
Insulin resistance rs2126259 T 1 
Insulin resistance rs11577194 T 1 
Insulin resistance rs11130329 A 1 
Insulin resistance rs6536208 A 1 
Insulin resistance rs308971 G 1 
Insulin resistance rs12525532 T 1 
Insulin resistance rs731839 G 1 
Insulin resistance rs459193 G 1 
Insulin resistance rs718314 G 1 
Insulin resistance rs4846565 G 1 
Insulin resistance rs2249105 A 1 
Insulin resistance rs2434612 G 1 
Insulin resistance rs6887914 C 1 
Insulin resistance rs10995441 G 1 
Insulin resistance rs4804311 A 1 
Insulin resistance rs4976033 G 1 
Insulin resistance rs8101064 T 1 
Insulin resistance rs3861397 G 1 
Insulin resistance rs972283 G 1 
Insulin resistance rs7323406 A 1 
Insulin resistance rs1011685 C 1 
Insulin resistance rs132985 C 1 
Insulin resistance rs7227237 C 1 
Insulin resistance rs17169104 G 1 
Insulin resistance rs2699429 C 1 
Insulin resistance rs7176058 A 1 
Insulin resistance rs645040 T 1 
Insulin resistance rs9492443 C 1 
Insulin resistance rs683135 A 1 
Insulin resistance rs754814 T 1 
Insulin resistance rs17402950 G 1 
Insulin resistance rs7005992 C 1 
Insulin resistance rs4804833 A 1 
Insulin resistance rs498313 A 1 
Insulin resistance rs295449 A 1 
Insulin resistance rs3864041 T 1 
Insulin resistance rs9881942 A 1 




Phenotype SNP ID EA a Beta PMID 
MC4R β -arrestin biased GoF score rs52820871 G 1 
MC4R β -arrestin biased GoF score affx89015531 A 1 
MC4R β -arrestin biased GoF score affx89019383 C 1 
Abbreviations: WHRadjBMI; Waist-to-hip ratio adjusted for BMI; BMI, Body mass index; HbA1c, glycated 
haemoglobin; MC4R, Melanocortin 4 Receptor; GoF, Gain-of-function, EA; Effect allele; PMID, PubMed 
identification number. 




Table S4.8: Correlation of IL-6 levels with DEXA adiposity measures in Fenland. 
Adiposity trait (units)a 
Correlation with 
IL-6 levels b c 
P-value 
Waist-to-hip ratio 0.17 <0.0001 
BMI in kg/m2 0.25 <0.0001 
Body fat percentage in % 0.23 <0.0001 
Abdominal fat mass in grams 0.27 <0.0001 
Gluteofemoral fat mass in grams 0.20 <0.0001 
Leg fat mass in grams 0.18 <0.0001 
Abdominal to gluteofemoral fat mass ratio 0.17 <0.0001 
Peripheral fat mass in grams 0.20 <0.0001 
Visceral fat mass in grams 0.24 <0.0001 
Subcutaneous fat mass in grams 0.20 <0.0001 
Abbreviations: BMI, Body Mass Index; IL-6, interleukin-6.  
Adiposity measures accounted for 9% of the variance in IL-6 levels 
a. DEXA adiposity traits were inverse-rank normal transformed 
b. IL-6 levels were natural log transformed (pg/mL) 





Table S4.9: Variance and heritability in type 2 diabetes and coronary disease 





Outcome Variance explained (%) Heritability explained (%) 
Type 2 diabetes 0.007 0.04 




Table S4.10: Association of 358Ala with type 2 diabetes conditioning on rs2481065.  
Abbreviations: OR, Odds ratio; CI, Confidence interval 
Analysis Type 2 diabetes cases Controls OR (95% CI) P-value 
Main 22,182 424,361 0.96 (0.95-0.98) 3x10-4 




Table S5.1: Inflammatory proteins with evidence of an association with T2D or CHD.  
Target Full Name Gene 
6Ckine C-C motif chemokine 21 CCL21 
a1-Antitrypsin Alpha-1-antitrypsin SERPINA1 
a1-Microglobulin Alpha-1-microglobulin AMBP 
ABP1 Amiloride-sensitive amine oxidase [copper-containing] AOC1 
ACE Angiotensin-converting enzyme ACE 
Activin AC Inhibin beta A chain:Inhibin beta C chain heterodimer INHBA|INHBC 
ADAM 9 Disintegrin and metalloproteinase domain-containing protein 9 ADAM9 
Adiponectin Adiponectin ADIPOQ 
AIF1 Allograft inflammatory factor 1 AIF1 
ALCAM CD166 antigen ALCAM 
aldolase C Fructose-bisphosphate aldolase C ALDOC 
Alpha-1B-glycoprotein Alpha-1B-glycoprotein A1BG 
Angiostatin Angiostatin PLG 
ANXA9 Annexin A9 ANXA9 
Apo A-I Apolipoprotein A-I APOA1 
Apo B Apolipoprotein B APOB 
Apo E Apolipoprotein E APOE 
Apo L1 Apolipoprotein L1 APOL1 
ARF1 ADP-ribosylation factor 1 ARF1 
ARGI1 Arginase-1 ARG1 
AT1B2 Sodium/potassium-transporting ATPase subunit beta-2 ATP1B2 
ATS13 A disintegrin and metalloproteinase with thrombospondin motifs 13 ADAMTS13 
AZGP1 Zinc-alpha-2-glycoprotein AZGP1 
b2-Microglobulin Beta-2-microglobulin 0 
B4GT1 Beta-1,4-galactosyltransferase 1 B4GALT1 
BGLR Beta-glucuronidase GUSB 
BT3A3 Butyrophilin subfamily 3 member A3 BTN3A3 
BTNL8 Butyrophilin-like protein 8 BTNL8 
BTNL9 Butyrophilin-like protein 9 BTNL9 
C1-Esterase Inhibitor Plasma protease C1 inhibitor SERPING1 
C1QBP Complement component 1 Q subcomponent-binding protein, mitochondrial C1QBP 
C1QR1 Complement component C1q receptor CD93 
C1RL1 Complement C1r subcomponent-like protein C1RL 
C4a C4a anaphylatoxin C4A|C4B 
C4b-binding protein alpha 
chain 
C4b-binding protein alpha chain C4BPA 
C5b, 6 Complex Complement C5b-C6 complex C5|C6 
C9 Complement component C9 C9 
CAD17 Cadherin-17 CDH17 
Calpain I Calpain I CAPN1|CAPNS1 
CARD9 Caspase recruitment domain-containing protein 9 CARD9 
Caspase-3 Caspase-3 CASP3 




Target Full Name Gene 
CATF Cathepsin F CTSF 
Cathepsin B Cathepsin B CTSB 
Cathepsin D Cathepsin D CTSD 
Cathepsin H Cathepsin H CTSH 
Cathepsin V Cathepsin L2 CTSV 
CATZ Cathepsin Z CTSZ 
CCL28 C-C motif chemokine 28 CCL28 
CD109 CD109 antigen CD109 
CD23 Low affinity immunoglobulin epsilon Fc receptor FCER2 
CD248 Endosialin CD248 
CD30 Ligand Tumor necrosis factor ligand superfamily member 8 TNFSF8 
CD36 ANTIGEN Platelet glycoprotein 4 CD36 
CD46 Membrane cofactor protein CD46 
CD48 CD48 antigen CD48 
CD59 CD59 glycoprotein CD59 
CD5L CD5 antigen-like CD5L 
CD7 T-cell antigen CD7 CD7 
CD8A T-cell surface glycoprotein CD8 alpha chain CD8A 
CEAM8 Carcinoembryonic antigen-related cell adhesion molecule 8 CEACAM8 
CECR1 Adenosine deaminase CECR1 CECR1 
cIAP-1 Baculoviral IAP repeat-containing protein 2 BIRC2 
CIG49 Interferon-induced protein with tetratricopeptide repeats 3 IFIT3 
CLC4C C-type lectin domain family 4 member C CLEC4C 
CLC4G C-type lectin domain family 4 member G CLEC4G 
CLC4K C-type lectin domain family 4 member K CD207 
CLM6 CMRF35-like molecule 6 CD300C 
CM35H CMRF35-like molecule 8 CD300A 
CO1A1 Collagen alpha-1(I) chain COL1A1 
Coactosin-like protein Coactosin-like protein COTL1 
Coagulation Factor VII Coagulation factor VII F7 
COLEC12 Collectin-12 COLEC12 
Collagen Type III Collagen Type III COL3A1 
Complement receptor type 1 Complement receptor type 1 CR1 
Complement receptor type 2 Complement receptor type 2 CR2 
CPN2 Carboxypeptidase N subunit 2 CPN2 
CREG1 Protein CREG1 CREG1 
CRIP1 Cysteine-rich protein 1 CRIP1 
CRIP2 Cysteine-rich protein 2 CRIP2 
Cripto Teratocarcinoma-derived growth factor 1 TDGF1 
CRP C-reactive protein CRP 
CRTAM Cytotoxic and regulatory T-cell molecule CRTAM 
CXCL16, soluble C-X-C motif chemokine 16 CXCL16 




Target Full Name Gene 
DAF Complement decay-accelerating factor CD55 
DAN Neuroblastoma suppressor of tumorigenicity 1 NBL1 
DAPK2 Death-associated protein kinase 2 DAPK2 
DC-SIGN CD209 antigen CD209 
DLL1 Delta-like protein 1 DLL1 
DLL4 Delta-like protein 4 DLL4 
DPP2 Dipeptidyl peptidase 2 DPP7 
DQA2 HLA class II histocompatibility antigen, DQ alpha 2 chain HLA-DQA2 
DR6 Tumor necrosis factor receptor superfamily member 21 TNFRSF21 
DRB3 HLA class II histocompatibility antigen, DR beta 3 chain HLA-DRB3 
Dtk Tyrosine-protein kinase receptor TYRO3 TYRO3 
DTX1 E3 ubiquitin-protein ligase DTX1 DTX1 
ECM1 Extracellular matrix protein 1 ECM1 
EFNB1 Ephrin-B1 EFNB1 
EFNB2 Ephrin-B2 EFNB2 
EMAP-2 Endothelial monocyte-activating polypeptide 2 AIMP1 
EMBP Bone marrow proteoglycan PRG2 
Endothelin 2 Endothelin-2 EDN2 
ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 ENPP2 
Ephrin-A2 Ephrin-A2 EFNA2 
Epithelial cell kinase Ephrin type-A receptor 2 EPHA2 
Epo Erythropoietin EPO 
ERK-1 Mitogen-activated protein kinase 3 MAPK3 
Factor B Complement factor B CFB 
FADD FAS-associated death domain protein FADD 
FAIM3 Fas apoptotic inhibitory molecule 3 FAIM3 
Fas ligand, soluble Tumor necrosis factor ligand superfamily member 6, soluble form FASLG 
Fas, soluble Tumor necrosis factor receptor superfamily member 6 FAS 
FCAMR High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor FCAMR 
FCG3B Low affinity immunoglobulin gamma Fc region receptor III-B FCGR3B 
FCRL1 Fc receptor-like protein 1 FCRL1 
FGL1 Fibrinogen-like protein 1 FGL1 
Fibrinogen Fibrinogen FGA|FGB|FGG 
Ficolin-3 Ficolin-3 FCN3 
FN1.3 Fibronectin Fragment 3 FN1 
Fractalkine/CX3CL-1 Fractalkine CX3CL1 
FSTL3 Follistatin-related protein 3 FSTL3 
FUT10 Alpha-(1,3)-fucosyltransferase 10 FUT10 
Galectin-3 Galectin-3 LGALS3 
GAS-6 Growth arrest-specific protein 6 GAS6 
GBP2 Guanylate-binding protein 2 GBP2 
GCP-2 C-X-C motif chemokine 6 CXCL6 




Target Full Name Gene 
GDF-11/8 Growth/differentiation factor 11/8 GDF11|MSTN 
Gelsolin Gelsolin GSN 
GEM GTP-binding protein GEM GEM 
GGH Gamma-glutamyl hydrolase GGH 
GGT2 Inactive gamma-glutamyltranspeptidase 2 GGT2 
GIB Phospholipase A2 PLA2G1B 
Glypican 3 Glypican-3 GPC3 
GM-CSF Granulocyte-macrophage colony-stimulating factor CSF2 
GNS N-acetylglucosamine-6-sulfatase GNS 
GON1 Progonadoliberin-1 GNRH1 
GP116 Adhesion G protein-coupled receptor F5 ADGRF5 
gp130, soluble Interleukin-6 receptor subunit beta IL6ST 
GP1BA Platelet glycoprotein Ib alpha chain GP1BA 
gpIIbIIIa Integrin alpha-IIb: beta-3 complex ITGA2B|ITGB3 
GPNMB Transmembrane glycoprotein NMB GPNMB 
Granulysin Granulysin GNLY 
granzyme A Granzyme A GZMA 
Granzyme B Granzyme B GZMB 
GRB14 Growth factor receptor-bound protein 14 GRB14 
GRB2-related adapter protein 
2 
GRB2-related adapter protein 2 GRAP2 
GRN Granulins GRN 
Haptoglobin, Mixed Type Haptoglobin HP 
HBAZ Hemoglobin subunit zeta HBZ 
HBD-1 Beta-defensin 1 DEFB1 
HD-5 Defensin-5 DEFA5 
Hemoglobin Hemoglobin HBA1|HBB 
HERC5 E3 ISG15--protein ligase HERC5 HERC5 
Hexosaminidase B Beta-hexosaminidase subunit beta HEXB 
HO-1 Heme oxygenase 1 HMOX1 
HS71B Heat shock 70 kDa protein 1B HSPA1B 
HSP 70 Heat shock protein 70 HSPA2 
HSP70 protein 8 Heat shock cognate 71 kDa protein HSPA8 
HVEM Tumor necrosis factor receptor superfamily member 14 TNFRSF14 
ICAM4 Intercellular adhesion molecule 4 ICAM4 
IDE Insulin-degrading enzyme IDE 
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 IFIT2 
IgA Immunoglobulin A IGHA1|IGHA2 
IgD Immunoglobulin D IGHD 
IgE Immunoglobulin E IGHE 
IGFBP-2 Insulin-like growth factor-binding protein 2 IGFBP2 
IGF-I sR Insulin-like growth factor 1 receptor IGF1R 
IGLL1 Immunoglobulin lambda-like polypeptide 1 IGLL1 




Target Full Name Gene 
IL-1 R4 Interleukin-1 receptor-like 1 IL1RL1 
IL-1 sRI Interleukin-1 receptor type 1 IL1R1 
IL-1 sRII Interleukin-1 receptor type 2 IL1R2 
IL-18 BPa Interleukin-18-binding protein IL18BP 
IL-1F6 Interleukin-36 alpha IL36A 
IL-1Rrp2 Interleukin-1 receptor-like 2 IL1RL2 
IL-21 Interleukin-21 IL21 
IL-23 Interleukin-23 IL12B|IL23A 
IL-23 R Interleukin-23 receptor IL23R 
IL-6 sRa Interleukin-6 receptor subunit alpha IL6R 
ILT-2 Leukocyte immunoglobulin-like receptor subfamily B member 1 LILRB1 
ILT-4 Leukocyte immunoglobulin-like receptor subfamily B member 2 LILRB2 
INDO Indoleamine 2,3-dioxygenase 1 IDO1 
IP-10 C-X-C motif chemokine 10 CXCL10 
ISGF3 Interferon regulatory factor 9 IRF9 
I-TAC C-X-C motif chemokine 11 CXCL11 
JAG1 Protein jagged-1 JAG1 
Kallikrein 7 Kallikrein-7 KLK7 
KI2L2 Killer cell immunoglobulin-like receptor 2DL2 KIR2DL2 
KI2L3 Killer cell immunoglobulin-like receptor 2DL3 KIR2DL3 
KI2S2 Killer cell immunoglobulin-like receptor 2DS2 KIR2DS2 
KIF3A Kinesin-like protein KIF3A KIF3A 
KLC1 Kinesin light chain 1 KLC1 
KMT2C Histone-lysine N-methyltransferase 2C KMT2C 
LAG-1 C-C motif chemokine 4-like CCL4L1 
LAG-3 Lymphocyte activation gene 3 protein LAG3 
LEAP2 Liver-expressed antimicrobial peptide 2 LEAP2 
Leptin Leptin LEP 
LFA-1 beta-2 Integrin beta-2 ITGB2 
LGMN Legumain LGMN 
LGP2 Probable ATP-dependent RNA helicase DHX58 DHX58 
Lipocalin 2 Neutrophil gelatinase-associated lipocalin LCN2 
LIRA3 Leukocyte immunoglobulin-like receptor subfamily A member 3 LILRA3 
LIRA4 Leukocyte immunoglobulin-like receptor subfamily A member 4 LILRA4 
LIRA5 Leukocyte immunoglobulin-like receptor subfamily A member 5 LILRA5 
LIRB4 Leukocyte immunoglobulin-like receptor subfamily B member 4 LILRB4 
LL-37 Antibacterial protein LL-37 CAMP 
L-plastin Plastin-2 LCP1 
LPLC1 BPI fold-containing family B member 1 BPIFB1 
LRC32 Leucine-rich repeat-containing protein 32 LRRC32 
LRP8 Low-density lipoprotein receptor-related protein 8 LRP8 
LRRK2 Leucine-rich repeat serine/threonine-protein kinase 2 LRRK2 




Target Full Name Gene 
L-VEGF165 Isoform L-VEGF165 VEGFA 
Lymphotoxin a1/b2 Lymphotoxin alpha1:beta2 LTA|LTB 
MANBA Beta-mannosidase MANBA 
MBL Mannose-binding protein C MBL2 
M-CSF R Macrophage colony-stimulating factor 1 receptor CSF1R 
MFAP5 Microfibrillar-associated protein 5 MFAP5 
MICA MHC class I polypeptide-related sequence A MICA 
MICB MHC class I polypeptide-related sequence B MICB 
Midkine Midkine MDK 
MIP-3b C-C motif chemokine 19 CCL19 
MLF1 Myeloid leukemia factor 1 MLF1 
MMP-8 Neutrophil collagenase MMP8 
MO2R1 Cell surface glycoprotein CD200 receptor 1 CD200R1 
Moesin Moesin MSN 
MSP Hepatocyte growth factor-like protein MST1 
MSP R Macrophage-stimulating protein receptor MST1R 
Mx1 Interferon-induced GTP-binding protein Mx1 MX1 
Myeloperoxidase Myeloperoxidase MPO 
NCAM-120 Neural cell adhesion molecule 1, 120 kDa isoform NCAM1 
NCAM-L1 Neural cell adhesion molecule L1 L1CAM 
NEUR1 Sialidase-1 NEU1 
NFASC Neurofascin NFASC 
NKp46 Natural cytotoxicity triggering receptor 1 NCR1 
Notch 1 Neurogenic locus notch homolog protein 1 NOTCH1 
NPFF Pro-FMRFamide-related neuropeptide FF NPFF 
NR1H2 Oxysterols receptor LXR-beta NR1H2 
NR1H4 Bile acid receptor NR1H4 
Osteocalcin Osteocalcin BGLAP 
OX2G OX-2 membrane glycoprotein CD200 
p15-INK4b Cyclin-dependent kinase 4 inhibitor B CDKN2B 
PACAP Marginal zone B- and B1-cell-specific protein PACAP 
PAFAH Platelet-activating factor acetylhydrolase PLA2G7 
PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A 
PDGFD Platelet-derived growth factor D PDGFD 
PEBB Core-binding factor subunit beta CBFB 
PGM1 Phosphoglucomutase-1 PGM1 
PGRP-L N-acetylmuramoyl-L-alanine amidase PGLYRP2 
PIGR Polymeric immunoglobulin receptor PIGR 
PKHA1 Pleckstrin homology domain-containing family A member 1 PLEKHA1 
prosaposin Prosaposin PSAP 
Proteasome beta chain Proteasome subunit beta type-4 PSMB4 
Proteasome subunit alpha 
type 5 
Proteasome subunit alpha type-5 PSMA5 




Target Full Name Gene 
P-Selectin P-selectin SELP 
PSME1 Proteasome activator complex subunit 1 PSME1 
PSP Lithostathine-1-alpha REG1A 
PTPRS Receptor-type tyrosine-protein phosphatase S PTPRS 
PXDN Peroxidasin homolog PXDN 
PYGL Glycogen phosphorylase, liver form PYGL 
RAB14 Ras-related protein Rab-14 RAB14 
RAB4A Ras-related protein Rab-4A RAB4A 
Rb Retinoblastoma-associated protein RB1 
RBP Retinol-binding protein 4 RBP4 
REG1B Lithostathine-1-beta REG1B 
REG3G Regenerating islet-derived protein 3-gamma REG3G 
RGAP1 Rac GTPase-activating protein 1 RACGAP1 
RNF8 E3 ubiquitin-protein ligase RNF8 RNF8 
ROR2 Tyrosine-protein kinase transmembrane receptor ROR2 ROR2 
S100A13 Protein S100-A13 S100A13 
SAA Serum amyloid A-1 protein SAA1 
SAP3 Ganglioside GM2 activator GM2A 
SARP-2 Secreted frizzled-related protein 1 SFRP1 
SCF Kit ligand KITLG 
SDC3 Syndecan-3 SDC3 
SEC13 Protein SEC13 homolog SEC13 
SECTM1 Secreted and transmembrane protein 1 SECTM1 
SELS Selenoprotein S VIMP 
SEM4A Semaphorin-4A SEMA4A 
SEM4D Semaphorin-4D SEMA4D 
Sema E Semaphorin-3C SEMA3C 
Semaphorin-7A Semaphorin-7A SEMA7A 
sE-Selectin E-selectin SELE 
SG11A Sperm-associated antigen 11A SPAG11A 
SH21B SH2 domain-containing protein 1B SH2D1B 
sICAM-1 Intercellular adhesion molecule 1 ICAM1 
sICAM-2 Intercellular adhesion molecule 2 ICAM2 
sICAM-5 Intercellular adhesion molecule 5 ICAM5 
SLAF6 SLAM family member 6 SLAMF6 
sLeptin R Leptin receptor LEPR 
sL-Selectin L-Selectin SELL 
Sonic Hedgehog Sonic hedgehog protein SHH 
SP-D Pulmonary surfactant-associated protein D SFTPD 
Sperm-associated antigen 11 Sperm-associated antigen 11B SPAG11B 
SPLC2 BPI fold-containing family A member 2 BPIFA2 
sRAGE Advanced glycosylation end product-specific receptor, soluble AGER 




Target Full Name Gene 
STAT3 Signal transducer and activator of transcription 3 STAT3 
sTie-2 Angiopoietin-1 receptor, soluble TEK 
STOM Erythrocyte band 7 integral membrane protein STOM 
suPAR Urokinase plasminogen activator surface receptor PLAUR 
SWP70 Switch-associated protein 70 SWAP70 
Syntenin 1 Syntenin-1 SDCBP 
SYT11 Synaptotagmin-11 SYT11 
TAFI Carboxypeptidase B2 CPB2 
TCCR Interleukin-27 receptor subunit alpha IL27RA 
TECK C-C motif chemokine 25 CCL25 
TGF-b R III Transforming growth factor beta receptor type 3 TGFBR3 
Thrombin Thrombin F2 
Thrombopoietin Receptor Thrombopoietin Receptor MPL 
TIGIT T-cell immunoreceptor with Ig and ITIM domains TIGIT 
TIMP-2 Metalloproteinase inhibitor 2 TIMP2 
TLR1 Toll-like receptor 1 TLR1 
TLR4:MD-2 complex Toll-like receptor 4:Lymphocyte antigen 96 complex TLR4|LY96 
TLR5 Toll-like receptor 5 TLR5 
TNF sR-II Tumor necrosis factor receptor superfamily member 1B TNFRSF1B 
TNFSF15 Tumor necrosis factor ligand superfamily member 15 TNFSF15 
TPSN Tapasin TAPBP 
TR Transferrin receptor protein 1 TFRC 
TRML2 Trem-like transcript 2 protein TREML2 
TRY3 Trypsin-3 PRSS3 
Trypsin 2 Trypsin-2 PRSS2 
TSG-6 Tumor necrosis factor-inducible gene 6 protein TNFAIP6 
TSP4 Thrombospondin-4 THBS4 
UB2D2 Ubiquitin-conjugating enzyme E2 D2 UBE2D2 
UB2D3 Ubiquitin-conjugating enzyme E2 D3 UBE2D3 
Uromodulin Uromodulin UMOD 
VCAM-1 Vascular cell adhesion protein 1 VCAM1 
VEGF sR2 Vascular endothelial growth factor receptor 2 KDR 
VEGF-D Vascular endothelial growth factor D FIGF 
WNT3A Protein Wnt-3a WNT3A 






Table S5.2: Sentinel variants for the 85 loci used in multi-trait colocalisation. 
Variant Chr Pos Gene Consequence Locus 
rs55730499 6 1.61E+08 LPA intron variant 1 
rs10882101 10 94462427 - intergenic variant 2 
rs602633 1 1.1E+08 CELSR2 downstream gene variant 3 
rs2972144 2 2.27E+08 - intergenic variant 4 
rs6511720 19 11202306 LDLR intron variant 5 
rs7412 19 45412079 APOE missense variant 6 
rs11637783 15 79139000 MORF4L1 intron variant 7 
rs3184504 12 1.12E+08 SH2B3 missense variant 8 
rs115505614 5 1.02E+08 GIN1 3 prime UTR variant 9 
rs974819 11 1.04E+08 RP11-563P16.1 
intron variant 
non-coding transcript variant 
10 
rs72802342 16 75234872 CTRB2 downstream gene variant 11 
rs5213 11 17408404 KCNJ11 3 prime UTR variant 12 
rs3768321 1 40035928 SNORA55 upstream gene variant 13 
rs11591147 1 55505647 PCSK9 missense variant 14 
rs2954029 8 1.26E+08 RP11-136O12.2 
intron variant 
non-coding transcript variant 
15 
rs1260326 2 27730940 GCKR 
missense variant 
splice region variant 
16 
rs2246942 10 91004886 LIPA intron variant 17 
rs4736819 8 41509915 ANK1 downstream gene variant 18 
rs1561198 2 85809989 VAMP8 downstream gene variant 19 
rs3918226 7 1.51E+08 NOS3 intron variant 20 
rs601945 6 32573415 HLA-DRB1 intron variant 21 
rs28505901 9 1.39E+08 GPSM1 intron variant 22 
rs243024 2 60583665 AC007381.2 downstream gene variant 23 
rs507666 9 1.36E+08 ABO 
intron variant 
non-coding transcript variant 
24 
rs56348580 12 1.21E+08 HNF1A synonymous variant 25 
rs1250229 2 2.16E+08 FN1 upstream gene variant 26 
rs9379084 6 7231843 RREB1 missense variant 27 
rs3887925 3 1.87E+08 ST6GAL1 intron variant 28 
rs668948 2 21291529 - intergenic variant 29 
rs4845625 1 1.54E+08 IL6R intron variant 30 
rs2028150 2 65655012 SPRED2 intron variant 31 
rs2681492 12 90013089 ATP2B1 intron variant 32 
rs3740390 10 1.05E+08 AS3MT intron variant 33 
rs12980942 19 41832231 TGFB1 downstream gene variant 34 
rs8107974 19 19388500 TM6SF2 upstream gene variant 35 
rs964184 11 1.17E+08 ZNF259 3 prime UTR variant 36 
rs2925979 16 81534790 CMIP intron variant 37 
rs1783541 11 65294799 SCYL1 intron variant 38 
rs348330 1 2.3E+08 ABCB10 intron variant 39 
rs17689007 8 9974824 MSRA intron variant 40 
rs15285 8 19824667 LPL 3 prime UTR variant 41 




Variant Chr Pos Gene Consequence Locus 
rs11070332 15 41809205 LTK upstream gene variant 43 
rs58730668 4 1.86E+08 ACSL1 intron variant 44 
rs4678145 3 1.24E+08 UMPS intron variant 45 
rs2800733 6 1.27E+08 - intergenic variant 46 
rs2072633 6 31919578 CFB intron variant 47 
rs10840293 11 9751196 SWAP70 intron variant 48 
rs6600191 16 295795 ITFG3 intron variant 49 
rs3111316 19 13038415 FARSA intron variant 50 
rs34855406 17 40731411 FAM134C downstream gene variant 51 
rs6905288 6 43758873 VEGFA downstream gene variant 52 
rs2814993 6 34618893 C6orf106 intron variant 53 
rs6984210 8 22033615 BMP1 intron variant 54 
rs57327348 8 10808687 XKR6 intron variant 55 
rs17680741 10 82251514 TSPAN14 intron variant 56 
rs7617773 3 48193515 - intergenic variant 57 
rs1050362 16 72130815 DHX38 synonymous variant 58 
rs11642430 16 30045789 FAM57B upstream gene variant 59 
rs738408 22 44324730 PNPLA3 synonymous variant 60 
rs1580278 4 1.04E+08 - intergenic variant 61 
rs12001437 9 34074476 - intergenic variant 62 
rs12500824 4 77416627 SHROOM3 intron variant 63 
rs4688760 3 49980596 RBM6 intron variant 64 
rs7178762 15 63871292 USP3 intron variant 65 
rs362307 4 3241845 HTT 3 prime UTR variant 66 
rs7947761 11 1.01E+08 ARHGAP42 intron variant 67 
rs73082363 3 49130378 QRICH1 intron variant 68 
rs329122 5 1.34E+08 JADE2 intron variant 69 
rs7124681 11 47529947 CELF1 intron variant 70 
rs11926707 3 46925539 PTH1R intron variant 71 
rs10512861 3 1.32E+08 DNAJC13 downstream gene variant 72 
rs699 1 2.31E+08 AGT missense variant 73 
rs2581787 3 53127677 RFT1 intron variant 74 
rs3741414 12 57844049 INHBC 3 prime UTR variant 75 
rs62007683 14 1.04E+08 MARK3 intron variant 76 
rs145904381 1 1.51E+08 BNIPL intron variant 77 
rs78840640 7 23434606 IGF2BP3 intron variant 78 
rs2269247 1 64107284 PGM1 intron variant 79 
rs35497231 3 1.52E+08 - intergenic variant 80 
rs2727301 17 61965043 RP11-630H24.3 downstream gene variant 81 
rs12802972 11 1704596 FAM99B Non-coding transcript exon variant 82 
rs80223330 4 1.2E+08 PDE5A intron variant 83 
rs76549422 20 31760953 BPIFA2 intron variant 84 





Table S5.3: Gene sets in which inflammatory proteins colocalising with T2D are 
significantly enriched. 














457 89 8.17E-09 1.5E-05 
TNFRSF1B, EPHA2, NBL1, LEPR, 
FCRL1, CRP, SLAMF6, CD48, 
FCGR3B, CREG1, SELL, NFASC, 
C4BPA, CD55, MBL2, PSAP, RBP4, 
CTSD, CD59, CTSF, MMP8, NCAM1, 
APOA1, CRTAM, C1RL, CPB2, LCP1, 
F7, LGALS3, SERPINA1, HP, GRN, 
MPO, CD300A, CD300C, TIMP2, 
CLEC4G, CD209, IL27RA, PGLYRP2, 
PLAUR, APOE, LILRB2, LILRA3, 
LILRA5, LILRB1, LILRB4, NCR1, 
PXDN, APOB, REG3G, REG1A, IL1R2, 
IL1R1, TNFAIP6, CST3, BPIFA2, 
BPIFB1, CTSZ, CECR1, MST1, 
ALCAM, ADIPOQ, CPN2, FGG, C9, 
IL6ST, THBS4, LEAP2, CSF1R, 
BTN3A3, AIF1, NEU1, CD109, ARG1, 
PLG, DLL1, GPNMB, AOC1, DEFB1, 
CTSB, FGL1, GGH, LY96, B4GALT1, 
CCL21, SEMA4D, TLR4, GSN 
Cancer gene 
neighbourhoods 
CAR HPX 28 15 9.11E-08 3.9E-05 
C4BPA, MBL2, RBP4, F2, APOA1, 
CPB2, HP, APOB, FGB, FGA, FGG, 
C9, ARG1, PLG, FGL1 
Computational 
gene sets 
CAR HPX 28 15 9.11E-08 7.8E-05 
C4BPA, MBL2, RBP4, F2, APOA1, 
CPB2, HP, APOB, FGB, FGA, FGG, 






103 31 2.86E-07 2.0E-04 
SDC3, MBL2, PSAP, CTSD, MDK, F2, 
PRG2, CTSF, MMP8, NCAM1, APOA1, 
MFAP5, F7, LGALS3, SERPINA1, 
SEMA7A, TIMP2, APOE, A1BG, PXDN, 
CTSZ, MST1, WNT5A, ADIPOQ, FGB, 






126 35 3.92E-07 2.0E-04 
SDC3, TGFBR3, MBL2, PSAP, CTSD, 
MDK, F2, PRG2, CD248, CTSF, 
LRRC32, MMP8, NCAM1, APOA1, 
MFAP5, F7, LGALS3, SERPINA1, 
SEMA7A, TIMP2, APOE, A1BG, PXDN, 
CTSZ, MST1, WNT5A, ADIPOQ, 








44 17 4.42E-06 8.2E-04 
C4BPA, CD55, CR2, CR1, CD46, 
MBL2, CD59, F2, CPB2, F7, 








56 21 5.32E-07 1.8E-03 
CRP, PSAP, F2, PRG2, CPB2, LCP1, 
SERPINA1, HP, MPO, APOE, APOB, 
MST1, FGB, FGA, FGG, C9, GM2A, 
ARG1, PLG, GSN, LCN2 




56 21 5.32E-07 2.9E-03 
CRP, PSAP, F2, PRG2, CPB2, LCP1, 
SERPINA1, HP, MPO, APOE, APOB, 
MST1, FGB, FGA, FGG, C9, GM2A, 




266 54 1.26E-05 4.2E-03 
EPHA2, SDC3, LEPR, TGFBR3, 
FCRL1, SELL, FASLG, CD55, CR1, 
CD46, MBL2, CD59, F2, CD248, 
LRRC32, NCAM1, APOA1, PLA2G1B, 
LGALS3, IGHA2, IGHA1, B2M, 
SEMA7A, C1QBP, TIMP2, CD209, 
IL27RA, CEACAM8, PLAUR, LILRB2, 
LILRA5, LILRB1, IL1R1, CD93, CTSZ, 
WNT5A, ALCAM, ADIPOQ, TFRC, 
AIMP1, FGB, FGA, FGG, IL6ST, 
























44 17 4.42E-06 9.7E-03 
C4BPA, CD55, CR2, CR1, CD46, 
MBL2, CD59, F2, CPB2, F7, 






25 12 8.78E-06 9.7E-03 
BGLAP, MFAP5, GAS6, PXDN, 
TNFAIP6, IGFBP2, ADIPOQ, FGB, 
FGA, FGG, THBS4, FGL1 
Cancer gene 
neighborhoods 
CAR IGFBP1 17 9 4.75E-05 0.01 
C4BPA, MBL2, F2, APOA1, CPB2, 





30 13 1.47E-05 0.01 
BGLAP, PRG2, MFAP5, GAS6, PXDN, 
TNFAIP6, IGFBP2, ADIPOQ, FGB, 






64 21 6.72E-06 0.01 
CRP, C4BPA, MBL2, RBP4, F2, 
APOA1, CPB2, F7, SERPINA1, HP, 
APOE, APOB, MST1, CPN2, FGB, 
FGA, FGG, C9, ARG1, PLG, FGL1 






44 17 4.42E-06 0.01 
C4BPA, CD55, CR2, CR1, CD46, 
MBL2, CD59, F2, CPB2, F7, 
SERPINA1, PLAUR, FGB, FGA, FGG, 
C9, PLG 
Curated gene sets 
HSIAO LIVER 
SPECIFIC GENES 
64 21 6.72E-06 0.01 
CRP, C4BPA, MBL2, RBP4, F2, 
APOA1, CPB2, F7, SERPINA1, HP, 
APOE, APOB, MST1, CPN2, FGB, 
FGA, FGG, C9, ARG1, PLG, FGL1 
Curated gene sets 
NABA ECM 
GLYCOPROTEINS 
25 12 8.78E-06 0.01 
BGLAP, MFAP5, GAS6, PXDN, 
TNFAIP6, IGFBP2, ADIPOQ, FGB, 
FGA, FGG, THBS4, FGL1 
Curated gene sets 
NABA CORE 
MATRISOME 
30 13 1.47E-05 0.02 
BGLAP, PRG2, MFAP5, GAS6, PXDN, 
TNFAIP6, IGFBP2, ADIPOQ, FGB, 
FGA, FGG, THBS4, FGL1 





19 10 1.86E-05 0.02 
NBL1, LEPR, NCAM1, GAS6, APOE, 





8 6 6.67E-05 0.02 F2, CPB2, FGB, FGA, FGG, PLG 
Computational 
gene sets 
CAR IGFBP1 17 9 4.75E-05 0.02 
C4BPA, MBL2, F2, APOA1, CPB2, 
APOB, C9, ARG1, PLG 
Computational 
gene sets 
MODULE 88 161 36 6.81E-05 0.02 
TNFRSF1B, EPHA2, C4BPA, RBP4, 
MDK, F2, PRG2, LRRC32, APOA1, 
CPB2, SERPINA1, HP, GRN, MPO, 
FSTL3, EFNA2, APOE, APOB, REG1B, 
REG1A, IL1R1, IGFBP2, MST1, CPN2, 
FGB, FGA, ARG1, PLG, GPNMB, 









19 10 1.86E-05 0.02 
NBL1, LEPR, NCAM1, GAS6, APOE, 























64 19 9.40E-05 0.03 
CRP, SELL, C4BPA, CD55, CR2, CR1, 
CD46, MBL2, CD59, APOA1, C1QBP, 
PLAUR, CD93, ADIPOQ, FGB, FGA, 




9 6 0.00018 0.03 F2, F7, FGB, FGA, FGG, PLG 
Computational 
gene sets 
MODULE 131 15 8 0.000122 0.03 
CD59, F2, PLAUR, MST1, FGB, FGA, 
FGG, PLG 
Cancer modules MODULE 88 161 36 6.81E-05 0.03 
TNFRSF1B, EPHA2, C4BPA, RBP4, 
MDK, F2, PRG2, LRRC32, APOA1, 
CPB2, SERPINA1, HP, GRN, MPO, 
FSTL3, EFNA2, APOE, APOB, REG1B, 
REG1A, IL1R1, IGFBP2, MST1, CPN2, 
FGB, FGA, ARG1, PLG, GPNMB, 
AOC1, DEFB1, FGL1, ENPP2, CCL21, 
LCN2, L1CAM 
Cancer modules MODULE 131 15 8 0.000122 0.03 
CD59, F2, PLAUR, MST1, FGB, FGA, 
FGG, PLG 
Cancer modules MODULE 23 108 26 0.000237 0.03 
TNFRSF1B, C4BPA, RBP4, F2, CTSF, 
APOA1, NPFF, CPB2, F7, SERPINA1, 
HP, TIMP2, EFNA2, APOE, APOB, 
IGFBP2, MST1, CPN2, FGB, FGA, 







8 6 6.67E-05 0.04 F2, CPB2, FGB, FGA, FGG, PLG 
Curated gene sets 
APPEL IMATINIB 
RESPONSE 
17 9 4.75E-05 0.04 
CTSD, CD300A, APOE, CTSZ, HEXB, 






17 9 4.75E-05 0.04 
CTSD, CD300A, APOE, CTSZ, HEXB, 
GM2A, NEU1, GUSB, CTSB 
Computational 
gene sets 
MODULE 23 108 26 0.000237 0.04 
TNFRSF1B, C4BPA, RBP4, F2, CTSF, 
APOA1, NPFF, CPB2, F7, SERPINA1, 
HP, TIMP2, EFNA2, APOE, APOB, 
IGFBP2, MST1, CPN2, FGB, FGA, 











33 12 0.000247 0.04 
CRP, F2, APOA1, F7, VIMP, MPO, 
APOB, GGT2, FGB, FGA, FGG, PLG 










Table S5.4: Gene sets in which inflammatory proteins colocalising with CHD are 
significantly enriched. 











GWAScatalog Blood protein levels 457 103 4.04E-11 7.33E-08 
NBL1, LRP8, PGM1, IL6R, FCRL1, 
CD5L, CRP, SLAMF6, CD48, 
FCGR3B, CREG1, SELP, SELL, 
SELE, PIGR, CD55, PSAP, IFIT2, 
CTSD, SAA1, SERPING1, CTSF, 
MMP8, APOA1, LAG3, C1RL, 
CPB2, LGALS3, LGMN, CXCL16, 
GP1BA, ATP1B2, ACE, ACE, 
CD300A, CD300C, TIMP2, CD7, 
SECTM1, COLEC12, CLEC4G, 
CD209, CCL25, ICAM1, ICAM4, 
ICAM5, APOE, KLK7, LILRB1, 
LILRB4, NCR1, APOB, CD8A, 
IL1R2, IL1R1, IL1RL1, CST3, 
BPIFA2, CTSZ, CECR1, TDGF1, 
CAMP, CD200, CD200R1, 
ADIPOQ, CPN2, KDR, CXCL6, 
CXCL10, CXCL11, MANBA, FGG, 
C9, IL6ST, CSF1R, IL12B, BTNL8, 
BTN3A3, MICA, LTA, TNF, LTB, 
HSPA1A, NEU1, CFB, CFB, 
TAPBP, TREML2, PLA2G7, PLG, 
IL6, GPNMB, SEMA3C, EPO, 
DEFB1, DEFA5, CTSB, SFRP1, 
GGH, LY96, B4GALT1, CCL21, 
SEMA4D, TLR4, GSN 
GO cc GO CELL SURFACE 266 62 1.08E-06 0.001 
SDC3, MPL, TGFBR3, VCAM1, 
IL6R, FCRL1, SELP, SELL, CD55, 
CR1, CD46, APOA1, LAG3, 
PLA2G1B, LGALS3, IGHD, B2M, 
SEMA7A, GP1BA, C1QBP, 
ITGA2B, ITGB3, ITGB3, ACE, 
ACE, TIMP2, CD209, ICAM1, 
LILRB1, CD8A, IL1R1, IL1RL1, 
CD93, CTSZ, TDGF1, WNT5A, 
CD200, CD200R1, TIGIT, 
ADIPOQ, TFRC, CXCL10, AIMP1, 
FGB, FGA, FGG, IL6ST, CSF1R, 
IL12B, BTNL8, BTN3A3, MICA, 
TNF, TREML2, PLG, AZGP1, 
EPO, SHH, ADAM9, SFRP1, 




64 23 3.34E-06 0.002 
CRP, SELP, SELL, SELE, CD55, 
CR2, CR1, CD46, SERPING1, 
APOA1, C1QBP, ITGA2B, ITGB3, 
ITGB3, ICAM2, ICAM1, CD93, 
ADIPOQ, FGB, FGA, FGG, C9, 




126 34 2.28E-05 0.01 
SDC3, TGFBR3, PSAP, CTSD, 
MDK, PRG2, SERPING1, CTSF, 
MMP8, APOA1, MFAP5, LGALS3, 
SEMA7A, GP1BA, COL1A1, 
TIMP2, COLEC12, ICAM1, APOE, 
COL3A1, IHH, CTSZ, WNT5A, 
ADIPOQ, CPN2, FGB, FGA, FGG, 
PLG, AZGP1, SHH, CTSB, 
SFRP1, L1CAM 
GO cc 
GO EXTERNAL SIDE 
OF PLASMA 
MEMBRANE 
137 36 2.40E-05 0.01 
TGFBR3, VCAM1, IL6R, SELP, 
SELL, LAG3, IGHD, B2M, 
SEMA7A, GP1BA, ITGA2B, ACE, 
ACE, CD209, ICAM1, LILRB1, 
CD8A, IL1R1, IL1RL1, CD200R1, 
TFRC, CXCL10, FGB, FGA, FGG, 
IL6ST, IL12B, BTNL8, BTN3A3, 
MICA, TNF, PLG, AZGP1, 




33 14 3.79E-05 0.01 
CRP, SAA1, APOA1, IFNG, VIMP, 
ICAM1, APOB, GGT2, FGB, FGA, 




















103 29 4.23E-05 0.01 
SDC3, PSAP, CTSD, MDK, PRG2, 
SERPING1, CTSF, MMP8, 
APOA1, MFAP5, LGALS3, 
SEMA7A, COL1A1, TIMP2, 
ICAM1, APOE, COL3A1, CTSZ, 
WNT5A, ADIPOQ, FGB, FGA, 






100 31 2.32E-06 0.02 
VCAM1, MMP8, APOA1, MFAP5, 
CPB2, GAS6, ITGA2B, ITGB3, 
ITGB3, COL1A1, ICAM2, TIMP2, 
ICAM1, ICAM4, ICAM5, APOE, 
KLK7, APOB, COL3A1, IHH, 
CST3, KDR, FGB, FGA, FGG, 







73 24 1.22E-05 0.02 
SDC3, VCAM1, CTSD, MMP8, 
MFAP5, ITGA2B, ITGB3, ITGB3, 
COL1A1, ICAM2, TIMP2, PTPRS, 
ICAM1, ICAM4, ICAM5, KLK7, 
COL3A1, KDR, FGB, FGA, FGG, 





64 19 0.000486 0.02 
S100A13, CTSE, SERPING1, 
MMP8, APOA1, CPB2, LGMN, 
CRIP2, GP1BA, ITGB3, ITGB3, 
FGA, FGG, C9, CFB, CFB, PLG, 







73 24 1.22E-05 0.03 
SDC3, VCAM1, CTSD, MMP8, 
MFAP5, ITGA2B, ITGB3, ITGB3, 
COL1A1, ICAM2, TIMP2, PTPRS, 
ICAM1, ICAM4, ICAM5, KLK7, 
COL3A1, KDR, FGB, FGA, FGG, 




33 13 0.000182 0.04 
SDC3, PSAP, CTSD, CTSF, GNS, 
LGMN, APOB, MANBA, HEXB, 
NEU1, GUSB, CTSB, CTSV 
GO cc 
GO LOW DENSITY 
LIPOPROTEIN 
PARTICLE 
6 5 0.000243 0.04 
APOA1, VIMP, APOE, APOB, 
PLA2G7 
GO cc 
GO SIDE OF 
MEMBRANE 
169 39 0.000257 0.04 
TGFBR3, VCAM1, IL6R, SELP, 
SELL, BIRC2, LAG3, LRRK2, 
IGHD, B2M, SEMA7A, GP1BA, 
ITGA2B, ACE, ACE, CD209, 
ICAM1, LILRB1, CD8A, IL1R1, 
IL1RL1, CD200R1, TFRC, 
CXCL10, FGB, FGA, FGG, IL6ST, 
IL12B, BTNL8, BTN3A3, MICA, 
TNF, TAPBP, PLG, AZGP1, 




484 91 4.04E-05 0.04 
NBL1, TGFBR3, VCAM1, 
S100A13, IL6R, SEMA4A, CRP, 
TLR5, RAB4A, PSAP, SAA1, 
MDK, IL18BP, APOA1, LAG3, 
NPFF, GDF11, IL23A, IFNG, 
KITLG, NR1H4, PLA2G1B, 
EFNB2, GAS6, LGALS3, IGHD, 
SEMA7A, IGF1R, CXCL16, 
C1QBP, ITGB3, ITGB3, ACE, 
ACE, ICAM2, TIMP2, SECTM1, 
CCL25, ICAM1, ICAM4, ICAM5, 
APOE, LILRB1, APOB, CD8A, 
IL1R1, GRB14, COL3A1, MSTN, 
STAT1, IHH, CECR1, TDGF1, 
WNT5A, TIGIT, ADIPOQ, KDR, 
CXCL6, CXCL10, CXCL11, 
AIMP1, FGB, FGA, FGG, CCL28, 
IL6ST, IL12B, BTNL8, BTN3A3, 
MICA, LTA, TNF, LTB, HSPA1A, 
TAPBP, PLG, IL6, GPNMB, 
GUSB, SEMA3C, EPO, SHH, 















LY96, CCL19, CCL21, SEMA4D, 





5 5 4.56E-05 0.04 
SEMA4A, APOA1, SEMA7A, 
SEMA3C, SEMA4D 
KEGG KEGG LYSOSOME 34 13 0.00026 0.05 
CTSE, PSAP, CTSD, CTSF, GNS, 
LGMN, CTSZ, MANBA, HEXB, 





87 22 0.001963 0.05 
S100A13, CD55, CR2, CR1, 
CD46, CTSD, SERPING1, MMP8, 
LGALS3, LGMN, GP1BA, TIMP2, 
C9, GZMA, HSPA1A, CFB, CFB, 











  Search Terms 
#7 #1 AND #2 AND #3 AND #4 AND #5 AND #6 
#6 English[lang] 
#5  "humans"[MeSH Terms] 
#4 ("2007/06/01"[PDAT] : "2019/11/04"[PDAT]) 
#3 
(Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR systematic[sb] OR Journal Article[ptyp] OR 
Review[ptyp]) 
#2 
((((((((((((((((((("genome-wide association study"[MeSH Terms] OR ("genome-wide"[All Fields] AND 
"association"[All Fields] AND "study"[All Fields]) OR "genome-wide association study"[All Fields] OR 
"gwas"[All Fields]) OR "GWA study"[All Fields]) OR "Genome-wide association study"[All Fields]) OR 
"Genome wide association analysis"[All Fields]) OR "Genome wide association scan"[All Fields]) OR 
"Genome wide association"[All Fields]) OR "Genome-wide association"[All Fields]) OR "Genome 
wide"[All Fields]) OR ("Socioaffect Neurosci Psychol"[Journal] OR "snp"[All Fields])) OR "Single 
nucleotide polymorphism"[All Fields]) OR "Genetic variant"[All Fields]) OR "Genetic variants"[All 
Fields]) OR "Genetic variation"[All Fields]) OR "Genetic variations"[All Fields]) OR "Genetic 
mutation"[All Fields]) OR "Genetic mutations"[All Fields]) OR "Genetic mutant"[All Fields]) OR "Genetic 
mutants"[All Fields]) OR "genome-wide association study"[MeSH Terms]) 
#1 
((((((((((((((((((((((((((((((((((((((((((((((("glucagon-like peptide 1"[MeSH Terms] OR "glucagon-like peptide 
1"[All Fields] OR "glp 1"[All Fields]) OR GLP1[All Fields]) OR "Glucagon-like peptide-1"[All Fields]) OR 
"Glucagon-like peptide 1"[All Fields]) OR "Glucagon-like peptide-I"[All Fields]) OR "Glucagon-like 
peptide I"[All Fields]) OR GIP[All Fields]) OR "Glucose-dependent insulinotropic polypeptide"[All 
Fields]) OR "Glucose dependent insulinotropic polypeptide"[All Fields]) OR "Glucose-dependent 
insulinotropic peptide"[All Fields]) OR "Glucose dependent insulinotropic peptide"[All Fields]) OR 
"Gastric inhibitory polypeptide"[All Fields]) OR "Gastric inhibitory peptide"[All Fields]) OR 
(Gastroinhibitory[All Fields] AND ("peptides"[MeSH Terms] OR "peptides"[All Fields] OR 
"polypeptide"[All Fields]))) OR (Gastroinhibitory[All Fields] AND ("peptides"[MeSH Terms] OR 
"peptides"[All Fields] OR "peptide"[All Fields]))) OR ("glucagon-like peptide 2"[MeSH Terms] OR 
"glucagon-like peptide 2"[All Fields] OR "glp 2"[All Fields])) OR GLP2[All Fields]) OR "Glucagon-like 
peptide-2"[All Fields]) OR "Glucagon-like peptide-2"[All Fields]) OR "Glucagon-like peptide-II"[All 
Fields]) OR "Glucagon-like peptide-II"[All Fields]) OR ("secretin"[MeSH Terms] OR "secretin"[All 
Fields])) OR SCT[All Fields]) OR ("oxyntomodulin"[MeSH Terms] OR "oxyntomodulin"[All Fields])) OR 
OXM[All Fields]) OR ("glucagon"[MeSH Terms] OR "glucagon"[All Fields])) OR GCG[All Fields]) OR 
("proglucagon"[MeSH Terms] OR "proglucagon"[All Fields] OR "preproglucagon"[All Fields])) OR 
"Peptide YY"[All Fields]) OR "Peptide tyrosine tyrosine"[All Fields]) OR PYY[All Fields]) OR 
("gastrins"[MeSH Terms] OR "gastrins"[All Fields] OR "gastrin"[All Fields])) OR GAST[All Fields]) OR 
("ghrelin"[MeSH Terms] OR "ghrelin"[All Fields])) OR GHRL[All Fields]) OR ("glicentin"[MeSH Terms] 
OR "glicentin"[All Fields])) OR "gastric inhibitory polypeptide"[MeSH Terms]) OR "gastric inhibitory 
polypeptide"[MeSH Terms]) OR "peptide yy"[MeSH Terms]) OR "secretin"[MeSH Terms]) OR 
"ghrelin"[MeSH Terms]) OR "glucagon"[MeSH Terms]) OR "glicentin"[MeSH Terms]) OR "glucagon-
like peptide 1"[MeSH Terms]) OR "glucagon-like peptide 2"[MeSH Terms]) OR "oxyntomodulin"[MeSH 



























Type 2 diabetes 74,124 842,006 DIAMANTE 30297969 
Type 2 diabetes (BMI adjusted) 74,124 842,006 DIAMANTE 30297969 





Any Stroke 40,585 
406,111 MEGASTROKE 29531354 
Any Ischemic Stroke 34,217 
Cardioembolic Stroke 7,193 
Large Artery Stroke 4,373 
Small Vessel Stroke 5,386 
Abdominal Aortic Aneurysm 1,094 366,492 
UK Biobank 31756303 
Atrial Fibrillation 16,945 350,641 
Aortic Valve Stenosis 2,244 365,342 
Coronary Artery Disease 29,278 338,308 
Deep Vein Thrombosis 9,454 358,132 
Haemorrhagic Stroke (all) 1,981 365,605 
Heart Failure 6,712 360,874 
Ischaemic Cerebrovascular Disease (all) 8,084 359,502 
Pulmonary Embolism 6,148 361,438 
Peripheral Vascular Disease 3,415 364,171 
Thoracic Aortic Aneurysm 347 367,239 
Transient Ischaemic Attack 3,962 363,624 
Intracerebral Haemorrhage 1,064 366,522 
Subarachnoid Haemorrhage 1,084 366,502 
Ischaemic Stroke 4,602 362,984 
Ischaemic stroke plus haemorrhagic 
stroke plus unknown stroke (but not TIA) 
9,652 357,934 
Venous Thromboembolism (all) 14,097 353,489 
Glycaemic 
outcomes 
Fasting glucose (BMI adjusted)  51,750 MAGIC 22581228 
Non-fasted plasma glucose  413,905 UK Biobank; InterAct 25826379 
2-hr glucose (BMI adjusted)  41,888 MAGIC 20081857 
Fasting insulin (BMI adjusted)  51,750 MAGIC 22581228 
Corrected insulin response  5,318 MAGIC 24699409 




Apolipoprotein A1  412,328 
UK Biobank; InterAct 25826379 
High-density lipoprotein  450,957 
Apolipoprotein B  448,859 
Low-density lipoprotein  375,774 
Lipoprotein A  406,825 
























Triglycerides  450,625 
C-reactive protein  465,067 
Anthropometric 
outcomes 
BMI  738,628 
GIANT, UK Biobank 
25673413; 
25826379 
Hip circumference  568,765 
Hip circumference (BMI adjusted)  633,860 
Waist circumference  654,577 
Waist circumference (BMI adjusted)  654,253 
Waist-to-hip ratio  636,672 




Albumin  415,714 
UK Biobank; InterAct 25826379 
Alkaline phosphatase  450,743 
Alanine aminotransferase  452,291 
Aspartate transaminase  450,594 
Bilirubin  448,652 
Calcium  414,173 
Creatinine  451,942 
Gamma-glutamyl transpeptidase  450,745 






Android fat mass  
435,387 UK Biobank 25826379 
Arms fat mass  
Gynoid fat mass  
Legs fat mass  
Peripheral fat mass  
Subcutaneous fat mass  
Total fat mass  
Trunk fat mass  
Visceral fat mass  
Appendicular lean mass  
Android lean mass  
Arms lean mass  
Gynoid lean mass  
Legs lean mass  
Total lean mass  
Trunk lean mass  
Plasma proteins 4,979 proteins  10,708 Fenland 27841877 
Metabolites 1,008 metabolites  11,539 EPIC-Norfolk 10466767 






Table S7.2: Clusters of colocalised traits identified by the main analysis across the 
permutations of prior 2 and the regional and alignment thresholds. 
















LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.02 0.5 
GIPR 
Glucose, HbA1c, ApoA1, WHRadjBMI, Waist 
circumference adjBMI, WHR 
0.7034 rs4420638 1 425 0.02 0.5 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Hip circumference, Waist circumference, 2hr 
Glucose adjBMI 
0.9707 rs11672660 0.9994 425 0.02 0.5 
GIPR Hip circumference adjBMI, T2D 0.9717 rs10408179 1 425 0.02 0.5 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.02 0.6 
GIPR 
Glucose, HbA1c, ApoA1, WHRadjBMI, Waist 
circumference adjBMI, WHR 
0.7034 rs4420638 1 425 0.02 0.6 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Hip circumference, Waist circumference, 2hr 
Glucose adjBMI 
0.9707 rs11672660 0.9994 425 0.02 0.6 
GIPR Hip circumference adjBMI, T2D 0.9717 rs10408179 1 425 0.02 0.6 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.02 0.7 
GIPR 
Glucose, HbA1c, ApoA1, WHRadjBMI, Waist 
circumference adjBMI, WHR 
0.7034 rs4420638 1 425 0.02 0.7 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Hip circumference, Waist circumference, 2hr 
Glucose adjBMI 
0.9707 rs11672660 0.9994 425 0.02 0.7 
GIPR Hip circumference adjBMI, T2D 0.9717 rs10408179 1 425 0.02 0.7 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.02 0.8 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9994 rs4420638 1 425 0.02 0.8 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.9683 rs11672660 0.9995 425 0.02 0.8 
GIPR Hip circumference adjBMI, T2D 0.9717 rs10408179 1 425 0.02 0.8 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.02 0.9 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9994 rs4420638 1 425 0.02 0.9 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.9683 rs11672660 0.9995 425 0.02 0.9 
GIPR Hip circumference adjBMI, T2D 0.9717 rs10408179 1 425 0.02 0.9 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.01 0.5 
GIPR 
Glucose, HbA1c, ApoA1, WHRadjBMI, Waist 
circumference adjBMI, WHR 
0.5466 rs4420638 1 425 0.01 0.5 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Hip circumference, Waist circumference, 2hr 
Glucose adjBMI 
0.9441 rs11672660 0.9994 425 0.01 0.5 
GIPR Hip circumference adjBMI, T2D 0.945 rs10408179 1 425 0.01 0.5 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.01 0.6 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9989 rs4420638 1 425 0.01 0.6 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.9397 rs11672660 0.9995 425 0.01 0.6 




















LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.01 0.7 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9989 rs4420638 1 425 0.01 0.7 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.9397 rs11672660 0.9995 425 0.01 0.7 
GIPR Hip circumference adjBMI, T2D 0.945 rs10408179 1 425 0.01 0.7 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.01 0.8 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9989 rs4420638 1 425 0.01 0.8 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.9397 rs11672660 0.9995 425 0.01 0.8 
GIPR Hip circumference adjBMI, T2D 0.945 rs10408179 1 425 0.01 0.8 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.01 0.9 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9989 rs4420638 1 425 0.01 0.9 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.9397 rs11672660 0.9995 425 0.01 0.9 
GIPR Hip circumference adjBMI, T2D 0.945 rs10408179 1 425 0.01 0.9 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.001 0.5 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9889 rs4420638 1 425 0.001 0.5 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.5855 rs11672660 0.9995 425 0.001 0.5 
GIPR Hip circumference adjBMI, T2D 0.6322 rs10408179 1 425 0.001 0.5 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.001 0.6 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9889 rs4420638 1 425 0.001 0.6 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.5855 rs11672660 0.9995 425 0.001 0.6 
GIPR Hip circumference adjBMI, T2D 0.6322 rs10408179 1 425 0.001 0.6 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.001 0.7 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9889 rs4420638 1 425 0.001 0.7 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Glucose, Hip circumference, Waist 
circumference, 2hr Glucose adjBMI 
0.5855 rs11672660 0.9995 425 0.001 0.7 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.001 0.8 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9889 rs4420638 1 425 0.001 0.8 
GIPR 
GIP SOMAmer 16292_288, Fasting GIP, 2hr GIP, 
BMI, Hip circumference, Waist circumference 
0.7977 rs11672660 0.9994 425 0.001 0.8 
GIPR Glucose, Hip circumference adjBMI 0.8674 rs725660 0.7079 425 0.001 0.8 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 425 0.001 0.9 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 



















GIPR BMI, Waist circumference 0.9524 rs1800437 0.6839 425 0.001 0.9 
GIPR Fasting GIP, Hip circumference 0.921 rs11672660 0.9998 425 0.001 0.9 
Abbreviations: PP, Posterior probability; N, Number; LDL, Low-density lipoprotein; CHD, Coronary heart disease; 
HDL, High-density lipoprotein; ApoB, Apolipoprotein B; ApoA1, Apolipoprotein A1; HbA1c, Glycated haemoglobin; 




Table S7.3: Clusters of colocalised traits identified by the sensitivity analysis across 
the permutations of prior 2 and the regional and alignment thresholds. 
















LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.02 0.5 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR, T2D 
0.8471 rs429358 1 5016 0.02 0.5 
GIPR BMI, Waist circumference 0.9975 rs1800437 0.6839 5016 0.02 0.5 
GIPR Triglycerides, Hip circumference adjBMI 0.983 rs5117 0.9328 5016 0.02 0.5 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.8999 rs11672660 0.9996 5016 0.02 0.5 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.02 0.6 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR, T2D 
0.8471 rs429358 1 5016 0.02 0.6 
GIPR BMI, Waist circumference 0.9975 rs1800437 0.6839 5016 0.02 0.6 
GIPR Triglycerides, Hip circumference adjBMI 0.983 rs5117 0.9328 5016 0.02 0.6 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.8999 rs11672660 0.9996 5016 0.02 0.6 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.02 0.7 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR, T2D 
0.8471 rs429358 1 5016 0.02 0.7 
GIPR BMI, Waist circumference 0.9975 rs1800437 0.6839 5016 0.02 0.7 
GIPR Triglycerides, Hip circumference adjBMI 0.983 rs5117 0.9328 5016 0.02 0.7 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.8999 rs11672660 0.9996 5016 0.02 0.7 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.02 0.8 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR, T2D 
0.8471 rs429358 1 5016 0.02 0.8 
GIPR BMI, Waist circumference 0.9975 rs1800437 0.6839 5016 0.02 0.8 
GIPR Triglycerides, Hip circumference adjBMI 0.983 rs5117 0.9328 5016 0.02 0.8 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.8999 rs11672660 0.9996 5016 0.02 0.8 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.02 0.9 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9651 rs429358 1 5016 0.02 0.9 
GIPR BMI, Waist circumference 0.9975 rs1800437 0.6839 5016 0.02 0.9 
GIPR Triglycerides, Hip circumference adjBMI 0.983 rs5117 0.9328 5016 0.02 0.9 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.8999 rs11672660 0.9996 5016 0.02 0.9 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.01 0.5 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR, T2D 
0.7384 rs429358 1 5016 0.01 0.5 
GIPR BMI, Waist circumference 0.995 rs1800437 0.6839 5016 0.01 0.5 
GIPR Triglycerides, Hip circumference adjBMI 0.9665 rs5117 0.9328 5016 0.01 0.5 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.815 rs11672660 0.9996 5016 0.01 0.5 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.01 0.6 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR, T2D 
0.7384 rs429358 1 5016 0.01 0.6 



















GIPR Triglycerides, Hip circumference adjBMI 0.9665 rs5117 0.9328 5016 0.01 0.6 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.815 rs11672660 0.9996 5016 0.01 0.6 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.01 0.7 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR, T2D 
0.7384 rs429358 1 5016 0.01 0.7 
GIPR BMI, Waist circumference 0.995 rs1800437 0.6839 5016 0.01 0.7 
GIPR Triglycerides, Hip circumference adjBMI 0.9665 rs5117 0.9328 5016 0.01 0.7 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.815 rs11672660 0.9996 5016 0.01 0.7 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.01 0.8 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9334 rs429358 1 5016 0.01 0.8 
GIPR BMI, Waist circumference 0.995 rs1800437 0.6839 5016 0.01 0.8 
GIPR Triglycerides, Hip circumference adjBMI 0.9665 rs5117 0.9328 5016 0.01 0.8 
GIPR 
GIP SOMAmer 16292_288, Hip circumference, 
2hr Glucose adjBMI 
0.815 rs11672660 0.9996 5016 0.01 0.8 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.01 0.9 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.9334 rs429358 1 5016 0.01 0.9 
GIPR BMI, Waist circumference 0.995 rs1800437 0.6839 5016 0.01 0.9 
GIPR Triglycerides, Hip circumference adjBMI 0.9665 rs5117 0.9328 5016 0.01 0.9 
GIPR GIP SOMAmer 16292_288, Hip circumference 0.9509 rs11672660 0.9996 5016 0.01 0.9 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.001 0.5 
GIPR 
HbA1c, ApoA1, WHRadjBMI, Waist circumference 
adjBMI, WHR 
0.5827 rs429358 1 5016 0.001 0.5 
GIPR BMI, Waist circumference 0.9524 rs1800437 0.6839 5016 0.001 0.5 
GIPR Triglycerides, Hip circumference adjBMI 0.7428 rs5117 0.9328 5016 0.001 0.5 
GIPR GIP SOMAmer 16292_288, Hip circumference 0.6348 rs11672660 0.9996 5016 0.001 0.5 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.001 0.6 
GIPR HbA1c, ApoA1, WHRadjBMI, WHR 0.8888 rs429358 1 5016 0.001 0.6 
GIPR BMI, Waist circumference 0.9524 rs1800437 0.6839 5016 0.001 0.6 
GIPR Triglycerides, Hip circumference adjBMI 0.7428 rs5117 0.9328 5016 0.001 0.6 
GIPR GIP SOMAmer 16292_288, Hip circumference 0.6348 rs11672660 0.9996 5016 0.001 0.6 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.001 0.7 
GIPR HbA1c, ApoA1, WHRadjBMI, WHR 0.8888 rs429358 1 5016 0.001 0.7 
GIPR BMI, Waist circumference 0.9524 rs1800437 0.6839 5016 0.001 0.7 
GIPR Triglycerides, Hip circumference adjBMI 0.7428 rs5117 0.9328 5016 0.001 0.7 
GIPR GIP SOMAmer 16292_288, Hip circumference 0.6348 rs11672660 0.9996 5016 0.001 0.7 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 
1 rs7412 1 5016 0.001 0.8 
GIPR HbA1c, ApoA1, WHRadjBMI, WHR 0.8888 rs429358 1 5016 0.001 0.8 
GIPR BMI, Waist circumference 0.9524 rs1800437 0.6839 5016 0.001 0.8 
GIPR 
LDL, CHD, HDL, Total Cholesterol, Lipoprotein A, 
ApoB 



















GIPR HbA1c, ApoA1, WHR 0.9999 rs429358 1 5016 0.001 0.9 
GIPR BMI, Waist circumference 0.9524 rs1800437 0.6839 5016 0.001 0.9 
Abbreviations: PP, Posterior probability; N, Number; LDL, Low-density lipoprotein; CHD, Coronary heart disease; 
HDL, High-density lipoprotein; ApoB, Apolipoprotein B; ApoA1, Apolipoprotein A1; HbA1c, Glycated haemoglobin; 




Table S7.4: Association of E354 with the traits it was associated with at nominal 
significance from the 2SMR analysis, after conditioning on independent SNPs for each 
trait. Estimates of 2-hour glucose, Total cholesterol and BMI were not included in this table 
as the independent signal selection showed that E354 was one of the independent variants. 
 2SMR result Conditional result Independent variant 





T2D -0.03 (0.007) 7x10-5 -0.03 (0.008) 4x10-4 rs3810291 0.001 
T2DadjBMI -0.07 (0.009) 2x10-14 -0.02 (0.009) 0.04 rs2238689 0.363 
CHD 0.03 (0.007) 2x10-6 0.01 (0.007) 0.06 rs1964272 0.269 
SVS -0.08 (0.029) 0.009 -0.04 (0.029) 0.12 rs1964272 0.269 
Non-fasted 
plasma glucose 
0.02 (0.003) 3x10-8 0.01 (0.003) 0.05 rs1964272 0.269 
HbA1c -0.01 (0.003) 1x10-7 
-0.0003 
(0.003) 
0.92 rs9676912 0.356 
ApoA1 0.01 (0.003) 3x10-6 0.002 (0.003) 0.37 rs2238689 0.363 
HDL 0.02 (0.003) 7x10-9 0.003 (0.003) 0.31 rs2238689 0.363 
ApoB 0.02 (0.002) 5x10-13 0.01 (0.002) 2x10-5 rs7412 0.004 
LDL 0.02 (0.003) 2x10-16 0.016 (0.003) 1x10-8 rs7412 0.004 
Triglycerides -0.01 (0.003) 2x10-5 -0.01 (0.003) 5x10-5 rs4803936 0.001 
CRP -0.01 (0.002) 0.02 -0.004 (0.002) 0.07 rs7412 0.004 
Albumin -0.01 (0.003) 6x10-6 -0.01 (0.003) 0.001 rs35114617 0.061 
Creatinine -0.02 (0.002) 1x10-11 -0.02 (0.002) 3x10-11 rs7412 0.004 




-0.08 (0.017) 6x10-7 -0.04 (0.017) 0.01 rs61703905 0.1 
Abbreviations: SE, Standard error; T2D, Type 2 diabetes; adjBMI, Adjusted for BMI; CHD, Coronary heart disease; 
SVS, Small vessel stroke; HbA1c, Glycated haemoglobin; Apo, Apolipoprotein; HDL, High-density lipoprotein; LDL, 
Low-density lipoprotein; CRP, C-reactive protein; QPCTL, Glutaminyl-peptide cyclotransferase like 
a. The independent variant showing the greatest attenuation of the E354 association estimate with the 
respective trait 




Table S7.5: Association of other previously identified fasting GIP variants with CHD. 
The association of rs2287019 with CHD was not considered, as it is in high LD with E354. 
Variant Chr:pos EA EAF Beta SE P-value Cases Controls 
rs17681684 17:9792768 A 0.3082 -0.0074 0.0057 0.1925 34,541 261,984 







Figure S2.1: Associations of IFNγ, IL-6, IL-8 and TNFα with cardiometabolic risk factors 
per 1 SD higher cytokine levels, adjusting for fasting insulin levels. Risk factors are 
grouped into anthropometric, DEXA, glycaemic, lipid and physical activity categories. All traits 
are adjusted for BMI, additional adjustments for fasting insulin levels are marked as (adj. BMI 
+ Ins) in the trait name. Traits that are significantly associated (P<0.003) with a respective 
cytokine are coloured in red, non-significant results are in black. Effect estimates are 
expressed per 1 SD higher cytokine levels.   
Abbreviations: BMI, Body mass index; adj., Adjusted for; WHR, Waist-to-hip ratio; mmol/L, millimoles per Litre; 
HbA1c, Glycated haemoglobin; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; g, Grams; Avg., 
Average; kJ, Kilojoules; Kg, Kilograms; IFNγ, Interferon gamma, IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, 





Figure S2.2: Association of natural log transformed cytokine levels with incident 
cardiometabolic diseases in EPIC-Norfolk. Extensively adjusted results for T2D and CHD 
are shown in blue and orange respectively. T2D specific covariates: age, sex, BMI, WHR, 
ethnicity, education level, family history of diabetes, smoking status, units of alcohol per week 
and physical activity. CHD specific covariates: age, sex, BMI, WHR, education level, 
smoking status, physical activity, systolic blood pressure, prevalent diabetes and total 
cholesterol.  
Abbreviations: HR, Hazard ratio; SD, Standard deviation; BMI, Body mass index; WHR, Waist-to-hip ratio; T2D, 
Type 2 diabetes; CHD, Coronary heart disease; IFNγ, Interferon gamma, IL-6, Interleukin-6; IL-8, Interleukin-8; 
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Figure S2.3: Association of deciles of inverse-rank normal transformed cytokine levels 
with incident T2D in EPIC-Norfolk. Extensively adjusted results for T2D are shown. T2D 
specific covariates: age, sex, BMI, WHR, ethnicity, education level, family history of 
diabetes, smoking status, units of alcohol per week and physical activity.  
Abbreviations: HR, Hazard ratio; SD, Standard deviation; BMI, Body mass index; WHR, Waist-to-hip ratio; T2D, 















































































































































































































1.4 .6 2 4
HR(95% CI) for type 2 diabetes per 1 SD








Figure S2.4: Association of deciles of inverse-rank normal transformed cytokine levels 
with incident CHD in EPIC-Norfolk. Extensively adjusted results for T2D are shown. CHD 
specific covariates: age, sex, BMI, WHR, education level, smoking status, physical activity, 
systolic blood pressure, prevalent diabetes and total cholesterol.  
Abbreviations: HR, Hazard ratio; SD, Standard deviation; BMI, Body mass index; WHR, Waist-to-hip ratio; CHD, 
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Figure S2.5: Association of cytokine levels with incident T2D, defined using an 
established definition248 of incident T2D. Association of inverse-rank normal transformed 
cytokine levels with incident T2D (defined using an established definition248 for incident T2D) 
in EPIC-Norfolk. Results for T2D adjusted for age and sex only are shown in green. 
Extensively adjusted models are shown in orange. T2D specific covariates: age, sex, BMI, 
WHR, ethnicity, education level, family history of diabetes, smoking status, units of alcohol per 
week and physical activity.  
Abbreviations: HR, Hazard ratio; SD, Standard deviation; BMI, Body mass index; WHR, Waist-to-hip ratio; T2D, 
Type 2 diabetes; IFNγ, Interferon gamma, IL-6, Interleukin-6; IL-8, Interleukin-8; TNFα, Tumour necrosis factor 
alpha. 
  






1.07 (0.93, 1.24) 0.34
1.01 (0.88, 1.17) 0.86
IL-6 214 7,423
1.59 (1.40, 1.80) 1x10-12
1.28 (1.10, 1.49) 0.001
IL-8 215 7,516
1.30 (1.15, 1.47) 4x10-5
1.23 (1.09, 1.39) 0.001
TNFα 212 7,451
1.67 (1.44, 1.93) 5x10-12
1.44 (1.23, 1.68) 5x10-6
1.8 1.5 2
HR(95% CI) for type 2 diabetes per 




Figure S2.6: Association of inverse-rank normal transformed cytokine levels with 
incident cardiometabolic diseases in EPIC-Norfolk. Extensively adjusted results for T2D 
and CHD are shown in blue and orange respectively. In Model 1, all T2D and CHD covariates 
aside from BMI and WHR were adjusted for. Subsequent models added BMI or WHR 
separately to the covariates to estimate their independent effects.  
Abbreviations: HR, Hazard ratio; SD, Standard deviation; BMI, Body mass index; WHR, Waist-to-hip ratio; T2D, 
Type 2 diabetes; CHD, Coronary heart disease; IFNγ, Interferon gamma, IL-6, Interleukin-6; IL-8, Interleukin-8; 
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CHD: Age, sex, education level, smoking status, avg. physical activity per week, systolic blood pressure, prevalent T2D, tota l cholesterol




Figure S2.7: Association of BMI, WHR and WHRadjBMI with incident cardiometabolic 
diseases in EPIC-Norfolk. Extensively adjusted results for T2D and CHD are shown in blue 
and orange respectively. In Model 1, all T2D and CHD covariates aside from BMI and WHR 
were adjusted for. Subsequent models added IL-6 or TNFα separately to the covariates to 
estimate their independent effects. 
 
Abbreviations: HR, Hazard ratio; SD, Standard deviation; BMI, Body mass index; WHR, Waist-to-hip ratio; 
WHRadjBMI, Waist-to-hip ratio adjusted for BMI; T2D, Type 2 diabetes; CHD, Coronary heart disease; IL-6, 
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CHD: Age, sex, education level, smoking status, avg. physical activity per week, systolic blood pressure, prevalent T2D, tota l cholesterol




Figure S2.8: Interaction between cytokine levels and anthropometric traits on incident 
cardiometabolic diseases. Shown is the interaction between inverse-rank normal 
transformed cytokine levels and anthropometric traits on the association with incident 
cardiometabolic diseases in EPIC-Norfolk. Extensively adjusted results for T2D and CHD are 
shown in blue and orange respectively within tertiles of either BMI or WHR. T2D specific 
covariates: age, sex, BMI, WHR, ethnicity, education level, family history of diabetes, 
smoking status, units of alcohol per week and physical activity. CHD specific covariates: 
age, sex, BMI, WHR, education level, smoking status, physical activity, systolic blood 
pressure, prevalent diabetes and total cholesterol. 
 
Abbreviations: HR, Hazard ratio; SD, Standard deviation; BMI, Body mass index; WHR, Waist-to-hip ratio; T2D, 
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Figure S3.1: Regional association plot depicting the 10Mb region of chromosome 12 
associated with TNFα. This is a 5Mb region either side of rs3184504 (chr12:111884608) in 
SH2B3 used for independent signal selection and conditional analysis. The extensive LD in 
the region is shown, variants in very high LD (R2 ≥ 0.8) with rs3184504 are shown in red. Plot 
drawn using LocusZoom v1.2278.  
 
Abbreviations: chr12:111884608, rs3184504; TNFα, Tumour necrosis factor α; LD, Linkage disequilibrium; SH2B3, 





Figure S3.2: Quantile-quantile plots for the respective cytokine meta-analyses. The 
inflation of association test statistics compared to what is expected under the null hypothesis. 
The IL-6 and TNFα plots include only the Fenland and EPIC-Norfolk datasets. Data from the 
CoLaus population study is available for these two cytokines but was not included for this 








Figure S4.1: Design of the observational and genetic mediation analyses. The cohorts in 
which each coefficient was estimated are reported in the inner part of each panel. Panel A 
illustrates the design of the observational mediation analysis, estimated in the EPIC-Norfolk 
cohort. Panels B and C illustrate the design of the genetic mediation analyses, for 
cardiometabolic diseases and fasting insulin levels respectively estimated in the EPIC-Norfolk, 
































































Figure S4.2: Conditional quantile regression of CRP levels in EPIC-Norfolk. The 
association of 358Ala with ln-CRP levels was estimated in EPIC-Norfolk. The ordinary least 
squares (OLS) regression line is shown in red with the corresponding 95% confidence interval 
denoted by the dashed red lines. The OLS beta estimate and p-value are provided within the 
plot. The beta estimates from conditional quantile regression per ln-CRP quantile are shown 
by the black line and the corresponding 95% confidence interval is shown by the grey ribbon. 
The blue line shows the meta-regression line. The meta-regression estimate, and P-value are 
provided within the plot. No statistically significant difference in the effect of Asp358Ala across 
CRP quantiles is shown by the meta-regression model. 
 
 
Abbreviations: OLS, Ordinary least squares; MR, Meta-regression; CRP, C-reactive protein; mg, milligrams; L, 
Litre; Asp, Aspartic acid; Ala, Alanine.    
  
OLS: β= -0.079   P = 1.04x10-10













































Figure S4.3: Association of IL-6 levels in deciles with incident type 2 diabetes in EPIC-
Norfolk. Estimates were adjusted for age, sex, BMI, WHR, ethnicity, education level, family 
history of type 2 diabetes, smoking status, average units of alcohol per week and average 
physical activity per week. Hazard ratios for type 2 diabetes were estimated relative to the 
lowest decile.  
 
Abbreviations: HR, Hazard ratio; CI, Confidence interval; BMI, Body mass index; WHR, Waist-to-hip ratio; T2D, 
Type 2 diabetes; Avg., Average; pg/mL, picograms per millilitre; IL-6, Interleukin 6.   
IL-6
Decile





HR (95% CI) for type 2 diabetes 
relative to the lowest decile
IL-6 in pg/mL
median (IQR)






2 1.31 (0.68, 2.52) 0.4321 7010.33 (0.31-0.36) 0.5 (-0.5, 1.5)
3 1.60 (0.86, 2.99) 0.1431 7010.41 (0.40-0.43) 1.1 (0.0,2.2)
4 1.43 (0.77, 2.68) 0.2630 7010.48 (0.46-0.50) 1.1 (0.0,2.2)
5 1.77 (0.97, 3.22) 0.0638 7010.55 (0.53-0.57) 1.8 (0.6, 3.0)
6 1.68 (0.93, 3.04) 0.0945 7010.63 (0.61-0.65) 2.3 (1.1, 3.6)
7 1.68 (0.93, 3.03) 0.0950 7010.72 (0.69-0.75) 2.7 (1.4, 4.0)
8 1.67 (0.93, 3.00) 0.0948 7010.85 (0.81-0.89) 2.6 (1.3, 3.8)
9 1.88 (1.05, 3.37) 0.0362 7011.07 (1.00-1.15) 3.7 (2.3, 5.1)





Figure S4.4: Association of BMI deciles with incident type 2 diabetes in EPIC-Norfolk. 
The association of BMI deciles with incident type 2 diabetes was estimated using multivariable 
Cox regression in the EPIC-Norfolk study. Age, sex, IL-6 levels, WHR, ethnicity, education 
level, family history of type 2 diabetes, smoking status, average physical activity per week, 
and average units of alcohol per week were covariates in the models. Hazard ratios for type 2 
diabetes were estimated per kg/m2 higher BMI, relative to the lowest decile. 
 
 
Abbreviations: HR, Hazard ratio; CI, Confidence interval; BMI, Body mass index; WHR, Waist-to-hip ratio; IL-6, 








HR (95% CI) P-value
2 17 701 1.58 (0.70, 3.55) 0.27
3 20 701 1.70 (0.77, 3.75) 0.19
4 22 701 1.71 (0.78, 3.74) 0.18
5 25 701 1.73 (0.80, 3.74) 0.16
6 41 702 2.65 (1.27, 5.54) 0.01
7 37 700 2.25 (1.07, 4.72) 0.03
8 53 701 3.01 (1.46, 6.22) 0.003
9 70 701 3.61 (1.77, 7.40) 4x10-4
10 117 701 5.64 (2.77, 11.49) 2x10-6
1.7 2 3 6 9 12
HR(95% CI) for type 2 diabetes 
relative to the lowest decile




Figure S4.5: Association of Asp358Ala with type 2 diabetes and coronary heart disease 
by genotype in UK Biobank. Type 2 diabetes results are shown in blue and those of coronary 
heart disease in orange. Multivariable logistic regression models were adjusted for age, sex, 
genotyping chip, the first 40 principal components and a kinship matrix. Odds ratios were 
estimated per copy of Asp358Ala relative to the wild-type Asp/Asp genotype. No statistical 
evidence of deviation from an additive association was observed for type 2 diabetes (Pnon-
linearity = 0·13) or coronary heart disease (Pnon-linearity = 0·84).  
 
Abbreviations: T2D, Type 2 diabetes; CHD, Coronary heart disease; OR, Odds ratio; CI, Confidence interval; Asp, 
Aspartic acid; Ala, Alanine.   
  
Per copy of Asp358Ala
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Figure S4.6: Association of Asp358Ala with type 1 diabetes. In UK Biobank, the 
association of Asp358Ala with type 1 diabetes was estimated using multivariable logistic 
regression adjusted for age, sex, genotyping chip, the first 40 principal components and a 
kinship matrix. The result was meta-analysed with summary statistics from the type 1 diabetes 
genetics consortium and the Million Veteran Program respectively. Odds ratios for type 1 
diabetes were estimated per copy of Asp358Ala. It should be noted that despite the use of the 
largest available studies and the sufficient power of this analysis, there may too few studies to 




Abbreviations: OR, Odds ratio; CI, Confidence interval; Asp, Aspartic acid; Ala, Alanine. 
  







(I2 = 0%, p = 0.39)
0.97 (0.95, 0.99)758,24024,209 0.007
Million Veteran 
Program
0.98 (0.95, 1.01)321,61711,182 0.13
P-value
Type 1 Diabetes 
Genetics 
Consortium
0.95 (0.92, 0.99)12,26212,079 0.008
UK Biobank 0.99 (0.91, 1.09)424,361948 0.90





Figure S4.7: Excluding type 1 diabetes cases using a 29-variant polygenic risk score. 
Panel A. Theoretical distribution of the polygenic score in diabetes cases·350 Type 2 diabetes 
cases are shown in blue and type 1 diabetes cases in red. A z-score of 0·053 (actual value in 
UK Biobank, 13·04) denotes the median of the overall diabetes distribution (Table 2). Panels 
B and C show the number and percentage, respectively, of type 1 diabetes cases 
misclassified as type 2 diabetes that would be included in the analysis before and after 
applying the polygenic score exclusion. These simulations assume a 10% prevalence of type 
1 diabetes amongst people with diabetes in the UK Biobank study350 and simulate percentage 
misclassification ranging from 100% to 0%.  
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Figure S4.8: Association of Asp358Ala with continuous metabolic traits. A Bonferroni 
corrected significance threshold of P<·005 (·05 / 10 continuous traits) was used.  
Abbreviations: HbA1c, glycated haemoglobin; BMI, Body mass index; WHR, Waist-to-hip ratio; WHRadjBMI, WHR 
adjusted for BMI; mmol, millimoles; L, Litre; pmol, picomoles; Kg, Kilograms; m, meters; cm, centimetres Asp, 
Aspartic acid; Ala, Alanine; N, Number of participants. 
 
  






2hr glucose, mmol/L 42,854-0.01 (-0.04, 0.01) -0.008 (-0.022, 0.006) 0.21
Fasting plasma 
glucose, mmol/L
133,0108x10-4 (-0.003, 0.005) 0.001 (-0.005, 0.007) 0.70
HbA1c, % 479,942-0.004 (-0.006, -0.001) -0.007 (-0.012, -0.003) 0.002
Fasting insulin,
log(pmol/L)
108,5574x10-4 (-0.005, 0.005) 0.001 (-0.008, 0.009) 0.88
Body mass index, kg/m2 772,0660.01 (-0.002, 0.03) 0.003 (-3x10-4, 0.006) 0.07
Hip circumference, cm 604,1430.02 (-0.01, 0.05) 0.002 (-0.002, 0.006) 0.27
Waist circumference, cm 615,3050.009 (-0.04, 0.06) 7x10-4 (-0.003, 0.004) 0.68
Waist-to-hip ratio 
adjusted for BMI
625,123-2x10-4 (-4x10-4, -3x10-5) -0.004 (-0.008, -5x10-3) 0.03
Waist-to-hip ratio 602,940-1x10-4 (-4x10-4, 2x10-4) -0.001 (-0.005, 0.002) 0.48
Non-fasted 
glucose, mmol/L
355,817-3x10-4 (-0.004, 0.004) -3x10-4 (-0.005, 0.004) 0.90
0-.015 -.01 -.005 .005 .01
Beta (95% CI) in SD units of outcome 




Figure S4.9: Interaction of Asp358Ala with type 2 diabetes genetic risk factors on type 
2 diabetes. Panel a. The association of IL6R Asp358Ala with type 2 diabetes was estimated 
in individuals above or below the median value for 10 polygenic scores capturing genetic 
predisposition to risk factors for type 2 diabetes. The association with type 2 diabetes from the 
main analysis is shown below each score for comparison. A Bonferroni corrected significance 
threshold of P<·005 (·05/10 tests for heterogeneity) for the heterogeneity P-value was used. 
Panel b. The association of IL6R Asp358Ala with HbA1c levels was estimated in individuals 
above or below the median value for a polygenic score capturing genetic predisposition to 
higher BMI. The association with HbA1c in UK Biobank is shown for comparison. Estimates 
for HbA1c are expressed in % per copy of Asp358Ala. 
 
Abbreviations: HbA1c, glycated haemoglobin; SNPs, Single nucleotide polymorphisms; BMI, Body mass index; 



















Controls OR (95% CI) P-interaction
22,182 424,361
OR (95% CI) for type 2 diabetes 
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Insulin resistance (10 SNPs; Scott)
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Figure S4.10: Projection of the range of possible effects of IL6R blocking therapy on 
the risk of type 2 diabetes in a primary prevention setting. The ratio between lifetime 
exposure (genetic association) to short-term exposure (clinical trial) to lower IL-6R-mediated 
inflammation is on the x-axis. Lower ratio values correspond to estimates of longer treatment 
duration. The projected % reduction in diabetes risk, projected based on data from clinical 
trials of different dosages of tocilizumab, is represented on the y-axis. 
 
Abbreviations: CI, Confidence interval; mg, milligrams; kg, kilograms 
  

















































Effect ratio of lifetime exposure to genetic variant 
to short-term exposure to drug
Shorter drug treatment duration
Projection on the basis of data 
from trials of Tocilizumab 8 mg/kg
Projection on the basis of data 




Figure S4.11: Funnel plot for publication bias assessment. Illustration of the relationship 
between the hazard ratio for type 2 diabetes per log-pg/mL higher IL-6 levels and standard 
error for each study in included in the systematic review of prospective studies. Each study is 
represented by a dot and the estimated hazard ratio is depicted by the red line. The 95% 
confidence interval is shown by the grey contours.  
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Figure S5.1: Correlation heatmap illustrating the pairwise genetic correlation between 
autoimmune diseases and cardiometabolic traits. Positive correlations are shown in red 
whereas inverse correlations are shown in blue. Colour saturation denotes the strength of 
the correlation between traits. 
 
Abbreviations: BMI, Body mass index; HbA1c, Glycated haemoglobin; T2D, Type 2 diabetes; CHD, Coronary heart 
disease; HDL, High density lipoprotein; LDL, Low-density lipoprotein; RA, Rheumatoid arthritis; UC, Ulcerative 





Figure S5.2: Volcano plot of the association between a polygenic score for higher 
triglyceride levels with levels of the inflammatory proteins which colocalised with T2D 
at non-pleiotropic loci. The number of proteins significantly associated (P<1.5x10-4) with the 
score is shown. Markers for each protein are sized according to their association with the 
triglycerides score and coloured according to their colocalisation with T2D.  





Figure S5.3: Volcano plot of the association between a polygenic score for higher 
triglyceride levels with levels of the inflammatory proteins which colocalised with CHD 
at non-pleiotropic loci. The number of proteins significantly associated (P<1.5x10-4) with the 
score is shown. Markers for each protein are sized according to their association with the 
triglycerides score and coloured according to their colocalisation with CHD. 





Figure S7.1: Association of E354 and cardiovascular disease sub-types in UK Biobank. 
Cardiovascular disease sub-types were defined in UK Biobank and tested for association with 
E354 using multivariable logistic regression adjusting for age, sex and 10 principal 
components535. Estimates for each disease are expressed per copy of E354. A Bonferroni 
corrected significance threshold of P<0.0029 was used. 
Abbreviations: TIA, Transient ischaemic attack; PC, principal component; OR, Odds ratio; CI, Confidence interval 
  
0.6 0.8 1 1.2 1.4
OR (95% CI) for cardiovascular disease subtype 
per copy of E354
0.65Heart Failure 6,712 360,874 1.01 [0.97, 1.05]
Atrial Fibrillation 16,945 350,641 0.891.00 [0.97, 1.03]
Aortic Valve Stenosis 2,244 365,342 0.050.93 [0.86, 1.00]
Peripheral Vascular Disease 3,415 364,171 0.131.05 [0.99, 1.11]
Pulmonary Embolism 6,148 361,438 0.131.04 [0.99, 1.08]
Deep Vein Thrombosis 9,454 358,132 0.021.05 [1.01, 1.08]
Venous Thromboembolism (all) 14,097 353,489 0.031.03 [1.00, 1.06]
Abdominal Aortic Aneurysm 1,094 366,492 0.0031.19 [1.07, 1.30]
Subarachnoid Haemorrhage 1,084 366,502 0.730.98 [0.88, 1.09]
Intracerebral Haemorrhage 1,064 366,522 0.750.98 [0.88, 1.09]
Haemorrhagic Stroke (all) 1,981 365,605 0.430.97 [0.89, 1.05]
Transient Ischaemic Attack 3,962 363,624 0.911.00 [0.94, 1.05]
Ischaemic Stroke 4,602 362,984 0.971.00 [0.95, 1.05]
Ischaemic Cerebrovascular Disease (all) 8,084 359,502 0.911.00 [0.96, 1.04]
Ischaemic, haemorrhagic and unknown
stroke (but not TIA)
9,652 357,934 0.871.00 [0.97, 1.04]
Cardiovascular disease 
subtype OR (95% CI)Cases Controls P-value
Thoracic Aortic Aneurysm 347 367,239 0.10.86 [0.68, 1.04]




Figure S7.2: Associations between E354 and regional adiposity compartments in 
435,387 participants measured by bio-impedance. Fat mass in each compartment is 
shown in orange and lean mass in blue. Estimates for each compartment are in SD per copy 
of E354 (rs1800437). 
Abbreviations: CI, Confidence interval 
  
-0.01 0 0.01 0.02 0.03 0.04
Beta (95% CI) for bio-impedance compartment per copy of E354
Visceral fat mass 4x10-310.03 (0.02, 0.03)
Trunk fat mass 6x10-360.03 (0.03, 0.04)
Total fat mass 6x10-350.03 (0.03, 0.04)
Subcutaneous fat mass 4x10-330.03 (0.03, 0.04)
Legs fat mass 4x10-290.03 (0.02, 0.03)
Trunk lean mass 2x10-240.02 (0.02, 0.03)
Total lean mass 1x10-240.02 (0.02, 0.03)
Legs lean mass 1x10-220.02 (0.02, 0.03)
Gynoid lean mass 5x10-210.02 (0.02, 0.03)
Arms lean mass 1x10-270.03 (0.02, 0.03)
Appendicular lean mass 5x10-250.02 (0.02, 0.03)
Android lean mass 1x10-230.02 (0.02, 0.03)
Gynoid fat mass 3x10-300.03 (0.02, 0.03)
Arms fat mass 4x10-370.03 (0.03, 0.04)
Android fat mass 6x10-350.03 (0.03, 0.04)
Peripheral fat mass 3x10-310.03 (0.02, 0.03)
Bio-impedance 
compartment






Figure S7.3: Associations between E354 and human protein levels. Panel A. Volcano 
plot showing the associations between E354 and 4,979 human protein levels. The dashed line 
indicates the Bonferroni significance threshold P ≤ 1x10-5. The point size for each protein is 
proportional to its effect size. Significant protein associations with E354 are shown in blue, 
non-significant proteins are shown in yellow. Associations with significant proteins and 
proteins of interest are labelled. Two SOMAmers from the SOMAscan® 4k assay target GIP 
levels, both are labelled. Panels B & C. Regional association plots depicting the E354 
(rs1800437) association with both GIP SOMAmers, X16292_288 and X5755_29 respectively. 

































Figure S7.4: Associations between E354 and human metabolite levels. Volcano plot 
showing the associations between E354 and the levels of 1,008 human plasma metabolites. 
The dashed line indicates the Bonferroni significance threshold P ≤ 5x10-5. The point size for 
each protein is proportional to its effect size. Metabolites are coloured according to their 



































Figure S7.5: Gaussian graphical model illustrating the partial correlation network in 11,966 participants between X-12283 and first and 
second order connections most correlated with X-12283. Metabolites directly connected with X-12283 represent first order connections, 
others are second order connections. Metabolites clustered closest to X-12283 are more strongly correlated. Metabolite nodes are coloured by 
their super pathway. The table outlines the 5 metabolites with a first order connection to X-12283 and shows their partial correlation coefficients 

















X - 21821 0.41 <1x10-300
X - 17351 0.29 6.19x10-138
Indolepropionate 0.23 2.14x10-51
N-acetyltryptophan 0.16 2.49x10-33




Figure S7.6: Stacked regional association plot showing the cluster of cardiovascular-related traits which colocalise near the GIPR 
locus. The purple diamond represents the rs7412 variant, a missense variant in APOE. variant markers are coloured by their LD with rs7412, 





Figure S7.7: Regional association plot illustrating the cluster of traits which colocalise with the GIP measures at the GIPR locus. The 
purple diamond represents the rs11672660 variant which is in perfect LD with rs1800437 (E354). variant markers are coloured by their LD with 
rs11672660, with red indicating LD (R2 > 0.8). Fasting and 2-hour GIP levels are from the MDC cohort of Almgren et al. 2017508. 




Figure S7.8: Heatmap matrix depicting the pairwise colocalisation between 
cardiometabolic traits at the GIPR locus. The largest pairwise colocalisation estimate 
between fasting GIP measures from SomaLogic, fasting and 2-hour GIP measures from 
Almgren et al. 2017508, 2hr glucose adjusted for BMI ,BMI, LDL, CHD and T2D is shown. Each 
colocalisation hypothesis is coloured differently with the colour saturation referring to the 
evidential strength. Trait-pairs with significant posterior probability estimates of colocalisation 
were outlined in black. To discriminate between H1 and H2 hypotheses, traits along the X-
axis were used as “Trait 1” in the analysis and traits listed on the Y-axis were used as “Trait 
2”. 
Abbreviations: H, Hypothesis; BMI, Body mass index; CHD, Coronary heart disease; GIP, Gastric inhibitory 






Figure S7.9: Matrix illustrating the LD between each of the independent CHD variants 
and rs1800437 (E354) estimated using 5 European populations in LDlink590. Pairwise R2 
values between variants are shown in red in the lower triangle, whereas D’ values are shown 
in blue in the top triangle. Colour saturation represents the strength of the LD estimate 
between two variants. The LD between rs1800437 and rs1964272 (R2 = 0.27) is depicted in 
light pink, whereas the very low LD between rs1800437 and the other CHD variants are shown 






Figure S7.10: Volcano plot showing the associations between rs1964272 and 4,979 
human protein levels. The dashed line indicates the Bonferroni significance threshold P ≤ 
1x10-5. The point size for each protein is proportional to its effect size. Significant protein 
associations with rs1964272 are shown in blue, non-significant proteins are shown in yellow.  
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